{"docstore/data": {"8beb377c-a871-454d-a190-40a59f113749": {"__data__": {"id_": "8beb377c-a871-454d-a190-40a59f113749", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n", "original_text": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "496cb412-8c22-4165-a632-a1fde8751108", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "original_text": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. "}, "hash": "f3d65d8709e88559e9d2406602ffb178ec553b4a275fb3bc2136989cf8c0fb3e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "496cb412-8c22-4165-a632-a1fde8751108": {"__data__": {"id_": "496cb412-8c22-4165-a632-a1fde8751108", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "original_text": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8beb377c-a871-454d-a190-40a59f113749", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n", "original_text": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0daf6418348bd32313a7f405e02922f71c33a9a180f5e0f697cc4ae23fef47f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd2598f-9126-4dda-92e6-caf7228e2a59", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.  "}, "hash": "7c34b4017945b7b96fcc20c78236120abf5cc14387e0514ce1abbc7e9f7cdb69", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "start_char_idx": 48, "end_char_idx": 172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd2598f-9126-4dda-92e6-caf7228e2a59": {"__data__": {"id_": "8bd2598f-9126-4dda-92e6-caf7228e2a59", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "496cb412-8c22-4165-a632-a1fde8751108", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "original_text": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abbcb35bde912e72b598d19cd0766aa6e57b78eecf434ba25db642f554de6267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14d3e932-3ae5-465e-840c-5a28a2085a20", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  ", "original_text": "Today's conference is being recorded.   \n \n"}, "hash": "2f8875d7877d8166c68723fa6733f1c8bc51c91c14ef53bea64a0c4d9e6b3b3f", "class_name": "RelatedNodeInfo"}}, "text": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "start_char_idx": 172, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14d3e932-3ae5-465e-840c-5a28a2085a20": {"__data__": {"id_": "14d3e932-3ae5-465e-840c-5a28a2085a20", "embedding": null, "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  ", "original_text": "Today's conference is being recorded.   \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd2598f-9126-4dda-92e6-caf7228e2a59", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdd73b398931520f395bad5248fe3ec5e34206858e844a50342360980070192d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31b499e4-bcd0-48eb-aa5d-b2444b8d4491", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "original_text": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  "}, "hash": "88f6fae281e3accb947821d1799fe51d4be82c9cc0f1fed260b395f19c9a4a35", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded.   \n \n", "start_char_idx": 231, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31b499e4-bcd0-48eb-aa5d-b2444b8d4491": {"__data__": {"id_": "31b499e4-bcd0-48eb-aa5d-b2444b8d4491", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "original_text": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14d3e932-3ae5-465e-840c-5a28a2085a20", "node_type": "1", "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.  ", "original_text": "Today's conference is being recorded.   \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f8a248f9c3fce7042be548815085ff86aa73b1e6b04bc21d11000dc8abaa474", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c1c555-51c3-418a-a6f9-1be9282da356", "node_type": "1", "metadata": {"window": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n"}, "hash": "68d7b42244591cf8780d0282e849aa43098ce0e6853288f2a8f25ef3986c5aa6", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "start_char_idx": 274, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c1c555-51c3-418a-a6f9-1be9282da356": {"__data__": {"id_": "e0c1c555-51c3-418a-a6f9-1be9282da356", "embedding": null, "metadata": {"window": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31b499e4-bcd0-48eb-aa5d-b2444b8d4491", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "original_text": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "201402b925389d3fba68ce03cb001080f91ee496b4601183110f4df446606661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fbb80f7-2542-443f-a077-5ee48929f542", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:  Good morning, and welcome.  "}, "hash": "79ca8b09bb67d6b7d65bcf6e2a1012c1c693f9c5048ccb86fa4ad863a1f78880", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 385, "end_char_idx": 406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fbb80f7-2542-443f-a077-5ee48929f542": {"__data__": {"id_": "3fbb80f7-2542-443f-a077-5ee48929f542", "embedding": null, "metadata": {"window": "Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:  Good morning, and welcome.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c1c555-51c3-418a-a6f9-1be9282da356", "node_type": "1", "metadata": {"window": "Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8227d29840777cadff59c95434e026a9ac01a7726a0fbb8e3b8fcf9eb97beea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cd213ee-49f3-4f69-82ff-8b81d38bae29", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  "}, "hash": "e867585c88aafa50a694ede8299ee634052e6b695e9edd4737585334367a070d", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Good morning, and welcome.  ", "start_char_idx": 406, "end_char_idx": 448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cd213ee-49f3-4f69-82ff-8b81d38bae29": {"__data__": {"id_": "7cd213ee-49f3-4f69-82ff-8b81d38bae29", "embedding": null, "metadata": {"window": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fbb80f7-2542-443f-a077-5ee48929f542", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.   \n \n At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:  Good morning, and welcome.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bebf2573888929ae1a35baf6e2582aa6da587d3be82ce5175ac3c64f9025dc1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15d6c122-f5d1-4f2c-b08d-f89042b63ffb", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  "}, "hash": "a8a14bd5ad12606598fe98165b44ca10ffdf9a532197f292ec7d3530633afdcf", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "start_char_idx": 448, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15d6c122-f5d1-4f2c-b08d-f89042b63ffb": {"__data__": {"id_": "15d6c122-f5d1-4f2c-b08d-f89042b63ffb", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cd213ee-49f3-4f69-82ff-8b81d38bae29", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the conference over to Kevin Moran, Vice President of Investor \nRelations.   Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  ", "original_text": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0e4666f2830047cd27487030eb60706cd5445c0d4f488a6ad2cd4ccb45cefd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8869667-ce0c-446d-8054-e7995c86ab5f", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n"}, "hash": "49f59f411c0f0b0dc50d01197e3972ccb102a172bd3fd3b5d1fc0c4e6b8f39bc", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "start_char_idx": 570, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8869667-ce0c-446d-8054-e7995c86ab5f": {"__data__": {"id_": "e8869667-ce0c-446d-8054-e7995c86ab5f", "embedding": null, "metadata": {"window": "Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15d6c122-f5d1-4f2c-b08d-f89042b63ffb", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baaec8e56a23f9f750d73a37b85d7f9871c3b16d59efeb3fe5c8db81b11c32e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1587a637-ec15-4b5a-83d9-732b3e1f45ca", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  "}, "hash": "21e926ca74e0c2486b25e2130b542ef06cd445a5394a9e759959ace0bbc57a38", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "start_char_idx": 683, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1587a637-ec15-4b5a-83d9-732b3e1f45ca": {"__data__": {"id_": "1587a637-ec15-4b5a-83d9-732b3e1f45ca", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8869667-ce0c-446d-8054-e7995c86ab5f", "node_type": "1", "metadata": {"window": "Kevin Moran:  Good morning, and welcome.   Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da6c2d04cf960cacbdae97368b51a480b5a29a9ccfb30b07ed2abc52ce79f725", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44ee8614-ccbb-4016-b6eb-2d7d5902581b", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  "}, "hash": "a1c63a2de1ab8b8c00df29485643d0b128938f2b4b84b45b95ca24f2b7a7fd5a", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements.  ", "start_char_idx": 792, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44ee8614-ccbb-4016-b6eb-2d7d5902581b": {"__data__": {"id_": "44ee8614-ccbb-4016-b6eb-2d7d5902581b", "embedding": null, "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1587a637-ec15-4b5a-83d9-732b3e1f45ca", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health's third quarter \nfiscal 2021 results, along with an update to our FY '21 outlook.   You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "original_text": "During the call, we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed7e55e96f16e70f49fab22ac84766a9237ac04bc13ade5cbf5e0e9a671540c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2507baf1-7ec9-47f6-b8e9-23e511fdae53", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  "}, "hash": "bd2f17b520e925e5339ec73fb188cc06ce7d9142c61a6f30ebc944ee2de1dfdd", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "start_char_idx": 857, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2507baf1-7ec9-47f6-b8e9-23e511fdae53": {"__data__": {"id_": "2507baf1-7ec9-47f6-b8e9-23e511fdae53", "embedding": null, "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44ee8614-ccbb-4016-b6eb-2d7d5902581b", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.   Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28a96466f3c729abb90af10f8e0167e60fdd0b22e68b6b86e3d03abb10653cfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "140d34f2-6eb4-4c64-a104-8dff33c05b0b", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  "}, "hash": "3782924d62c616bf11445bba0f879909f5ec150f0ea9ef42148b5b6f3289c744", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "start_char_idx": 1029, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "140d34f2-6eb4-4c64-a104-8dff33c05b0b": {"__data__": {"id_": "140d34f2-6eb4-4c64-a104-8dff33c05b0b", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2507baf1-7ec9-47f6-b8e9-23e511fdae53", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer; and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "original_text": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9be65fdd952363c886923ad8a8a0c88adb54b5297116bdb6cb6a7ec4c1c2a4ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5000e02-0577-481a-a48b-a47e0d963d7a", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "9e3025269805c1f93278ece77ce4e3f2d5799b1b95fc7cc6d4147d1f7bed35c3", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "start_char_idx": 1194, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5000e02-0577-481a-a48b-a47e0d963d7a": {"__data__": {"id_": "a5000e02-0577-481a-a48b-a47e0d963d7a", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "140d34f2-6eb4-4c64-a104-8dff33c05b0b", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.   The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57b626b89e8f50f298dac74cfa982f8f8b600dbf5e0e688eef0d2128a569e723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4", "node_type": "1", "metadata": {"window": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n"}, "hash": "5827af5b69b7096005a4f37eba2bf6815d61276606b258c40faeedd8a78de44b", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1335, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4": {"__data__": {"id_": "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4", "embedding": null, "metadata": {"window": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5000e02-0577-481a-a48b-a47e0d963d7a", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.   Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d430c3ebcb104f2d3391bd86864131fdeb7d1c9072544180da0a066bf5a01b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b426df16-bf28-4931-8c0e-8f5e0678eca4", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "original_text": "With that, I'll now turn the call over to Mike.  \n \n"}, "hash": "40a164e56f0418d7149c0e331518627a2bb8a8c7f7954ff00d49622d22bb5275", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "start_char_idx": 1460, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b426df16-bf28-4931-8c0e-8f5e0678eca4": {"__data__": {"id_": "b426df16-bf28-4931-8c0e-8f5e0678eca4", "embedding": null, "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4", "node_type": "1", "metadata": {"window": "Please refer to our S EC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.   Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ec9ad82b9afad6c78238bab67e46f41e97b210cd6d7bd74c1c3d535ecee0b60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecfcbae9-f33e-40d2-8587-15827497aab4", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  "}, "hash": "ce3582d1a29ff043f331a25c916019d34b4865c7fc80a52ce430c7a1f349f7f7", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn the call over to Mike.  \n \n", "start_char_idx": 1621, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecfcbae9-f33e-40d2-8587-15827497aab4": {"__data__": {"id_": "ecfcbae9-f33e-40d2-8587-15827497aab4", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b426df16-bf28-4931-8c0e-8f5e0678eca4", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non -GAAP basis unless they're \nspecifically  called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "274644d8dcb18714243d75ba6584248219762d98090e166e8ed75be0dfa319ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49ddd235-9682-430d-a22d-92871c4f55dd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "original_text": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  "}, "hash": "3a71236bb22a5e12682545450f453f517ca5a3b1659b84e622aa055ca6c767f5", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "start_char_idx": 1673, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49ddd235-9682-430d-a22d-92871c4f55dd": {"__data__": {"id_": "49ddd235-9682-430d-a22d-92871c4f55dd", "embedding": null, "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "original_text": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecfcbae9-f33e-40d2-8587-15827497aab4", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b49d67337ad8781c50a120aef1ff76d06e51f4fc46c640c34fbf6a2ffb0a106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "942b2370-8993-42b8-8413-e0baf35b6e0c", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "original_text": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  "}, "hash": "d44d607eab24175855f8832699d4fdcbe321251abbc1c598e6f66f64c16ed12c", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "start_char_idx": 1733, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "942b2370-8993-42b8-8413-e0baf35b6e0c": {"__data__": {"id_": "942b2370-8993-42b8-8413-e0baf35b6e0c", "embedding": null, "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "original_text": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49ddd235-9682-430d-a22d-92871c4f55dd", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we c an try and give everyone an opportunity.  \n \n With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "original_text": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbc212156a0d0b25c86acf2132f65bd4c197fa37c0ddd7cc1aa6021bf66edaa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aab9ef67-62fe-4869-9bb5-c63abcbaf373", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "original_text": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  "}, "hash": "c13865f008af7c22eebc22104c1fd4d134bb7f8091bad7d2bccbb468cc1a8c45", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "start_char_idx": 1810, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aab9ef67-62fe-4869-9bb5-c63abcbaf373": {"__data__": {"id_": "aab9ef67-62fe-4869-9bb5-c63abcbaf373", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "original_text": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "942b2370-8993-42b8-8413-e0baf35b6e0c", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "original_text": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1af1c7cf4ceedf10f4f0844d7ae3b1cfa62777f7cc919c939607fda58b10ed8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "390c8658-af12-4e0b-a275-69da913bfbf1", "node_type": "1", "metadata": {"window": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "original_text": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  "}, "hash": "acf4ce6d57a2205b50b9f595b81251e649ed7f12b61e1d8d0400b6f44d17a448", "class_name": "RelatedNodeInfo"}}, "text": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "start_char_idx": 1924, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "390c8658-af12-4e0b-a275-69da913bfbf1": {"__data__": {"id_": "390c8658-af12-4e0b-a275-69da913bfbf1", "embedding": null, "metadata": {"window": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "original_text": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aab9ef67-62fe-4869-9bb5-c63abcbaf373", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.   Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "original_text": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9b7e46204390fc24666b62f638ff2353ee0fcb6aaecd3b123e1cfd9d25346a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee", "node_type": "1", "metadata": {"window": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "original_text": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  "}, "hash": "8ce89d8ddf362f867bc591056253e61a632642281f02365a35c4176a4694e065", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "start_char_idx": 2027, "end_char_idx": 2149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee": {"__data__": {"id_": "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee", "embedding": null, "metadata": {"window": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "original_text": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "390c8658-af12-4e0b-a275-69da913bfbf1", "node_type": "1", "metadata": {"window": "Before I turn it over to Jason, I will \nprovide a few high -level thoughts.   We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "original_text": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "804eedd468aab6c161ffd0dd51c94033b8735edb1d50c6e4bead6e3b72771cc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28e83bc7-4f57-4189-8db0-a342bf649477", "node_type": "1", "metadata": {"window": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n"}, "hash": "4b9a61cdce87ae3eb05977825d9b1100c292d2340f4abe8c4f690c19685d1570", "class_name": "RelatedNodeInfo"}}, "text": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "start_char_idx": 2149, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28e83bc7-4f57-4189-8db0-a342bf649477": {"__data__": {"id_": "28e83bc7-4f57-4189-8db0-a342bf649477", "embedding": null, "metadata": {"window": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee", "node_type": "1", "metadata": {"window": "We remain focused on serving our customers and their patients \nand continue to advance our strategic priorities.   With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "original_text": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3269b4a6b584de4fb467130b0752458c7314eb2e66321a69a1eccc45d54e8dde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "146db715-528f-41aa-85d2-f711536ab1ce", "node_type": "1", "metadata": {"window": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  "}, "hash": "ce17ea2d9615a4094113a1180ada226934c4b0e967fe9e9aaba4ad62daad8813", "class_name": "RelatedNodeInfo"}}, "text": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "start_char_idx": 2345, "end_char_idx": 2426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "146db715-528f-41aa-85d2-f711536ab1ce": {"__data__": {"id_": "146db715-528f-41aa-85d2-f711536ab1ce", "embedding": null, "metadata": {"window": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28e83bc7-4f57-4189-8db0-a342bf649477", "node_type": "1", "metadata": {"window": "With our  resilient business model, we are navigating \nthe effects of the pandemic on our businesses.   In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7b708d1de84d54b1442eb9af793b297e6cb64e18e5e4d527bed56bbe0981c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a678addb-29d7-4ada-bb87-de3c5adc552a", "node_type": "1", "metadata": {"window": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "As we navigate the pandemic, our customer focus remains \ncentral to our activities.  "}, "hash": "b635ea1e9caa9486118be4731c4fe3019e074590b28771e3e8251fc1f932cbfd", "class_name": "RelatedNodeInfo"}}, "text": "Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "start_char_idx": 2426, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a678addb-29d7-4ada-bb87-de3c5adc552a": {"__data__": {"id_": "a678addb-29d7-4ada-bb87-de3c5adc552a", "embedding": null, "metadata": {"window": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "146db715-528f-41aa-85d2-f711536ab1ce", "node_type": "1", "metadata": {"window": "In the quarter, we continued to see strong demand \nfor lab and PPE products and volume recovery in our nuclear business.   Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0be22ebccc875ca7dd0b8c7d57df4877230bdf5b7b53b2087e2cba146618501a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73bbfac3-28f8-4f54-8470-e5de66e4a1d1", "node_type": "1", "metadata": {"window": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  "}, "hash": "f14a9ce42101c7ed37894d5c9b2db7e25f278110821866f4a9cd0516bec934c2", "class_name": "RelatedNodeInfo"}}, "text": "As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "start_char_idx": 2752, "end_char_idx": 2837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73bbfac3-28f8-4f54-8470-e5de66e4a1d1": {"__data__": {"id_": "73bbfac3-28f8-4f54-8470-e5de66e4a1d1", "embedding": null, "metadata": {"window": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d91a3ec0fa7de811aef78afbe47bf044d4ca67e84d6dbf75d7df3b3f5051ef78", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a678addb-29d7-4ada-bb87-de3c5adc552a", "node_type": "1", "metadata": {"window": "Medical elective procedure \nutilization exp erienced some volatility, and we saw ongoing COVID -19 related softness in generics \nvolumes, which we now expect to extend into the next fiscal year.   With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "As we navigate the pandemic, our customer focus remains \ncentral to our activities.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f33689f0420993b16caf186fc6643a9aaad8d4c4708e5c40d1203238913e23e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066cd2ee-3f53-4003-aded-cc2b3f98d309", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "original_text": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.  "}, "hash": "a6101196e7b32c371b5edc5cf8ee6c53b4d40831a0c32a6338745174df54f19f", "class_name": "RelatedNodeInfo"}}, "text": "We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "start_char_idx": 2837, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066cd2ee-3f53-4003-aded-cc2b3f98d309": {"__data__": {"id_": "066cd2ee-3f53-4003-aded-cc2b3f98d309", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "original_text": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73bbfac3-28f8-4f54-8470-e5de66e4a1d1", "node_type": "1", "metadata": {"window": "With th is updated assumption , we \nhave revised our Pharma segment outlook.  \n \n Despite the impacts of COVID -19, our business fundamentals are strong, demonstrated by the \nunderlying growth we are seeing in both segments, and we continue to advance our strategic \npriorities including optimizing our supply chain and portfolio as you saw in our recently announced \nagreement to sell the Cordis business.   As we navigate the pandemic, our customer focus remains \ncentral to our activities.   We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "original_text": "We deeply appreciate that it is our responsibility to serve health care \nproviders, their patients and those on the front lines.  ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "387b96b26891332437d0cfe7388542762dccef2c5717ca9405b16d5e0a930629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a085bdf0-943a-47a9-af27-8a9ce3fe6389", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "original_text": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n"}, "hash": "ab47874099f9c9cb248ef1ff8421d449a2d8fb3fddeb3d49253e22fd654f5804", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.  ", "start_char_idx": 0, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a085bdf0-943a-47a9-af27-8a9ce3fe6389": {"__data__": {"id_": "a085bdf0-943a-47a9-af27-8a9ce3fe6389", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "original_text": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066cd2ee-3f53-4003-aded-cc2b3f98d309", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "original_text": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d76c4f1f290feff394bd4cefe8ff7eda358369573b0bd619bbf4192b1387ee42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6378db28-b35c-45d0-8ceb-afccd2a4fa47", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike.  "}, "hash": "38ee0e4b34b6853a004e996fd8f1f8c8806c0856eaef13e3f1123283caaeb1f4", "class_name": "RelatedNodeInfo"}}, "text": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n", "start_char_idx": 226, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6378db28-b35c-45d0-8ceb-afccd2a4fa47": {"__data__": {"id_": "6378db28-b35c-45d0-8ceb-afccd2a4fa47", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a085bdf0-943a-47a9-af27-8a9ce3fe6389", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "original_text": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16e25402e942547384c434367976e776c68ce670f0bfa502dd5ef3bf5525be01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "original_text": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n"}, "hash": "c2493240664296bee0bc56dc71bdd4df428e73a92b6f4576d28690c640448c35", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Mike.  ", "start_char_idx": 397, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c": {"__data__": {"id_": "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c", "embedding": null, "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "original_text": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6378db28-b35c-45d0-8ceb-afccd2a4fa47", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.  ", "original_text": "Jason Hollar:  Thanks, Mike.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50600da77ff6fd7c928a0b316c92a605c31912394ec8b2ef51b46302d861499b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1859a71-7f53-42eb-9a3e-6cf5afedb668", "node_type": "1", "metadata": {"window": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "original_text": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  "}, "hash": "53faef8d06a4715aae94d0b92a493dff51820cae72b1aa0c83941cb3005fc4ce", "class_name": "RelatedNodeInfo"}}, "text": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "start_char_idx": 427, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1859a71-7f53-42eb-9a3e-6cf5afedb668": {"__data__": {"id_": "f1859a71-7f53-42eb-9a3e-6cf5afedb668", "embedding": null, "metadata": {"window": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "original_text": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c", "node_type": "1", "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "original_text": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "003f68c559643b3c139d5935b5514dad73d319dafe322ef48189e010383ff360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae28b9a-6a30-4f4e-b752-77958f987840", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "original_text": "Consolidated gross margin for the period was $1.8 billion.  "}, "hash": "adfd2662bd15b01044f88db307ea715a778c82bf8a61554d25005a2a5c96891a", "class_name": "RelatedNodeInfo"}}, "text": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "start_char_idx": 657, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae28b9a-6a30-4f4e-b752-77958f987840": {"__data__": {"id_": "2ae28b9a-6a30-4f4e-b752-77958f987840", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "original_text": "Consolidated gross margin for the period was $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1859a71-7f53-42eb-9a3e-6cf5afedb668", "node_type": "1", "metadata": {"window": "I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "original_text": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b202192092a804b3a87cb4deb3b72cdd9b08fbfaf4caabbff6444e3cfffb735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7678b756-eabe-47ef-8f4d-d018d4fd416d", "node_type": "1", "metadata": {"window": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "original_text": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n"}, "hash": "af52ca61a51bee042f8011cba9954716b5c73d4c3dea06e5d7b9aca165446928", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated gross margin for the period was $1.8 billion.  ", "start_char_idx": 778, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7678b756-eabe-47ef-8f4d-d018d4fd416d": {"__data__": {"id_": "7678b756-eabe-47ef-8f4d-d018d4fd416d", "embedding": null, "metadata": {"window": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "original_text": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ae28b9a-6a30-4f4e-b752-77958f987840", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "original_text": "Consolidated gross margin for the period was $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f010601225bf8b2e313a164a4f369becf4be44626ca2e6af93157c2331c354a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc02e04b-0c30-490c-ba41-bfa1612d5068", "node_type": "1", "metadata": {"window": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "original_text": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  "}, "hash": "b2a6acddaa7829c46cd7444b731df3bc623f3bf32bbfc3910f753f0a47e70fdb", "class_name": "RelatedNodeInfo"}}, "text": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "start_char_idx": 838, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc02e04b-0c30-490c-ba41-bfa1612d5068": {"__data__": {"id_": "cc02e04b-0c30-490c-ba41-bfa1612d5068", "embedding": null, "metadata": {"window": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "original_text": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7678b756-eabe-47ef-8f4d-d018d4fd416d", "node_type": "1", "metadata": {"window": "Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "original_text": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48fe033f7f34045e8a42d1a48e3071810836819521ded926f84ad3fd95c2fe36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "069e4c99-a628-4a78-aa04-a13b7e6d846e", "node_type": "1", "metadata": {"window": "Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.  ", "original_text": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n"}, "hash": "b13506d3d838e122dbed112123bd38d6ce5aa8642304a3037c2adbedd9cc287e", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "start_char_idx": 967, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "069e4c99-a628-4a78-aa04-a13b7e6d846e": {"__data__": {"id_": "069e4c99-a628-4a78-aa04-a13b7e6d846e", "embedding": null, "metadata": {"window": "Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.  ", "original_text": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc02e04b-0c30-490c-ba41-bfa1612d5068", "node_type": "1", "metadata": {"window": "Now for our consolidated third quarter results, total company revenue of $39.3 billion was inline with \nthe prior year.   Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "original_text": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b380444adb01649656ccc845468e75fea365148e65ef47cd977e47583346e09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ad081e7-351a-45c8-aef2-514a938f717b", "node_type": "1", "metadata": {"window": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "original_text": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n"}, "hash": "bbe196c763261d57d2185fec86bef809e8ceca7b8f1cc73b4b78dd967908d2f3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "start_char_idx": 1136, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ad081e7-351a-45c8-aef2-514a938f717b": {"__data__": {"id_": "0ad081e7-351a-45c8-aef2-514a938f717b", "embedding": null, "metadata": {"window": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "original_text": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "069e4c99-a628-4a78-aa04-a13b7e6d846e", "node_type": "1", "metadata": {"window": "Consolidated gross margin for the period was $1.8 billion.   SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.  ", "original_text": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b56f01fb088070570b3d9a94e67d0d136449a20a994ee5f899b2882d370e538", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c", "node_type": "1", "metadata": {"window": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "original_text": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  "}, "hash": "2c590f2837772b75312c8d297a9789aaaaacb8e7593d44cdea55bfa08ca2c6e1", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "start_char_idx": 1249, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c": {"__data__": {"id_": "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c", "embedding": null, "metadata": {"window": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "original_text": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ad081e7-351a-45c8-aef2-514a938f717b", "node_type": "1", "metadata": {"window": "SG&A decreased nearly \n4% to $1.1 billion, demonstrating our enterprise -wide commitment to disciplined expense \nmanagement.  \n \n The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "original_text": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68dfd79111d0c67a729eef0ff2f541e6f1e84fc3b008368e5c71f4b18fc9a763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1981c8f-c334-415d-9f27-c457ebc19f82", "node_type": "1", "metadata": {"window": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "original_text": "Average diluted shares \noutstanding were $294 million.  "}, "hash": "32e12a3c10072086e3c6ed6dc5f61d94e03b1b5a6d9c3ee96d6e9516687156aa", "class_name": "RelatedNodeInfo"}}, "text": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "start_char_idx": 1552, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1981c8f-c334-415d-9f27-c457ebc19f82": {"__data__": {"id_": "f1981c8f-c334-415d-9f27-c457ebc19f82", "embedding": null, "metadata": {"window": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "original_text": "Average diluted shares \noutstanding were $294 million.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c", "node_type": "1", "metadata": {"window": "The net result for the quarter was operating earnings of $689 million, a decrease of 4% due to the \nimpa ct of COVID -19, primarily concentrated in the Pharma segment.   Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "original_text": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "781c0742f1f1e6eed36f8b38ef11c84cdfb039eed99ee5f2b7ae5715035ca403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac8557d-2ce7-4ab3-8893-342337dfed35", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "original_text": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n"}, "hash": "f8b27ce383b3f3ad4651e4fc7bb4ddf24574b1c3f7ff7f57eed2c812c0cf562a", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares \noutstanding were $294 million.  ", "start_char_idx": 1723, "end_char_idx": 1779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac8557d-2ce7-4ab3-8893-342337dfed35": {"__data__": {"id_": "1ac8557d-2ce7-4ab3-8893-342337dfed35", "embedding": null, "metadata": {"window": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "original_text": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1981c8f-c334-415d-9f27-c457ebc19f82", "node_type": "1", "metadata": {"window": "Adjusted for COVID -19, we \nestimate operating earnings would have grown mid -single digits in the quarter.   \n \n Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "original_text": "Average diluted shares \noutstanding were $294 million.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "343217b638bf8349590ae383454a51dd01949d18166ebf22ea16d704e6325a7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4663a1f5-23a0-425a-bc28-cd35f827239c", "node_type": "1", "metadata": {"window": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "original_text": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  "}, "hash": "172a42698b8623f9f987c5321b19d2d93d3a85c65ae17f51bce11d3ee92f8d01", "class_name": "RelatedNodeInfo"}}, "text": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "start_char_idx": 1779, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4663a1f5-23a0-425a-bc28-cd35f827239c": {"__data__": {"id_": "4663a1f5-23a0-425a-bc28-cd35f827239c", "embedding": null, "metadata": {"window": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "original_text": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac8557d-2ce7-4ab3-8893-342337dfed35", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other income and expense decreased significantly in the quarter, \ndriven by multiple items, including an increase in the value of our deferred compensation plan \ninvestments, lower interest expense from prior period debt reduction and one-time investment gains.   \n \n As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "original_text": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed4e093d7bd8bd41274a38331297f8447557b95e16ada5a5a0cfa4d9febacef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59e3fa8d-f058-4e23-a2cc-1aba133bced1", "node_type": "1", "metadata": {"window": "Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "original_text": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n"}, "hash": "89615c3bd222323dc91f21a70660d8bf14ddc71ec36a194bc0fd502d1ab83671", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "start_char_idx": 1851, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59e3fa8d-f058-4e23-a2cc-1aba133bced1": {"__data__": {"id_": "59e3fa8d-f058-4e23-a2cc-1aba133bced1", "embedding": null, "metadata": {"window": "Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "original_text": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4663a1f5-23a0-425a-bc28-cd35f827239c", "node_type": "1", "metadata": {"window": "As we previously mentioned, deferred compen sation gains or losses reported in interest and other \nare fully offset in corporate SG&A and net neutral to our bottom line.   Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "original_text": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61fe74d6b719a9f7c2b646edbb3d0e19e2a1b949eef256b9c0a18a8132b73a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79a49e34-7bc5-403c-8950-832f91442e8b", "node_type": "1", "metadata": {"window": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.  ", "original_text": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  "}, "hash": "b81b54f332bfecc0e329044945b5dcb5326b8f51d7b4c4621ed7db87de9917c8", "class_name": "RelatedNodeInfo"}}, "text": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "start_char_idx": 2025, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79a49e34-7bc5-403c-8950-832f91442e8b": {"__data__": {"id_": "79a49e34-7bc5-403c-8950-832f91442e8b", "embedding": null, "metadata": {"window": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.  ", "original_text": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59e3fa8d-f058-4e23-a2cc-1aba133bced1", "node_type": "1", "metadata": {"window": "Average diluted shares \noutstanding were $294 million.   Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "original_text": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93e9569e731b7b5e441858342c9e0407d95078d7d2b2d1962b6dc6e105c477d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba", "node_type": "1", "metadata": {"window": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.  ", "original_text": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n"}, "hash": "59d207f6b370c5ad0eca92211b01cb1873f5cfc3c7e3ceb073dde79cc169c2d2", "class_name": "RelatedNodeInfo"}}, "text": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "start_char_idx": 2264, "end_char_idx": 2420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba": {"__data__": {"id_": "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba", "embedding": null, "metadata": {"window": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.  ", "original_text": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79a49e34-7bc5-403c-8950-832f91442e8b", "node_type": "1", "metadata": {"window": "Of note, during the quarter, we repurchased $200 million of shares.  \n \n Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.  ", "original_text": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7786903c363d8cc85e69c5678687deab656437b957eb6057d56775b827ec6a15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47", "node_type": "1", "metadata": {"window": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "original_text": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n"}, "hash": "c26e96fc39c0781bf89d2edf108a5c7cbf8dcf894eb9ce7c2e2969925f6822ea", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "start_char_idx": 2420, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47": {"__data__": {"id_": "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47", "embedding": null, "metadata": {"window": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "original_text": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba", "node_type": "1", "metadata": {"window": "Third quarter EPS was $1.53, which reflects an effective tax rate of 31.2%, approximately 5.5 \npercentage points above the prior year, due to the timing of discre te items.   This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.  ", "original_text": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e30b81637e79b2afcbb3fcb4d109e74891f713b7b403032bc549242db3ade1ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e15210ed-8502-4920-b869-c26d6a7b0aa2", "node_type": "1", "metadata": {"window": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Now f or the segment results, beginning with Pharma on slide five.  "}, "hash": "cd0f63d2b2c2642004024c1207ecad4356f1d8e2912fecee6e96bc93c6a8efd6", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "start_char_idx": 2521, "end_char_idx": 2643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e15210ed-8502-4920-b869-c26d6a7b0aa2": {"__data__": {"id_": "e15210ed-8502-4920-b869-c26d6a7b0aa2", "embedding": null, "metadata": {"window": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Now f or the segment results, beginning with Pharma on slide five.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47", "node_type": "1", "metadata": {"window": "This includes adjustments \nfor the resolution of all open  issues with the IRS for fiscal yea rs 2008 to 2010 as well as certain \ntransfer pricing matters for fiscal years 2011 to 2014, which also impacted res erves  for later years.   \n \n Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "original_text": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92f0b57bdb38e9c9b12ab28d5c1d6756addf735369cb54b9d33fd55b90178b99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1f1dcbb-9bff-4823-9072-54855381e1c5", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Pharma segment revenue was flat \n$35.1 billion.  "}, "hash": "3812f327500ebed17be622e8ac27efc6b89b7203a1764f57a9a167f335394bdb", "class_name": "RelatedNodeInfo"}}, "text": "Now f or the segment results, beginning with Pharma on slide five.  ", "start_char_idx": 2643, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1f1dcbb-9bff-4823-9072-54855381e1c5": {"__data__": {"id_": "c1f1dcbb-9bff-4823-9072-54855381e1c5", "embedding": null, "metadata": {"window": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Pharma segment revenue was flat \n$35.1 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e15210ed-8502-4920-b869-c26d6a7b0aa2", "node_type": "1", "metadata": {"window": "Turning to cash and the balance sheet, we generated operating cash flow of $277 million, bringing \nour year -to-date op erating cash flow to $1.8 billion.   As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Now f or the segment results, beginning with Pharma on slide five.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b79de231d6c7e6d7ada53c18e2d28dc4cb7935beb339f1abdcd3d40e4c53cbe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64c08634-b82d-4fdc-a41e-6a50e5f1d36c", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  "}, "hash": "a91429ece387fae66a447b84234a78617946f78efeebfdbb0d8cc0aeb3c1dbb4", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment revenue was flat \n$35.1 billion.  ", "start_char_idx": 2711, "end_char_idx": 2760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64c08634-b82d-4fdc-a41e-6a50e5f1d36c": {"__data__": {"id_": "64c08634-b82d-4fdc-a41e-6a50e5f1d36c", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1f1dcbb-9bff-4823-9072-54855381e1c5", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in which the \nquarter ends affects point -in-time cash flows.  \n \n We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Pharma segment revenue was flat \n$35.1 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6b3f9961f358200e8633c679ea837911228106c666e736b4a49aa1a16ffc7b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94348840-d81a-4deb-8c34-bef36b3fe554", "node_type": "1", "metadata": {"window": "Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales "}, "hash": "ad2f7b6174a94b476fdef94a3eedcf937e630dea69d8ea23e79ba83b3f94812d", "class_name": "RelatedNodeInfo"}}, "text": "This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "start_char_idx": 2760, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94348840-d81a-4deb-8c34-bef36b3fe554": {"__data__": {"id_": "94348840-d81a-4deb-8c34-bef36b3fe554", "embedding": null, "metadata": {"window": "Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d121091a7bcdbd1e6ad64aa1895c6f2d1bd434a7e09de20021205f73313f61f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64c08634-b82d-4fdc-a41e-6a50e5f1d36c", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $3.5 billion and no outstanding borrowings under our \ncredit facilities.   \n \n Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d133fe80d8011f96bb506d8e55cf373e8005805aaf0347dbaae7f3d24bddc38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ea61269-732d-4fe4-9816-182772aa4ef0", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "original_text": " \nPage 3 of 14 \n \nmix.  "}, "hash": "7b474c4e5ea36b3db0491655c77b120f91793dc41ae8ddfbde79ee3bdb57ac1c", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "start_char_idx": 2956, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ea61269-732d-4fe4-9816-182772aa4ef0": {"__data__": {"id_": "1ea61269-732d-4fe4-9816-182772aa4ef0", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "original_text": " \nPage 3 of 14 \n \nmix.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94348840-d81a-4deb-8c34-bef36b3fe554", "node_type": "1", "metadata": {"window": "Now f or the segment results, beginning with Pharma on slide five.   Pharma segment revenue was flat \n$35.1 billion.   This reflects sales growth from Pharmaceutical Distribution and Specialty Solutions \ncustomers, compared against the previously mentioned COVID -19-related sales acceleration in the \nprior year.   Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "original_text": "Segment profit decreased 4% to $511 million, primarily due to COVID -19-related volume \ndeclines in our generics program, which was partially offset by a higher contribution for brand sales ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9243df68fcb36a42bb33975fd45d4fc6c4b34e2d7ee168a682579bd80f2bf838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44e0c185-c8e8-4747-8485-c9f18d4759c4", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "original_text": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n"}, "hash": "61303e11e6d175dc17a0867291a3bd05ff40e71fc742ca2bf2101bd36d50d4c4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 14 \n \nmix.  ", "start_char_idx": 0, "end_char_idx": 24, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44e0c185-c8e8-4747-8485-c9f18d4759c4": {"__data__": {"id_": "44e0c185-c8e8-4747-8485-c9f18d4759c4", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "original_text": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea61269-732d-4fe4-9816-182772aa4ef0", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "original_text": " \nPage 3 of 14 \n \nmix.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "529b81cf19f24758c09b2a2c5433f6d9cf3914f5369119939c3e981ea1fa11b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e773678a-c457-4fdb-9a9d-b03073e411a3", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.  ", "original_text": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.  "}, "hash": "d30a364616d5fccd66de3a7d8a7ee79ea0c26b4e699b0847e9c0b26569a71650", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n", "start_char_idx": 24, "end_char_idx": 136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e773678a-c457-4fdb-9a9d-b03073e411a3": {"__data__": {"id_": "e773678a-c457-4fdb-9a9d-b03073e411a3", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.  ", "original_text": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44e0c185-c8e8-4747-8485-c9f18d4759c4", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "original_text": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9451fc5083a62e2f227b8600757691e1ac64a4e5b56a6fe08824dc35ab815b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebbec759-af7d-4521-b9be-02b41c944cda", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "original_text": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  "}, "hash": "6e5dcdb888bfd74df21ccf3703e461d13ee13f918f87ea08b6a378fe5c5b093c", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.  ", "start_char_idx": 136, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebbec759-af7d-4521-b9be-02b41c944cda": {"__data__": {"id_": "ebbec759-af7d-4521-b9be-02b41c944cda", "embedding": null, "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "original_text": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e773678a-c457-4fdb-9a9d-b03073e411a3", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.  ", "original_text": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c68fcb5af63a3e42ccdddd6ddbb17f755de75b31282116d6005b37df031c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e10e9cb-5835-4c94-bc8b-c1c041872d1e", "node_type": "1", "metadata": {"window": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "original_text": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n"}, "hash": "a6ec3981af3eadd79647e6379cccb15d7859d41c7cf37a1ea679c27788844f7d", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "start_char_idx": 283, "end_char_idx": 408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e10e9cb-5835-4c94-bc8b-c1c041872d1e": {"__data__": {"id_": "5e10e9cb-5835-4c94-bc8b-c1c041872d1e", "embedding": null, "metadata": {"window": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "original_text": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebbec759-af7d-4521-b9be-02b41c944cda", "node_type": "1", "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "original_text": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f809681991936e333313f7909f25d00bb9bbec81594e22d0312c9ee34f236b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d", "node_type": "1", "metadata": {"window": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.  ", "original_text": "Now, transitioning to Medical on slide six.  "}, "hash": "e535cd803cdb86c78664c3e880ef5c6cdc785ed7a958af605827dc72b2b60759", "class_name": "RelatedNodeInfo"}}, "text": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "start_char_idx": 408, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d": {"__data__": {"id_": "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d", "embedding": null, "metadata": {"window": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.  ", "original_text": "Now, transitioning to Medical on slide six.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e10e9cb-5835-4c94-bc8b-c1c041872d1e", "node_type": "1", "metadata": {"window": "Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "original_text": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe8bb9e1a7525c55a7a7bc84dc746985ece08ace3816e34a3dfe047cb3f190b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93e1967a-b5b8-44d7-ba15-e90ee09eb529", "node_type": "1", "metadata": {"window": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "original_text": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  "}, "hash": "ac6952630a1e85a04c5f8a6505ce94d571115a53c38c9bb7a134d58c76042612", "class_name": "RelatedNodeInfo"}}, "text": "Now, transitioning to Medical on slide six.  ", "start_char_idx": 528, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93e1967a-b5b8-44d7-ba15-e90ee09eb529": {"__data__": {"id_": "93e1967a-b5b8-44d7-ba15-e90ee09eb529", "embedding": null, "metadata": {"window": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "original_text": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d", "node_type": "1", "metadata": {"window": "Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.  ", "original_text": "Now, transitioning to Medical on slide six.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88c051213dbe742ef1de7202577a738cbf29a9bfe1687696c8941bd860551637", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22e10ace-2871-4bb0-9233-9aa7cb24b455", "node_type": "1", "metadata": {"window": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "original_text": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  "}, "hash": "5cb05c3d5d2a887207f8186c574e6ce53cf598bcf0e2c1b5c01010ab7b6a7417", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "start_char_idx": 573, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22e10ace-2871-4bb0-9233-9aa7cb24b455": {"__data__": {"id_": "22e10ace-2871-4bb0-9233-9aa7cb24b455", "embedding": null, "metadata": {"window": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "original_text": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93e1967a-b5b8-44d7-ba15-e90ee09eb529", "node_type": "1", "metadata": {"window": "In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.   And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "original_text": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1365836820f542b691b908ccd18afade2af1d2ab3c17ffcc1643a0f4b58c833d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0251ac7-cef8-4b12-ad30-634bde10f084", "node_type": "1", "metadata": {"window": "Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "original_text": "Segment profit decreased 2% to $174 million.  "}, "hash": "ec29f7dc282c97ea3d6a4f9d51f975dfde86a8654e90acfdcf9919d605e3bc98", "class_name": "RelatedNodeInfo"}}, "text": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "start_char_idx": 717, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0251ac7-cef8-4b12-ad30-634bde10f084": {"__data__": {"id_": "d0251ac7-cef8-4b12-ad30-634bde10f084", "embedding": null, "metadata": {"window": "Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "original_text": "Segment profit decreased 2% to $174 million.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22e10ace-2871-4bb0-9233-9aa7cb24b455", "node_type": "1", "metadata": {"window": "And the pharma team \nremains focused on diligent expense management, delivering strong cost savings in the quarter.  \n \n Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "original_text": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a205d7eef1daa78385f7480ef8aebad321d75b2319d5f4f998d9c87b70d1f35c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b25cf9a-3537-460a-afd9-e6e0de6422f8", "node_type": "1", "metadata": {"window": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "original_text": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n"}, "hash": "03d55b60c5c577c540fdac8ee4c238ebb0ecd02080ef7ea1faf6a360dabc3d2e", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 2% to $174 million.  ", "start_char_idx": 937, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b25cf9a-3537-460a-afd9-e6e0de6422f8": {"__data__": {"id_": "5b25cf9a-3537-460a-afd9-e6e0de6422f8", "embedding": null, "metadata": {"window": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "original_text": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0251ac7-cef8-4b12-ad30-634bde10f084", "node_type": "1", "metadata": {"window": "Now, transitioning to Medical on slide six.   Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "original_text": "Segment profit decreased 2% to $174 million.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c4faa017c1fd971b607d8c6517dfd1429d299a938ed1ddfaeb1007b082ee4f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71bfec4e-723e-428a-93cb-78364dd38a78", "node_type": "1", "metadata": {"window": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "original_text": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n"}, "hash": "8fb7b7e267033389403fae467cafb62b64bcffd4f3249b9cd62970f6e9df894d", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "start_char_idx": 983, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71bfec4e-723e-428a-93cb-78364dd38a78": {"__data__": {"id_": "71bfec4e-723e-428a-93cb-78364dd38a78", "embedding": null, "metadata": {"window": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "original_text": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b25cf9a-3537-460a-afd9-e6e0de6422f8", "node_type": "1", "metadata": {"window": "Medical segment revenue increased 3% to $4.2 billion, \ndriven primarily by a net pos itive impact from COVID -19 on products and distribution.   As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "original_text": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "034a9865a687a3ee3b3ddd27198b89eb7e171de1a8e94d454ab0db1c1cc8fce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44690154-b479-4035-b422-2109bc827d4b", "node_type": "1", "metadata": {"window": "Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "original_text": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  "}, "hash": "b017893c1ff40b37a4c66a002872d0022f6554df0b3f44f739d167d2d18733e2", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "start_char_idx": 1122, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44690154-b479-4035-b422-2109bc827d4b": {"__data__": {"id_": "44690154-b479-4035-b422-2109bc827d4b", "embedding": null, "metadata": {"window": "Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "original_text": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71bfec4e-723e-428a-93cb-78364dd38a78", "node_type": "1", "metadata": {"window": "As in prior \nquarters, we saw higher selling prices and volumes in PPE as well as higher volumes in our lab \nbusiness, partially offset by lower demand for surgical products resulting from reduced elective \nprocedures.   Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "original_text": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db2416da77d73389ecac13d5e204c243e592fc238219d7c6936db34dbcc60707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de447f9f-0989-4229-b785-781ac18c4395", "node_type": "1", "metadata": {"window": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.  ", "original_text": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  "}, "hash": "e8afcf8de34b82d793c5e130a3cc2ad47f89dbf7337d07b390b0da6f27a64609", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "start_char_idx": 1281, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de447f9f-0989-4229-b785-781ac18c4395": {"__data__": {"id_": "de447f9f-0989-4229-b785-781ac18c4395", "embedding": null, "metadata": {"window": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.  ", "original_text": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44690154-b479-4035-b422-2109bc827d4b", "node_type": "1", "metadata": {"window": "Segment profit decreased 2% to $174 million.   During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "original_text": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0405137d631a5512609adbbbf70de22af3a23fb20ebf2c26f769d70f94ca43e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1882b37-a83a-4613-9f0f-de402e6c09b8", "node_type": "1", "metadata": {"window": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "original_text": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  "}, "hash": "a3b6355516d6b3446c8b20799d56a47263a036b800f25a180d7dea93e2bb0106", "class_name": "RelatedNodeInfo"}}, "text": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "start_char_idx": 1406, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1882b37-a83a-4613-9f0f-de402e6c09b8": {"__data__": {"id_": "b1882b37-a83a-4613-9f0f-de402e6c09b8", "embedding": null, "metadata": {"window": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "original_text": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de447f9f-0989-4229-b785-781ac18c4395", "node_type": "1", "metadata": {"window": "During the quarter, cost savings , \nincluding global manufacturing efficienci es, were offset by a decline in products and distribution.  \n Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.  ", "original_text": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "776db9af69e6ecf99086c68b23b4dfa04b2933b17fe38fe6c5bcc60bfd308a0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d4cf190-65b5-4636-9962-9357c7b15855", "node_type": "1", "metadata": {"window": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "original_text": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n"}, "hash": "37155000a8bc5a84e71c35dc2d19d108ab38576b2f43b083661dae593cbca09a", "class_name": "RelatedNodeInfo"}}, "text": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "start_char_idx": 1594, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d4cf190-65b5-4636-9962-9357c7b15855": {"__data__": {"id_": "7d4cf190-65b5-4636-9962-9357c7b15855", "embedding": null, "metadata": {"window": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "original_text": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1882b37-a83a-4613-9f0f-de402e6c09b8", "node_type": "1", "metadata": {"window": "Additionally, segment profit experienced a slight net negative impact due to COVID -19, driven by the \nsell-through of PPE safety stock in the prior year.  \n \n Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "original_text": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d08f9bfa15ea9d46e31af9ecde150f72c9dc3cefe6c4d34e4e282ae913142897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca34b06-46fe-4f1c-899a-27f828c6857a", "node_type": "1", "metadata": {"window": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "original_text": "Regarding PPE, we continue to see elevated volumes.  "}, "hash": "985a002c31c4b40f67bb1d6ce21a07015b97c3fdc2fa0c7cba05bb193b6fbf8f", "class_name": "RelatedNodeInfo"}}, "text": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "start_char_idx": 1798, "end_char_idx": 1978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca34b06-46fe-4f1c-899a-27f828c6857a": {"__data__": {"id_": "8ca34b06-46fe-4f1c-899a-27f828c6857a", "embedding": null, "metadata": {"window": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "original_text": "Regarding PPE, we continue to see elevated volumes.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d4cf190-65b5-4636-9962-9357c7b15855", "node_type": "1", "metadata": {"window": "Now, let me step back to help frame our per formance sequentially within the context of the \npreviously -discussed factors.   During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "original_text": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55291dfc29b959889a5394322e1e4e81c520e8b82d2daa5451c796a44e7018df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "838cdfd2-af73-41eb-9298-2d0c4d5d23b6", "node_type": "1", "metadata": {"window": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "original_text": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  "}, "hash": "debe0330a880af11114b9e6af75baaf4daf2b5c917bb0436742c5ff68105faf2", "class_name": "RelatedNodeInfo"}}, "text": "Regarding PPE, we continue to see elevated volumes.  ", "start_char_idx": 1978, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "838cdfd2-af73-41eb-9298-2d0c4d5d23b6": {"__data__": {"id_": "838cdfd2-af73-41eb-9298-2d0c4d5d23b6", "embedding": null, "metadata": {"window": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "original_text": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca34b06-46fe-4f1c-899a-27f828c6857a", "node_type": "1", "metadata": {"window": "During the third quarter, demand for surgical products used in elective \nprocedures averaged approximately 90% of pre -COVID -19 levels compared to the 95% average in \nthe prior quarter.   We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "original_text": "Regarding PPE, we continue to see elevated volumes.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b41b2f90ea7c99689d606a5087486f4f0c3f706f6f9ec2cc62c8bcaa12f1aaaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9", "node_type": "1", "metadata": {"window": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n", "original_text": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n"}, "hash": "891cc068155098948e599e1737754324af502056811a523dd7bdca62ce58e2c3", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "start_char_idx": 2031, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9": {"__data__": {"id_": "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9", "embedding": null, "metadata": {"window": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n", "original_text": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "838cdfd2-af73-41eb-9298-2d0c4d5d23b6", "node_type": "1", "metadata": {"window": "We saw choppiness especially early in the quarter, consistent with the evolution of \nthe virus in various geographies, but as we exited the third quarter, elective volumes rebounded back \nto around 95%.   Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "original_text": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31e4226ff1e20893e2c917df1d6e3a412ff5c701479e1ada5ae65309ef1415bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fd32894-812b-4a08-b285-f20f7dd7f5c1", "node_type": "1", "metadata": {"window": "Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "original_text": "Next, on slide eight, I will review updates to our fiscal '21 outlook.  "}, "hash": "184b4c86ce152f0df6c0685fe0a70242ed4aebd71e26413540f6789e37b1fc65", "class_name": "RelatedNodeInfo"}}, "text": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "start_char_idx": 2164, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fd32894-812b-4a08-b285-f20f7dd7f5c1": {"__data__": {"id_": "0fd32894-812b-4a08-b285-f20f7dd7f5c1", "embedding": null, "metadata": {"window": "Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "original_text": "Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9", "node_type": "1", "metadata": {"window": "Our lab business continued to experience the tailwind from increased demand for \nCOVID -19 testing products, though as expected, not quite at the peak level seen last quarter.  \n \n Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n", "original_text": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21674f70dccf86ee6cc27640c10e31c38b29269934429bd391a3e9e8f99de840", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f7a0bd-bf26-4d5d-ad38-efca53aae941", "node_type": "1", "metadata": {"window": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "original_text": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  "}, "hash": "2f593f1d2a417806a29a4d9ad5bfad818d21518147ef5afcbe8612c2d9a2394a", "class_name": "RelatedNodeInfo"}}, "text": "Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "start_char_idx": 2414, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f7a0bd-bf26-4d5d-ad38-efca53aae941": {"__data__": {"id_": "65f7a0bd-bf26-4d5d-ad38-efca53aae941", "embedding": null, "metadata": {"window": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "original_text": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fd32894-812b-4a08-b285-f20f7dd7f5c1", "node_type": "1", "metadata": {"window": "Regarding PPE, we continue to see elevated volumes.   In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "original_text": "Next, on slide eight, I will review updates to our fiscal '21 outlook.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "210404eedf813bbacf8331f1ffe11388eb3d712ef11fbbe1f8dbc01d9d09d74e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e603a2-3733-4cd7-922d-ededb7583d37", "node_type": "1", "metadata": {"window": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "original_text": "We are making the following \nchanges to our corporate assumptions.   \n \n"}, "hash": "7c95ebd48dd9bcccabb53d38f6eb6bbf20a9725be05450fd1222615ac7b4bb67", "class_name": "RelatedNodeInfo"}}, "text": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "start_char_idx": 2486, "end_char_idx": 2699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e603a2-3733-4cd7-922d-ededb7583d37": {"__data__": {"id_": "e5e603a2-3733-4cd7-922d-ededb7583d37", "embedding": null, "metadata": {"window": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "original_text": "We are making the following \nchanges to our corporate assumptions.   \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f7a0bd-bf26-4d5d-ad38-efca53aae941", "node_type": "1", "metadata": {"window": "In the quarter, we were successful in \nmanaging the significant cost increases that  we've incurred to procure select PPE products.   As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "original_text": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d774a4e3ad82aaf1b25de17c132cd5bd9bb0220444b907643f5eeebbe051840", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6de7dd80-0b69-452b-bc3e-5dbd597f8152", "node_type": "1", "metadata": {"window": "Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "original_text": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  "}, "hash": "bad86e27333ead72c492cf13d3193b161aa9397d8a8d518f5491768981df8464", "class_name": "RelatedNodeInfo"}}, "text": "We are making the following \nchanges to our corporate assumptions.   \n \n", "start_char_idx": 2699, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6de7dd80-0b69-452b-bc3e-5dbd597f8152": {"__data__": {"id_": "6de7dd80-0b69-452b-bc3e-5dbd597f8152", "embedding": null, "metadata": {"window": "Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "original_text": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e603a2-3733-4cd7-922d-ededb7583d37", "node_type": "1", "metadata": {"window": "As we \npreviously mentioned, many of our customers have chosen to leverage our supply assurance \nprogram to manage market uncertainties, and we continue to expect timing variability as we support \nour customers  through this dynamic environment.  \n \n Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "original_text": "We are making the following \nchanges to our corporate assumptions.   \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b131b488c79261e58fa5db861ef4822d56cf4b9fac1aa0ee334338175da352a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f45cbfe-1512-42e8-af70-f4a785491a90", "node_type": "1", "metadata": {"window": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.  ", "original_text": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n"}, "hash": "22a4e26bb6a72cdeb605916bd230df7bdd3ab653898f248b24679d1cf43a3f82", "class_name": "RelatedNodeInfo"}}, "text": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "start_char_idx": 2771, "end_char_idx": 2968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f45cbfe-1512-42e8-af70-f4a785491a90": {"__data__": {"id_": "4f45cbfe-1512-42e8-af70-f4a785491a90", "embedding": null, "metadata": {"window": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.  ", "original_text": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6de7dd80-0b69-452b-bc3e-5dbd597f8152", "node_type": "1", "metadata": {"window": "Next, on slide eight, I will review updates to our fiscal '21 outlook.   Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "original_text": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89a580eaf3959d0e64e7d41f2ad4121fd755bafb426dc885f0be37332f1eac7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41a77174-c675-42a5-ba6e-71e9b5f41dcb", "node_type": "1", "metadata": {"window": "We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "original_text": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  "}, "hash": "0a92b3bd8f4cc870f9dcfa3baabd27b0838522f9b67e46a10684b4c2560defd9", "class_name": "RelatedNodeInfo"}}, "text": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "start_char_idx": 2968, "end_char_idx": 3081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41a77174-c675-42a5-ba6e-71e9b5f41dcb": {"__data__": {"id_": "41a77174-c675-42a5-ba6e-71e9b5f41dcb", "embedding": null, "metadata": {"window": "We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "original_text": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f45cbfe-1512-42e8-af70-f4a785491a90", "node_type": "1", "metadata": {"window": "Based on our performance to date \nand increase d visibility for the balance of the fiscal year, we are narrowing our EPS guidance to $5.90 \nto $6.05, wh ich continues to reflect 10% EPS growth at the mid -point.   We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.  ", "original_text": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "023b83f50f5f9da1ebfd74d91a729b8dfa1a76a1c23217bc4240f9e2e36218c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ff5dc63-26c7-41f7-a908-42796b8daef6", "node_type": "1", "metadata": {"window": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n"}, "hash": "efd8c4f3ff7f872263a6f83e65cc87a313290204da42f273f34220d74934f1ba", "class_name": "RelatedNodeInfo"}}, "text": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "start_char_idx": 3081, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff5dc63-26c7-41f7-a908-42796b8daef6": {"__data__": {"id_": "4ff5dc63-26c7-41f7-a908-42796b8daef6", "embedding": null, "metadata": {"window": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41a77174-c675-42a5-ba6e-71e9b5f41dcb", "node_type": "1", "metadata": {"window": "We are making the following \nchanges to our corporate assumptions.   \n \n We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "original_text": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d26e9756ac07f197140f5eb8c6fe5092c5fcc8c6920ab833cac5deb6e27db4ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe", "node_type": "1", "metadata": {"window": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Moving to the segment outlook on slide nine.  "}, "hash": "0a653ccc4e957d18272a3982b07a010ead9065c43960d0e20d7ed30f4712eb00", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "start_char_idx": 3236, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe": {"__data__": {"id_": "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe", "embedding": null, "metadata": {"window": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Moving to the segment outlook on slide nine.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ff5dc63-26c7-41f7-a908-42796b8daef6", "node_type": "1", "metadata": {"window": "We now expect interest and other in the range of $145 million to $160 million, driven primarily by the \ndeferred compensation fav orability to date, which as a reminder, is offset above the line.   We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cb7821d72608d996bb83c0045dda4bf9b7a197ef4b2bbca10d8e6669cee2e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f5b7cdf-3055-4d8a-ad21-1865fb64131b", "node_type": "1", "metadata": {"window": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  "}, "hash": "7664a93dd7f1aede370f6f3ebadd0e461b34466346145a3a01b67fb7a6a2cdab", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the segment outlook on slide nine.  ", "start_char_idx": 3339, "end_char_idx": 3385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f5b7cdf-3055-4d8a-ad21-1865fb64131b": {"__data__": {"id_": "9f5b7cdf-3055-4d8a-ad21-1865fb64131b", "embedding": null, "metadata": {"window": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe", "node_type": "1", "metadata": {"window": "We are \nnarrowing our effective tax rate to 23.5% to 25%, reflecting the previously mentioned IRS resolutions.  \n We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Moving to the segment outlook on slide nine.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662021bd4e872ef591a0155f459c9515db6713068baaf6031733b4d33a1a4913", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33fff532-487b-4496-8bf4-e8c71f47eee8", "node_type": "1", "metadata": {"window": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Based on our third quarter "}, "hash": "727857ddfd206c43fd7946f55c45d2d36358ac9435f9443a9f8408df1f048848", "class_name": "RelatedNodeInfo"}}, "text": "We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "start_char_idx": 3385, "end_char_idx": 3515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33fff532-487b-4496-8bf4-e8c71f47eee8": {"__data__": {"id_": "33fff532-487b-4496-8bf4-e8c71f47eee8", "embedding": null, "metadata": {"window": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Based on our third quarter ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6140e6a8362b3cc8502fae8df92e28752749a1a5a42051d679d842d775a9013", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f5b7cdf-3055-4d8a-ad21-1865fb64131b", "node_type": "1", "metadata": {"window": "We expect diluted weighted average shares outstanding of approximately 294 mil lion shares, which \nincludes the repurchases completed during the quarter.   Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1d4a43ea88ba6e41877397e0e6affa4b587390499d297f3297f6493c9d9d4e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05baa260-0d9f-4b66-8f22-a925c2442af3", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "original_text": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n"}, "hash": "c5167db3495ff71a3ebcf2a0bc6378afa911de4aeb80ce5945e03bd90230a906", "class_name": "RelatedNodeInfo"}}, "text": "Based on our third quarter ", "start_char_idx": 3515, "end_char_idx": 3542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05baa260-0d9f-4b66-8f22-a925c2442af3": {"__data__": {"id_": "05baa260-0d9f-4b66-8f22-a925c2442af3", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "original_text": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33fff532-487b-4496-8bf4-e8c71f47eee8", "node_type": "1", "metadata": {"window": "Additionally, capital expenditures are now \nexpected in the range of $400 million to $430 million.  \n \n Moving to the segment outlook on slide nine.   We are updating our Pharma segment p rofit outlook to \nflat to down low single digits due to updated expectations for COVID -19.   Based on our third quarter ", "original_text": "Based on our third quarter ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97e7fbeb23d3cf4663b1a7c4e485114426a5a769e7bb7c0b62fad38c337602f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "459334b1-bf15-4dda-ae1a-60178b47c32f", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.  ", "original_text": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n"}, "hash": "dc2541dcfd5ca74c1f697e6f4ed11665af84f5edb49cbd84470225dd18d43853", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n", "start_char_idx": 0, "end_char_idx": 304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "459334b1-bf15-4dda-ae1a-60178b47c32f": {"__data__": {"id_": "459334b1-bf15-4dda-ae1a-60178b47c32f", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.  ", "original_text": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05baa260-0d9f-4b66-8f22-a925c2442af3", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "original_text": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1680c4cc3034f99bf5cd5010796b2950488714cbadf3a700b148bd909dd60777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "original_text": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n"}, "hash": "9032d591378c0d4b1310541ec8235a72cd96d5670d0ba4a9423c3570f93a9bc3", "class_name": "RelatedNodeInfo"}}, "text": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n", "start_char_idx": 304, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f": {"__data__": {"id_": "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "original_text": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "459334b1-bf15-4dda-ae1a-60178b47c32f", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.  ", "original_text": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5d3a94d3cc0fc416018399205184c51e19b75fff84f161c6640a2dfcb917c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76aa1ac1-bfe9-4d52-93b2-ad54fc307953", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "original_text": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n"}, "hash": "59fda592c41f5ffbfbaa94f3d172f5487c95dec723b201cb73b6f83ccd04d694", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n", "start_char_idx": 535, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76aa1ac1-bfe9-4d52-93b2-ad54fc307953": {"__data__": {"id_": "76aa1ac1-bfe9-4d52-93b2-ad54fc307953", "embedding": null, "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "original_text": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "original_text": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23755ecf9136b5f1b2086aea40cf92a2c76544d4b518d365aa4ad9ca4d9dceee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0d8dd74-2054-40e1-8eb8-0ea7cd872292", "node_type": "1", "metadata": {"window": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "original_text": "Before I conclude, let me take a moment to provide an update on capital allocation.  "}, "hash": "3559017f08c502b6790688e3e620b493c948f631bc3e0784b1146e98a631b160", "class_name": "RelatedNodeInfo"}}, "text": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "start_char_idx": 637, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0d8dd74-2054-40e1-8eb8-0ea7cd872292": {"__data__": {"id_": "a0d8dd74-2054-40e1-8eb8-0ea7cd872292", "embedding": null, "metadata": {"window": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "original_text": "Before I conclude, let me take a moment to provide an update on capital allocation.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76aa1ac1-bfe9-4d52-93b2-ad54fc307953", "node_type": "1", "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "original_text": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d016dbe20a1c42a20383f7e847b9ff1589a7b025455cc3c01dc6f999b85933d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3eeb89f-0c30-48a8-8780-4f9b9ff49355", "node_type": "1", "metadata": {"window": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "original_text": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  "}, "hash": "2f5889c1728f4713aead6515115cdf8d0a536d5d076b018a588275b2e439d4ec", "class_name": "RelatedNodeInfo"}}, "text": "Before I conclude, let me take a moment to provide an update on capital allocation.  ", "start_char_idx": 783, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3eeb89f-0c30-48a8-8780-4f9b9ff49355": {"__data__": {"id_": "b3eeb89f-0c30-48a8-8780-4f9b9ff49355", "embedding": null, "metadata": {"window": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "original_text": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0d8dd74-2054-40e1-8eb8-0ea7cd872292", "node_type": "1", "metadata": {"window": "As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "original_text": "Before I conclude, let me take a moment to provide an update on capital allocation.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5886ebf9cac6613553eb135ad66621c27e7813b7f3e70ef6b85e814eb0941ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9", "node_type": "1", "metadata": {"window": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "original_text": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  "}, "hash": "746f925cc359c6849c310f90424b7a1cc6fdaab1cf13a28952462e0e17eb4240", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "start_char_idx": 868, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9": {"__data__": {"id_": "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9", "embedding": null, "metadata": {"window": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "original_text": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3eeb89f-0c30-48a8-8780-4f9b9ff49355", "node_type": "1", "metadata": {"window": "With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "original_text": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f26dcec84377a1882ad4f516ba781143d52d7a81b94e45c695a75ee2984653fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620", "node_type": "1", "metadata": {"window": "Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "original_text": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  "}, "hash": "87d617505fa13d9dcf06efa2346feeb43b36a21b0807bec65525e0bf57f14feb", "class_name": "RelatedNodeInfo"}}, "text": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "start_char_idx": 1043, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620": {"__data__": {"id_": "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620", "embedding": null, "metadata": {"window": "Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "original_text": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9", "node_type": "1", "metadata": {"window": "This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "original_text": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd3ab0e893079919f4bf8c5b0e3bb843062626bafbccaedb526b2f29aeb9eb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3", "node_type": "1", "metadata": {"window": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "original_text": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n"}, "hash": "51b63d231ef85eb3edebc80f6c81c9cadcb2f92ebb29da5c8df899926089b249", "class_name": "RelatedNodeInfo"}}, "text": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "start_char_idx": 1123, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3": {"__data__": {"id_": "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3", "embedding": null, "metadata": {"window": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "original_text": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620", "node_type": "1", "metadata": {"window": "Before I conclude, let me take a moment to provide an update on capital allocation.   We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "original_text": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96d7b0892ea6080e28d408d9e0fcf9bb58bfa6f31c4ffb1b3e17ba5bbb28a9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc0f3ed6-52c8-4996-88e7-97ee099c9505", "node_type": "1", "metadata": {"window": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "original_text": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  "}, "hash": "d5308b320fd62210c5a3e4cc3594d427e556fb6573aef4c42d15c340c05e4fe4", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "start_char_idx": 1298, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc0f3ed6-52c8-4996-88e7-97ee099c9505": {"__data__": {"id_": "bc0f3ed6-52c8-4996-88e7-97ee099c9505", "embedding": null, "metadata": {"window": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "original_text": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3", "node_type": "1", "metadata": {"window": "We continue to \nmanage our portfolio and the balance sheet in a prudent manner consistent with our priorities while at \nthe same time driving improved financial flexibility.   We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "original_text": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01f79ba39d0ec343be357fde26993a92fb4692c76ea4e4e83edc966633a98e9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262e2047-5ba8-4bc6-96ea-02a342036f26", "node_type": "1", "metadata": {"window": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "original_text": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n"}, "hash": "d3ddff7c01f857b601866b63d7f08f8dab8411631efb8101da2ff67c17b6328f", "class_name": "RelatedNodeInfo"}}, "text": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "start_char_idx": 1510, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262e2047-5ba8-4bc6-96ea-02a342036f26": {"__data__": {"id_": "262e2047-5ba8-4bc6-96ea-02a342036f26", "embedding": null, "metadata": {"window": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "original_text": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc0f3ed6-52c8-4996-88e7-97ee099c9505", "node_type": "1", "metadata": {"window": "We expect the sale of Cordis to close in the first \nquarter of our fiscal '22.   This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "original_text": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "925d11746c711618f9938611ed2c0c12df7662b689f479f6d352cee737ff8b15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5e3ed92-5db8-4f47-9202-652722cd863e", "node_type": "1", "metadata": {"window": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "original_text": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  "}, "hash": "7dcac5a78d7189d77c4a6bf089791cc689fe908dd498ae25f6730d8a49507f34", "class_name": "RelatedNodeInfo"}}, "text": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "start_char_idx": 1690, "end_char_idx": 1817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5e3ed92-5db8-4f47-9202-652722cd863e": {"__data__": {"id_": "b5e3ed92-5db8-4f47-9202-652722cd863e", "embedding": null, "metadata": {"window": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "original_text": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262e2047-5ba8-4bc6-96ea-02a342036f26", "node_type": "1", "metadata": {"window": "This transaction, along with the previously announced tax receivable, is \nexpected to generate nearly $2 billion of incremental proceeds in the first half of our fiscal '22.   We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "original_text": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4ebffca59969450999561520c717d5521baf3ccc2a5f72fe436876827324e3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "153e5912-87bb-4afd-b8b9-38416f2dbc0e", "node_type": "1", "metadata": {"window": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "original_text": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  "}, "hash": "39eb1cbc183bb70159e74cfde90517fdb50945bca14fe0a1133ba30be88ccfb7", "class_name": "RelatedNodeInfo"}}, "text": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "start_char_idx": 1817, "end_char_idx": 1940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "153e5912-87bb-4afd-b8b9-38416f2dbc0e": {"__data__": {"id_": "153e5912-87bb-4afd-b8b9-38416f2dbc0e", "embedding": null, "metadata": {"window": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "original_text": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5e3ed92-5db8-4f47-9202-652722cd863e", "node_type": "1", "metadata": {"window": "We \nexpect to utilize these proceeds in a manner consistent with our stated capital allocation priorities : \ninvesting in the business, maintaining a strong balance sh eet and returning cash to shareholders.  \n \n With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "original_text": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f009ed58d66b0203137395fca782e49ed10d062ca175301a99acae3d9b178dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acd95833-236c-48fd-bc2f-d85ac86ae9f4", "node_type": "1", "metadata": {"window": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "original_text": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n"}, "hash": "4f8053b67f1fa8746f2c07d9ef246e000bdd1361fcd1d68d1e02fe48200a7e69", "class_name": "RelatedNodeInfo"}}, "text": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "start_char_idx": 1940, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acd95833-236c-48fd-bc2f-d85ac86ae9f4": {"__data__": {"id_": "acd95833-236c-48fd-bc2f-d85ac86ae9f4", "embedding": null, "metadata": {"window": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "original_text": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "153e5912-87bb-4afd-b8b9-38416f2dbc0e", "node_type": "1", "metadata": {"window": "With respect to our first priority, investing in the business to enable our strong pipeline of organic \ngrowth opportunities, we continue to be excited by the projects in flight.   We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "original_text": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24031e2dfc6b82dd181b1d4420a68cd5affc399568d8dcc649b88972b3e73b9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da63a396-a4b5-4da5-862c-e9738beba8cd", "node_type": "1", "metadata": {"window": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "original_text": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  "}, "hash": "dd07ea4099b6c1c532796eb0502945b2d5c934b7184b7b09930bb6f62282215b", "class_name": "RelatedNodeInfo"}}, "text": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "start_char_idx": 2057, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da63a396-a4b5-4da5-862c-e9738beba8cd": {"__data__": {"id_": "da63a396-a4b5-4da5-862c-e9738beba8cd", "embedding": null, "metadata": {"window": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "original_text": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acd95833-236c-48fd-bc2f-d85ac86ae9f4", "node_type": "1", "metadata": {"window": "We expect this to remain our \nhighest  focus for capital deployment and to continue to prioritize investment in these areas.  \n Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "original_text": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "158e4a550059a57dffcba89177f4e9430182bb56937b8ca790ab9ef7c05b5afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a13a1d4-325f-47e0-8ac7-634f6349caab", "node_type": "1", "metadata": {"window": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n", "original_text": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  "}, "hash": "a6a02c299875fa2c2615d18bf5dd1e6733ded7c0ec5dfeef61f3db4938e85baa", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "start_char_idx": 2230, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a13a1d4-325f-47e0-8ac7-634f6349caab": {"__data__": {"id_": "6a13a1d4-325f-47e0-8ac7-634f6349caab", "embedding": null, "metadata": {"window": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n", "original_text": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da63a396-a4b5-4da5-862c-e9738beba8cd", "node_type": "1", "metadata": {"window": "Regarding the balance sheet, as previously communicated, we expect to repay $1.4 billion of debt on \nor before June 2022.   Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "original_text": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "664313efa2791c741b92b57b2e3f6153ae72e9789f73ccf7a2deb8cdeb9d77cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6570468b-1fe1-43f2-9a1a-65d046e123cb", "node_type": "1", "metadata": {"window": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  "}, "hash": "59f7ce8f558f087775c979f58ecbcafafc5d5fca5b327a499ca33e662acbb470", "class_name": "RelatedNodeInfo"}}, "text": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "start_char_idx": 2357, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6570468b-1fe1-43f2-9a1a-65d046e123cb": {"__data__": {"id_": "6570468b-1fe1-43f2-9a1a-65d046e123cb", "embedding": null, "metadata": {"window": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a13a1d4-325f-47e0-8ac7-634f6349caab", "node_type": "1", "metadata": {"window": "Combined with prior repayments, this would rep resent a total debt reduction of \nnearly $5 billion over five years.   While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n", "original_text": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a793eb13a6a58330a7b0653f55e48c23a3c9007b50c9d7a0b76cf6670938f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63b7165-4b10-4729-885f-ac9830b070d4", "node_type": "1", "metadata": {"window": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "original_text": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  "}, "hash": "d50c9042cbb85700cff13a4603e8de11ae9d79d331a3414246244bae540680c0", "class_name": "RelatedNodeInfo"}}, "text": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "start_char_idx": 2445, "end_char_idx": 2598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63b7165-4b10-4729-885f-ac9830b070d4": {"__data__": {"id_": "f63b7165-4b10-4729-885f-ac9830b070d4", "embedding": null, "metadata": {"window": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "original_text": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6570468b-1fe1-43f2-9a1a-65d046e123cb", "node_type": "1", "metadata": {"window": "While we will continue to evaluate additional opportunities to reduce \ndebt, we anticipate our future repayments will be more modest as we approach our leverage target.  \n \n At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  ", "original_text": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2b5f71676f3539b9ef81a8930d41ba78754efc9cf777c029d0e6d644d64d50c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d02a1c-3913-4569-bb38-ba79482217bc", "node_type": "1", "metadata": {"window": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "original_text": "With that, \nI'll turn it back ove r to Mike.  \n \n"}, "hash": "548cdb072101df35059580298096a77c58b423ca5cbda9cb35a61abaec8f97e7", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "start_char_idx": 2598, "end_char_idx": 2734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d02a1c-3913-4569-bb38-ba79482217bc": {"__data__": {"id_": "38d02a1c-3913-4569-bb38-ba79482217bc", "embedding": null, "metadata": {"window": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "original_text": "With that, \nI'll turn it back ove r to Mike.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63b7165-4b10-4729-885f-ac9830b070d4", "node_type": "1", "metadata": {"window": "At the same time, we are committed to our dividend, which remains an important component of our \ncapital allocation strategy.   With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "original_text": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ab56b54591f567b1994297d322121245628fb7eae7d361a9f804bd2ce5dadc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e1e5ca-11ee-4686-9411-0951f3e11071", "node_type": "1", "metadata": {"window": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.  ", "original_text": "Mike Kaufmann:  Thanks, Jason.  "}, "hash": "39f4fcd1bb918014004d9faf9e79dcd5ef62b946709a9c1adc9217479d55f5a3", "class_name": "RelatedNodeInfo"}}, "text": "With that, \nI'll turn it back ove r to Mike.  \n \n", "start_char_idx": 2734, "end_char_idx": 2783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e1e5ca-11ee-4686-9411-0951f3e11071": {"__data__": {"id_": "37e1e5ca-11ee-4686-9411-0951f3e11071", "embedding": null, "metadata": {"window": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.  ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d02a1c-3913-4569-bb38-ba79482217bc", "node_type": "1", "metadata": {"window": "With that in mind, our Board recently approved a 1% dividend increase for \nfiscal '22.   Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "original_text": "With that, \nI'll turn it back ove r to Mike.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cb0e204552fb328bf662646764389388edfc528c42af031429d0560dd4e99f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5047f53-7729-449a-a767-8ea0b5d209ab", "node_type": "1", "metadata": {"window": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "original_text": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n"}, "hash": "ddc7de24a49223424cedd54ced2dec379c7670dc60f904e66628353002d1ba0a", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Jason.  ", "start_char_idx": 2783, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5047f53-7729-449a-a767-8ea0b5d209ab": {"__data__": {"id_": "b5047f53-7729-449a-a767-8ea0b5d209ab", "embedding": null, "metadata": {"window": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "original_text": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e1e5ca-11ee-4686-9411-0951f3e11071", "node_type": "1", "metadata": {"window": "Outside of these three key priorities, we'll continue to eval uate tuck -in M&A within our \nstrategic growth areas and opportunistic share repurchases.   As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.  ", "original_text": "Mike Kaufmann:  Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69eda99dff76a1ca6938782509eaae0868239cfb5b3f36b27973c34f669f6388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9", "node_type": "1", "metadata": {"window": "With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.  "}, "hash": "ba9cf313ef1a8ae4ec32cb9ef2de1cef79604d35a8f2c1816ec6466a4edf47dc", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "start_char_idx": 2815, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9": {"__data__": {"id_": "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9", "embedding": null, "metadata": {"window": "With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5047f53-7729-449a-a767-8ea0b5d209ab", "node_type": "1", "metadata": {"window": "As I mentioned, our improving financial \nflexibility enabled the deployment of capital for share repurchases during the third quarter.   With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "original_text": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f253c1c3aace0bbd35335ac90e38586bcd6f9012e4a537a6d078b84b48c6b050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf5049f-967c-4115-a8df-ee338b357cdf", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "Our business model \nis resilient.  "}, "hash": "94d8f93cf75af519197862fbbdae4d6223a79027d63fabdad88ed3cb4c260cfc", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "start_char_idx": 3041, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf5049f-967c-4115-a8df-ee338b357cdf": {"__data__": {"id_": "8cf5049f-967c-4115-a8df-ee338b357cdf", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "Our business model \nis resilient.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9", "node_type": "1", "metadata": {"window": "With that, \nI'll turn it back ove r to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0603d54155038ccf585baace391cacb1153efb79e8ee54fadf1f1aef9ea78704", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da6e86e1-9912-4bf1-b432-08757e0cf441", "node_type": "1", "metadata": {"window": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  "}, "hash": "adf3acdc8ebeac8aefc94c9b2a139dc16db9e94ae492e6e8032421dace8432f4", "class_name": "RelatedNodeInfo"}}, "text": "Our business model \nis resilient.  ", "start_char_idx": 3125, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da6e86e1-9912-4bf1-b432-08757e0cf441": {"__data__": {"id_": "da6e86e1-9912-4bf1-b432-08757e0cf441", "embedding": null, "metadata": {"window": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf5049f-967c-4115-a8df-ee338b357cdf", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Jason.   As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "Our business model \nis resilient.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa4f99ffe611395ad134255378b133a6ca82b0652320955b8e11a7df1b31df59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "418c33a6-f6b3-4e31-a438-f0cae45b9cee", "node_type": "1", "metadata": {"window": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n "}, "hash": "c974c4d1f1c25e7fe01e22855342d159b5f9c5ff3c04444019280f7d54e45dce", "class_name": "RelatedNodeInfo"}}, "text": "We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "start_char_idx": 3160, "end_char_idx": 3416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "418c33a6-f6b3-4e31-a438-f0cae45b9cee": {"__data__": {"id_": "418c33a6-f6b3-4e31-a438-f0cae45b9cee", "embedding": null, "metadata": {"window": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2340916e1192c30f18560dc6ad944aee21698f0313a2656800d933b05233d53f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da6e86e1-9912-4bf1-b432-08757e0cf441", "node_type": "1", "metadata": {"window": "As I mentioned earlier, the last year has highlighted certain \nopportunities for growth, transformation and innovation, and we're confident that our strategic \ndirection will deliver both short - and long -term succe ss.   \n \n In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.  ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d3c3509c2a5f2a9d06e28dbc07c65f9c6ae8bdf166bd588deda389a7c1de30c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2aad3e-569d-49d6-ac61-29d3e7933a66", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S. ", "original_text": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.  "}, "hash": "371adc463bd6a5767c6d53b5672bdaeb85796ec6410eab5f28ba677e4730f764", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "start_char_idx": 3416, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2aad3e-569d-49d6-ac61-29d3e7933a66": {"__data__": {"id_": "5b2aad3e-569d-49d6-ac61-29d3e7933a66", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S. ", "original_text": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "418c33a6-f6b3-4e31-a438-f0cae45b9cee", "node_type": "1", "metadata": {"window": "In Pharma, we are excited about the mid - to long -term trajectory of the segment.   Our business model \nis resilient.   We're expecting strong long -term growth in key areas like specialty and nuclear, both of \nwhich are rebounding well from prior COVID -related impacts, and we are executing a robust pipeline \nof initiatives in PD to support our customers' evolving needs.   We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "original_text": "We also continue to invest in new \ntechnology solutions that enhance the customer experience and improve patient care.  \n ", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b77c21312c58d3c043d5d4ad2b524080c1f9c9d639282300456d8317fb7579e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb887675-d93d-4a7c-ab82-3357bf947839", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "original_text": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.  "}, "hash": "14c7ea14e2c1eeda4f9ac40bc98af2933d4daaaffc00c3bc5fd7b312966c63c2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.  ", "start_char_idx": 0, "end_char_idx": 167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb887675-d93d-4a7c-ab82-3357bf947839": {"__data__": {"id_": "bb887675-d93d-4a7c-ab82-3357bf947839", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "original_text": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2aad3e-569d-49d6-ac61-29d3e7933a66", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S. ", "original_text": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c3451c263617e978c7bbe7f86883dd79ea6bb401ecb34a593eda6d822e27155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "original_text": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n"}, "hash": "afbacaca4427b8ba05be62007e33dcf82b6bc73bc69b5f4f4e74e2cdee6e85a0", "class_name": "RelatedNodeInfo"}}, "text": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.  ", "start_char_idx": 167, "end_char_idx": 280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1": {"__data__": {"id_": "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "original_text": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb887675-d93d-4a7c-ab82-3357bf947839", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "original_text": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ba3ecc153e2fbb6537255d5555f0b9a7c7ebe2c879929bb67c5dc2d1e0dbf65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef79d564-7d7f-4b65-b4a6-4734763fddb8", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "original_text": "Each year, medication non -adherence cost s the U.S. "}, "hash": "2527d30af4d842d026dd353688491f206aee918f53a9c696197c9d1abb261bbc", "class_name": "RelatedNodeInfo"}}, "text": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n", "start_char_idx": 280, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef79d564-7d7f-4b65-b4a6-4734763fddb8": {"__data__": {"id_": "ef79d564-7d7f-4b65-b4a6-4734763fddb8", "embedding": null, "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "original_text": "Each year, medication non -adherence cost s the U.S. ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "original_text": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbd69df84bdd4dca84856bf24492f2d503728b5227cb6bb6510b5263980f8bff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0ddfcc-1609-4822-b5ab-0a02df0e163b", "node_type": "1", "metadata": {"window": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "original_text": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  "}, "hash": "defe11b486552e479404703a443c283a1b9a43384a6a4a9293e96e70eb35acdb", "class_name": "RelatedNodeInfo"}}, "text": "Each year, medication non -adherence cost s the U.S. ", "start_char_idx": 409, "end_char_idx": 462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0ddfcc-1609-4822-b5ab-0a02df0e163b": {"__data__": {"id_": "7c0ddfcc-1609-4822-b5ab-0a02df0e163b", "embedding": null, "metadata": {"window": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "original_text": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef79d564-7d7f-4b65-b4a6-4734763fddb8", "node_type": "1", "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "original_text": "Each year, medication non -adherence cost s the U.S. ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53810d8ab88fcdd8c431d18b78cf39cc84ca6cc4f400f335353d804edb048fe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "208d54de-cacd-48b6-8ad7-5929f8e6c6ef", "node_type": "1", "metadata": {"window": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.  ", "original_text": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  "}, "hash": "aece0a05777b4f78c6d2e81cd966a0bed2522c82f667409c2941271688f6e91f", "class_name": "RelatedNodeInfo"}}, "text": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "start_char_idx": 462, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "208d54de-cacd-48b6-8ad7-5929f8e6c6ef": {"__data__": {"id_": "208d54de-cacd-48b6-8ad7-5929f8e6c6ef", "embedding": null, "metadata": {"window": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.  ", "original_text": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0ddfcc-1609-4822-b5ab-0a02df0e163b", "node_type": "1", "metadata": {"window": "These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "original_text": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2833e233a4673a9ad07f9fecce0aa4b900d2138c0a65facd3c4657ddbca1d52e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ccdcf75-a189-4b8c-88dc-05833a4f80f5", "node_type": "1", "metadata": {"window": "Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.  ", "original_text": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n"}, "hash": "bbfd204bb1fa468979116759d3f31c225d0a98bf599759430fc9162a113150e1", "class_name": "RelatedNodeInfo"}}, "text": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "start_char_idx": 560, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ccdcf75-a189-4b8c-88dc-05833a4f80f5": {"__data__": {"id_": "4ccdcf75-a189-4b8c-88dc-05833a4f80f5", "embedding": null, "metadata": {"window": "Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.  ", "original_text": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "208d54de-cacd-48b6-8ad7-5929f8e6c6ef", "node_type": "1", "metadata": {"window": "We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.  ", "original_text": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "674c7d587c5177383858f43315759c3d22c113f4d38f6d8ee341b90921ab9d9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f899676-dfc9-4f37-ab22-a7603026db76", "node_type": "1", "metadata": {"window": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "original_text": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n"}, "hash": "68b8ce303092199bb6c6655378016a7f86ff04a702b9d6221b4abb941dcb7b06", "class_name": "RelatedNodeInfo"}}, "text": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "start_char_idx": 756, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f899676-dfc9-4f37-ab22-a7603026db76": {"__data__": {"id_": "8f899676-dfc9-4f37-ab22-a7603026db76", "embedding": null, "metadata": {"window": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "original_text": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ccdcf75-a189-4b8c-88dc-05833a4f80f5", "node_type": "1", "metadata": {"window": "Each year, medication non -adherence cost s the U.S.  health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.  ", "original_text": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33c002cd090a508b87bc4c8204f37afeba8e7763d3ec4ff205488a9bae4dc532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7e154f8-470d-4b5e-9d23-08e890615e84", "node_type": "1", "metadata": {"window": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "original_text": "Turning to Medical.  "}, "hash": "1322bbaed62c7908580d9b7845ed38d134d5a870992ba28e1e671835acd4d0fc", "class_name": "RelatedNodeInfo"}}, "text": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "start_char_idx": 966, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7e154f8-470d-4b5e-9d23-08e890615e84": {"__data__": {"id_": "a7e154f8-470d-4b5e-9d23-08e890615e84", "embedding": null, "metadata": {"window": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "original_text": "Turning to Medical.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f899676-dfc9-4f37-ab22-a7603026db76", "node_type": "1", "metadata": {"window": "health care system over $500 billion and \ncontributes to around 275,000 avoidable patient death.   With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "original_text": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de4d8b35da9e9142d0c22ed1e86108bf060abae181c8761beadbe7de3b9d1732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5786927-bd45-45df-88e5-f4294baa073b", "node_type": "1", "metadata": {"window": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "original_text": "We continue to enhance our operations to better serve our customers and their \npatients.  "}, "hash": "605fdaadae96c056bcf0574e0b28b51a576b6700a802067106f05fcff86c9e07", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical.  ", "start_char_idx": 1255, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5786927-bd45-45df-88e5-f4294baa073b": {"__data__": {"id_": "a5786927-bd45-45df-88e5-f4294baa073b", "embedding": null, "metadata": {"window": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "original_text": "We continue to enhance our operations to better serve our customers and their \npatients.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7e154f8-470d-4b5e-9d23-08e890615e84", "node_type": "1", "metadata": {"window": "With Outcomes, we've created a digital \necosystem that unites pharmacists, payers and pharmaceutical companies to improve medication \nadherence, drive better outcomes and lower the cost of care.   Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "original_text": "Turning to Medical.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16abcef0d6e6e2d38b6a4531d5e48ed441006573f41b470a7a2c5f24f2a71f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e91b913e-7520-458d-9bab-d87e670a0d5e", "node_type": "1", "metadata": {"window": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "original_text": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  "}, "hash": "b63880447ffe24f17bd7135f1a71e837efe8dd113b35b873fee52fe26dfdf30b", "class_name": "RelatedNodeInfo"}}, "text": "We continue to enhance our operations to better serve our customers and their \npatients.  ", "start_char_idx": 1276, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e91b913e-7520-458d-9bab-d87e670a0d5e": {"__data__": {"id_": "e91b913e-7520-458d-9bab-d87e670a0d5e", "embedding": null, "metadata": {"window": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "original_text": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5786927-bd45-45df-88e5-f4294baa073b", "node_type": "1", "metadata": {"window": "Outcomes currently supports a network \nof 23 million patients and more than 60,000 pharmacy sites nationwide and through continued \ngrowth, it's positioned to address the challenge of medication adherence.  \n \n As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "original_text": "We continue to enhance our operations to better serve our customers and their \npatients.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddb49b6ed0edd9f067430cd45a78464cc38692e9e99d31acb859f62edde303b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db154aa5-3c99-4693-a245-5e82ec80fabb", "node_type": "1", "metadata": {"window": "Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "original_text": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n"}, "hash": "065752a2a998d4cbcafb64bccffe3dbd3323a0d2c35c1223829e0c187570e3fc", "class_name": "RelatedNodeInfo"}}, "text": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "start_char_idx": 1366, "end_char_idx": 1504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db154aa5-3c99-4693-a245-5e82ec80fabb": {"__data__": {"id_": "db154aa5-3c99-4693-a245-5e82ec80fabb", "embedding": null, "metadata": {"window": "Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "original_text": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e91b913e-7520-458d-9bab-d87e670a0d5e", "node_type": "1", "metadata": {"window": "As I look towards the future, I am excited about these innovations across the segment that combine \nour heritage and strengths with new technologies to create unique solutions that support our \ncustomers' ever -changing needs and create long -term value across  the continuum of care.  \n \n Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "original_text": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f3da5854d9d47f6b71391da5e378773fb6fdef26201aff4268dd065343627b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d40534c-5bdd-44db-ae56-c88df2301c16", "node_type": "1", "metadata": {"window": "We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.  ", "original_text": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n"}, "hash": "588e035dd50d0d30c41b98f2033d32b458c833c9a59a8fca8613f848c58a2040", "class_name": "RelatedNodeInfo"}}, "text": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "start_char_idx": 1504, "end_char_idx": 1708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d40534c-5bdd-44db-ae56-c88df2301c16": {"__data__": {"id_": "4d40534c-5bdd-44db-ae56-c88df2301c16", "embedding": null, "metadata": {"window": "We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.  ", "original_text": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db154aa5-3c99-4693-a245-5e82ec80fabb", "node_type": "1", "metadata": {"window": "Turning to Medical.   We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "original_text": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7540a696d0afe017841dcfa29b083d671e398b0ed563b49727452a5b91d0525d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "293d38b5-fdcf-4606-a456-2ec46b413071", "node_type": "1", "metadata": {"window": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "original_text": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  "}, "hash": "fb3be5fb8f5ff3c2bd99b8063612fc913b653c0779c0473569b4d2fee58e2e34", "class_name": "RelatedNodeInfo"}}, "text": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "start_char_idx": 1708, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "293d38b5-fdcf-4606-a456-2ec46b413071": {"__data__": {"id_": "293d38b5-fdcf-4606-a456-2ec46b413071", "embedding": null, "metadata": {"window": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "original_text": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d40534c-5bdd-44db-ae56-c88df2301c16", "node_type": "1", "metadata": {"window": "We continue to enhance our operations to better serve our customers and their \npatients.   For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.  ", "original_text": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de27ee10144e4014c717b83acf04222c8efad25223bfb27d1a47e3e688a1405c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0", "node_type": "1", "metadata": {"window": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "original_text": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n"}, "hash": "598d7bd0acf4dd38c261b45f536997c609df1f8783ed9de1c2cb267035326788", "class_name": "RelatedNodeInfo"}}, "text": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "start_char_idx": 1916, "end_char_idx": 2027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0": {"__data__": {"id_": "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0", "embedding": null, "metadata": {"window": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "original_text": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "293d38b5-fdcf-4606-a456-2ec46b413071", "node_type": "1", "metadata": {"window": "For example, we continue to diversify the geographic concentration of our sourcing and \ninvest in our self -manufacturing c apabilities.   This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "original_text": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0a8023f9bf5feba40e76b8475a6e1fef2abd359f05494d739707a4bb25211d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f645b43-96e2-4fc9-89d6-ce270cb1a28c", "node_type": "1", "metadata": {"window": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "original_text": "We also continue to invest in key areas across the segment.  "}, "hash": "ad9760b6622a7b0b7c7f0ef5449107662369d014eb521d317c3287f7a6554a7e", "class_name": "RelatedNodeInfo"}}, "text": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "start_char_idx": 2027, "end_char_idx": 2145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f645b43-96e2-4fc9-89d6-ce270cb1a28c": {"__data__": {"id_": "8f645b43-96e2-4fc9-89d6-ce270cb1a28c", "embedding": null, "metadata": {"window": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "original_text": "We also continue to invest in key areas across the segment.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0", "node_type": "1", "metadata": {"window": "This includes producing 15 million more safety needles \nand syringes, 20 million more isolation gowns and 150 million more surgical and procedure masks \nannually in our own North American facilities.  \n \n We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "original_text": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c49861f3ba8811f4c8db4d2874433b874333138fb671f1cc309417f5337b8341", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da988f8-232f-4b90-8703-c8f731d893d5", "node_type": "1", "metadata": {"window": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "original_text": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  "}, "hash": "afdbbf36c855cebebdbb2b545d099fab8224bd241c3ea59e4adf0d1da4dbe0e0", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to invest in key areas across the segment.  ", "start_char_idx": 2145, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da988f8-232f-4b90-8703-c8f731d893d5": {"__data__": {"id_": "5da988f8-232f-4b90-8703-c8f731d893d5", "embedding": null, "metadata": {"window": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "original_text": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f645b43-96e2-4fc9-89d6-ce270cb1a28c", "node_type": "1", "metadata": {"window": "We are also supporting customers' inventory  needs with stockpile as -a-service storage solution in \npartnering with the Strategic National Stockpile to store and distribute 80,000 pallets of critical PPE.  \n We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "original_text": "We also continue to invest in key areas across the segment.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e68afe0585edc94c4605894e1971089dbc62a512612935e01764bd9b3ef29e2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc9d668-2570-4b39-83e8-3109c60ee090", "node_type": "1", "metadata": {"window": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "original_text": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n"}, "hash": "d29fbeee6eb64ee88c5036f2bbed0e27f75c50af001237b664a19a2d8c7c67b6", "class_name": "RelatedNodeInfo"}}, "text": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "start_char_idx": 2206, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc9d668-2570-4b39-83e8-3109c60ee090": {"__data__": {"id_": "dcc9d668-2570-4b39-83e8-3109c60ee090", "embedding": null, "metadata": {"window": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "original_text": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da988f8-232f-4b90-8703-c8f731d893d5", "node_type": "1", "metadata": {"window": "We are incorporating robotics, automation and data analytics across our warehouse and distribut ion \nprocess.   We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "original_text": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b44aa1eea750f3b5826b28d2195306d25127185b6411b7457c7463dee99921a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0860d945-f451-4735-943c-a57ba78f73cc", "node_type": "1", "metadata": {"window": "We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "original_text": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  "}, "hash": "94aff4902807c2d53df1358f6d7b896693787acfa3ec160ec96a0603003edd64", "class_name": "RelatedNodeInfo"}}, "text": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "start_char_idx": 2527, "end_char_idx": 2702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0860d945-f451-4735-943c-a57ba78f73cc": {"__data__": {"id_": "0860d945-f451-4735-943c-a57ba78f73cc", "embedding": null, "metadata": {"window": "We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "original_text": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc9d668-2570-4b39-83e8-3109c60ee090", "node_type": "1", "metadata": {"window": "We are piloting various technologies and being thoughtful about how and where to scale \nthem across our network.   \n \n We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "original_text": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdbe5d0a59712cf74106ba37c9b9ff71fe84cf952cd3bf1a60da36e4f1bb9dc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22343999-c1c4-476f-ad6a-47d3ec681a2d", "node_type": "1", "metadata": {"window": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  "}, "hash": "f4da2b336288d59defc8de63323d09ccee1f4d9f9b2bc496b9a46ae9d28e559c", "class_name": "RelatedNodeInfo"}}, "text": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "start_char_idx": 2702, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22343999-c1c4-476f-ad6a-47d3ec681a2d": {"__data__": {"id_": "22343999-c1c4-476f-ad6a-47d3ec681a2d", "embedding": null, "metadata": {"window": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0860d945-f451-4735-943c-a57ba78f73cc", "node_type": "1", "metadata": {"window": "We also continue to invest in key areas across the segment.   For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "original_text": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff0ed5ce830cbed214c4e2ae822da5bb694ab3746ea2351c022a9950281693da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e254792b-89fd-4e5a-9a30-cf9a00298dfe", "node_type": "1", "metadata": {"window": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n"}, "hash": "c08bf83476eb90a044bbe136ca67420dcec0a97c9717c01db374f2322a540b07", "class_name": "RelatedNodeInfo"}}, "text": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "start_char_idx": 2961, "end_char_idx": 3073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e254792b-89fd-4e5a-9a30-cf9a00298dfe": {"__data__": {"id_": "e254792b-89fd-4e5a-9a30-cf9a00298dfe", "embedding": null, "metadata": {"window": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22343999-c1c4-476f-ad6a-47d3ec681a2d", "node_type": "1", "metadata": {"window": "For example, we are expanding our lab \nkitting services to support home collection for a broad array of lab tests from wellness to infectious \ndisease, and we are coupling these services with capabilities in our Cardinal Health at -Home and \nOptiFreight businesses to maximize value and create differentiated solutions.   By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ccb07624d1341a237bae10a11017be49f3b23b01da60a5ab8a62de4332487d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd65626b-d42f-46b7-9502-27237d86a408", "node_type": "1", "metadata": {"window": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  "}, "hash": "4f4fda13202f7ebe83fc711cede60a9944f7ddbaa54d3cd1c56d6002a2d5cf2b", "class_name": "RelatedNodeInfo"}}, "text": "Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "start_char_idx": 3073, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd65626b-d42f-46b7-9502-27237d86a408": {"__data__": {"id_": "cd65626b-d42f-46b7-9502-27237d86a408", "embedding": null, "metadata": {"window": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e254792b-89fd-4e5a-9a30-cf9a00298dfe", "node_type": "1", "metadata": {"window": "By me eting the patient \nwhere they are, our lab kitting supports testing protocol adherence and detection of early onset \ndisease, ultimately, lowering the cost of care.  \n \n And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0b6d2519552c9951f2a65811d6889b3e9e640e5d534eac93a689150b6521ad0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6", "node_type": "1", "metadata": {"window": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time "}, "hash": "5e83456c4536a97cbd5566bda09e1125c5354609f67df9012b29f48015eeb1d7", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "start_char_idx": 3266, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6": {"__data__": {"id_": "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6", "embedding": null, "metadata": {"window": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4e7c4b19fc9d334f43965f38173fa524c7af0c7eafb4c874b2d6582eb27b09c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd65626b-d42f-46b7-9502-27237d86a408", "node_type": "1", "metadata": {"window": "And in Medical Services, our OptiFreight Logistics business is launching innovative and \ncomp rehensive health care logistics offerings like our same -day solutions, which is being scaled \nnationally to support the time -critical logistics of our customers.   Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daab336839447700b183eef2ead97305387f3e3bd127418890f70fe072305b1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b7c5d28-1a07-4880-b6cc-240aa2f775f9", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "original_text": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.  "}, "hash": "2230d7eb06550f2d3c3ceec79231ae4bcf9c90d308f24ede5932332e0b63ef1e", "class_name": "RelatedNodeInfo"}}, "text": "For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "start_char_idx": 3382, "end_char_idx": 3574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7c5d28-1a07-4880-b6cc-240aa2f775f9": {"__data__": {"id_": "7b7c5d28-1a07-4880-b6cc-240aa2f775f9", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "original_text": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6", "node_type": "1", "metadata": {"window": "Together, these work streams across \nMedical position us to support our customers and drive lon g-term growth.   Along with these work \nstreams in each segment, we are also focused on enterprise -wide investments as well as advancing \nour capital allocation, portfolio optimization and ESG priorities.  \n \n We continue to invest in our delivery networks, cold chain capabilities and supply chain capacity and \nvisibility.   For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "original_text": "For example, we are partnering with FourKites, the largest predictive supply chain visibility \nplatform to create a cognitive network spanning both pharma and medical that combines real -time ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "265715db7c3330ae6bd4966a0d132bc6d12fd831c5150355d77ef44a20760367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67a9fc82-c3bc-4ae7-a56f-caa106895f14", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "original_text": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n"}, "hash": "679579e917fa62b44325317a71c7c73533a3c15ea08f2ddfe4c311595946c5be", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.  ", "start_char_idx": 0, "end_char_idx": 91, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67a9fc82-c3bc-4ae7-a56f-caa106895f14": {"__data__": {"id_": "67a9fc82-c3bc-4ae7-a56f-caa106895f14", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "original_text": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7c5d28-1a07-4880-b6cc-240aa2f775f9", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "original_text": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9c8cb25b223273b563a38258f1dbed104c703fea1ce06e657183ba4b35b4413", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "594d167e-0c25-421d-8b78-f20f1425bb4c", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.  ", "original_text": "Regarding our capital allocation priorities, we have strong momentum.  "}, "hash": "92b4cb24049a95dc48d29f22dfd8f17701201db9869e2639e54124ab3185f289", "class_name": "RelatedNodeInfo"}}, "text": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n", "start_char_idx": 91, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "594d167e-0c25-421d-8b78-f20f1425bb4c": {"__data__": {"id_": "594d167e-0c25-421d-8b78-f20f1425bb4c", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.  ", "original_text": "Regarding our capital allocation priorities, we have strong momentum.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67a9fc82-c3bc-4ae7-a56f-caa106895f14", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "original_text": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "337dfd64e632374044910cfd0affaa3bf4a3fd5a112fc296fe8ac6cf941da388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "409128f2-9cb0-4d15-a072-82450c173a7f", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "original_text": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n"}, "hash": "79bcf157d003e63a3980f39e29731da8ed5940984101272ee5ff6db72329cc90", "class_name": "RelatedNodeInfo"}}, "text": "Regarding our capital allocation priorities, we have strong momentum.  ", "start_char_idx": 331, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "409128f2-9cb0-4d15-a072-82450c173a7f": {"__data__": {"id_": "409128f2-9cb0-4d15-a072-82450c173a7f", "embedding": null, "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "original_text": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "594d167e-0c25-421d-8b78-f20f1425bb4c", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.  ", "original_text": "Regarding our capital allocation priorities, we have strong momentum.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c11a1ad92cba3c717f10f3a963b32a7187c918e70e5e09eb440fd7857b2124ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f17ac49-de54-42d4-b149-7b9bd9aaa728", "node_type": "1", "metadata": {"window": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "original_text": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n"}, "hash": "f1cbff9efa3930730f629b4e2b786b9ea39c848095c9dbd5185e27368d3e85c8", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "start_char_idx": 402, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f17ac49-de54-42d4-b149-7b9bd9aaa728": {"__data__": {"id_": "6f17ac49-de54-42d4-b149-7b9bd9aaa728", "embedding": null, "metadata": {"window": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "original_text": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "409128f2-9cb0-4d15-a072-82450c173a7f", "node_type": "1", "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "original_text": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25a4fc7f87905832d5c08645e3875b9111ed0a6ecf4dfaa2d9157a0dae0dd5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2696cb6c-6ce9-48b5-b044-166a5e561fd0", "node_type": "1", "metadata": {"window": "Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.  ", "original_text": "We also remain focused on optimizing our portfolio.  "}, "hash": "7e4033f011a1be9c29b67d90956128a4c28304a147c2dd34b6f39f54b1e343d0", "class_name": "RelatedNodeInfo"}}, "text": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "start_char_idx": 531, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2696cb6c-6ce9-48b5-b044-166a5e561fd0": {"__data__": {"id_": "2696cb6c-6ce9-48b5-b044-166a5e561fd0", "embedding": null, "metadata": {"window": "Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.  ", "original_text": "We also remain focused on optimizing our portfolio.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f17ac49-de54-42d4-b149-7b9bd9aaa728", "node_type": "1", "metadata": {"window": "This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "original_text": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04ce72947ef2fd9063448726f146493265d6ecff005685fdf5e728410d29fbaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dcf2000-aa61-4d85-8db0-b83499056baa", "node_type": "1", "metadata": {"window": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "original_text": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  "}, "hash": "ddf8ea0b9eec3d0fcdce48cd5360c2d3a090a0f23bc176f9a38149e02205c3ca", "class_name": "RelatedNodeInfo"}}, "text": "We also remain focused on optimizing our portfolio.  ", "start_char_idx": 661, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dcf2000-aa61-4d85-8db0-b83499056baa": {"__data__": {"id_": "2dcf2000-aa61-4d85-8db0-b83499056baa", "embedding": null, "metadata": {"window": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "original_text": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2696cb6c-6ce9-48b5-b044-166a5e561fd0", "node_type": "1", "metadata": {"window": "Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.  ", "original_text": "We also remain focused on optimizing our portfolio.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50fbb868584a84f5e9c240bd779c366b4a026e9acac889872b0fe0122b19d279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fe033e2-7c12-4616-809d-945340d3a7b0", "node_type": "1", "metadata": {"window": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "original_text": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n"}, "hash": "8426935e0090f5894310231c32244f16f45d9a8b0b0399f597822ae6bba4c1a1", "class_name": "RelatedNodeInfo"}}, "text": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "start_char_idx": 714, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fe033e2-7c12-4616-809d-945340d3a7b0": {"__data__": {"id_": "8fe033e2-7c12-4616-809d-945340d3a7b0", "embedding": null, "metadata": {"window": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "original_text": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dcf2000-aa61-4d85-8db0-b83499056baa", "node_type": "1", "metadata": {"window": "We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "original_text": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77b86282b5a184f1a1ab666aa04f8ad5761013945ad55ee14d9f53a7799e60ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f", "node_type": "1", "metadata": {"window": "We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "original_text": "Finally, we're also advancing our environmental, social and governance activities.  "}, "hash": "477bb4ac88d0e568642ec17146e99a514c6dd4096afae7a84d022e9ed2e78f07", "class_name": "RelatedNodeInfo"}}, "text": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "start_char_idx": 947, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f": {"__data__": {"id_": "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f", "embedding": null, "metadata": {"window": "We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "original_text": "Finally, we're also advancing our environmental, social and governance activities.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fe033e2-7c12-4616-809d-945340d3a7b0", "node_type": "1", "metadata": {"window": "We are on tra ck to exceed our savings targets and are continuing to use some of these savings to \nreinvest in the business.   \n \n We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "original_text": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3363b7ee87917aa37e85da6fdf30c200f2c81e6fbe9dfa9dc904654939c4a736", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3", "node_type": "1", "metadata": {"window": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n", "original_text": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  "}, "hash": "349266c48ae4722f2ba1125f0ddc88084a4ea691b86b418c2ae00840dfc6c6b5", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we're also advancing our environmental, social and governance activities.  ", "start_char_idx": 1131, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3": {"__data__": {"id_": "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3", "embedding": null, "metadata": {"window": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n", "original_text": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f", "node_type": "1", "metadata": {"window": "We also remain focused on optimizing our portfolio.   The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "original_text": "Finally, we're also advancing our environmental, social and governance activities.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1ea1110745a88aa583c9e1497fc44e0938f9a9bf04c0f90cdc00c61a87163f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0", "node_type": "1", "metadata": {"window": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.  ", "original_text": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n"}, "hash": "34575b3e085a828c2a58304a6ac575e47624e5e1a5402f8a46b469b0966370a5", "class_name": "RelatedNodeInfo"}}, "text": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "start_char_idx": 1215, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0": {"__data__": {"id_": "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0", "embedding": null, "metadata": {"window": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.  ", "original_text": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3", "node_type": "1", "metadata": {"window": "The pending sale of Cordis is progressing as \nexpected and this divestiture enables us to s implify our operating model, further optimize our \ninfrastructure and focus on our strategic growth areas where we are an advantaged owner.   We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n", "original_text": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41788cbd99414592473f80578206a7ee7d43e1bff8a907b244c0054c412abc40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a070461e-6ac7-4879-8f66-b7ff663ba1e1", "node_type": "1", "metadata": {"window": "Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "original_text": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n"}, "hash": "45709b21e09d5cc7b720c9962a76e7b2182dc82e45ce937405f3baaf5eaebadb", "class_name": "RelatedNodeInfo"}}, "text": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "start_char_idx": 1335, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a070461e-6ac7-4879-8f66-b7ff663ba1e1": {"__data__": {"id_": "a070461e-6ac7-4879-8f66-b7ff663ba1e1", "embedding": null, "metadata": {"window": "Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "original_text": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0", "node_type": "1", "metadata": {"window": "We are \ncommitted to our strategy as a global medical products and distribution leader and are focused on \nconducting business in markets and areas that align with our priorities.  \n \n Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.  ", "original_text": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e2d1170a42203b350018fc612487d72d74412f9dfe5b128f719c8b0f7f1bc71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45af1486-299d-474d-88cb-011c65998cf5", "node_type": "1", "metadata": {"window": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "With that, I'll pause to open it up for questions.  \n \n"}, "hash": "4affc7f510f0f34142b601f8db675be2aaf1aa9e503a908b58926281966dd1ca", "class_name": "RelatedNodeInfo"}}, "text": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "start_char_idx": 1510, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45af1486-299d-474d-88cb-011c65998cf5": {"__data__": {"id_": "45af1486-299d-474d-88cb-011c65998cf5", "embedding": null, "metadata": {"window": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "With that, I'll pause to open it up for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a070461e-6ac7-4879-8f66-b7ff663ba1e1", "node_type": "1", "metadata": {"window": "Finally, we're also advancing our environmental, social and governance activities.   We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "original_text": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b753405fda6c1f77e23034e79a67ebc20fc776ddac83f0ad9ccd9e4d145bd23d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cf061c9-97f6-48b8-be19-bbe33eec6f37", "node_type": "1", "metadata": {"window": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "original_text": "Operator:  Thank you.  "}, "hash": "24fe486842e1f12f7149614fa83caf0716b67dd1744ff4a7ba2aa8a613600087", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll pause to open it up for questions.  \n \n", "start_char_idx": 1679, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cf061c9-97f6-48b8-be19-bbe33eec6f37": {"__data__": {"id_": "7cf061c9-97f6-48b8-be19-bbe33eec6f37", "embedding": null, "metadata": {"window": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "original_text": "Operator:  Thank you.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45af1486-299d-474d-88cb-011c65998cf5", "node_type": "1", "metadata": {"window": "We recently \npartnered with AEP to power our global headquarters and our National Logistics Center with clean \nenergy.   And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "original_text": "With that, I'll pause to open it up for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2898e17579c92861b264ea99d5c36353ec2f380098bdbd7f2ee67804d32fe676", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ae0781-98fa-4778-8d13-9b48ee5af840", "node_type": "1", "metadata": {"window": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "original_text": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  "}, "hash": "20228143f2cb82b0660fdd4e9dc8dd7c0b32ace6698f5190a0d90feb770308c5", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 1734, "end_char_idx": 1757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ae0781-98fa-4778-8d13-9b48ee5af840": {"__data__": {"id_": "73ae0781-98fa-4778-8d13-9b48ee5af840", "embedding": null, "metadata": {"window": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "original_text": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cf061c9-97f6-48b8-be19-bbe33eec6f37", "node_type": "1", "metadata": {"window": "And we remain deeply committed to advancing diversity, equity and inclusion at every level \nto ensure all of our employees can bring 100% of themselves to work every day.  \n \n To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "original_text": "Operator:  Thank you.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1db50365ef245cd63ea6d5a1c34fe565e9f168a21387f55631ab03ebdcd4d988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc7cbce-92ea-4572-9729-f97c300445d5", "node_type": "1", "metadata": {"window": "With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "original_text": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  "}, "hash": "e723547cb3c01e4b350108acd92a5cb174e79ba3cbfaf86b44d7eb3fe40aee9c", "class_name": "RelatedNodeInfo"}}, "text": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "start_char_idx": 1757, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc7cbce-92ea-4572-9729-f97c300445d5": {"__data__": {"id_": "2bc7cbce-92ea-4572-9729-f97c300445d5", "embedding": null, "metadata": {"window": "With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "original_text": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ae0781-98fa-4778-8d13-9b48ee5af840", "node_type": "1", "metadata": {"window": "To close, I want to thank each of our employees whose commitment and ingenui ty enable us to \nsupport our customers, their patients and our collective communities.   \n \n With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "original_text": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "904932ac095ad3ce50da3be92e366c8b42ca9479687ecf3ca1eb41ef9d7c8a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10eefb74-22c3-4e62-9193-5b34e671b57d", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n", "original_text": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  "}, "hash": "236634602beb9739b232f493c4f1dca345c28f99994a6ff516d3b43715fcf9fa", "class_name": "RelatedNodeInfo"}}, "text": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "start_char_idx": 1864, "end_char_idx": 1993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10eefb74-22c3-4e62-9193-5b34e671b57d": {"__data__": {"id_": "10eefb74-22c3-4e62-9193-5b34e671b57d", "embedding": null, "metadata": {"window": "Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n", "original_text": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc7cbce-92ea-4572-9729-f97c300445d5", "node_type": "1", "metadata": {"window": "With that, I'll pause to open it up for questions.  \n \n Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "original_text": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b60c495504ea98b8bf9c5c4f8538086cf5005ab20c502ca03a1876c7ae99c667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a6ea236-58a6-4b08-811b-21f92e359dad", "node_type": "1", "metadata": {"window": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.  ", "original_text": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n"}, "hash": "3a2f6e829641ce1f9444e2773fbdd2b414d5f6693b178e0557988c014fe75120", "class_name": "RelatedNodeInfo"}}, "text": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "start_char_idx": 1993, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a6ea236-58a6-4b08-811b-21f92e359dad": {"__data__": {"id_": "1a6ea236-58a6-4b08-811b-21f92e359dad", "embedding": null, "metadata": {"window": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.  ", "original_text": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10eefb74-22c3-4e62-9193-5b34e671b57d", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n", "original_text": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a29ffe30cea09d51f0251eb38ddf4e0765c97c6460df8e32e15a7e11d30d1dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee124cba-fd27-4503-84a8-3567722d045c", "node_type": "1", "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "original_text": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.  "}, "hash": "67d9ebb14599e8a86765a12ebe8ba2f6570329f11a69109b7247a2b94342445f", "class_name": "RelatedNodeInfo"}}, "text": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "start_char_idx": 2056, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee124cba-fd27-4503-84a8-3567722d045c": {"__data__": {"id_": "ee124cba-fd27-4503-84a8-3567722d045c", "embedding": null, "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "original_text": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a6ea236-58a6-4b08-811b-21f92e359dad", "node_type": "1", "metadata": {"window": "And if you would like to ask a question, please signal by pressing \"star\" \"1\" on \nyour teleph one keypad.   If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.  ", "original_text": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3790de521959e8d3da4b3ca2b28b452791584d748389e02ce423272f7a7af77f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70d549ff-c723-4bd1-9df3-3be6f419cc9f", "node_type": "1", "metadata": {"window": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.  ", "original_text": "Please go \nahead.  \n \n"}, "hash": "7e0695e6ab1b5d4b8ba81a5d09bf6eeb685ddf0698fa6c2f95c2000ca607c28d", "class_name": "RelatedNodeInfo"}}, "text": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "start_char_idx": 2153, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70d549ff-c723-4bd1-9df3-3be6f419cc9f": {"__data__": {"id_": "70d549ff-c723-4bd1-9df3-3be6f419cc9f", "embedding": null, "metadata": {"window": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee124cba-fd27-4503-84a8-3567722d045c", "node_type": "1", "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is \nturned off to allow your signal to reach our equipment.   Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "original_text": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3078571d24896a30989f796ef738fbf14ac1f3903f984f57b47fd9442dc49bf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf319f61-67ba-46a0-aa39-3e99ae4e716d", "node_type": "1", "metadata": {"window": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question.  "}, "hash": "05d17946fd2bb71f7a435ba3dfec28a1dbd28cc7554dc696f18d1af9f3697757", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 2243, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf319f61-67ba-46a0-aa39-3e99ae4e716d": {"__data__": {"id_": "bf319f61-67ba-46a0-aa39-3e99ae4e716d", "embedding": null, "metadata": {"window": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70d549ff-c723-4bd1-9df3-3be6f419cc9f", "node_type": "1", "metadata": {"window": "Again, it is \"star\" \"1\" if you would like to ask a \nquestion.   And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa08fefd776a945336b196c0ddd6bedb20b9a2546defe957ce018d4ab5f57ec8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfe658aa-62a8-48a8-8b6e-480de935ee16", "node_type": "1", "metadata": {"window": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "original_text": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  "}, "hash": "6c05caff72216009b705d3983ce9d8e582f84c7341cc2181ef08a341279231b7", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Good morning and thanks for taking the question.  ", "start_char_idx": 2265, "end_char_idx": 2332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfe658aa-62a8-48a8-8b6e-480de935ee16": {"__data__": {"id_": "bfe658aa-62a8-48a8-8b6e-480de935ee16", "embedding": null, "metadata": {"window": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "original_text": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf319f61-67ba-46a0-aa39-3e99ae4e716d", "node_type": "1", "metadata": {"window": "And we'll pause just for a moment to allow everyone a n opportunity to signal for questions.  \n \n And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "original_text": "Michael Cherny:  Good morning and thanks for taking the question.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a101112104941ef6d9bca1e1b7ade676473ff4f2729da1e29a1beec8a225380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef1388a4-13ad-4a75-b666-72a2f11b5435", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "original_text": "And I believe you said that \nwould be mid -single digits.  "}, "hash": "c0766452d02c752c7038c26c8e9599a46bd108c02378e9e1c9835a0dcae35d1b", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "start_char_idx": 2332, "end_char_idx": 2438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef1388a4-13ad-4a75-b666-72a2f11b5435": {"__data__": {"id_": "ef1388a4-13ad-4a75-b666-72a2f11b5435", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "original_text": "And I believe you said that \nwould be mid -single digits.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfe658aa-62a8-48a8-8b6e-480de935ee16", "node_type": "1", "metadata": {"window": "And we'll go ahead and take our first question from Michael Cherny from Bank of America.   Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "original_text": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b9f0b68a553a7c67b41f4d7ebd021b653c8219b7b01d57715c54e96f80a0b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a9dfb0-50c8-4dac-958e-dfed2e906c33", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.  ", "original_text": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  "}, "hash": "c71a90c6da7c42026e9d4205a8bd2ecdcabb274845c1f5caa10a9ca39b768bad", "class_name": "RelatedNodeInfo"}}, "text": "And I believe you said that \nwould be mid -single digits.  ", "start_char_idx": 2438, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a9dfb0-50c8-4dac-958e-dfed2e906c33": {"__data__": {"id_": "d0a9dfb0-50c8-4dac-958e-dfed2e906c33", "embedding": null, "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.  ", "original_text": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef1388a4-13ad-4a75-b666-72a2f11b5435", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "original_text": "And I believe you said that \nwould be mid -single digits.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63423244811a42026f31fc70e890bb0ce857eb4439e65c846fe549359ae1a84e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6eb5a4-295a-4df3-962f-238a145ac64f", "node_type": "1", "metadata": {"window": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.  ", "original_text": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  "}, "hash": "d099602db39357a024ff96dfc9a709698d82bb504e314bc9b150d22bfad8d081", "class_name": "RelatedNodeInfo"}}, "text": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "start_char_idx": 2497, "end_char_idx": 2609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6eb5a4-295a-4df3-962f-238a145ac64f": {"__data__": {"id_": "cf6eb5a4-295a-4df3-962f-238a145ac64f", "embedding": null, "metadata": {"window": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.  ", "original_text": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a9dfb0-50c8-4dac-958e-dfed2e906c33", "node_type": "1", "metadata": {"window": "Michael Cherny:  Good morning and thanks for taking the question.   I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.  ", "original_text": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffe9cf5af850d924d2d821e85c802bf028915be412aff4dae88df489bf448403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12bda2bb-2bc7-454f-ada5-f973653b7a94", "node_type": "1", "metadata": {"window": "And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.  ", "original_text": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n"}, "hash": "1c3b74f5c10a52046522a3cc7bd9daf5930e9fdcd330d5f3727d113ed7320105", "class_name": "RelatedNodeInfo"}}, "text": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "start_char_idx": 2609, "end_char_idx": 2746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12bda2bb-2bc7-454f-ada5-f973653b7a94": {"__data__": {"id_": "12bda2bb-2bc7-454f-ada5-f973653b7a94", "embedding": null, "metadata": {"window": "And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.  ", "original_text": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6eb5a4-295a-4df3-962f-238a145ac64f", "node_type": "1", "metadata": {"window": "I want to dive in a little bit to a \ncomme nt you made about your expected growth on the EBIT ex -COVID.   And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.  ", "original_text": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45dc26bf853fb918318fbff036e66e9af375c07fa466fe57254d66dd78efa3b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5778de3c-90b3-4519-af60-3b9d82ebee63", "node_type": "1", "metadata": {"window": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.  ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "87bffea11402e5ddbb056bcf293d4c9fd6d3b8f643d904d2789b4bdf36f141bf", "class_name": "RelatedNodeInfo"}}, "text": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "start_char_idx": 2746, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5778de3c-90b3-4519-af60-3b9d82ebee63": {"__data__": {"id_": "5778de3c-90b3-4519-af60-3b9d82ebee63", "embedding": null, "metadata": {"window": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12bda2bb-2bc7-454f-ada5-f973653b7a94", "node_type": "1", "metadata": {"window": "And I believe you said that \nwould be mid -single digits.   By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.  ", "original_text": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05d90a163ab715131c07c606126e5234c311e13d5f7efb0ccd756da9227c9aaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75914680-435d-49e9-9b27-832ed28fdfd8", "node_type": "1", "metadata": {"window": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "original_text": "Yes, this is Jason.  "}, "hash": "c4158b01edd3989c72d88d854be405c344ff6e747ac73aec9525db6af9a53081", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 2974, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75914680-435d-49e9-9b27-832ed28fdfd8": {"__data__": {"id_": "75914680-435d-49e9-9b27-832ed28fdfd8", "embedding": null, "metadata": {"window": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "original_text": "Yes, this is Jason.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5778de3c-90b3-4519-af60-3b9d82ebee63", "node_type": "1", "metadata": {"window": "By my simple math, if you assume it's 5%, that gets you to roughly $66 \nmillion headwind versus the base line.   So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "638e90beb2b29d23e4452be2183f9310f436d223bb156b70d4b7eb8edc8d928d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd75096a-f09f-46d7-845e-5059e4590a5a", "node_type": "1", "metadata": {"window": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.  ", "original_text": "Let me start with your first question there.  "}, "hash": "005a592aaa7513c80eddd271bbceb1879c93c5a93f9514e4fb953e780dab155c", "class_name": "RelatedNodeInfo"}}, "text": "Yes, this is Jason.  ", "start_char_idx": 2996, "end_char_idx": 3017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd75096a-f09f-46d7-845e-5059e4590a5a": {"__data__": {"id_": "bd75096a-f09f-46d7-845e-5059e4590a5a", "embedding": null, "metadata": {"window": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.  ", "original_text": "Let me start with your first question there.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75914680-435d-49e9-9b27-832ed28fdfd8", "node_type": "1", "metadata": {"window": "So along those lines, can you break down a little bit within that \narea, what some of the biggest drivers were of the underperformance?   And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "original_text": "Yes, this is Jason.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdeb7238d239952f1298a5c392e9712159755094ead89970470b9101181c19e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96ffd680-3d7b-4043-9915-edbee5b39ddf", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "And your math is \nvery accurate.  "}, "hash": "446880bdcb5c48a74f0eaf8aa943f84f81e30ffb6db55c0eb4084c44da944844", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with your first question there.  ", "start_char_idx": 3017, "end_char_idx": 3063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96ffd680-3d7b-4043-9915-edbee5b39ddf": {"__data__": {"id_": "96ffd680-3d7b-4043-9915-edbee5b39ddf", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "And your math is \nvery accurate.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd75096a-f09f-46d7-845e-5059e4590a5a", "node_type": "1", "metadata": {"window": "And then in particular, with \nregards to that question and the generic volumes, any more color you can give us on some of the \nclasses that you expe ct to continue to contribute to weakness over the next couple of quarters?  \n \n Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.  ", "original_text": "Let me start with your first question there.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "142eb98c0aec1dfe073c8303fa682d0c4b00f9c0e9383e361263952bcf109a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb60112f-e943-4e51-ac8a-4a86c001cc91", "node_type": "1", "metadata": {"window": "Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That would represent right around $60 million of overall enterprise impact due to \nCOVID.  "}, "hash": "8036b9329703a4121fc4e0df7d79b0165f949dd86c7efd4363fcc1cf3f31986a", "class_name": "RelatedNodeInfo"}}, "text": "And your math is \nvery accurate.  ", "start_char_idx": 3063, "end_char_idx": 3097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb60112f-e943-4e51-ac8a-4a86c001cc91": {"__data__": {"id_": "bb60112f-e943-4e51-ac8a-4a86c001cc91", "embedding": null, "metadata": {"window": "Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96ffd680-3d7b-4043-9915-edbee5b39ddf", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "And your math is \nvery accurate.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c045295dfb1a0e8621ac76327f3e312c15f97e5fbcc171ff99ffa42df5e43f74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bc1aea3-b5cb-498b-9223-8a15460c9cf1", "node_type": "1", "metadata": {"window": "Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That is entirely in the pharma segment.  "}, "hash": "ca92d8c4492e7c302027b11789cc8bd13f8b0bea0db4a48171fd1d6a56aa718a", "class_name": "RelatedNodeInfo"}}, "text": "That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "start_char_idx": 3097, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bc1aea3-b5cb-498b-9223-8a15460c9cf1": {"__data__": {"id_": "4bc1aea3-b5cb-498b-9223-8a15460c9cf1", "embedding": null, "metadata": {"window": "Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That is entirely in the pharma segment.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb60112f-e943-4e51-ac8a-4a86c001cc91", "node_type": "1", "metadata": {"window": "Yes, this is Jason.   Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That would represent right around $60 million of overall enterprise impact due to \nCOVID.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82aee3786f704c860ce0f463d27adb361a724587a5ee8bd914da39392ec9b516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00", "node_type": "1", "metadata": {"window": "And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "Wit hin Medical, there was a very insignificant impact "}, "hash": "d90760b9807329ec67afdf31b2a1325fb6618fb3982fe9f3f51e906df2f0009b", "class_name": "RelatedNodeInfo"}}, "text": "That is entirely in the pharma segment.  ", "start_char_idx": 3188, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00": {"__data__": {"id_": "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00", "embedding": null, "metadata": {"window": "And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "Wit hin Medical, there was a very insignificant impact ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b463bae0edf079e048c99b26794d7253a79d6cad293557c30f06ae7964537172", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bc1aea3-b5cb-498b-9223-8a15460c9cf1", "node_type": "1", "metadata": {"window": "Let me start with your first question there.   And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "That is entirely in the pharma segment.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdca42f1844ff26220c9ba101a8018d106ca600ad9198d6572fd32047cd544a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37066222-a152-4f2a-a6f6-8d2663e1b09e", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the quarter due to COVID.  "}, "hash": "bc77c6904a355be298d1196c41eca6dd4e165c0da69e343d33e5c63fc898550d", "class_name": "RelatedNodeInfo"}}, "text": "Wit hin Medical, there was a very insignificant impact ", "start_char_idx": 3229, "end_char_idx": 3284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37066222-a152-4f2a-a6f6-8d2663e1b09e": {"__data__": {"id_": "37066222-a152-4f2a-a6f6-8d2663e1b09e", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the quarter due to COVID.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00", "node_type": "1", "metadata": {"window": "And your math is \nvery accurate.   That would represent right around $60 million of overall enterprise impact due to \nCOVID.   That is entirely in the pharma segment.   Wit hin Medical, there was a very insignificant impact ", "original_text": "Wit hin Medical, there was a very insignificant impact ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12ca3cba300c7898cc9fac73d6ba95a982c673c846808e0316f377509dd9b91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17e374ab-051d-4bef-8b28-c6811643176c", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n"}, "hash": "1702f367a4b3844612719b3f6593038d1ba6663ed96be206d6a200bc48b95fb6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 14 \n \nin the quarter due to COVID.  ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17e374ab-051d-4bef-8b28-c6811643176c": {"__data__": {"id_": "17e374ab-051d-4bef-8b28-c6811643176c", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37066222-a152-4f2a-a6f6-8d2663e1b09e", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the quarter due to COVID.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "348c53bd265811829993a8389de8e503e91f502573413d5f681c75a287e31873", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60330a11-96d6-44d5-9beb-e1fc29898633", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.  ", "original_text": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.  "}, "hash": "c497aaa179a4e9ac78d0083b34e52b9b9fcbcd54e81fcc777a0295cc90b2d278", "class_name": "RelatedNodeInfo"}}, "text": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n", "start_char_idx": 48, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60330a11-96d6-44d5-9beb-e1fc29898633": {"__data__": {"id_": "60330a11-96d6-44d5-9beb-e1fc29898633", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.  ", "original_text": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17e374ab-051d-4bef-8b28-c6811643176c", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fba00b5d8901ccfda1941c793af9fe18360a51f038456e75188c0bbb913379d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e9de19b-e263-44ae-ab37-80ba68cb128b", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "original_text": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n"}, "hash": "8216cee4141bb1e3064127a41d1fb2dc0b7a2c7672e6c7e27e249350dd2b929e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.  ", "start_char_idx": 174, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e9de19b-e263-44ae-ab37-80ba68cb128b": {"__data__": {"id_": "3e9de19b-e263-44ae-ab37-80ba68cb128b", "embedding": null, "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "original_text": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60330a11-96d6-44d5-9beb-e1fc29898633", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.  ", "original_text": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b72a35f5f0b6f249dfc328574d4d79a201b1d5c73b2d67d248e3003741dc3034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6fdd9c1-30db-408e-a233-0b49e61e999d", "node_type": "1", "metadata": {"window": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "a0657074b9b20994f74c2003ab0d740c8f9da17b998200a5cc14204f9d2cc998", "class_name": "RelatedNodeInfo"}}, "text": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "start_char_idx": 330, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6fdd9c1-30db-408e-a233-0b49e61e999d": {"__data__": {"id_": "a6fdd9c1-30db-408e-a233-0b49e61e999d", "embedding": null, "metadata": {"window": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e9de19b-e263-44ae-ab37-80ba68cb128b", "node_type": "1", "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "original_text": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dc03454eb39c3a2aea8a62c8b931c844b3073777ba85dfb35c1250108b8dd50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9f9646d-4120-4933-99fe-c2716e3c06e4", "node_type": "1", "metadata": {"window": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "original_text": "Michael, thanks for the question.  "}, "hash": "8dac8653c315a04bcfa992e120694d3068d51011e0e4f41a3accbf9ed7f6e2d3", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 441, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9f9646d-4120-4933-99fe-c2716e3c06e4": {"__data__": {"id_": "e9f9646d-4120-4933-99fe-c2716e3c06e4", "embedding": null, "metadata": {"window": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "original_text": "Michael, thanks for the question.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6fdd9c1-30db-408e-a233-0b49e61e999d", "node_type": "1", "metadata": {"window": "Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3f5abc0a38c80cfe1bcc16a6459c2f6f64e9aa4ce77814cf392bddae036535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1", "node_type": "1", "metadata": {"window": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "original_text": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  "}, "hash": "94822d33a3dd78420862ff4a91ffca35633c66fb7062e27a5e3539e7e949fe3f", "class_name": "RelatedNodeInfo"}}, "text": "Michael, thanks for the question.  ", "start_char_idx": 463, "end_char_idx": 498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1": {"__data__": {"id_": "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1", "embedding": null, "metadata": {"window": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "original_text": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9f9646d-4120-4933-99fe-c2716e3c06e4", "node_type": "1", "metadata": {"window": "As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "original_text": "Michael, thanks for the question.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cafb37fb6b6bd677fedf300dcc8e64866bebad9912c555be80eb3385bb67f657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec18de9-1014-4107-a938-6648c52a5a89", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.  ", "original_text": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  "}, "hash": "579ad9ba129a983ee4ee1fbfa8e35ce49fd0bff6166231aef25e575ffa32eccf", "class_name": "RelatedNodeInfo"}}, "text": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "start_char_idx": 498, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec18de9-1014-4107-a938-6648c52a5a89": {"__data__": {"id_": "0ec18de9-1014-4107-a938-6648c52a5a89", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.  ", "original_text": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1", "node_type": "1", "metadata": {"window": "And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "original_text": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc04b4d09f14923e005b07e3460c28aa023b565b7cc6513996c62685faa4d8f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8970f95b-66fe-45c5-acac-603efb4c2334", "node_type": "1", "metadata": {"window": "Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "original_text": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  "}, "hash": "6f235b2524b78b1386973b7b326ff544850917a45848c24e26109a32e0749359", "class_name": "RelatedNodeInfo"}}, "text": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "start_char_idx": 720, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8970f95b-66fe-45c5-acac-603efb4c2334": {"__data__": {"id_": "8970f95b-66fe-45c5-acac-603efb4c2334", "embedding": null, "metadata": {"window": "Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "original_text": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec18de9-1014-4107-a938-6648c52a5a89", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.  ", "original_text": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17ee41f6fe600552f13334d70d34bd81d822065565cc7ef48fc29aa676247f72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d63e035-b793-40a4-bfe4-9d5336bb32f8", "node_type": "1", "metadata": {"window": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "original_text": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n"}, "hash": "9b78e72d2e486f8c5244c1ed59150ab90b073b2c9d6a2441029b32143fcf30e0", "class_name": "RelatedNodeInfo"}}, "text": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "start_char_idx": 870, "end_char_idx": 975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d63e035-b793-40a4-bfe4-9d5336bb32f8": {"__data__": {"id_": "9d63e035-b793-40a4-bfe4-9d5336bb32f8", "embedding": null, "metadata": {"window": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "original_text": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8970f95b-66fe-45c5-acac-603efb4c2334", "node_type": "1", "metadata": {"window": "Michael, thanks for the question.   And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "original_text": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e5262095df73fe3e4215d30afd2ee200b7e2173e49366d474984d2417a15474", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c8d1933-67ee-45d8-bba4-f3811937b2ea", "node_type": "1", "metadata": {"window": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "original_text": "We think as kids get back to school, more people are  unmasking and all those types of things.  "}, "hash": "921ca4560155fd27b2f64a6c61051208298757e6a1798c829a6e13fe6c92bf61", "class_name": "RelatedNodeInfo"}}, "text": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "start_char_idx": 975, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c8d1933-67ee-45d8-bba4-f3811937b2ea": {"__data__": {"id_": "2c8d1933-67ee-45d8-bba4-f3811937b2ea", "embedding": null, "metadata": {"window": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "original_text": "We think as kids get back to school, more people are  unmasking and all those types of things.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d63e035-b793-40a4-bfe4-9d5336bb32f8", "node_type": "1", "metadata": {"window": "And as it relates to generics, remember, we \nhave -- what we always talk about is our overall generics program and what we're seeing here in our \noverall generics program is that market dynamics are generally consistent.   The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "original_text": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "554d9221bc7d1420d60fcb21ecfa7585e1de4723e745447cc981c357b14fe4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "249487ae-256d-40de-8c7e-f7d459d12af9", "node_type": "1", "metadata": {"window": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.  ", "original_text": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  "}, "hash": "282d36a38f3cc4ba06e651ea8e54f5743d2f4ca02824a8ecc0e60746eadbb58c", "class_name": "RelatedNodeInfo"}}, "text": "We think as kids get back to school, more people are  unmasking and all those types of things.  ", "start_char_idx": 1131, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "249487ae-256d-40de-8c7e-f7d459d12af9": {"__data__": {"id_": "249487ae-256d-40de-8c7e-f7d459d12af9", "embedding": null, "metadata": {"window": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.  ", "original_text": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c8d1933-67ee-45d8-bba4-f3811937b2ea", "node_type": "1", "metadata": {"window": "The only thing that h as \nany real material impact on the program right now is generic volumes in certain therapeutic classes \nrelated to COVID -19.   And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "original_text": "We think as kids get back to school, more people are  unmasking and all those types of things.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d34c661466d4d463a69e83fc20c2e9ecc7acdcaef5cc5a4314cd642675ee729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9714f56-c652-450f-a349-0ec2f490baec", "node_type": "1", "metadata": {"window": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.  ", "original_text": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n"}, "hash": "3cf59a9faedf2976a8915f050cc24e8e9d3eb81de861f96fa027818fd3a746da", "class_name": "RelatedNodeInfo"}}, "text": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "start_char_idx": 1227, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9714f56-c652-450f-a349-0ec2f490baec": {"__data__": {"id_": "b9714f56-c652-450f-a349-0ec2f490baec", "embedding": null, "metadata": {"window": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.  ", "original_text": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "249487ae-256d-40de-8c7e-f7d459d12af9", "node_type": "1", "metadata": {"window": "And it's probably not hard to think about if you've been following the IQVIA data \nand the other da ta.   There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.  ", "original_text": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f7c1f385e1cbf95476b76edc46f5b9d7c2a2d3529f51b105330dc82ca216efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc90613-0d31-4df0-a236-f5198e45cf46", "node_type": "1", "metadata": {"window": "We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n", "original_text": "Jason Hollar:  And I'd just like to add one more thing that $60 million.  "}, "hash": "1c14e8422886f0fc535a610488115babfe26df5d562a82d0340942980e42815f", "class_name": "RelatedNodeInfo"}}, "text": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "start_char_idx": 1437, "end_char_idx": 1585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc90613-0d31-4df0-a236-f5198e45cf46": {"__data__": {"id_": "2bc90613-0d31-4df0-a236-f5198e45cf46", "embedding": null, "metadata": {"window": "We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n", "original_text": "Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9714f56-c652-450f-a349-0ec2f490baec", "node_type": "1", "metadata": {"window": "There are certain classes, pa rticularly around acute scripts where we don't see \nthose getting back to pre -COVID levels prior to our fiscal year -end. \n \n We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.  ", "original_text": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1021a7326eb9762c6dd7960ed7be3befbd255978a78b369198f2c63f98dffc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78f18a19-4998-4cc7-b0e3-78387247646b", "node_type": "1", "metadata": {"window": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.  ", "original_text": "Remember, there was a pull \nahead last year.  "}, "hash": "ee40e272c58bfa5883a9fcf095851893974582eac32a8eec3d3b9b3d58e6f783", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "start_char_idx": 1585, "end_char_idx": 1659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78f18a19-4998-4cc7-b0e3-78387247646b": {"__data__": {"id_": "78f18a19-4998-4cc7-b0e3-78387247646b", "embedding": null, "metadata": {"window": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.  ", "original_text": "Remember, there was a pull \nahead last year.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc90613-0d31-4df0-a236-f5198e45cf46", "node_type": "1", "metadata": {"window": "We think as kids get back to school, more people are  unmasking and all those types of things.   We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n", "original_text": "Jason Hollar:  And I'd just like to add one more thing that $60 million.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "812b334509e315a8026c3a1ba22422c61ce77fca2e79c9e9d3592d59c24ef7c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8361e8e-5473-446a-b895-d7f262260012", "node_type": "1", "metadata": {"window": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n", "original_text": "So only about half of it is an adverse impact in the current year.  "}, "hash": "51cb88d19a5f9ce2c61a247320edfb85781c1a0fc95dfeeb0fd3bb97857bde3c", "class_name": "RelatedNodeInfo"}}, "text": "Remember, there was a pull \nahead last year.  ", "start_char_idx": 1659, "end_char_idx": 1705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8361e8e-5473-446a-b895-d7f262260012": {"__data__": {"id_": "d8361e8e-5473-446a-b895-d7f262260012", "embedding": null, "metadata": {"window": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n", "original_text": "So only about half of it is an adverse impact in the current year.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78f18a19-4998-4cc7-b0e3-78387247646b", "node_type": "1", "metadata": {"window": "We \nwould expect the environment to general ly return, but we don't now seeing that set of certain \ntherapeutic classes within generics returning to more pre -COVID levels until the end of the calendar \nyear.   So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.  ", "original_text": "Remember, there was a pull \nahead last year.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a032ad67f61555fc81f7584d90923132871f15e2fdaf9a522b6eb289f931b79b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a56b0f2f-2f15-4533-8ce1-81adc25b2725", "node_type": "1", "metadata": {"window": "Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "original_text": "The other half is \nrelated to the comparison to the prior year.  \n \n"}, "hash": "f6436a8961cf78c4a004448addb70412016a5730762d5c56d9044481e6d3ab5e", "class_name": "RelatedNodeInfo"}}, "text": "So only about half of it is an adverse impact in the current year.  ", "start_char_idx": 1705, "end_char_idx": 1773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a56b0f2f-2f15-4533-8ce1-81adc25b2725": {"__data__": {"id_": "a56b0f2f-2f15-4533-8ce1-81adc25b2725", "embedding": null, "metadata": {"window": "Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "original_text": "The other half is \nrelated to the comparison to the prior year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8361e8e-5473-446a-b895-d7f262260012", "node_type": "1", "metadata": {"window": "So overall, again, good market, consistent market dynamics in the generics program really jus t \nfocused on those few classes related to COVID.  \n \n Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n", "original_text": "So only about half of it is an adverse impact in the current year.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df32a4b524811ef1afdef5d0ee05ea586be2c0e30075263b86e4750ac6a1391a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ddb327e-d59a-4b8a-9d22-3959f52ade52", "node_type": "1", "metadata": {"window": "Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n", "original_text": "Michael Cherny:  Got it.  "}, "hash": "a32948074d48c3d3245c57267a629ccd65b166ca7493e5df54fa1972dc1cb609", "class_name": "RelatedNodeInfo"}}, "text": "The other half is \nrelated to the comparison to the prior year.  \n \n", "start_char_idx": 1773, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ddb327e-d59a-4b8a-9d22-3959f52ade52": {"__data__": {"id_": "2ddb327e-d59a-4b8a-9d22-3959f52ade52", "embedding": null, "metadata": {"window": "Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n", "original_text": "Michael Cherny:  Got it.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a56b0f2f-2f15-4533-8ce1-81adc25b2725", "node_type": "1", "metadata": {"window": "Jason Hollar:  And I'd just like to add one more thing that $60 million.   Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "original_text": "The other half is \nrelated to the comparison to the prior year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "977ea615451037d39eec9c3f8dd3ac12a11c236c0f23c007a684234764fd500e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "612b0421-eeb5-42f6-8fcb-74ccdf25e976", "node_type": "1", "metadata": {"window": "So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.  ", "original_text": "Thanks.  \n \n"}, "hash": "4cd8d46fb7363b7242fe4ef760a536803a00ab235a9724ebbed473a041df344d", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  Got it.  ", "start_char_idx": 1841, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "612b0421-eeb5-42f6-8fcb-74ccdf25e976": {"__data__": {"id_": "612b0421-eeb5-42f6-8fcb-74ccdf25e976", "embedding": null, "metadata": {"window": "So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.  ", "original_text": "Thanks.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ddb327e-d59a-4b8a-9d22-3959f52ade52", "node_type": "1", "metadata": {"window": "Remember, there was a pull \nahead last year.   So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n", "original_text": "Michael Cherny:  Got it.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dda67e9673cd4bc5c88367e694d502f73d8bdb2ff2033e25afb31884733803f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fee5ecd-a777-4770-92b5-0d26b08583fb", "node_type": "1", "metadata": {"window": "The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.  ", "original_text": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n"}, "hash": "5a87ef49c34f6d31c10b136b6219dc6af6f4658d542b585a1b9e4f4281af7c99", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1867, "end_char_idx": 1879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fee5ecd-a777-4770-92b5-0d26b08583fb": {"__data__": {"id_": "6fee5ecd-a777-4770-92b5-0d26b08583fb", "embedding": null, "metadata": {"window": "The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.  ", "original_text": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "612b0421-eeb5-42f6-8fcb-74ccdf25e976", "node_type": "1", "metadata": {"window": "So only about half of it is an adverse impact in the current year.   The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.  ", "original_text": "Thanks.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a19deded3050bdb701171f5fd2f4c844974ea1f2fb6e468764fd09143800ec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5bcf21-1e8f-40e5-8603-505407482277", "node_type": "1", "metadata": {"window": "Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "original_text": "Please go ahead.  \n \n"}, "hash": "d6686295e9e12040c5335cd024ba545f763744f96858aa6a0e0ef17738fa2063", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "start_char_idx": 1879, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f5bcf21-1e8f-40e5-8603-505407482277": {"__data__": {"id_": "2f5bcf21-1e8f-40e5-8603-505407482277", "embedding": null, "metadata": {"window": "Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fee5ecd-a777-4770-92b5-0d26b08583fb", "node_type": "1", "metadata": {"window": "The other half is \nrelated to the comparison to the prior year.  \n \n Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.  ", "original_text": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e448414176882790cd0d74a42effcf08cb801bb5e0ee721ad70a7151d61f485e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f49bf105-cbf0-4033-9f03-7c16fd34c701", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "original_text": "Charles Rhyee:  Yes, thanks for taking the question.  "}, "hash": "2f5a96184ddee89bff2e75876d375f6ca205d8a3d7859082168eccffa8b4f83b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1975, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f49bf105-cbf0-4033-9f03-7c16fd34c701": {"__data__": {"id_": "f49bf105-cbf0-4033-9f03-7c16fd34c701", "embedding": null, "metadata": {"window": "Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "original_text": "Charles Rhyee:  Yes, thanks for taking the question.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f5bcf21-1e8f-40e5-8603-505407482277", "node_type": "1", "metadata": {"window": "Michael Cherny:  Got it.   Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "original_text": "Please go ahead.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da9a72e64758d3461d7a403cffbe1fdaf2b09beb82a2a03974f9c4d982f1e44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8009b2d7-913f-4f84-8938-58d77c400890", "node_type": "1", "metadata": {"window": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.  ", "original_text": "If I coul d follow up on that.  "}, "hash": "ced075a8ac1450921e74b70d6f151ba0e79371a28a374adc89c3350d02c45a8a", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yes, thanks for taking the question.  ", "start_char_idx": 1996, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8009b2d7-913f-4f84-8938-58d77c400890": {"__data__": {"id_": "8009b2d7-913f-4f84-8938-58d77c400890", "embedding": null, "metadata": {"window": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.  ", "original_text": "If I coul d follow up on that.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f49bf105-cbf0-4033-9f03-7c16fd34c701", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "original_text": "Charles Rhyee:  Yes, thanks for taking the question.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5daffb586bfbfae2da3ca79c4438a1cac368ea6c4ddacb311893236d99021e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "122b460e-b1be-49f1-9554-d076a6c0245e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "original_text": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n"}, "hash": "95a7ebadc570a52660647c4d0c769ba2d97440c76d4bff496773a058c7b2c412", "class_name": "RelatedNodeInfo"}}, "text": "If I coul d follow up on that.  ", "start_char_idx": 2050, "end_char_idx": 2082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "122b460e-b1be-49f1-9554-d076a6c0245e": {"__data__": {"id_": "122b460e-b1be-49f1-9554-d076a6c0245e", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "original_text": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8009b2d7-913f-4f84-8938-58d77c400890", "node_type": "1", "metadata": {"window": "Operator:  And we'll go ahead and move on to our next question from Charles Rhyee from Cowen.  \n Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.  ", "original_text": "If I coul d follow up on that.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e60c50a0b73e9bd3ce916aa107979dcc9166413b92b18bbaf34c47610b9821b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f22c999-ac2e-4537-b9d1-f007df441296", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "original_text": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  "}, "hash": "c16cc3b571568dc525e2e3fe9e613a4dd7d783a02e758df7b393c6cfe46b9e83", "class_name": "RelatedNodeInfo"}}, "text": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "start_char_idx": 2082, "end_char_idx": 2390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f22c999-ac2e-4537-b9d1-f007df441296": {"__data__": {"id_": "5f22c999-ac2e-4537-b9d1-f007df441296", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "original_text": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "122b460e-b1be-49f1-9554-d076a6c0245e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "original_text": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6803b17cdb0bf90723c3ecd38b3dd2f58e7d820b8cd752c0f0e237eabac6f378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc66d8e-61c9-4906-aac7-ca402f125d63", "node_type": "1", "metadata": {"window": "If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.  ", "original_text": "Yes, I would say flu season, \nas we know, has been light.  "}, "hash": "ded1907a5d94ab11d7784bff55e9b0f0ea3a831a752ce337600b4bce804a8519", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "start_char_idx": 2390, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc66d8e-61c9-4906-aac7-ca402f125d63": {"__data__": {"id_": "8fc66d8e-61c9-4906-aac7-ca402f125d63", "embedding": null, "metadata": {"window": "If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.  ", "original_text": "Yes, I would say flu season, \nas we know, has been light.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f22c999-ac2e-4537-b9d1-f007df441296", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yes, thanks for taking the question.   If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "original_text": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aa3ae4925767bb62ce5a701f119969c88d6c4fa785921a711b6fcfc6193d444", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4980837-814b-4947-804d-2641dc0fdbd0", "node_type": "1", "metadata": {"window": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "original_text": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  "}, "hash": "fb3a1b4df35064b4529f5ba97631ffdf795c71291e183940cab87772f0bc93f6", "class_name": "RelatedNodeInfo"}}, "text": "Yes, I would say flu season, \nas we know, has been light.  ", "start_char_idx": 2468, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4980837-814b-4947-804d-2641dc0fdbd0": {"__data__": {"id_": "c4980837-814b-4947-804d-2641dc0fdbd0", "embedding": null, "metadata": {"window": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "original_text": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc66d8e-61c9-4906-aac7-ca402f125d63", "node_type": "1", "metadata": {"window": "If I coul d follow up on that.   When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.  ", "original_text": "Yes, I would say flu season, \nas we know, has been light.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "487a4d93eae914dc11ea37ac2a5ee6ae7e6d2bcad047dc6395ccc275badf8fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "234442cf-8d4e-46f2-915b-f3d67e7e91d2", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n"}, "hash": "70b131ec27ef1fc0f2606ff645d4c49dbe7e0b46b251e04528a2b156c0499c11", "class_name": "RelatedNodeInfo"}}, "text": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "start_char_idx": 2527, "end_char_idx": 2724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "234442cf-8d4e-46f2-915b-f3d67e7e91d2": {"__data__": {"id_": "234442cf-8d4e-46f2-915b-f3d67e7e91d2", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4980837-814b-4947-804d-2641dc0fdbd0", "node_type": "1", "metadata": {"window": "When you say \ncertain therapeutic classes related to COVID, so are we talking like cold, cough and flu like kind of flu \nand antibiotics, these kind of generic that might have been -- we're not seeing it because we had a \nweak flu season  and you wouldn't expect that until maybe this coming flu season?  \n \n Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "original_text": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0ff0b4e5d7f07f9b4c449bd55482e8514f7e6eeaefda430c0d40df8084ce2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea5e92a7-5303-4abb-bfe8-829a244cc39d", "node_type": "1", "metadata": {"window": "Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "But you sai d it well at the beginning, it's really the broader list of categories.  "}, "hash": "2ea81fe16799c69989f4b2d997c0bae2d078b6d085ae696e681206569350216f", "class_name": "RelatedNodeInfo"}}, "text": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "start_char_idx": 2724, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea5e92a7-5303-4abb-bfe8-829a244cc39d": {"__data__": {"id_": "ea5e92a7-5303-4abb-bfe8-829a244cc39d", "embedding": null, "metadata": {"window": "Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "But you sai d it well at the beginning, it's really the broader list of categories.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "234442cf-8d4e-46f2-915b-f3d67e7e91d2", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes, it's a great question, and I'll try to be helpful here.   Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "048b2e331fe29c00be8263314dc8f8eafd757ea2fd3cfbe5400a19c69a856de5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09222fa2-8fdd-4b8c-a641-51cae817ccd1", "node_type": "1", "metadata": {"window": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  "}, "hash": "d97babe301c5a9392936142ddc1a280c8af3d3aa247bce8e5ff73016ec364da7", "class_name": "RelatedNodeInfo"}}, "text": "But you sai d it well at the beginning, it's really the broader list of categories.  ", "start_char_idx": 2831, "end_char_idx": 2916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09222fa2-8fdd-4b8c-a641-51cae817ccd1": {"__data__": {"id_": "09222fa2-8fdd-4b8c-a641-51cae817ccd1", "embedding": null, "metadata": {"window": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea5e92a7-5303-4abb-bfe8-829a244cc39d", "node_type": "1", "metadata": {"window": "Yes, I would say flu season, \nas we know, has been light.   But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "But you sai d it well at the beginning, it's really the broader list of categories.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ca3cfe52dfbe3b8217df4a5adce8d9c42d29848adf4208253bab3d538d04465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b376c7d6-4227-4f91-9332-c0e3123443f4", "node_type": "1", "metadata": {"window": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations "}, "hash": "cee3081dc7812c6f40d87f9701e13e5f5c097144705f1697ec76faaed0d1e46f", "class_name": "RelatedNodeInfo"}}, "text": "So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "start_char_idx": 2916, "end_char_idx": 3097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b376c7d6-4227-4f91-9332-c0e3123443f4": {"__data__": {"id_": "b376c7d6-4227-4f91-9332-c0e3123443f4", "embedding": null, "metadata": {"window": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "610f525b-1228-48cd-9459-b6dfe9861109", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "251044f2ff314e3d118cbe3f8e1535e2a991239e9a43e130725af47f578d2d21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09222fa2-8fdd-4b8c-a641-51cae817ccd1", "node_type": "1", "metadata": {"window": "But we've also said in the past, generally, if it wer e just flu season itself \nand just flu specific, like focused on just like a Tamiflu and some of those, it wouldn't be that big of a \ndriver.   It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810df5a3935b2bb9597f70aa002aaa3c8a2ea0afcb6c2dbda88a2b7b40da09d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e0cd6e-35b4-45f7-a0df-70ce442d3271", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?  ", "original_text": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n"}, "hash": "c6d74c8ae6c20ab4e4a3d8a9648fdd54642591dd155e9eec76dc84169c62148d", "class_name": "RelatedNodeInfo"}}, "text": "And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "start_char_idx": 3097, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e0cd6e-35b4-45f7-a0df-70ce442d3271": {"__data__": {"id_": "c9e0cd6e-35b4-45f7-a0df-70ce442d3271", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?  ", "original_text": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b376c7d6-4227-4f91-9332-c0e3123443f4", "node_type": "1", "metadata": {"window": "It would be a negative for us, but it wouldn't be probably a material driver that we would call \nout.   \n \n But you sai d it well at the beginning, it's really the broader list of categories.   So it's antibacterials, \nantibiotics, antivirals and pain meds, those generics and those categories are what we're seeing that \nare -- have just not returned t o pre-COVID levels.   And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "original_text": "And if you look at the IQVIA data in these \ncategories, what we're seeing both in our own data per -- as you can imagine, a lot of conversations ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12dee4e73d86e519543edc16d1b6984078e376395495e23537c968109527c568", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a700827e-6225-41a1-b9ee-fdcd783efc4f", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "original_text": "Charles Rhyee:  Thanks.  "}, "hash": "1cb98e155a41cd7bac07f5e40ce9f217e2748098694e6c63fcd5aa45b2fa9e1c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n", "start_char_idx": 0, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a700827e-6225-41a1-b9ee-fdcd783efc4f": {"__data__": {"id_": "a700827e-6225-41a1-b9ee-fdcd783efc4f", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "original_text": "Charles Rhyee:  Thanks.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e0cd6e-35b4-45f7-a0df-70ce442d3271", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?  ", "original_text": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2783ae1478db81786e67bab59e5a579ae0468cf67c6a691e75c0f97212dfa200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8710d00-4346-466b-80ac-7504eaebb158", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "original_text": "And if I could just follow up real quick.  "}, "hash": "f29ef42ff4b17996777ad97d184ad9936824c2f201bb98eb2ac1346dd686f71e", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Thanks.  ", "start_char_idx": 141, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8710d00-4346-466b-80ac-7504eaebb158": {"__data__": {"id_": "f8710d00-4346-466b-80ac-7504eaebb158", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "original_text": "And if I could just follow up real quick.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a700827e-6225-41a1-b9ee-fdcd783efc4f", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "original_text": "Charles Rhyee:  Thanks.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94a3e33d5138a032356f06baed3c79a6e366a9c8838deac1f68c81713521a8d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Were these -- were we seeing these \ndynamics last quarter?  "}, "hash": "3416b00ccf28026f5de5305de0a28ffd2068be7944b25ec08f3790d18594cf4b", "class_name": "RelatedNodeInfo"}}, "text": "And if I could just follow up real quick.  ", "start_char_idx": 166, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8": {"__data__": {"id_": "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8", "embedding": null, "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Were these -- were we seeing these \ndynamics last quarter?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8710d00-4346-466b-80ac-7504eaebb158", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "original_text": "And if I could just follow up real quick.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3007a344df60e6004f5eda133540fd5e19ff4f5230feb297cfb2576c679171f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.  ", "original_text": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?  "}, "hash": "a2343a15bd9c6d5fdc6b9ef594e25fad24194ae77c6418f9f8654dbd8884edcb", "class_name": "RelatedNodeInfo"}}, "text": "Were these -- were we seeing these \ndynamics last quarter?  ", "start_char_idx": 209, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d": {"__data__": {"id_": "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d", "embedding": null, "metadata": {"window": "Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.  ", "original_text": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8", "node_type": "1", "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Were these -- were we seeing these \ndynamics last quarter?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aec6e93850273a5a534d46fe2c30ff752817ce58372754ada5ab949c849f149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7afa82b8-c91f-4014-90f5-5dc54874624d", "node_type": "1", "metadata": {"window": "And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.  ", "original_text": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n"}, "hash": "3bab3dc664b0749f22c5200b5d33767ffc4fa0c7c18cef0bf7457796fc8daeda", "class_name": "RelatedNodeInfo"}}, "text": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "start_char_idx": 269, "end_char_idx": 363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7afa82b8-c91f-4014-90f5-5dc54874624d": {"__data__": {"id_": "7afa82b8-c91f-4014-90f5-5dc54874624d", "embedding": null, "metadata": {"window": "And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.  ", "original_text": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.  ", "original_text": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "560117c81e0650b28210b938d309742e065fa89fdda7424c40e506776a6d3fbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d25315c-bb90-44ec-ae6e-e87ba96d59f2", "node_type": "1", "metadata": {"window": "Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "f7472babd45422377c424ddee12a0e67a0670cae25853b8110610c1da0a97c88", "class_name": "RelatedNodeInfo"}}, "text": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "start_char_idx": 363, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d25315c-bb90-44ec-ae6e-e87ba96d59f2": {"__data__": {"id_": "8d25315c-bb90-44ec-ae6e-e87ba96d59f2", "embedding": null, "metadata": {"window": "Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7afa82b8-c91f-4014-90f5-5dc54874624d", "node_type": "1", "metadata": {"window": "And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.  ", "original_text": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ec36b96b83d5041fe02e47495a81c4f85b5aae5c14207a17d5356b267af09f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35019b05-e992-4b14-8575-7fb6f5264087", "node_type": "1", "metadata": {"window": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "original_text": "It's hard to know for sure, but I'll give you a couple of thoughts.  "}, "hash": "7d90a19c7da3de8a3e1da4594e6b4b2fe0da03e36a683065f71e23d21eecb68b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 556, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35019b05-e992-4b14-8575-7fb6f5264087": {"__data__": {"id_": "35019b05-e992-4b14-8575-7fb6f5264087", "embedding": null, "metadata": {"window": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "original_text": "It's hard to know for sure, but I'll give you a couple of thoughts.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d25315c-bb90-44ec-ae6e-e87ba96d59f2", "node_type": "1", "metadata": {"window": "Were these -- were we seeing these \ndynamics last quarter?   And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07950872b29798ca5ee22754adb4021a80482ba3774b8460aa4a381b51cc2c01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d394f55-2286-46f0-b208-ff1f39bdead3", "node_type": "1", "metadata": {"window": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n", "original_text": "One is I t hink \nit is somewhat related to the physician office visits.  "}, "hash": "8d66bb92ca7ec7736e6e4cae533d5b73b969b2fdb6554b575ff89fc92927697e", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to know for sure, but I'll give you a couple of thoughts.  ", "start_char_idx": 578, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d394f55-2286-46f0-b208-ff1f39bdead3": {"__data__": {"id_": "5d394f55-2286-46f0-b208-ff1f39bdead3", "embedding": null, "metadata": {"window": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n", "original_text": "One is I t hink \nit is somewhat related to the physician office visits.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35019b05-e992-4b14-8575-7fb6f5264087", "node_type": "1", "metadata": {"window": "And is it more that -- more of this was prescribed last year during COVID \nversus this year?   And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "original_text": "It's hard to know for sure, but I'll give you a couple of thoughts.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeafc133d5b47105d33b58cc3f7b377c05170a9f9379142a254aab056050f8d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af0639e5-296d-4341-b79e-9cc165ecbaa9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.  ", "original_text": "Second of all, people are masking, social \ndistancing, washing hands.  "}, "hash": "c712b7f1bb4fd86b859e207a2fff76c0332e2480e7f66e352ae9cf93ae5e7a50", "class_name": "RelatedNodeInfo"}}, "text": "One is I t hink \nit is somewhat related to the physician office visits.  ", "start_char_idx": 647, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af0639e5-296d-4341-b79e-9cc165ecbaa9": {"__data__": {"id_": "af0639e5-296d-4341-b79e-9cc165ecbaa9", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.  ", "original_text": "Second of all, people are masking, social \ndistancing, washing hands.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d394f55-2286-46f0-b208-ff1f39bdead3", "node_type": "1", "metadata": {"window": "And so that's what we -- or is it  the depression that people haven't been going to \nthe doctors and you don't see people still really going back to the doctor as much that's driving this?  \n \n Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n", "original_text": "One is I t hink \nit is somewhat related to the physician office visits.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee2ae58cca709a88e777922b67814a72a86451c698b5c605ec8a40d43d6def75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff95534-2d60-48ae-924b-96ef7ba19f76", "node_type": "1", "metadata": {"window": "It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "original_text": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  "}, "hash": "418b648af53cb7164dcb3a74acc68fcf63263128d9823080d0eae31e9b5aac5b", "class_name": "RelatedNodeInfo"}}, "text": "Second of all, people are masking, social \ndistancing, washing hands.  ", "start_char_idx": 720, "end_char_idx": 791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff95534-2d60-48ae-924b-96ef7ba19f76": {"__data__": {"id_": "7ff95534-2d60-48ae-924b-96ef7ba19f76", "embedding": null, "metadata": {"window": "It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "original_text": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af0639e5-296d-4341-b79e-9cc165ecbaa9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.  ", "original_text": "Second of all, people are masking, social \ndistancing, washing hands.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e223f93685b894be9b05d0e8626766ce351243fc8750f8e4f2d6128476f10ddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b25c7311-f66f-44f0-b4cc-2bd076136279", "node_type": "1", "metadata": {"window": "One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.  ", "original_text": "So I think it's a \ncombination of a lot of those things adding up.  \n \n"}, "hash": "6813ab1c9725de2ece3bde3a25a8d7712e22764e3e2512c5e47d85cbfa91b82d", "class_name": "RelatedNodeInfo"}}, "text": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "start_char_idx": 791, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b25c7311-f66f-44f0-b4cc-2bd076136279": {"__data__": {"id_": "b25c7311-f66f-44f0-b4cc-2bd076136279", "embedding": null, "metadata": {"window": "One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.  ", "original_text": "So I think it's a \ncombination of a lot of those things adding up.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff95534-2d60-48ae-924b-96ef7ba19f76", "node_type": "1", "metadata": {"window": "It's hard to know for sure, but I'll give you a couple of thoughts.   One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "original_text": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c43cac3b7a8aa6aa09f6f951b2ea82701698da7788211747fc11a14890f46f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7accb29c-cfa4-45a2-a3f9-7fcb18233e51", "node_type": "1", "metadata": {"window": "Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.  ", "original_text": "We've been seeing this in monitoring all the categories.  "}, "hash": "3e1b2e120eabc941775c6f8c060345df3f80d0a5d0b283aec1155431562ca565", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's a \ncombination of a lot of those things adding up.  \n \n", "start_char_idx": 948, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7accb29c-cfa4-45a2-a3f9-7fcb18233e51": {"__data__": {"id_": "7accb29c-cfa4-45a2-a3f9-7fcb18233e51", "embedding": null, "metadata": {"window": "Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.  ", "original_text": "We've been seeing this in monitoring all the categories.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b25c7311-f66f-44f0-b4cc-2bd076136279", "node_type": "1", "metadata": {"window": "One is I t hink \nit is somewhat related to the physician office visits.   Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.  ", "original_text": "So I think it's a \ncombination of a lot of those things adding up.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70d76a185a634efe52c66b3652113e0fce05ae8cbdb9a9dcae677269c2c9df4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32775294-3530-4b3e-a9e4-28a2da3b7f77", "node_type": "1", "metadata": {"window": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "original_text": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  "}, "hash": "a793f4dd463355df4a1a53d06f5cd19c2763c058a9d97d9b642191cff8b81b67", "class_name": "RelatedNodeInfo"}}, "text": "We've been seeing this in monitoring all the categories.  ", "start_char_idx": 1019, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32775294-3530-4b3e-a9e4-28a2da3b7f77": {"__data__": {"id_": "32775294-3530-4b3e-a9e4-28a2da3b7f77", "embedding": null, "metadata": {"window": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "original_text": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7accb29c-cfa4-45a2-a3f9-7fcb18233e51", "node_type": "1", "metadata": {"window": "Second of all, people are masking, social \ndistancing, washing hands.   You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.  ", "original_text": "We've been seeing this in monitoring all the categories.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dedc1b6a34f40afeece17c2bff0e54ee647962fa707dd298d89388dc02b5e18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d60de4d-0465-4590-ae96-aecd11ffbdc4", "node_type": "1", "metadata": {"window": "So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.  ", "original_text": "And it's good to note that we're seeing that \nin brands.  "}, "hash": "63b742b4c9562c746b1524a9477b29fae8bfe9939b379dd9e18631f899b186e7", "class_name": "RelatedNodeInfo"}}, "text": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "start_char_idx": 1077, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d60de4d-0465-4590-ae96-aecd11ffbdc4": {"__data__": {"id_": "1d60de4d-0465-4590-ae96-aecd11ffbdc4", "embedding": null, "metadata": {"window": "So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.  ", "original_text": "And it's good to note that we're seeing that \nin brands.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32775294-3530-4b3e-a9e4-28a2da3b7f77", "node_type": "1", "metadata": {"window": "You don't have the people playing like sports at the same level and all \nthose things and having the injuries related to pain meds and all of those things.   So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "original_text": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0ed14b86708cc898420e15fff7ca5c66965ea8cdff71eeca518f041685a1707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "248bb780-e9fc-4005-9ae9-2e31f32f48db", "node_type": "1", "metadata": {"window": "We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.  ", "original_text": "We're still expecting that.  "}, "hash": "1620e707228028a46d1a7bf5ea39b41631ec05ca98a7e3a75288ecc5f394a8be", "class_name": "RelatedNodeInfo"}}, "text": "And it's good to note that we're seeing that \nin brands.  ", "start_char_idx": 1276, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "248bb780-e9fc-4005-9ae9-2e31f32f48db": {"__data__": {"id_": "248bb780-e9fc-4005-9ae9-2e31f32f48db", "embedding": null, "metadata": {"window": "We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.  ", "original_text": "We're still expecting that.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d60de4d-0465-4590-ae96-aecd11ffbdc4", "node_type": "1", "metadata": {"window": "So I think it's a \ncombination of a lot of those things adding up.  \n \n We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.  ", "original_text": "And it's good to note that we're seeing that \nin brands.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "829055e38eaaf8e1fb8f5058cf935ffde8cc65c31b98461013dc6939f957690b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69fbc218-5940-490a-9c54-fbd33f013a9f", "node_type": "1", "metadata": {"window": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.  ", "original_text": "We're seeing that in the majority of generics, particularly th e \nchronic generics.  "}, "hash": "bd1c661868d0788ae4077d58b995e56a1adfac63823cbeafc5b1fb3db2399cd7", "class_name": "RelatedNodeInfo"}}, "text": "We're still expecting that.  ", "start_char_idx": 1334, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69fbc218-5940-490a-9c54-fbd33f013a9f": {"__data__": {"id_": "69fbc218-5940-490a-9c54-fbd33f013a9f", "embedding": null, "metadata": {"window": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.  ", "original_text": "We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "248bb780-e9fc-4005-9ae9-2e31f32f48db", "node_type": "1", "metadata": {"window": "We've been seeing this in monitoring all the categories.   And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.  ", "original_text": "We're still expecting that.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac511dd8279b78926e5c49713c4f2730561b30ce76da4864cdd2fd2f6c729aee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4641f689-7662-4594-a354-c5e780aa1ce6", "node_type": "1", "metadata": {"window": "And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "original_text": "Those are coming back.  "}, "hash": "973938c35866089a8dde93f0ac6834f2e1adf27371f0dbb55d291946abe877f0", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "start_char_idx": 1363, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4641f689-7662-4594-a354-c5e780aa1ce6": {"__data__": {"id_": "4641f689-7662-4594-a354-c5e780aa1ce6", "embedding": null, "metadata": {"window": "And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "original_text": "Those are coming back.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69fbc218-5940-490a-9c54-fbd33f013a9f", "node_type": "1", "metadata": {"window": "And we've been saying since the beginning \nof the year, our assumption for guidance for both pharma a nd the overall company has been about \ngetting back to at or near pre -COVID levels by June 30.   And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.  ", "original_text": "We're seeing that in the majority of generics, particularly th e \nchronic generics.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7831a9946cee972137b558666bf66350124fec139f79be7c674b2111c938561", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ab74aa1-2596-467f-8cae-eeb7723936bd", "node_type": "1", "metadata": {"window": "We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "original_text": "But we were hoping to see more of a ramp in these other \nones.  "}, "hash": "13ac50cdcaf2ed6670de443dc2a5a3ca965130e4b5de992163e5bad22d8cefc2", "class_name": "RelatedNodeInfo"}}, "text": "Those are coming back.  ", "start_char_idx": 1448, "end_char_idx": 1472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ab74aa1-2596-467f-8cae-eeb7723936bd": {"__data__": {"id_": "4ab74aa1-2596-467f-8cae-eeb7723936bd", "embedding": null, "metadata": {"window": "We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "original_text": "But we were hoping to see more of a ramp in these other \nones.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4641f689-7662-4594-a354-c5e780aa1ce6", "node_type": "1", "metadata": {"window": "And it's good to note that we're seeing that \nin brands.   We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "original_text": "Those are coming back.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44cfadac9118fa6e5e2177b2893f8efc48cd3ff941ab3aee85d5231f1c587def", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32ac90d9-cf26-411b-8ccd-1809e9ed8abc", "node_type": "1", "metadata": {"window": "We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.  ", "original_text": "We're just not seeing it.  "}, "hash": "50eb60904002eac8de9635715ababed6c10cc2b8caf0cad28c4c66f34d2c24bf", "class_name": "RelatedNodeInfo"}}, "text": "But we were hoping to see more of a ramp in these other \nones.  ", "start_char_idx": 1472, "end_char_idx": 1536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32ac90d9-cf26-411b-8ccd-1809e9ed8abc": {"__data__": {"id_": "32ac90d9-cf26-411b-8ccd-1809e9ed8abc", "embedding": null, "metadata": {"window": "We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.  ", "original_text": "We're just not seeing it.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ab74aa1-2596-467f-8cae-eeb7723936bd", "node_type": "1", "metadata": {"window": "We're still expecting that.   We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "original_text": "But we were hoping to see more of a ramp in these other \nones.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edc1d9da4f0676b338d77859e5bd407bffff4ff373502ecf6df53efeae59050b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea72776-28fa-4436-816b-d320fae30087", "node_type": "1", "metadata": {"window": "Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n", "original_text": "So we believe that it's important not only through March, but we also \nlooked at our April data.  "}, "hash": "ffc9dde1517dcfe7d4fb9f44860ca5a33b32dd33da35411965e1db9a5117de1d", "class_name": "RelatedNodeInfo"}}, "text": "We're just not seeing it.  ", "start_char_idx": 1536, "end_char_idx": 1563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea72776-28fa-4436-816b-d320fae30087": {"__data__": {"id_": "5ea72776-28fa-4436-816b-d320fae30087", "embedding": null, "metadata": {"window": "Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n", "original_text": "So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32ac90d9-cf26-411b-8ccd-1809e9ed8abc", "node_type": "1", "metadata": {"window": "We're seeing that in the majority of generics, particularly th e \nchronic generics.   Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.  ", "original_text": "We're just not seeing it.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "002ea3930f0e4da4be762ffc607af86b40e044f2b40098e6392bf2ac2f97df51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db656077-de90-4395-9376-53743860018a", "node_type": "1", "metadata": {"window": "But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "original_text": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n"}, "hash": "c7e9b812696fee6fd85a4928d46dbecfd5c4e52ad027cc1956953735cd8c4c61", "class_name": "RelatedNodeInfo"}}, "text": "So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "start_char_idx": 1563, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db656077-de90-4395-9376-53743860018a": {"__data__": {"id_": "db656077-de90-4395-9376-53743860018a", "embedding": null, "metadata": {"window": "But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "original_text": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea72776-28fa-4436-816b-d320fae30087", "node_type": "1", "metadata": {"window": "Those are coming back.   But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n", "original_text": "So we believe that it's important not only through March, but we also \nlooked at our April data.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2652abebfff0cb69640f7b5e37d77b36475f88c5d395a3097e6815e3cb04cb35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22efa82d-8a48-4003-ba93-e524f5869f86", "node_type": "1", "metadata": {"window": "We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n", "original_text": "Charles Rhyee:  Great.  "}, "hash": "b3b237a805eea1336f307cf03fe1959ff35fe86e9d3b3f4ec95d1f01932b6c1e", "class_name": "RelatedNodeInfo"}}, "text": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "start_char_idx": 1661, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22efa82d-8a48-4003-ba93-e524f5869f86": {"__data__": {"id_": "22efa82d-8a48-4003-ba93-e524f5869f86", "embedding": null, "metadata": {"window": "We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n", "original_text": "Charles Rhyee:  Great.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db656077-de90-4395-9376-53743860018a", "node_type": "1", "metadata": {"window": "But we were hoping to see more of a ramp in these other \nones.   We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "original_text": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4af5b3341e1128f0de305c7e5b9a53e1936463444c7ebc7c636e891c9ce7e456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db934e86-d388-4680-abb9-c7109944387a", "node_type": "1", "metadata": {"window": "So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Thank you.  \n \n"}, "hash": "edce44fc9a91282c1f2d9c7419b640c00f03d87b07894e5f477086d4218bcc32", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Great.  ", "start_char_idx": 1746, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db934e86-d388-4680-abb9-c7109944387a": {"__data__": {"id_": "db934e86-d388-4680-abb9-c7109944387a", "embedding": null, "metadata": {"window": "So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Thank you.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22efa82d-8a48-4003-ba93-e524f5869f86", "node_type": "1", "metadata": {"window": "We're just not seeing it.   So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n", "original_text": "Charles Rhyee:  Great.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b7a3def164848a70a8bee0902f73bede2c9437be7171503edb7b06af27f9c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b99f08-5ec1-47a0-a699-f3de6765e8bf", "node_type": "1", "metadata": {"window": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  "}, "hash": "131e9063533f13241c5f8be979012cea7b3de6deb07ab0e9c51e8e5a1da62484", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1770, "end_char_idx": 1785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b99f08-5ec1-47a0-a699-f3de6765e8bf": {"__data__": {"id_": "18b99f08-5ec1-47a0-a699-f3de6765e8bf", "embedding": null, "metadata": {"window": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db934e86-d388-4680-abb9-c7109944387a", "node_type": "1", "metadata": {"window": "So we believe that it's important not only through March, but we also \nlooked at our April data.   So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.  ", "original_text": "Thank you.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39b12c7e3be0449de246e34e33667c88ade6540ff1b73d8cb15849c013316061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54d47371-0848-4941-9297-b30a7e9334dc", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n", "original_text": "Please go ahead.  \n \n"}, "hash": "5eaa26fb335a7a415023af0e066f9fd5dbcb33d0ecd4b0658c540d22426bbc38", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "start_char_idx": 1785, "end_char_idx": 1889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54d47371-0848-4941-9297-b30a7e9334dc": {"__data__": {"id_": "54d47371-0848-4941-9297-b30a7e9334dc", "embedding": null, "metadata": {"window": "Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b99f08-5ec1-47a0-a699-f3de6765e8bf", "node_type": "1", "metadata": {"window": "So it drove us to make  a decision to change our pharma guidance for this \nyear.  \n \n Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.  ", "original_text": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "280917fd74d3e7809f8c82ad7c3b1a38dc8fafec68b739fd2573c13f6a996212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "906ed183-6d01-45ae-a52b-682c81cff839", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.  ", "original_text": "Ricky Goldwasser:  Yes, hi.  "}, "hash": "dec32021576ca8c8e0de7a22069e54923e002cd858432e57de5017a184cdb94a", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1889, "end_char_idx": 1910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "906ed183-6d01-45ae-a52b-682c81cff839": {"__data__": {"id_": "906ed183-6d01-45ae-a52b-682c81cff839", "embedding": null, "metadata": {"window": "Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.  ", "original_text": "Ricky Goldwasser:  Yes, hi.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54d47371-0848-4941-9297-b30a7e9334dc", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Great.   Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6b84ce03cd35f62369e069ab793f430e9b82d7bf4030932a8ba1654730411e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe2a8063-1a03-46f4-b17f-91952cd646a6", "node_type": "1", "metadata": {"window": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n", "original_text": "Good morning.  "}, "hash": "a26d66db990a1277eb471545e2073a3404aac639a454d48547cf3283f2e15b3b", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yes, hi.  ", "start_char_idx": 1910, "end_char_idx": 1939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe2a8063-1a03-46f4-b17f-91952cd646a6": {"__data__": {"id_": "fe2a8063-1a03-46f4-b17f-91952cd646a6", "embedding": null, "metadata": {"window": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n", "original_text": "Good morning.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "906ed183-6d01-45ae-a52b-682c81cff839", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.  ", "original_text": "Ricky Goldwasser:  Yes, hi.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfcba68eaba2cb6fcc39dcbb6f66198975103d73903961b9def0f0e2c37d1db0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a0e0b48-f006-42a7-84a3-072c9bb00a06", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?  ", "original_text": "So my question is still on generic s, but on pricing.  \n"}, "hash": "59125aec93fd6fd1a1225862b0206e493ce47468d372427fc74f1175dd6b1122", "class_name": "RelatedNodeInfo"}}, "text": "Good morning.  ", "start_char_idx": 1939, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a0e0b48-f006-42a7-84a3-072c9bb00a06": {"__data__": {"id_": "3a0e0b48-f006-42a7-84a3-072c9bb00a06", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?  ", "original_text": "So my question is still on generic s, but on pricing.  \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe2a8063-1a03-46f4-b17f-91952cd646a6", "node_type": "1", "metadata": {"window": "Operator:  We'll go ahead and move on to our next question from Ricky Goldwasser from Morgan \nStanley.   Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n", "original_text": "Good morning.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0514e6bd3d758dc5b8e14eb9923d8c6eebe66b64f37abc1479a3a972c8a4e0a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c34caac-0898-43d0-bf94-d93c7d13ef11", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "original_text": "Clearly, it's a big debate for investors now.  "}, "hash": "e8ddfe7eb16b925de643ea194bd3fb298cc3a19d3e282c23213e646adcf37f4d", "class_name": "RelatedNodeInfo"}}, "text": "So my question is still on generic s, but on pricing.  \n", "start_char_idx": 1954, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c34caac-0898-43d0-bf94-d93c7d13ef11": {"__data__": {"id_": "0c34caac-0898-43d0-bf94-d93c7d13ef11", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "original_text": "Clearly, it's a big debate for investors now.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a0e0b48-f006-42a7-84a3-072c9bb00a06", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?  ", "original_text": "So my question is still on generic s, but on pricing.  \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05d29544e2eb3d3227bc9ddd0bd3ce49004363e271b34ee704137eaf2023f690", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a17efe-a9eb-4caf-abc4-5422db2a0cf7", "node_type": "1", "metadata": {"window": "Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "So Mike, what are you seeing in terms of generic pricing?  \n"}, "hash": "dfe286eb8fa634237fde119adf00e5fb128e6e689de3e07aee61d7f879934877", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, it's a big debate for investors now.  ", "start_char_idx": 2010, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78a17efe-a9eb-4caf-abc4-5422db2a0cf7": {"__data__": {"id_": "78a17efe-a9eb-4caf-abc4-5422db2a0cf7", "embedding": null, "metadata": {"window": "Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "So Mike, what are you seeing in terms of generic pricing?  \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c34caac-0898-43d0-bf94-d93c7d13ef11", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yes, hi.   Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "original_text": "Clearly, it's a big debate for investors now.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa75aced37fd26e3d0d5a122f80b9253482713477af7d95557e06c8af4630a7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d89edbf-38bd-436a-a24f-f11e255953eb", "node_type": "1", "metadata": {"window": "So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.  ", "original_text": "Are you seeing accelerated deflation or any other tre nds?  "}, "hash": "a8d2925394d1f1a5c13077b3893be46fa5d9722a5e4ec8f8dca5861fe67c558b", "class_name": "RelatedNodeInfo"}}, "text": "So Mike, what are you seeing in terms of generic pricing?  \n", "start_char_idx": 2057, "end_char_idx": 2117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d89edbf-38bd-436a-a24f-f11e255953eb": {"__data__": {"id_": "7d89edbf-38bd-436a-a24f-f11e255953eb", "embedding": null, "metadata": {"window": "So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.  ", "original_text": "Are you seeing accelerated deflation or any other tre nds?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a17efe-a9eb-4caf-abc4-5422db2a0cf7", "node_type": "1", "metadata": {"window": "Good morning.   So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "So Mike, what are you seeing in terms of generic pricing?  \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a709ff4dbfc016e070bd3b096ec9b3b4d9cbf1d528de58c5925f9b32e49bca31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbb3654-ea29-40bc-8e83-6e9a3408b315", "node_type": "1", "metadata": {"window": "Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.  ", "original_text": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n"}, "hash": "a80e4b8423c349eceedcf2998eb5fcd2c897b64f63419d91b12e6b4f4ad0c2f5", "class_name": "RelatedNodeInfo"}}, "text": "Are you seeing accelerated deflation or any other tre nds?  ", "start_char_idx": 2117, "end_char_idx": 2177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbb3654-ea29-40bc-8e83-6e9a3408b315": {"__data__": {"id_": "7fbb3654-ea29-40bc-8e83-6e9a3408b315", "embedding": null, "metadata": {"window": "Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.  ", "original_text": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d89edbf-38bd-436a-a24f-f11e255953eb", "node_type": "1", "metadata": {"window": "So my question is still on generic s, but on pricing.  \n Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.  ", "original_text": "Are you seeing accelerated deflation or any other tre nds?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c7022f0671946724e709c904951cdfdc90890544e96cf58c392a87f3c33aaf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a53f78c-79cb-4f66-a582-68381004215d", "node_type": "1", "metadata": {"window": "So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "25b4fa01ea3a62f3d255b2f6f3fd656cc5deba9a7f32232bc7b74af953f542bb", "class_name": "RelatedNodeInfo"}}, "text": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "start_char_idx": 2177, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a53f78c-79cb-4f66-a582-68381004215d": {"__data__": {"id_": "4a53f78c-79cb-4f66-a582-68381004215d", "embedding": null, "metadata": {"window": "So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbb3654-ea29-40bc-8e83-6e9a3408b315", "node_type": "1", "metadata": {"window": "Clearly, it's a big debate for investors now.   So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.  ", "original_text": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5adee715129a11a9a42b1d9820e3d07a264e7caffa0a27258e5d3c9113f6e0fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1a4e4fb-7401-48f0-8a82-d09de2e71df3", "node_type": "1", "metadata": {"window": "Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "original_text": "Thanks, Ricky.  "}, "hash": "3e0dc92415c5b757225d521bda099d33a464c62b80a5f3d28c5a72ef669e6faf", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 556, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1a4e4fb-7401-48f0-8a82-d09de2e71df3": {"__data__": {"id_": "c1a4e4fb-7401-48f0-8a82-d09de2e71df3", "embedding": null, "metadata": {"window": "Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "original_text": "Thanks, Ricky.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a53f78c-79cb-4f66-a582-68381004215d", "node_type": "1", "metadata": {"window": "So Mike, what are you seeing in terms of generic pricing?  \n Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "711ba04f0c0a61b9f35565bb6b65d000171b9a6ac4bd602d6f4ce4bd8864c36b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c", "node_type": "1", "metadata": {"window": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "original_text": "Thanks for the question.  "}, "hash": "bb2e77cbcb836801209ccff152ec4475e5af6dd9a48233dbfd5c410b6de83bfb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Ricky.  ", "start_char_idx": 2277, "end_char_idx": 2293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c": {"__data__": {"id_": "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c", "embedding": null, "metadata": {"window": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "original_text": "Thanks for the question.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1a4e4fb-7401-48f0-8a82-d09de2e71df3", "node_type": "1", "metadata": {"window": "Are you seeing accelerated deflation or any other tre nds?   And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "original_text": "Thanks, Ricky.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1b7fbc238d10089edafe6cf3582840cba00feb62cfa0cee7b2ba562928225cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7fc6563-99e4-49e4-a573-17c58195e5ce", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.  ", "original_text": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  "}, "hash": "7c075b4cc98a6f512cdc007128095dd89949855d8f978662d78b4ec00531da41", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 2293, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7fc6563-99e4-49e4-a573-17c58195e5ce": {"__data__": {"id_": "f7fc6563-99e4-49e4-a573-17c58195e5ce", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.  ", "original_text": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c", "node_type": "1", "metadata": {"window": "And also, if you can talk a little bit about \nthe sell, buy -side spread?  \n \n Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "original_text": "Thanks for the question.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08d60c3f22b1b8be2c12decd7e42c7208fbab06d1eb1bded14f643ef025e6ad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b", "node_type": "1", "metadata": {"window": "Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.  ", "original_text": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  "}, "hash": "51738ce855fa9d579ae36c01cc71bb1343f3445b4ba6227153fba1693bf1c3e9", "class_name": "RelatedNodeInfo"}}, "text": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "start_char_idx": 2319, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b": {"__data__": {"id_": "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b", "embedding": null, "metadata": {"window": "Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.  ", "original_text": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7fc6563-99e4-49e4-a573-17c58195e5ce", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.  ", "original_text": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e3488155e756b11e49677285848726d813ebf35ef449cb122f703aacb4dee29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e39035b0-03c1-4635-8385-fb1af6fc9b26", "node_type": "1", "metadata": {"window": "Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "original_text": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n"}, "hash": "5bb1220b3be2d2b70758b80edbde36aedd6655fb22be95ccb2ccdcc56132ac2d", "class_name": "RelatedNodeInfo"}}, "text": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "start_char_idx": 2626, "end_char_idx": 2741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e39035b0-03c1-4635-8385-fb1af6fc9b26": {"__data__": {"id_": "e39035b0-03c1-4635-8385-fb1af6fc9b26", "embedding": null, "metadata": {"window": "Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "original_text": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b", "node_type": "1", "metadata": {"window": "Thanks, Ricky.   Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.  ", "original_text": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2bb9af562f30b05831ec87d8ae86431f564c47af6d18a15ae90d2c942993467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bace7d26-825b-4412-9444-2364c9d82138", "node_type": "1", "metadata": {"window": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Ricky Goldwasser:  Okay.  "}, "hash": "55d804572edefc36b7cf4cea60b78bd253e348e855686745df946de8ad037b3f", "class_name": "RelatedNodeInfo"}}, "text": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "start_char_idx": 2741, "end_char_idx": 2924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bace7d26-825b-4412-9444-2364c9d82138": {"__data__": {"id_": "bace7d26-825b-4412-9444-2364c9d82138", "embedding": null, "metadata": {"window": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Ricky Goldwasser:  Okay.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e39035b0-03c1-4635-8385-fb1af6fc9b26", "node_type": "1", "metadata": {"window": "Thanks for the question.   As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "original_text": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35da50b366e6463e75cca4f161764927599403eab5c44e5e1bdd23a92b7e370f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6385328d-86d4-461d-a64d-91e1ee22a207", "node_type": "1", "metadata": {"window": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "And a follow -up question there.  "}, "hash": "c0e2fc0014823a073e726226f7e203b4a2431327af463542774ea8440cf82e9f", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Okay.  ", "start_char_idx": 2924, "end_char_idx": 2950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6385328d-86d4-461d-a64d-91e1ee22a207": {"__data__": {"id_": "6385328d-86d4-461d-a64d-91e1ee22a207", "embedding": null, "metadata": {"window": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "And a follow -up question there.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bace7d26-825b-4412-9444-2364c9d82138", "node_type": "1", "metadata": {"window": "As you know, it's really hard to get \ninto individual components of the generics program because as we've said for  a while now, just \ncalling out sell -side deflation without talking about the buy -side cost improvements or launches or \noverall volumes, it's -- you're really not giving a complete story.   And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Ricky Goldwasser:  Okay.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22ea99d89b61a2e29308f13172248b3d069a57b9951af229295b6c9ab873e6c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55fc10d0-7610-4553-9e93-6bc2c4c622d9", "node_type": "1", "metadata": {"window": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  "}, "hash": "b4e289c2fd163ad313e7fbe463268c92d0c4736824b7bdc066e06caf6f23ca39", "class_name": "RelatedNodeInfo"}}, "text": "And a follow -up question there.  ", "start_char_idx": 2950, "end_char_idx": 2984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55fc10d0-7610-4553-9e93-6bc2c4c622d9": {"__data__": {"id_": "55fc10d0-7610-4553-9e93-6bc2c4c622d9", "embedding": null, "metadata": {"window": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6385328d-86d4-461d-a64d-91e1ee22a207", "node_type": "1", "metadata": {"window": "And that's why we've really been \nfocused on just discussing how we s ee our overall generics program performing.   And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "And a follow -up question there.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7351a6800f6ef38223e948039d22a9d1771c6eb8e221b0ba04c3040d5f8c5af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4d210d4-e68e-4651-965a-2891a91fa9c9", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  "}, "hash": "c1510495f8c676334d4f7ae5911bb324b21482cb5d493a23df9687b7a02d5feb", "class_name": "RelatedNodeInfo"}}, "text": "When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "start_char_idx": 2984, "end_char_idx": 3111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4d210d4-e68e-4651-965a-2891a91fa9c9": {"__data__": {"id_": "a4d210d4-e68e-4651-965a-2891a91fa9c9", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "16391025-22a1-4d2d-8722-f0da12761ad5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5755abd97ecc088fe226dfba9acdd7e911ead4643c9ecf3721a6cb40810dbdd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55fc10d0-7610-4553-9e93-6bc2c4c622d9", "node_type": "1", "metadata": {"window": "And we really are \nseeing market dynamics that are generally consistent with the only driver in the programs I just \nmentioned being COVID -related volumes in certain categories.  \n \n Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "358d0e671591eb35a3d432f33dfb6039287f889242bbeed7c7ed2ca04bb1a3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "original_text": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.  "}, "hash": "da84942703f61900dabe54a73daa43f1b5b67cebc0e836baacbd013a5370e8c3", "class_name": "RelatedNodeInfo"}}, "text": "Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "start_char_idx": 3111, "end_char_idx": 3297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9": {"__data__": {"id_": "a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "original_text": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4d210d4-e68e-4651-965a-2891a91fa9c9", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Okay.   And a follow -up question there.   When we think about the sell side, I think \nwe also need to think about sort of contract renewals that could change dynamics.   Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "original_text": "Are there any \ncontract renewals either for your book of business or across the industry that either renewed re cently \nor that are upcoming that you can point us to, if there are any?  ", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "763fc98217363924c077cb0236add44dce4aaf0e5d7d44fdcb2ee35785b2f0cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3009e2c-984a-4b6a-a1bf-25040124b3ec", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n", "original_text": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.  "}, "hash": "d1234674199e5f14ef76f8307898cc734cea117d30bb7e62335d4198570ed371", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.  ", "start_char_idx": 0, "end_char_idx": 42, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3009e2c-984a-4b6a-a1bf-25040124b3ec": {"__data__": {"id_": "f3009e2c-984a-4b6a-a1bf-25040124b3ec", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n", "original_text": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "original_text": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c80967731b6a5dde73a81afe6965585a3f4614a743b9b42b9fdab34fe547b41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8595e5fb-a582-4093-ace2-f7a185deb709", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "original_text": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.  "}, "hash": "05c5386223cccf78249de8b8348b847ecc3c4592266b7c5971f6c86e951d6299", "class_name": "RelatedNodeInfo"}}, "text": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.  ", "start_char_idx": 42, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8595e5fb-a582-4093-ace2-f7a185deb709": {"__data__": {"id_": "8595e5fb-a582-4093-ace2-f7a185deb709", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "original_text": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3009e2c-984a-4b6a-a1bf-25040124b3ec", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n", "original_text": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e51b0c50ad924c2116cc8ff5311d2cd13be512a11cdb1c73c734257031dfa85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "452dc75a-541a-41e9-b8fd-103e288a9208", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n", "original_text": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n"}, "hash": "ba4a3fca070308a49dd9f5a82df7fc7a98638bd9c1fce580e40ecfca2c80d915", "class_name": "RelatedNodeInfo"}}, "text": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.  ", "start_char_idx": 267, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "452dc75a-541a-41e9-b8fd-103e288a9208": {"__data__": {"id_": "452dc75a-541a-41e9-b8fd-103e288a9208", "embedding": null, "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n", "original_text": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8595e5fb-a582-4093-ace2-f7a185deb709", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "original_text": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ee28c54ffacd07ecc69a5c8068a57d814926fe2d3feb65f9bca6125b7106de0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "391fabc8-3be9-490c-9db1-780371666771", "node_type": "1", "metadata": {"window": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.  ", "original_text": "Ricky Goldwasser:  Thank you.  \n \n"}, "hash": "192a6b3aab9f9b0517bff44a27b2a07bc05592f0d29276be8acb6fc647c8d90e", "class_name": "RelatedNodeInfo"}}, "text": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "start_char_idx": 373, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "391fabc8-3be9-490c-9db1-780371666771": {"__data__": {"id_": "391fabc8-3be9-490c-9db1-780371666771", "embedding": null, "metadata": {"window": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.  ", "original_text": "Ricky Goldwasser:  Thank you.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "452dc75a-541a-41e9-b8fd-103e288a9208", "node_type": "1", "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n", "original_text": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "332d833c9df25d4eb21e72a21d4625da82c1cc6038a4d836ccd6fad7be75fac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a49a769-f81b-4052-859b-dad86ecad1ee", "node_type": "1", "metadata": {"window": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n", "original_text": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  "}, "hash": "8f57e8946fd427b0e6ed699f46e348d8fbd9ee388b7c7adda5070cea8e634ebe", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Thank you.  \n \n", "start_char_idx": 514, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a49a769-f81b-4052-859b-dad86ecad1ee": {"__data__": {"id_": "2a49a769-f81b-4052-859b-dad86ecad1ee", "embedding": null, "metadata": {"window": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n", "original_text": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "391fabc8-3be9-490c-9db1-780371666771", "node_type": "1", "metadata": {"window": "As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.  ", "original_text": "Ricky Goldwasser:  Thank you.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd54c63f2931b0dc0595d20b55c862cec8ebec26cbece7a8f381018b16290703", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a62dfb0-d771-46fb-9567-ac2231f1ab19", "node_type": "1", "metadata": {"window": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "bdd2d85c90db6a118a36af5850a98765f289609b3603d3eb5fddc324038db660", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "start_char_idx": 548, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a62dfb0-d771-46fb-9567-ac2231f1ab19": {"__data__": {"id_": "8a62dfb0-d771-46fb-9567-ac2231f1ab19", "embedding": null, "metadata": {"window": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a49a769-f81b-4052-859b-dad86ecad1ee", "node_type": "1", "metadata": {"window": "And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n", "original_text": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "213366211aa8f6da6044e99ceffe00122523d4f2cfd02263760814e90e48b90a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c860879-0b4c-44ce-b5fb-dd7df32d486b", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "original_text": "Robert Jones:  Great, thanks for the questions.  "}, "hash": "40b4c186f9d5874a9ff2e7f8b98c18de5a62b88f9274b866696040451f24c821", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 637, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c860879-0b4c-44ce-b5fb-dd7df32d486b": {"__data__": {"id_": "7c860879-0b4c-44ce-b5fb-dd7df32d486b", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "original_text": "Robert Jones:  Great, thanks for the questions.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a62dfb0-d771-46fb-9567-ac2231f1ab19", "node_type": "1", "metadata": {"window": "It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d4c89009012f67040efea827fedc497964f82f32aaa6ad2a9d4027f520ad503", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbae3d10-ee5a-4968-9ac7-1461f40ce83f", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.  ", "original_text": "I guess maybe just to move over to Medical, Mike.  \n"}, "hash": "9d6458a8bd8fa11ac158d1dd0fea3b99b04d7cdc42719e7f7b475766110f8e4d", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones:  Great, thanks for the questions.  ", "start_char_idx": 659, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbae3d10-ee5a-4968-9ac7-1461f40ce83f": {"__data__": {"id_": "cbae3d10-ee5a-4968-9ac7-1461f40ce83f", "embedding": null, "metadata": {"window": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.  ", "original_text": "I guess maybe just to move over to Medical, Mike.  \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c860879-0b4c-44ce-b5fb-dd7df32d486b", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Thank you.  \n \n Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "original_text": "Robert Jones:  Great, thanks for the questions.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d4fd47e045a283875720d28cb177b8baf254d19a9c837d3eb1590d136cfef47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9da43c84-d05d-4983-8ab0-11a6e545dd28", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  "}, "hash": "361b8238d3429bce004bdbda3cdbc2dffa15f68badaf10669ae6cf433df4e71a", "class_name": "RelatedNodeInfo"}}, "text": "I guess maybe just to move over to Medical, Mike.  \n", "start_char_idx": 708, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9da43c84-d05d-4983-8ab0-11a6e545dd28": {"__data__": {"id_": "9da43c84-d05d-4983-8ab0-11a6e545dd28", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbae3d10-ee5a-4968-9ac7-1461f40ce83f", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Robert Jones from Goldman Sachs.   Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.  ", "original_text": "I guess maybe just to move over to Medical, Mike.  \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05e14b9a4bcabf11f758e0d98b6356cbed46dd6b0df30362e0fd41903432f5bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea60b11d-29ff-4613-a294-a7c3f520ae1c", "node_type": "1", "metadata": {"window": "Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.  ", "original_text": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n"}, "hash": "cfd3acc230a7965d2977ba90bc5642106e74ebf3faa19f3184d450472525c263", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "start_char_idx": 760, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea60b11d-29ff-4613-a294-a7c3f520ae1c": {"__data__": {"id_": "ea60b11d-29ff-4613-a294-a7c3f520ae1c", "embedding": null, "metadata": {"window": "Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.  ", "original_text": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9da43c84-d05d-4983-8ab0-11a6e545dd28", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.  ", "original_text": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc6032742ea67e93911020ad22e4424ff01966d0083a8c7fe00a45455f0ceea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8", "node_type": "1", "metadata": {"window": "I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "d2de34de713a809df2236e8d37ef052d411e39b6d6e33c4c5b0a802fc246eb11", "class_name": "RelatedNodeInfo"}}, "text": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "start_char_idx": 880, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8": {"__data__": {"id_": "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8", "embedding": null, "metadata": {"window": "I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea60b11d-29ff-4613-a294-a7c3f520ae1c", "node_type": "1", "metadata": {"window": "Robert Jones:  Great, thanks for the questions.   I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.  ", "original_text": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "553a40aae95dca004706a4dd733f5a1762a257a3d0ca32a6c759da2aff52ecbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3c64642-ad48-4923-83dd-8856980a3e90", "node_type": "1", "metadata": {"window": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "original_text": "This is Jason.  "}, "hash": "163ccef87e43b532868b1cff36cc338695388b3bb6c9ba2a8daa145eedb7b1d2", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 1162, "end_char_idx": 1183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3c64642-ad48-4923-83dd-8856980a3e90": {"__data__": {"id_": "e3c64642-ad48-4923-83dd-8856980a3e90", "embedding": null, "metadata": {"window": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "original_text": "This is Jason.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8", "node_type": "1", "metadata": {"window": "I guess maybe just to move over to Medical, Mike.  \n Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "491dabc41519e179777a1b5b10fa4e48175fada3b58592f74945a8d1438d21b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1f616ec-87b0-4faf-9025-b3bf5203434e", "node_type": "1", "metadata": {"window": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "original_text": "Thanks for the question.  "}, "hash": "331df0b235d69f8b34836fa79053193e74adc5f3b22f2475b9141f7c1bb03c79", "class_name": "RelatedNodeInfo"}}, "text": "This is Jason.  ", "start_char_idx": 1183, "end_char_idx": 1199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1f616ec-87b0-4faf-9025-b3bf5203434e": {"__data__": {"id_": "c1f616ec-87b0-4faf-9025-b3bf5203434e", "embedding": null, "metadata": {"window": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "original_text": "Thanks for the question.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3c64642-ad48-4923-83dd-8856980a3e90", "node_type": "1", "metadata": {"window": "Obviously, COVID has created a couple cross currents in that business as far as PPE and then the \nlack of utilization.   Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "original_text": "This is Jason.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12a34cb3dffe8e92e9491e0e972460877e5a0c5c86c935fbbeb2b47782fff76e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "218115ee-a111-43fa-bdf0-fb93cfe0d177", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "original_text": "I'll start.  "}, "hash": "5b5202a5d8c4719611e7480e386e8faf4a88105988770e1d1bb3a494c9ac45d0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question.  ", "start_char_idx": 1199, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "218115ee-a111-43fa-bdf0-fb93cfe0d177": {"__data__": {"id_": "218115ee-a111-43fa-bdf0-fb93cfe0d177", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "original_text": "I'll start.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1f616ec-87b0-4faf-9025-b3bf5203434e", "node_type": "1", "metadata": {"window": "Could you maybe just tell us kind of where we are today as we think about those \ntwo broad buckets, the benef its that obviously you had and probably continue to see from PPE and \ntesting versus kind of the core business coming back as utilization starts to become more normal?  \n \n Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "original_text": "Thanks for the question.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52f94c42847657d90b8e5790ebf2cb32e884b319981e9b120ba9ee8b7e2b3e24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "250df231-868a-450a-b6c5-7db52ff8b7d3", "node_type": "1", "metadata": {"window": "This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "original_text": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  "}, "hash": "38ea149e17ec29b54932551ffb7e6c26bb80f6ef54494e956c5dbbc2bac039ba", "class_name": "RelatedNodeInfo"}}, "text": "I'll start.  ", "start_char_idx": 1225, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "250df231-868a-450a-b6c5-7db52ff8b7d3": {"__data__": {"id_": "250df231-868a-450a-b6c5-7db52ff8b7d3", "embedding": null, "metadata": {"window": "This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "original_text": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "218115ee-a111-43fa-bdf0-fb93cfe0d177", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "original_text": "I'll start.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5f9855992b707722f5f450d231aee6ee8219b0ceea1744e89a717d2f4dd5066", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae1ae84a-ede3-4cc1-ab47-eab7a5195051", "node_type": "1", "metadata": {"window": "Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "original_text": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  "}, "hash": "fb3071f919afe2d3fd342d968847350a44d291285c4636265eac81be16da45db", "class_name": "RelatedNodeInfo"}}, "text": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "start_char_idx": 1238, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae1ae84a-ede3-4cc1-ab47-eab7a5195051": {"__data__": {"id_": "ae1ae84a-ede3-4cc1-ab47-eab7a5195051", "embedding": null, "metadata": {"window": "Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "original_text": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "250df231-868a-450a-b6c5-7db52ff8b7d3", "node_type": "1", "metadata": {"window": "This is Jason.   Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "original_text": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4a8e10bd4ebf4cfbc01defa66e3f2caaf47e1bf54879414e9c45ef0b3f51606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6be404c-c056-4ec4-8a30-ee223adf30af", "node_type": "1", "metadata": {"window": "I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "original_text": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n"}, "hash": "7186ee9a21bda1a94d870b7beecec819c2149b4240dd40b4830e6a13cdc99702", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "start_char_idx": 1338, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6be404c-c056-4ec4-8a30-ee223adf30af": {"__data__": {"id_": "e6be404c-c056-4ec4-8a30-ee223adf30af", "embedding": null, "metadata": {"window": "I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "original_text": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae1ae84a-ede3-4cc1-ab47-eab7a5195051", "node_type": "1", "metadata": {"window": "Thanks for the question.   I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "original_text": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7510021c701ef2072b9fd45ad0fdce725f066dd86e292466145e26938d564f25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cf7e2e9-b026-4c07-9882-7514209e912c", "node_type": "1", "metadata": {"window": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "original_text": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  "}, "hash": "83f06025d31e6446e3b74e28be938bc7440fcaabc01cdb3c5deadd8957217d68", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "start_char_idx": 1541, "end_char_idx": 1682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cf7e2e9-b026-4c07-9882-7514209e912c": {"__data__": {"id_": "1cf7e2e9-b026-4c07-9882-7514209e912c", "embedding": null, "metadata": {"window": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "original_text": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6be404c-c056-4ec4-8a30-ee223adf30af", "node_type": "1", "metadata": {"window": "I'll start.   Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "original_text": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c35c4166967fb3ca300bb200175e7f0ed3aaa37fcec265884ab0223b007fc2fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c746874b-6973-44f4-89b4-8d1379ac92d9", "node_type": "1", "metadata": {"window": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "original_text": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  "}, "hash": "19e92b2cef63ea760b4f525ba90690d62b43bc07d0a849cec9e22f91088c7878", "class_name": "RelatedNodeInfo"}}, "text": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "start_char_idx": 1682, "end_char_idx": 1829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c746874b-6973-44f4-89b4-8d1379ac92d9": {"__data__": {"id_": "c746874b-6973-44f4-89b4-8d1379ac92d9", "embedding": null, "metadata": {"window": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "original_text": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cf7e2e9-b026-4c07-9882-7514209e912c", "node_type": "1", "metadata": {"window": "Within -- let's just kind of step \nback from a COVID perspective overall for the medical business.   As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "original_text": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a70e7430478c2ecbd08c52e5facefa9ebbbdd5831a09ca5aa40edfe36a87294", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1cc786a-cedd-4017-9f9e-14b044c2b7c0", "node_type": "1", "metadata": {"window": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n", "original_text": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n"}, "hash": "e25767d02d3723d1c114768d98f6e26f54923f6992378000b977a51c8a5e251d", "class_name": "RelatedNodeInfo"}}, "text": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "start_char_idx": 1829, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1cc786a-cedd-4017-9f9e-14b044c2b7c0": {"__data__": {"id_": "a1cc786a-cedd-4017-9f9e-14b044c2b7c0", "embedding": null, "metadata": {"window": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n", "original_text": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c746874b-6973-44f4-89b4-8d1379ac92d9", "node_type": "1", "metadata": {"window": "As I mentioned in my prior answer, \noverall, for the quarter, there was an insignificant impact in the quarter related to COVID, a lot of \nmoving pieces, and I'll get into  a couple of the key drivers.   As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "original_text": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f07bc68991e891c7220c93cb70af55283ae2870955a65875bdb06e882f3f3ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f178c35-9f67-4e42-97e8-54142dbf3e6d", "node_type": "1", "metadata": {"window": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n", "original_text": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  "}, "hash": "dcd7f7967e5bfc81a40df52714a11953a35f74c2d3d370fb71840c02f9389fc0", "class_name": "RelatedNodeInfo"}}, "text": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "start_char_idx": 1915, "end_char_idx": 2016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f178c35-9f67-4e42-97e8-54142dbf3e6d": {"__data__": {"id_": "5f178c35-9f67-4e42-97e8-54142dbf3e6d", "embedding": null, "metadata": {"window": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n", "original_text": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1cc786a-cedd-4017-9f9e-14b044c2b7c0", "node_type": "1", "metadata": {"window": "As a reminder, just like the pharma \ncomment earlier, there was a prior year pull -forward for PPE volume that we sold out of inventory.  \n \n So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n", "original_text": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "511ce9e185971b87af136b94f292c35ccf7cc316359594647c7a68b37b7ecab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a4b9c11-2240-4e02-b3e4-4388e189334b", "node_type": "1", "metadata": {"window": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "original_text": "But as I highlighted, it did improve at the tail \nend and back to the 90%.  "}, "hash": "d4776b2227b9778747da97360f1a4e6fae4c8c3be47e8f8fbc4d9888bf0c8099", "class_name": "RelatedNodeInfo"}}, "text": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "start_char_idx": 2016, "end_char_idx": 2172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a4b9c11-2240-4e02-b3e4-4388e189334b": {"__data__": {"id_": "9a4b9c11-2240-4e02-b3e4-4388e189334b", "embedding": null, "metadata": {"window": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "original_text": "But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f178c35-9f67-4e42-97e8-54142dbf3e6d", "node_type": "1", "metadata": {"window": "So we do have a slight negative year -over-year impact, which is related to the prior year  tailwind that \ndid not repeat in the current quarter.   So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n", "original_text": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20ae6033d9738013d09c2253db25ffc7a2da45ea694ea25f4d8ade7eb0918f93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4300b776-a7e3-4dee-af8d-3469cd08ac02", "node_type": "1", "metadata": {"window": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "original_text": "And that was very consistent with what we saw wi th the surge in the virus.  \n"}, "hash": "474739dc0592ff5f8621f4f8874e24dada40807a83315d3562895aec8dba2491", "class_name": "RelatedNodeInfo"}}, "text": "But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "start_char_idx": 2172, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4300b776-a7e3-4dee-af8d-3469cd08ac02": {"__data__": {"id_": "4300b776-a7e3-4dee-af8d-3469cd08ac02", "embedding": null, "metadata": {"window": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "original_text": "And that was very consistent with what we saw wi th the surge in the virus.  \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a4b9c11-2240-4e02-b3e4-4388e189334b", "node_type": "1", "metadata": {"window": "So the pieces within the quarter that we saw was ongoing \nelective volume headwinds.   And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "original_text": "But as I highlighted, it did improve at the tail \nend and back to the 90%.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5f1af2ca6373411d6913e727a4996aa0861265bcf4845d253baeb5fd6583144", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3364da33-91f8-420f-9666-fc9670c59d0f", "node_type": "1", "metadata": {"window": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n", "original_text": "And so we feel better about how we exited that quarter.  \n \n"}, "hash": "7f512a236443ddfdf89f11de942fbff8298d285c7a68091163695bcca4b17ba7", "class_name": "RelatedNodeInfo"}}, "text": "And that was very consistent with what we saw wi th the surge in the virus.  \n", "start_char_idx": 2248, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3364da33-91f8-420f-9666-fc9670c59d0f": {"__data__": {"id_": "3364da33-91f8-420f-9666-fc9670c59d0f", "embedding": null, "metadata": {"window": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n", "original_text": "And so we feel better about how we exited that quarter.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4300b776-a7e3-4dee-af8d-3469cd08ac02", "node_type": "1", "metadata": {"window": "And what we did see in the quarter was a little bit of a deterioration from \nthe prior quarter.   \n \n So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "original_text": "And that was very consistent with what we saw wi th the surge in the virus.  \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab3867f5fdbfa74a6f9b6c79c703b1969a36b214dfb2b0b0af693457626b72c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f09d1ca8-8f1d-4f85-88ac-4f67957602d3", "node_type": "1", "metadata": {"window": "But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.  ", "original_text": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  "}, "hash": "7b61eb66e079309cde40729a71f6d360648ca479db84897a1771985dcb7f5d41", "class_name": "RelatedNodeInfo"}}, "text": "And so we feel better about how we exited that quarter.  \n \n", "start_char_idx": 2326, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f09d1ca8-8f1d-4f85-88ac-4f67957602d3": {"__data__": {"id_": "f09d1ca8-8f1d-4f85-88ac-4f67957602d3", "embedding": null, "metadata": {"window": "But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.  ", "original_text": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3364da33-91f8-420f-9666-fc9670c59d0f", "node_type": "1", "metadata": {"window": "So we saw -- in my  comments in the prepared remarks, we saw that the utilization went down from \n95% in the second quarter to closer to 90% in the third.   But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n", "original_text": "And so we feel better about how we exited that quarter.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a0ad2a5e41f1cce910c4d32eb87bf9b28d14a273b4cb7449ece0f8275ebb7df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbf67aa8-08bc-409e-9044-72e0ee47a7e8", "node_type": "1", "metadata": {"window": "And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.  ", "original_text": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  "}, "hash": "ee2a3625756ac15a45fabd42e3499fdf890797a62d3eb83f42d8488ea8fac4f4", "class_name": "RelatedNodeInfo"}}, "text": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "start_char_idx": 2386, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbf67aa8-08bc-409e-9044-72e0ee47a7e8": {"__data__": {"id_": "fbf67aa8-08bc-409e-9044-72e0ee47a7e8", "embedding": null, "metadata": {"window": "And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.  ", "original_text": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f09d1ca8-8f1d-4f85-88ac-4f67957602d3", "node_type": "1", "metadata": {"window": "But as I highlighted, it did improve at the tail \nend and back to the 90%.   And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.  ", "original_text": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90d3cadf3aa55a7c5770d3702185a6b8faeab6a0f3341c72a14736945b2c2270", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34841d75-9253-47f3-b46e-d525802fb945", "node_type": "1", "metadata": {"window": "And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "original_text": "And that was an offset.   \n \n"}, "hash": "d4b4a7c28d217e3a2fcd7ad8acb4815d27bf5262b84d55b010bf3b5e41ca433a", "class_name": "RelatedNodeInfo"}}, "text": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "start_char_idx": 2570, "end_char_idx": 2719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34841d75-9253-47f3-b46e-d525802fb945": {"__data__": {"id_": "34841d75-9253-47f3-b46e-d525802fb945", "embedding": null, "metadata": {"window": "And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "original_text": "And that was an offset.   \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbf67aa8-08bc-409e-9044-72e0ee47a7e8", "node_type": "1", "metadata": {"window": "And that was very consistent with what we saw wi th the surge in the virus.  \n And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.  ", "original_text": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "403f66fd8dd35134cd2956ea9a5e67c59d8c463b10fd4fd3b51259c5a2cdb4d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "812ae11a-e69f-4e47-b0f3-f940fc20d6ed", "node_type": "1", "metadata": {"window": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And then we continue to see strong volumes with PPE.  "}, "hash": "8fc8eac733ab62d011f746c7b2b705738998413dd4f2c4cfae183accd05497dc", "class_name": "RelatedNodeInfo"}}, "text": "And that was an offset.   \n \n", "start_char_idx": 2719, "end_char_idx": 2748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "812ae11a-e69f-4e47-b0f3-f940fc20d6ed": {"__data__": {"id_": "812ae11a-e69f-4e47-b0f3-f940fc20d6ed", "embedding": null, "metadata": {"window": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And then we continue to see strong volumes with PPE.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34841d75-9253-47f3-b46e-d525802fb945", "node_type": "1", "metadata": {"window": "And so we feel better about how we exited that quarter.  \n \n And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "original_text": "And that was an offset.   \n \n", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "039d165017ce7d8bf959c2c2732b1b49179efe657b339e6ac1cf887de56f059f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af4a3b8-b1ac-497e-9be1-02fc1a730f14", "node_type": "1", "metadata": {"window": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "But again, you're comparing against a strong \nvolume quarter last year.  "}, "hash": "181a9c4bd7f8c89c30d581f178c49ec4ac3320699992d89d01bdcd5453e4f331", "class_name": "RelatedNodeInfo"}}, "text": "And then we continue to see strong volumes with PPE.  ", "start_char_idx": 2748, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af4a3b8-b1ac-497e-9be1-02fc1a730f14": {"__data__": {"id_": "8af4a3b8-b1ac-497e-9be1-02fc1a730f14", "embedding": null, "metadata": {"window": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "But again, you're comparing against a strong \nvolume quarter last year.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "812ae11a-e69f-4e47-b0f3-f940fc20d6ed", "node_type": "1", "metadata": {"window": "And why we did not change our guidance for the medical business as it relates to this topic as well \njust that we expected to be at or near pre -COVID levels by the end of t he year.   We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And then we continue to see strong volumes with PPE.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c169908649d352ccb5a074b7ccde218ffe93fd02b78a5c5482f1680344cd40c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9fe0325-5182-4dbc-be26-73e441c42096", "node_type": "1", "metadata": {"window": "And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  "}, "hash": "911c0d2743f59cccfe47b131cbc908dd2f2aac648484bb05c19b4294446f2a39", "class_name": "RelatedNodeInfo"}}, "text": "But again, you're comparing against a strong \nvolume quarter last year.  ", "start_char_idx": 2802, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9fe0325-5182-4dbc-be26-73e441c42096": {"__data__": {"id_": "a9fe0325-5182-4dbc-be26-73e441c42096", "embedding": null, "metadata": {"window": "And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af4a3b8-b1ac-497e-9be1-02fc1a730f14", "node_type": "1", "metadata": {"window": "We did continue to \nsee strength in our lab business, although it was a little bit less than what we had in the prior quarter, \nbut still strength.   And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "But again, you're comparing against a strong \nvolume quarter last year.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98694fce38ed934640524920cecff7680e24a008f7609f04406910282546740b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9252b78f-9ae6-4484-b419-9c6c332802f9", "node_type": "1", "metadata": {"window": "And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n "}, "hash": "56d99782feccdced22714fa845bee2ac5f7643d2bba17fe1ba52a285e286c5c4", "class_name": "RelatedNodeInfo"}}, "text": "And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "start_char_idx": 2875, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9252b78f-9ae6-4484-b419-9c6c332802f9": {"__data__": {"id_": "9252b78f-9ae6-4484-b419-9c6c332802f9", "embedding": null, "metadata": {"window": "And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "880d9008-ddfd-47e4-9575-109e5311232f", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb55cbb33222014847661844d4266048387c11db2eaafd77cb6782bf4ae6fcf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9fe0325-5182-4dbc-be26-73e441c42096", "node_type": "1", "metadata": {"window": "And that was an offset.   \n \n And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb63fde037dce0ed73c6c1c04d2e4e70fbc1072bd7b8444f7b0f84e445d8dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8d360d2-d85f-4881-8af2-30735f17ffda", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n", "original_text": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n"}, "hash": "20342a6ec49c1e0c16775457ae08aae9b5e8374791dcf86eeaaaeef81e2a320c", "class_name": "RelatedNodeInfo"}}, "text": "And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "start_char_idx": 3018, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8d360d2-d85f-4881-8af2-30735f17ffda": {"__data__": {"id_": "b8d360d2-d85f-4881-8af2-30735f17ffda", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n", "original_text": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9252b78f-9ae6-4484-b419-9c6c332802f9", "node_type": "1", "metadata": {"window": "And then we continue to see strong volumes with PPE.   But again, you're comparing against a strong \nvolume quarter last year.   And we did have some favorability still for the timing of the recognition of \nthe pricing cost associated with the much higher cost with PPE.   And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "original_text": "And those dynamics continue to be \nsomewhat fluid, but we do definitely still see higher costs, higher prices for some of the PPE products, \nespecially gloves, some moderation, but generally still elevated.   \n ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0f06c3b9f0809cffdc3c20b429f3df13bb9f66d20016a3bf9b5917aac0bdf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6445f51d-073f-44d5-89d9-41eb445c5239", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "original_text": "Mike Kaufmann:  No, I think that sums it up well.  \n \n"}, "hash": "e3aa96b1ce60d45df7729cccf5829984f4c3de1f641fad7c65dabfaea6291d77", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n", "start_char_idx": 0, "end_char_idx": 55, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6445f51d-073f-44d5-89d9-41eb445c5239": {"__data__": {"id_": "6445f51d-073f-44d5-89d9-41eb445c5239", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "original_text": "Mike Kaufmann:  No, I think that sums it up well.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8d360d2-d85f-4881-8af2-30735f17ffda", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n", "original_text": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69a14aaf7a4a5a1c4bf21e988127df901316aa136aebc73a3d16a09f72f8662b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2edb8b29-c778-4a95-93ba-3351b0a4ce98", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n", "original_text": "Robert Jones:  Great.  "}, "hash": "c234fd2d47e5347493c383e5a20af30f176880e2f51672967e735c383184bd2f", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  No, I think that sums it up well.  \n \n", "start_char_idx": 55, "end_char_idx": 109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2edb8b29-c778-4a95-93ba-3351b0a4ce98": {"__data__": {"id_": "2edb8b29-c778-4a95-93ba-3351b0a4ce98", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n", "original_text": "Robert Jones:  Great.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6445f51d-073f-44d5-89d9-41eb445c5239", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "original_text": "Mike Kaufmann:  No, I think that sums it up well.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d5dae201fdfbc4b50b9067946ac130e9d7529e0222f889dd8078841ab2f1dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d201a471-b72e-43e5-8cf6-d0b4bf007294", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.  ", "original_text": "Thanks.  \n \n"}, "hash": "b842368bbc1c995a5a28958805789e380dc15399f8614179ef2cd3cc243a471e", "class_name": "RelatedNodeInfo"}}, "text": "Robert Jones:  Great.  ", "start_char_idx": 109, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d201a471-b72e-43e5-8cf6-d0b4bf007294": {"__data__": {"id_": "d201a471-b72e-43e5-8cf6-d0b4bf007294", "embedding": null, "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.  ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2edb8b29-c778-4a95-93ba-3351b0a4ce98", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n", "original_text": "Robert Jones:  Great.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e06fd96f0ac50ef8509994e01560529238f402aae96a4cced74b3fb595201bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5de277c-edc3-420e-96c0-6549e4a886a9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.  ", "original_text": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  "}, "hash": "a97990a55e7f74bda285f5c994534f1ec823be487142f092680b14129c915383", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 132, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5de277c-edc3-420e-96c0-6549e4a886a9": {"__data__": {"id_": "e5de277c-edc3-420e-96c0-6549e4a886a9", "embedding": null, "metadata": {"window": "Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.  ", "original_text": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d201a471-b72e-43e5-8cf6-d0b4bf007294", "node_type": "1", "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.  ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57b7714ca35342c4bbe4b126b1fd40c213dcd2e5c9953603f91efbaab23a430f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38beeca2-b856-4cc4-b35a-f408d27f02d9", "node_type": "1", "metadata": {"window": "Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "original_text": "Please go \nahead.  \n \n"}, "hash": "42ef27eeefaf5f239da55f5dd18671a22ba86835576c0d1261430de80cab0a42", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "start_char_idx": 144, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38beeca2-b856-4cc4-b35a-f408d27f02d9": {"__data__": {"id_": "38beeca2-b856-4cc4-b35a-f408d27f02d9", "embedding": null, "metadata": {"window": "Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5de277c-edc3-420e-96c0-6549e4a886a9", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.  ", "original_text": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38caa7e8152b4bd032d0bfb43db1810eac125219323a45554e0ea9594b9e7c45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ade424f1-82b1-44e0-a68e-221362971b95", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "original_text": "Steven Valiquette:  Hey, thanks.  "}, "hash": "1fd98800dec8b2c0f2372ed3fe96deae3105eb9bac15ab090572b7a37c260645", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 233, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ade424f1-82b1-44e0-a68e-221362971b95": {"__data__": {"id_": "ade424f1-82b1-44e0-a68e-221362971b95", "embedding": null, "metadata": {"window": "Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "original_text": "Steven Valiquette:  Hey, thanks.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38beeca2-b856-4cc4-b35a-f408d27f02d9", "node_type": "1", "metadata": {"window": "Robert Jones:  Great.   Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "original_text": "Please go \nahead.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4da1fa3699e2ceeb6f84af1c9192450647e1df0f1b406dc102426acbcf35f27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.  ", "original_text": "Good morning, guys.  "}, "hash": "18c793dabf0fe8cb5384b93a6824f6e87497e1cfd91f8233287bf5a8027ad56b", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Hey, thanks.  ", "start_char_idx": 255, "end_char_idx": 289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9": {"__data__": {"id_": "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9", "embedding": null, "metadata": {"window": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.  ", "original_text": "Good morning, guys.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ade424f1-82b1-44e0-a68e-221362971b95", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "original_text": "Steven Valiquette:  Hey, thanks.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56314b60164c57550ea052e9aa950b9405e6ed0bbe9d6ffa07be19713ebb5e04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f25631a-708e-4f79-a3ba-2d405df247df", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.  ", "original_text": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  "}, "hash": "bfac27c65a2def8202d2c62bc149dea59874c2e241381374703b393a3e04ba99", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys.  ", "start_char_idx": 289, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f25631a-708e-4f79-a3ba-2d405df247df": {"__data__": {"id_": "5f25631a-708e-4f79-a3ba-2d405df247df", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.  ", "original_text": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Steven Valiquette from Barclays.   Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.  ", "original_text": "Good morning, guys.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0fa9e1af8ce0745d2a6d9a7be0f2d59611de23e8c30d85ecba473046a6e68e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "original_text": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  "}, "hash": "a21dd7ed9620b40de2d338462634e7089bfeb6cc4811809cbf1abe651dfc6813", "class_name": "RelatedNodeInfo"}}, "text": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "start_char_idx": 310, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711": {"__data__": {"id_": "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711", "embedding": null, "metadata": {"window": "Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "original_text": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f25631a-708e-4f79-a3ba-2d405df247df", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.  ", "original_text": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fd9fe59bc6e9d546b621586c86a72fa3dd5720b58eff13fc47c8ac841fc45c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "129dd82f-985b-41ef-af0c-414af3fac587", "node_type": "1", "metadata": {"window": "Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I'm just curious if that's \nconsistent with what you saw.  "}, "hash": "8b3f518b34b76e7b5c08250cd941cb67289850a7302a5b009340d342109e4f29", "class_name": "RelatedNodeInfo"}}, "text": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "start_char_idx": 421, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "129dd82f-985b-41ef-af0c-414af3fac587": {"__data__": {"id_": "129dd82f-985b-41ef-af0c-414af3fac587", "embedding": null, "metadata": {"window": "Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I'm just curious if that's \nconsistent with what you saw.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Hey, thanks.   Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "original_text": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8f4dd81790e723b2ba6a19af54086d3e945f53a3e6b0bd212ddbc86ebd4df18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35aed165-5d68-446a-8260-4af44af5781c", "node_type": "1", "metadata": {"window": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "original_text": "I just want to confirm that one way or the other.  "}, "hash": "129a62ab2580de42e615242afed973198bb887aec6ec1f0788cac23a67b982a5", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious if that's \nconsistent with what you saw.  ", "start_char_idx": 730, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35aed165-5d68-446a-8260-4af44af5781c": {"__data__": {"id_": "35aed165-5d68-446a-8260-4af44af5781c", "embedding": null, "metadata": {"window": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "original_text": "I just want to confirm that one way or the other.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "129dd82f-985b-41ef-af0c-414af3fac587", "node_type": "1", "metadata": {"window": "Good morning, guys.   Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I'm just curious if that's \nconsistent with what you saw.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1599f4b16395db47777578ce2f933fe0d089abc096a3908b894cf7bb3a348573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ca90702-7116-43f8-b562-32f4d1457334", "node_type": "1", "metadata": {"window": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.  ", "original_text": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n"}, "hash": "54feb15d55880453343a42993823e106aa4b43eabbeaea96a337ff0568e0373c", "class_name": "RelatedNodeInfo"}}, "text": "I just want to confirm that one way or the other.  ", "start_char_idx": 789, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ca90702-7116-43f8-b562-32f4d1457334": {"__data__": {"id_": "1ca90702-7116-43f8-b562-32f4d1457334", "embedding": null, "metadata": {"window": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.  ", "original_text": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35aed165-5d68-446a-8260-4af44af5781c", "node_type": "1", "metadata": {"window": "Usually, when there is some negative \nsupply/demand imbalance o n commoditized products, it can impact price.   So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "original_text": "I just want to confirm that one way or the other.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7d78423bb06c53cd5dc0c8218a023fa7a517436834f0db26563ecde320443b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc2d91e3-7511-490d-be2a-87aabd798a79", "node_type": "1", "metadata": {"window": "I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "05f666f14cc9c3bc5931f6ebf09a293731b0b371f50bc6ae9266c1a1e2b8105c", "class_name": "RelatedNodeInfo"}}, "text": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "start_char_idx": 840, "end_char_idx": 935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc2d91e3-7511-490d-be2a-87aabd798a79": {"__data__": {"id_": "dc2d91e3-7511-490d-be2a-87aabd798a79", "embedding": null, "metadata": {"window": "I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ca90702-7116-43f8-b562-32f4d1457334", "node_type": "1", "metadata": {"window": "So with the softer generic \nvolume on those categories that you mentioned, the antibacterials, antibiotics, et cetera, I guess for \nme, I would just visualize that both the buy side and the sell -side pricing wou ld maybe come down \nsimultaneously on those products in conjunction with the softer Rx demand.   I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.  ", "original_text": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6baaee9c9ea66faffb4b977e9a655a3bb7fb8a888ba7d86dfd3be1066d8508f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef", "node_type": "1", "metadata": {"window": "I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n", "original_text": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  "}, "hash": "6d2548cfbcb83b9c9fb8fab610781e1e0469fb39ee7562201b858f2099086cd8", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 935, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef": {"__data__": {"id_": "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef", "embedding": null, "metadata": {"window": "I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n", "original_text": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc2d91e3-7511-490d-be2a-87aabd798a79", "node_type": "1", "metadata": {"window": "I'm just curious if that's \nconsistent with what you saw.   I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7086fe5b96c88b20004837e8555b947f04116b6179e90ea4f406356492e587e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f", "node_type": "1", "metadata": {"window": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "original_text": "Nothing pops out to \nme relat ed to that component of the driver.  "}, "hash": "30a71ffcd482dc33c3d257a751bb6ff4ddb46040d69b92e4817b03f2d6c2bb6c", "class_name": "RelatedNodeInfo"}}, "text": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "start_char_idx": 957, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f": {"__data__": {"id_": "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f", "embedding": null, "metadata": {"window": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "original_text": "Nothing pops out to \nme relat ed to that component of the driver.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef", "node_type": "1", "metadata": {"window": "I just want to confirm that one way or the other.   So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n", "original_text": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "915acf40e516ab37259fe0394c1ac7617ec9a479ee9aa19c52ee4b4188105406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0563140-608f-43f1-9704-83d84f28f481", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.  ", "original_text": "As I said, really, overall, the generics program market \ndynamics were generally consistent.  "}, "hash": "cece6a02ea88df0da3385edba899db7f7f5ee149103a5aac128907abad5f165b", "class_name": "RelatedNodeInfo"}}, "text": "Nothing pops out to \nme relat ed to that component of the driver.  ", "start_char_idx": 1125, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0563140-608f-43f1-9704-83d84f28f481": {"__data__": {"id_": "b0563140-608f-43f1-9704-83d84f28f481", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.  ", "original_text": "As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f", "node_type": "1", "metadata": {"window": "So not to beat this \ntopic to death, but just wanted to get some confirmation around that.  \n \n Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "original_text": "Nothing pops out to \nme relat ed to that component of the driver.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46600f14e62243b3d99f11abf42433635397b84ba41a4ef29bf406f0c28b78a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af93bc6c-8e7c-4d32-b074-b5501139faac", "node_type": "1", "metadata": {"window": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.  ", "original_text": "It was more just a volume -related item on those categories.  \n"}, "hash": "da67a52eeb5aa4ee60ec4bcb4f74bb9283ab31439da2c5e4a4c1479342e60108", "class_name": "RelatedNodeInfo"}}, "text": "As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "start_char_idx": 1192, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af93bc6c-8e7c-4d32-b074-b5501139faac": {"__data__": {"id_": "af93bc6c-8e7c-4d32-b074-b5501139faac", "embedding": null, "metadata": {"window": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.  ", "original_text": "It was more just a volume -related item on those categories.  \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0563140-608f-43f1-9704-83d84f28f481", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.  ", "original_text": "As I said, really, overall, the generics program market \ndynamics were generally consistent.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f84519a60df97423ce740f24e7f73dbbaa1045eba150b8cb4b8f7e989c30ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f945123-54eb-4191-a9a4-4e2ad371f67d", "node_type": "1", "metadata": {"window": "Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n", "original_text": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n"}, "hash": "5e031d997f06664fe491cf63dba0a179357a4f3cfd0160dc9465eca914c5c349", "class_name": "RelatedNodeInfo"}}, "text": "It was more just a volume -related item on those categories.  \n", "start_char_idx": 1286, "end_char_idx": 1349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f945123-54eb-4191-a9a4-4e2ad371f67d": {"__data__": {"id_": "2f945123-54eb-4191-a9a4-4e2ad371f67d", "embedding": null, "metadata": {"window": "Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n", "original_text": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af93bc6c-8e7c-4d32-b074-b5501139faac", "node_type": "1", "metadata": {"window": "That's a hard question to answer in the sense of the level of detail of looking \nat all of our -- both our buy side and sell side for all those individual categories.   Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.  ", "original_text": "It was more just a volume -related item on those categories.  \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46a0ef5ee44e42ef89e94bc618d6102180584be1fbe29cc3ab9f45a348e8d7f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5", "node_type": "1", "metadata": {"window": "As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "original_text": "Steven Valiquette:  Okay.  "}, "hash": "91a82d6ae709a2ab9434c04bcb0db9ef53047727eb6bd329315f6e731c882885", "class_name": "RelatedNodeInfo"}}, "text": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "start_char_idx": 1349, "end_char_idx": 1434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5": {"__data__": {"id_": "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5", "embedding": null, "metadata": {"window": "As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "original_text": "Steven Valiquette:  Okay.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f945123-54eb-4191-a9a4-4e2ad371f67d", "node_type": "1", "metadata": {"window": "Nothing pops out to \nme relat ed to that component of the driver.   As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n", "original_text": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f68fdb2f4d7aab4d7c8d96a6360cde773d2a70c7b6264ffa1e83c0c6877d2787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e", "node_type": "1", "metadata": {"window": "It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n", "original_text": "Okay.  "}, "hash": "8138f8f629b6957a0cfbaec6c2e2eb348d79e5794dd0c6c1d1a566daf92cf6c4", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquette:  Okay.  ", "start_char_idx": 1434, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e": {"__data__": {"id_": "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e", "embedding": null, "metadata": {"window": "It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n", "original_text": "Okay.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5", "node_type": "1", "metadata": {"window": "As I said, really, overall, the generics program market \ndynamics were generally consistent.   It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "original_text": "Steven Valiquette:  Okay.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba384ca866b50c76e508f946c9c523ad1005c08c3907bcd68415b0c50cf05381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "646b7f65-0d94-4154-825b-58f1a6df4d7e", "node_type": "1", "metadata": {"window": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.  ", "original_text": "All right, thanks.  \n \n"}, "hash": "ab6814b1de9bab7444dd0b26751a67c46d9136aab5ac01ffbce0b40e74543983", "class_name": "RelatedNodeInfo"}}, "text": "Okay.  ", "start_char_idx": 1454, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "646b7f65-0d94-4154-825b-58f1a6df4d7e": {"__data__": {"id_": "646b7f65-0d94-4154-825b-58f1a6df4d7e", "embedding": null, "metadata": {"window": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.  ", "original_text": "All right, thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e", "node_type": "1", "metadata": {"window": "It was more just a volume -related item on those categories.  \n Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n", "original_text": "Okay.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5bccdab4c3f8541a848d886d55ab8468594b2628c30df63cee3d31b97769a41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04741d67-dd61-4ecc-ae85-6565bfa16368", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.  ", "original_text": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  "}, "hash": "913b43550707eec12b4a2c0fdf112795b2da77125d4763667b48f3d1df42d57f", "class_name": "RelatedNodeInfo"}}, "text": "All right, thanks.  \n \n", "start_char_idx": 1468, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04741d67-dd61-4ecc-ae85-6565bfa16368": {"__data__": {"id_": "04741d67-dd61-4ecc-ae85-6565bfa16368", "embedding": null, "metadata": {"window": "Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.  ", "original_text": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "646b7f65-0d94-4154-825b-58f1a6df4d7e", "node_type": "1", "metadata": {"window": "Nothing stands out in pricing, whether it be buy or sell that I w ould call out.  \n \n Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.  ", "original_text": "All right, thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f303eb0e8094707de58bd5e37ec155788b4331a914777915292c148ce6842e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c313822b-6c9d-47c6-9ef3-ef7eec23143b", "node_type": "1", "metadata": {"window": "Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "original_text": "Please go ahead.  \n \n"}, "hash": "75a5e0a483ea92d4f09ea5feb348a1f7c8e7eed34d0887aaf6e6f52ed48c3262", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "start_char_idx": 1491, "end_char_idx": 1572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c313822b-6c9d-47c6-9ef3-ef7eec23143b": {"__data__": {"id_": "c313822b-6c9d-47c6-9ef3-ef7eec23143b", "embedding": null, "metadata": {"window": "Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04741d67-dd61-4ecc-ae85-6565bfa16368", "node_type": "1", "metadata": {"window": "Steven Valiquette:  Okay.   Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.  ", "original_text": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "828941c45cdb20c8cbd969399a2d0e79ab25cade0139bdec60d94c42a77d71b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03a6e726-26bb-4d57-9614-3dc47cbe817d", "node_type": "1", "metadata": {"window": "All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "original_text": "Lisa Gill:  Great.  "}, "hash": "ac4239c86fc0efa58662ddee1801c497f1b7dce4c1be26a74cf2f60a84dc1eb3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1572, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03a6e726-26bb-4d57-9614-3dc47cbe817d": {"__data__": {"id_": "03a6e726-26bb-4d57-9614-3dc47cbe817d", "embedding": null, "metadata": {"window": "All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "original_text": "Lisa Gill:  Great.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c313822b-6c9d-47c6-9ef3-ef7eec23143b", "node_type": "1", "metadata": {"window": "Okay.   All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9acdbd3191c7817834e4dd14bc89349ea3f139ef853d5003646571920cdd6484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a418f7b-7578-4777-b214-bbe9d20ddba2", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Thanks very much, and good morning, Mike and Jason.  "}, "hash": "fb1e4618069f8c5deef19c7a9bde6d56519598d11627e03fce2d31252a2115a8", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Great.  ", "start_char_idx": 1593, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a418f7b-7578-4777-b214-bbe9d20ddba2": {"__data__": {"id_": "9a418f7b-7578-4777-b214-bbe9d20ddba2", "embedding": null, "metadata": {"window": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Thanks very much, and good morning, Mike and Jason.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03a6e726-26bb-4d57-9614-3dc47cbe817d", "node_type": "1", "metadata": {"window": "All right, thanks.  \n \n Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "original_text": "Lisa Gill:  Great.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93ec0b9ea4631d32223ace3836e9cfaeda19a41fb4c39925504400f243d6af5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80dd576d-12af-4821-a5bf-5477db9b4257", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.  ", "original_text": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n"}, "hash": "0d428855b5c7bb9e7e42894d8d9a2fe556c23aab7df417053b5659ef9fc8f0eb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much, and good morning, Mike and Jason.  ", "start_char_idx": 1613, "end_char_idx": 1666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80dd576d-12af-4821-a5bf-5477db9b4257": {"__data__": {"id_": "80dd576d-12af-4821-a5bf-5477db9b4257", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.  ", "original_text": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a418f7b-7578-4777-b214-bbe9d20ddba2", "node_type": "1", "metadata": {"window": "Operator:  And we'll move on to our next question from Lisa Gill from JPMorgan.   Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.  ", "original_text": "Thanks very much, and good morning, Mike and Jason.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afeaa5111a18e97ce6bfa073a10eb2cfbf6f06bc9f45558fee1e7abd297482f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff9ee9e4-7df3-4779-b362-2bb511cb208f", "node_type": "1", "metadata": {"window": "Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.  ", "original_text": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n"}, "hash": "977beeb20cede8499d18a8c0793d9901ff9c36cd5864a56066b6d2a52ff7e5b5", "class_name": "RelatedNodeInfo"}}, "text": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "start_char_idx": 1666, "end_char_idx": 1792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff9ee9e4-7df3-4779-b362-2bb511cb208f": {"__data__": {"id_": "ff9ee9e4-7df3-4779-b362-2bb511cb208f", "embedding": null, "metadata": {"window": "Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.  ", "original_text": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80dd576d-12af-4821-a5bf-5477db9b4257", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.  ", "original_text": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "848b4b2774d46519d259b7ead7625e03b46c63227248c4dd20f08f832dcdd1f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d8cdcfb-63e9-424c-b06c-12864c385745", "node_type": "1", "metadata": {"window": "Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "original_text": "Mike Kaufmann:  Sure.  "}, "hash": "9b2f8ef3170e77b6d1b7df2b5c6d4b6056c8d055999f500d3aa611bdfe11b0c9", "class_name": "RelatedNodeInfo"}}, "text": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "start_char_idx": 1792, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d8cdcfb-63e9-424c-b06c-12864c385745": {"__data__": {"id_": "0d8cdcfb-63e9-424c-b06c-12864c385745", "embedding": null, "metadata": {"window": "Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff9ee9e4-7df3-4779-b362-2bb511cb208f", "node_type": "1", "metadata": {"window": "Lisa Gill:  Great.   Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.  ", "original_text": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da467e1411bb38c3ba20da8be444c8c419f708b67681288f935821d1613e1ef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d18f3f50-3610-4d00-a06e-aec47fa1cc38", "node_type": "1", "metadata": {"window": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.  ", "original_text": "Yes.  "}, "hash": "89bc94e1074aa833d8cc2eebb4c97f772bb458f0e76cb4788262468711562f82", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Sure.  ", "start_char_idx": 1954, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d18f3f50-3610-4d00-a06e-aec47fa1cc38": {"__data__": {"id_": "d18f3f50-3610-4d00-a06e-aec47fa1cc38", "embedding": null, "metadata": {"window": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.  ", "original_text": "Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d8cdcfb-63e9-424c-b06c-12864c385745", "node_type": "1", "metadata": {"window": "Thanks very much, and good morning, Mike and Jason.   Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "original_text": "Mike Kaufmann:  Sure.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee0135e5b0981e93b1353331812fdbf67257aa5b72dc64c3302f601347240c6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319", "node_type": "1", "metadata": {"window": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "original_text": "I can start and then turn it over to Jason.  "}, "hash": "f5f874474eb68ad94a9ca510c649595503f20de56e80396a0a6aacdadbd5fd25", "class_name": "RelatedNodeInfo"}}, "text": "Yes.  ", "start_char_idx": 951, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319": {"__data__": {"id_": "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319", "embedding": null, "metadata": {"window": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "original_text": "I can start and then turn it over to Jason.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d18f3f50-3610-4d00-a06e-aec47fa1cc38", "node_type": "1", "metadata": {"window": "Just really wa nt to try to \nunderstand the puts and takes as we think about COVID going into 2022 from a comp perspective.  \n Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.  ", "original_text": "Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "135cc5693d43e84da3e07660c278d9d4880795a51d45961da1f58c31ea04abad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "158b3ee0-e1b6-4311-8470-63a9eb958b88", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "original_text": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  "}, "hash": "9543627187d75398af0051cbbbb1f51d99d07954f96272fac0f77d4bd9537679", "class_name": "RelatedNodeInfo"}}, "text": "I can start and then turn it over to Jason.  ", "start_char_idx": 1983, "end_char_idx": 2028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "158b3ee0-e1b6-4311-8470-63a9eb958b88": {"__data__": {"id_": "158b3ee0-e1b6-4311-8470-63a9eb958b88", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "original_text": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319", "node_type": "1", "metadata": {"window": "Can you just remind us what the benefit or what the headwind has been for medical and pharmacy as \nwe think about trying to model that going into ne xt year?  \n \n Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "original_text": "I can start and then turn it over to Jason.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c877e37ad7545b39752d07c77fbbe36b7362397338ac3e2cb1fcb247c5af6d72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecee0e46-5ec0-4776-9e76-5313e43dd083", "node_type": "1", "metadata": {"window": "Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "original_text": "I'll st art with the fact that we still feel really good about our growth areas.  "}, "hash": "a174b936825f7a5364ff547e0d6adbac57ab9cf4872ec2469e0ad6ba4a2364c1", "class_name": "RelatedNodeInfo"}}, "text": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "start_char_idx": 2028, "end_char_idx": 2195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecee0e46-5ec0-4776-9e76-5313e43dd083": {"__data__": {"id_": "ecee0e46-5ec0-4776-9e76-5313e43dd083", "embedding": null, "metadata": {"window": "Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "original_text": "I'll st art with the fact that we still feel really good about our growth areas.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "158b3ee0-e1b6-4311-8470-63a9eb958b88", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Sure.   Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "original_text": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f36f4fd7840a2b9a891afe632c2c3f4daed6cf252da80ecab1d09005e40fd2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d39416e-829a-4cec-be1a-75868abadda6", "node_type": "1", "metadata": {"window": "I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "original_text": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n"}, "hash": "2bebe535d48b849e13a0ed4e5ab70f04843cdbc42597fad26eea9caa61733a8a", "class_name": "RelatedNodeInfo"}}, "text": "I'll st art with the fact that we still feel really good about our growth areas.  ", "start_char_idx": 2195, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d39416e-829a-4cec-be1a-75868abadda6": {"__data__": {"id_": "9d39416e-829a-4cec-be1a-75868abadda6", "embedding": null, "metadata": {"window": "I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "original_text": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecee0e46-5ec0-4776-9e76-5313e43dd083", "node_type": "1", "metadata": {"window": "Yes.   I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "original_text": "I'll st art with the fact that we still feel really good about our growth areas.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3cda9794ac107ddcea5c71fb886ae5068840204bb76c71c2130b0f4ddd23eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b365270-3af7-45c7-82f3-376d386bfe70", "node_type": "1", "metadata": {"window": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.  ", "original_text": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  "}, "hash": "207708ac151286ac7468aa56168c2261320a55a07b600cc04523ee9476eb04a2", "class_name": "RelatedNodeInfo"}}, "text": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "start_char_idx": 2277, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b365270-3af7-45c7-82f3-376d386bfe70": {"__data__": {"id_": "0b365270-3af7-45c7-82f3-376d386bfe70", "embedding": null, "metadata": {"window": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.  ", "original_text": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d39416e-829a-4cec-be1a-75868abadda6", "node_type": "1", "metadata": {"window": "I can start and then turn it over to Jason.   As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "original_text": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f830446a5393515320c2f6785591437cce72ab92422c73f0e6471d6f752f66a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e99b6fbf-9f1e-47c5-9364-532816425dbc", "node_type": "1", "metadata": {"window": "I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  "}, "hash": "bd9de99051572bc90e53df3072a81203091328b6c238d6d9bc2ace1362991680", "class_name": "RelatedNodeInfo"}}, "text": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "start_char_idx": 2419, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e99b6fbf-9f1e-47c5-9364-532816425dbc": {"__data__": {"id_": "e99b6fbf-9f1e-47c5-9364-532816425dbc", "embedding": null, "metadata": {"window": "I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b365270-3af7-45c7-82f3-376d386bfe70", "node_type": "1", "metadata": {"window": "As you know, our practice is \nthat we're not -- we don't provide formal guidance on '22 until August, but we'll try to give you a little \nbit of color to be helpful.   I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.  ", "original_text": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "217da00c7e3e4333a2391868a23f0b90fcc6801357843ff58bb4715df8e817aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50325fc1-a663-4da1-a8ac-9e5eafa8292a", "node_type": "1", "metadata": {"window": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.  ", "original_text": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n"}, "hash": "a2b47677cde64cb1d76639f4c0ff06f23e9248f10301853a49c4001ea451e7f6", "class_name": "RelatedNodeInfo"}}, "text": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "start_char_idx": 2613, "end_char_idx": 2716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50325fc1-a663-4da1-a8ac-9e5eafa8292a": {"__data__": {"id_": "50325fc1-a663-4da1-a8ac-9e5eafa8292a", "embedding": null, "metadata": {"window": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.  ", "original_text": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e99b6fbf-9f1e-47c5-9364-532816425dbc", "node_type": "1", "metadata": {"window": "I'll st art with the fact that we still feel really good about our growth areas.   So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.  ", "original_text": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7d7670750b70051820d85c07c797b9406d053a84472ee41e017ccfa5a25201f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a536b0-7a68-4e81-adfd-c524245e2f1d", "node_type": "1", "metadata": {"window": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "43586d2eeeeeaeb1d1f66a9bc7fc5f539fec8070c26ab87ababf79978bcc30e7", "class_name": "RelatedNodeInfo"}}, "text": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "start_char_idx": 2716, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a536b0-7a68-4e81-adfd-c524245e2f1d": {"__data__": {"id_": "54a536b0-7a68-4e81-adfd-c524245e2f1d", "embedding": null, "metadata": {"window": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50325fc1-a663-4da1-a8ac-9e5eafa8292a", "node_type": "1", "metadata": {"window": "So \nwhen we think about specialty, at -home, nuclear, medical services and Outcomes, we feel really good \nabout all of these businesses.   \n \n We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.  ", "original_text": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8a0a5fae4afc699b6926153a14c76499e000c5f10e1f909604886a58fff6064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1af5c3-58e7-43ce-bd1a-7d5964819955", "node_type": "1", "metadata": {"window": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Thanks, Mike.  "}, "hash": "992b9b9f22d24c2b6131464aa2988eaa77f87f40de4c7f5b175018d2dc58a699", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 2817, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1af5c3-58e7-43ce-bd1a-7d5964819955": {"__data__": {"id_": "ca1af5c3-58e7-43ce-bd1a-7d5964819955", "embedding": null, "metadata": {"window": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Thanks, Mike.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a536b0-7a68-4e81-adfd-c524245e2f1d", "node_type": "1", "metadata": {"window": "We think they all have strong industry trends , strong outlooks, complementary capabilities to our \nbusinesses and our -- we continue to adapt their offerings to focus on our customers' needs.   So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da38d8fd3b8deba74369bd0b463875c107174244e3c8402a198d31f958731c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe75f863-7c19-44db-b9db-2ec5b7f75979", "node_type": "1", "metadata": {"window": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Yes.  "}, "hash": "7cdc9a8bf3df6d3e5ac89e96aa33c0e23c7c5f8f836a218a0e74968032344ab5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Mike.  ", "start_char_idx": 2839, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe75f863-7c19-44db-b9db-2ec5b7f75979": {"__data__": {"id_": "fe75f863-7c19-44db-b9db-2ec5b7f75979", "embedding": null, "metadata": {"window": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1af5c3-58e7-43ce-bd1a-7d5964819955", "node_type": "1", "metadata": {"window": "So I \nwould say we would still expect all of those growth areas to be positive drivers for next year.   And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Thanks, Mike.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d06f31c3ee9b4a1efd59d5cedaf59a2e12078f43f55dd5978a5f2965533d104c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8c7523-ba18-49d0-a63c-d87b82a64ccd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments "}, "hash": "358830d455b6e0bdf7375c6e21dbee0976c982f6cb14507a866820558e9af651", "class_name": "RelatedNodeInfo"}}, "text": "Yes.  ", "start_char_idx": 951, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8c7523-ba18-49d0-a63c-d87b82a64ccd": {"__data__": {"id_": "8c8c7523-ba18-49d0-a63c-d87b82a64ccd", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0068e4db195012e6dcdea96ac17cdb5b7f834f00bbca1f71635b41b9dbc7c510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe75f863-7c19-44db-b9db-2ec5b7f75979", "node_type": "1", "metadata": {"window": "And \nthen let me have Jason give you a little bit of color on maybe a few of the other dynamics.  \n \n Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "Yes.  ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95260ecd2d04af15887755cbd858249f3c5253261370da3d4062ea0f10a9144a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "369c9ca2-833c-4b87-bc30-c07cc75bb060", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "original_text": " \nPage 11 of 14 \n \nin those businesses.  "}, "hash": "673946d814de7e1a5e92ab9688cc9d2f3a837c7a35beb7329442675b7dd16eb9", "class_name": "RelatedNodeInfo"}}, "text": "And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "start_char_idx": 2860, "end_char_idx": 3023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369c9ca2-833c-4b87-bc30-c07cc75bb060": {"__data__": {"id_": "369c9ca2-833c-4b87-bc30-c07cc75bb060", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "original_text": " \nPage 11 of 14 \n \nin those businesses.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8c7523-ba18-49d0-a63c-d87b82a64ccd", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Thanks, Mike.   Yes.   And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "original_text": "And to enable -- let me just start with, to enable those types \nof growth areas, we are making investments in our business, and we'll continue to make investments ", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11aa0b2a5492859acee6bfd34c0d4d0a35e5873cbd3555b26277e89fe7e93def", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6137a5de-b0e6-467b-95e7-f0f25b15f0b0", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.  ", "original_text": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n"}, "hash": "cbb46852a4e2e0b5fbc292646cec653b782831e7f837e5463728d2fd4c54aa41", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 14 \n \nin those businesses.  ", "start_char_idx": 0, "end_char_idx": 41, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6137a5de-b0e6-467b-95e7-f0f25b15f0b0": {"__data__": {"id_": "6137a5de-b0e6-467b-95e7-f0f25b15f0b0", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.  ", "original_text": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "369c9ca2-833c-4b87-bc30-c07cc75bb060", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "original_text": " \nPage 11 of 14 \n \nin those businesses.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9a1d27de447375a2bfd1fd36f914ecb5fa44038bf44b85708743cae70494a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16299bb6-77db-4803-8a1b-dd0a2c7596a9", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "original_text": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.  "}, "hash": "e62ca216a658104732fb0c6ef7d0a2519eed6d69d22df8b8f3b7d00685db15cb", "class_name": "RelatedNodeInfo"}}, "text": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n", "start_char_idx": 41, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16299bb6-77db-4803-8a1b-dd0a2c7596a9": {"__data__": {"id_": "16299bb6-77db-4803-8a1b-dd0a2c7596a9", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "original_text": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6137a5de-b0e6-467b-95e7-f0f25b15f0b0", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.  ", "original_text": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b4edc82371e6388a9a425c2638ce1ff9347eadeed26295e6c97f55b3eb5add", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80b354b2-d521-4469-8308-298a92ce654b", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "original_text": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n"}, "hash": "f2158db311eece2a3fb8379c3931a57bbd1d255eff353423c029bd11b122cb73", "class_name": "RelatedNodeInfo"}}, "text": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.  ", "start_char_idx": 238, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80b354b2-d521-4469-8308-298a92ce654b": {"__data__": {"id_": "80b354b2-d521-4469-8308-298a92ce654b", "embedding": null, "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "original_text": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16299bb6-77db-4803-8a1b-dd0a2c7596a9", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "original_text": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9242ff3ea7ebb5316c2f955bcf011f49a509ff2df74ce131a3d9e34edecf83a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb369d08-764d-4f5a-86b0-2d7346d69cb4", "node_type": "1", "metadata": {"window": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "original_text": "Getting into your question around COVID.  "}, "hash": "fa3bd4e4a992612a092bd467391f0a686a039cfc4f4aed1d791e604b46cdf366", "class_name": "RelatedNodeInfo"}}, "text": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "start_char_idx": 362, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb369d08-764d-4f5a-86b0-2d7346d69cb4": {"__data__": {"id_": "eb369d08-764d-4f5a-86b0-2d7346d69cb4", "embedding": null, "metadata": {"window": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "original_text": "Getting into your question around COVID.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80b354b2-d521-4469-8308-298a92ce654b", "node_type": "1", "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "original_text": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a83d7fd2037e4a05d41e4428f28916187ce8edecf09d08c4ba47251b7f8db1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c443ed9-f54e-4b11-9444-2d1eddc21b74", "node_type": "1", "metadata": {"window": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n", "original_text": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n"}, "hash": "b562a7ddb17989c0efb2f95dd66f185f14d42db223dcdf5b9e759abeb91c214c", "class_name": "RelatedNodeInfo"}}, "text": "Getting into your question around COVID.  ", "start_char_idx": 648, "end_char_idx": 690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c443ed9-f54e-4b11-9444-2d1eddc21b74": {"__data__": {"id_": "5c443ed9-f54e-4b11-9444-2d1eddc21b74", "embedding": null, "metadata": {"window": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n", "original_text": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb369d08-764d-4f5a-86b0-2d7346d69cb4", "node_type": "1", "metadata": {"window": "One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "original_text": "Getting into your question around COVID.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc77a7b0a7b773638c4c7f527dc1e92e06f4622afd0f8202a2c9c0b3eac2ca53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9122416a-8f5c-4533-a1ff-16fdf875d38b", "node_type": "1", "metadata": {"window": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.  ", "original_text": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  "}, "hash": "56ddfe91f157aef0185556d3e23dffd679a6adb83d24206c03d6665f3df7ba3e", "class_name": "RelatedNodeInfo"}}, "text": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "start_char_idx": 690, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9122416a-8f5c-4533-a1ff-16fdf875d38b": {"__data__": {"id_": "9122416a-8f5c-4533-a1ff-16fdf875d38b", "embedding": null, "metadata": {"window": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.  ", "original_text": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c443ed9-f54e-4b11-9444-2d1eddc21b74", "node_type": "1", "metadata": {"window": "But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n", "original_text": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89e8219641df2af505d879ae2cd9ee24b9da70e383c1aa8fcf9a0adfec689b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7c8144-0ac4-4a98-99b6-7079421f5530", "node_type": "1", "metadata": {"window": "Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "original_text": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  "}, "hash": "6e1bff439c4e2fb36bc577e160b1528a9f93284d3fb5b279cf2e337414ae10b1", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "start_char_idx": 784, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7c8144-0ac4-4a98-99b6-7079421f5530": {"__data__": {"id_": "7f7c8144-0ac4-4a98-99b6-7079421f5530", "embedding": null, "metadata": {"window": "Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "original_text": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9122416a-8f5c-4533-a1ff-16fdf875d38b", "node_type": "1", "metadata": {"window": "Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.  ", "original_text": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c3298eae3c7dd5970f2bd24c6acc22e62e2070c91eac562f6c4720c1b5d79d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e23607b7-7762-435c-b191-32c891a5606f", "node_type": "1", "metadata": {"window": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.  ", "original_text": "So that implies roughly $100 million included in \nfiscal '21.  \n \n"}, "hash": "e07d5ba4b47442d6a6de201b95b2167cfc2b37c34f9fc99ef94615689d67775b", "class_name": "RelatedNodeInfo"}}, "text": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "start_char_idx": 942, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e23607b7-7762-435c-b191-32c891a5606f": {"__data__": {"id_": "e23607b7-7762-435c-b191-32c891a5606f", "embedding": null, "metadata": {"window": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.  ", "original_text": "So that implies roughly $100 million included in \nfiscal '21.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7c8144-0ac4-4a98-99b6-7079421f5530", "node_type": "1", "metadata": {"window": "Getting into your question around COVID.   That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "original_text": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa4ed45f103cc0d31f0e538d72d3a70de3b710b3a25ea9281fdb1e34c68b1d8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97430787-843e-4721-a75c-6e9fe7fd12d3", "node_type": "1", "metadata": {"window": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "original_text": "Now the key question is exactly how does that roll off down to '2 2.  "}, "hash": "313bfd3673e6617c61ad733c37511f9a506f1eac06bfd9b3bdd8e1cd43ed9bf9", "class_name": "RelatedNodeInfo"}}, "text": "So that implies roughly $100 million included in \nfiscal '21.  \n \n", "start_char_idx": 1146, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97430787-843e-4721-a75c-6e9fe7fd12d3": {"__data__": {"id_": "97430787-843e-4721-a75c-6e9fe7fd12d3", "embedding": null, "metadata": {"window": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "original_text": "Now the key question is exactly how does that roll off down to '2 2.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e23607b7-7762-435c-b191-32c891a5606f", "node_type": "1", "metadata": {"window": "That is, of course, where we'll see a lot of movement from \na year-over-year perspective.  \n \n As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.  ", "original_text": "So that implies roughly $100 million included in \nfiscal '21.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be9546e18712d0ecfd6e8ccdeb9bca84918009168071e141f0800bb94f2556a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56263928-4223-406f-897c-9de894b6a51b", "node_type": "1", "metadata": {"window": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n", "original_text": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  "}, "hash": "028cbbe101efc5cbde5b529e5f14c2693014aa4e8efc29d455e322dc06fc0e24", "class_name": "RelatedNodeInfo"}}, "text": "Now the key question is exactly how does that roll off down to '2 2.  ", "start_char_idx": 1212, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56263928-4223-406f-897c-9de894b6a51b": {"__data__": {"id_": "56263928-4223-406f-897c-9de894b6a51b", "embedding": null, "metadata": {"window": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n", "original_text": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97430787-843e-4721-a75c-6e9fe7fd12d3", "node_type": "1", "metadata": {"window": "As a reminder, we highlighted in fiscal '20 that we had roughly $100 million headwind associated with \nCOVID, which was more than all in the fourth quarter.   Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "original_text": "Now the key question is exactly how does that roll off down to '2 2.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9393cbb54047f3b94dfe8920b87a6f800d0e6394febac4adcf626ab6a99772e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8", "node_type": "1", "metadata": {"window": "So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.  ", "original_text": "The brand volumes \nwe've highlighted are  also similar.  "}, "hash": "d1ee245dbf8da5e5a0fe1ae870ac0a09c239ec261b502115eaaa355debdb8878", "class_name": "RelatedNodeInfo"}}, "text": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "start_char_idx": 1282, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8": {"__data__": {"id_": "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8", "embedding": null, "metadata": {"window": "So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.  ", "original_text": "The brand volumes \nwe've highlighted are  also similar.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56263928-4223-406f-897c-9de894b6a51b", "node_type": "1", "metadata": {"window": "Now this year, and then just in today's script, \ntoday's prepared re marks, we commented that it was a relatively consiste nt or flat impact year -over-\nyear from a COVID perspective now in this update.   So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n", "original_text": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4c27b935b175e3c44bde68026216eb5f8df948102b16ba82cdd1a6c7aa0d946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cd22b3b-7b93-43a2-9289-de5d1dfcd197", "node_type": "1", "metadata": {"window": "Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "original_text": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  "}, "hash": "934c98e016757e69500ee03056a0538b4619a24b96616c68284a28583f4c04fb", "class_name": "RelatedNodeInfo"}}, "text": "The brand volumes \nwe've highlighted are  also similar.  ", "start_char_idx": 1498, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cd22b3b-7b93-43a2-9289-de5d1dfcd197": {"__data__": {"id_": "7cd22b3b-7b93-43a2-9289-de5d1dfcd197", "embedding": null, "metadata": {"window": "Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "original_text": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8", "node_type": "1", "metadata": {"window": "So that implies roughly $100 million included in \nfiscal '21.  \n \n Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.  ", "original_text": "The brand volumes \nwe've highlighted are  also similar.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08f6ecd0887652ce3452ef14e496028352c5f8edac911e05e69cae42a1218523", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7336e518-f3f0-404a-985b-625ed05b1b78", "node_type": "1", "metadata": {"window": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "original_text": "So there will be some offset there that will \ncontinue on into the next year.  \n \n"}, "hash": "551785d1eafe0e8becacbc052d5127185d2dc6a0229c3da926f337ff6f9dae10", "class_name": "RelatedNodeInfo"}}, "text": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "start_char_idx": 1555, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7336e518-f3f0-404a-985b-625ed05b1b78": {"__data__": {"id_": "7336e518-f3f0-404a-985b-625ed05b1b78", "embedding": null, "metadata": {"window": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "original_text": "So there will be some offset there that will \ncontinue on into the next year.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cd22b3b-7b93-43a2-9289-de5d1dfcd197", "node_type": "1", "metadata": {"window": "Now the key question is exactly how does that roll off down to '2 2.   And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "original_text": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e64a7c3871a1cc1bc00d433502a4d11d2bb3596b1e02930d7dc4d1340c3535f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0dbd568-f9b1-4166-b89a-7293aadd4957", "node_type": "1", "metadata": {"window": "The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "original_text": "Now there's going to be a lot of o ther moving pieces with COVID.  "}, "hash": "eed4afe021c3b789530cca0829683a0fff9819cb40f096a59455e697daee7783", "class_name": "RelatedNodeInfo"}}, "text": "So there will be some offset there that will \ncontinue on into the next year.  \n \n", "start_char_idx": 1684, "end_char_idx": 1766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0dbd568-f9b1-4166-b89a-7293aadd4957": {"__data__": {"id_": "a0dbd568-f9b1-4166-b89a-7293aadd4957", "embedding": null, "metadata": {"window": "The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "original_text": "Now there's going to be a lot of o ther moving pieces with COVID.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7336e518-f3f0-404a-985b-625ed05b1b78", "node_type": "1", "metadata": {"window": "And I would first go back and \nhighlight that a number of the areas we anticipate getting at or near pre -COVID levels by the end of \nthe fiscal year, like the medical elective volumes, nuclear to a similar extent.   The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "original_text": "So there will be some offset there that will \ncontinue on into the next year.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b34fe25e6e984abb0253e27d913390942c06dd2b006b03ab633b031b3d952fe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96340b8e-8fdb-4523-92f3-4be0bc87e715", "node_type": "1", "metadata": {"window": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "original_text": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  "}, "hash": "2cb7074728ca85aef5ff4d708e68218f0f961be5f31e7c4463ea4601881290e2", "class_name": "RelatedNodeInfo"}}, "text": "Now there's going to be a lot of o ther moving pieces with COVID.  ", "start_char_idx": 1766, "end_char_idx": 1833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96340b8e-8fdb-4523-92f3-4be0bc87e715": {"__data__": {"id_": "96340b8e-8fdb-4523-92f3-4be0bc87e715", "embedding": null, "metadata": {"window": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "original_text": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0dbd568-f9b1-4166-b89a-7293aadd4957", "node_type": "1", "metadata": {"window": "The brand volumes \nwe've highlighted are  also similar.   It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "original_text": "Now there's going to be a lot of o ther moving pieces with COVID.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df48237735a85c4fcde8ad3dd1ecd339c3b0802575df42c986fa138b944ac8d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e2c8b6-ce8c-4ddb-975a-9139b9f35880", "node_type": "1", "metadata": {"window": "So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.  ", "original_text": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n"}, "hash": "27fb5e9bfe7942d3e3d013b14abecdc23d597d7dcacd4f1fcde580b17623b3ff", "class_name": "RelatedNodeInfo"}}, "text": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "start_char_idx": 1833, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e2c8b6-ce8c-4ddb-975a-9139b9f35880": {"__data__": {"id_": "85e2c8b6-ce8c-4ddb-975a-9139b9f35880", "embedding": null, "metadata": {"window": "So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.  ", "original_text": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96340b8e-8fdb-4523-92f3-4be0bc87e715", "node_type": "1", "metadata": {"window": "It's those very specific therapeutic drugs within generics will be \ndeferred then until more like the middle of our fiscal '22.   So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "original_text": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e77d819dddce8ba953165dbfb121551f362b252806e0eaa72839ead30e92528b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11b025d2-19e8-4757-a605-669d481f825f", "node_type": "1", "metadata": {"window": "Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "original_text": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n"}, "hash": "e28657f041d09f4fbb7d5ea750584c64cb186fe7ece269721d7ecbc701f31124", "class_name": "RelatedNodeInfo"}}, "text": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "start_char_idx": 1931, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11b025d2-19e8-4757-a605-669d481f825f": {"__data__": {"id_": "11b025d2-19e8-4757-a605-669d481f825f", "embedding": null, "metadata": {"window": "Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "original_text": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e2c8b6-ce8c-4ddb-975a-9139b9f35880", "node_type": "1", "metadata": {"window": "So there will be some offset there that will \ncontinue on into the next year.  \n \n Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.  ", "original_text": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd324f830f192bee0751f2cb0b4becc3f46c074b16c4ad032ab8d8656fda689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7866d64-0860-4083-99e2-f4c64773e9ce", "node_type": "1", "metadata": {"window": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "original_text": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  "}, "hash": "a811bcdc277b0ef6e50fb5856145ad0ca194b378dd56f4cea908819e84e2b8cd", "class_name": "RelatedNodeInfo"}}, "text": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "start_char_idx": 2136, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7866d64-0860-4083-99e2-f4c64773e9ce": {"__data__": {"id_": "d7866d64-0860-4083-99e2-f4c64773e9ce", "embedding": null, "metadata": {"window": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "original_text": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11b025d2-19e8-4757-a605-669d481f825f", "node_type": "1", "metadata": {"window": "Now there's going to be a lot of o ther moving pieces with COVID.   We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "original_text": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcf325d1265fa322794c31bc9ac83d347953513efdf015a0d0f575d4b6964ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb5569c-28c6-44e6-95b9-89fd49362705", "node_type": "1", "metadata": {"window": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "original_text": "And so they will behave then differently next year.  "}, "hash": "126fa70d748a1d5becb48dfc05f80974eb9554a032f4c7e43e60fe824700893d", "class_name": "RelatedNodeInfo"}}, "text": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "start_char_idx": 2430, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb5569c-28c6-44e6-95b9-89fd49362705": {"__data__": {"id_": "dcb5569c-28c6-44e6-95b9-89fd49362705", "embedding": null, "metadata": {"window": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "original_text": "And so they will behave then differently next year.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7866d64-0860-4083-99e2-f4c64773e9ce", "node_type": "1", "metadata": {"window": "We would expect there still to be \nsome elevated demand for areas like PPE and the lab business.   But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "original_text": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bb731541dfa81bc32e5d69583b0923498069dfd152899c7f283159f47735c39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "892dbee9-e9c0-4b26-9203-36e0b58879c1", "node_type": "1", "metadata": {"window": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "original_text": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  "}, "hash": "a086e5e38d89deff09e9663b3793ab1118e03a41969b82bd49a4405dd99cfe52", "class_name": "RelatedNodeInfo"}}, "text": "And so they will behave then differently next year.  ", "start_char_idx": 2575, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "892dbee9-e9c0-4b26-9203-36e0b58879c1": {"__data__": {"id_": "892dbee9-e9c0-4b26-9203-36e0b58879c1", "embedding": null, "metadata": {"window": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "original_text": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb5569c-28c6-44e6-95b9-89fd49362705", "node_type": "1", "metadata": {"window": "But we also have the timing \nelements associated with PPE pricing costs that we continue to track very closely, and it will real ly be \na function of those pricing and cost dynamics as we go forward.   \n \n So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "original_text": "And so they will behave then differently next year.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad9c8f0d701f77d42bd8dcb6185bf1fea4b606d9055145b0b7e15fdedfb7e71c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99dd249d-397c-42b9-8a54-a0f10dacd806", "node_type": "1", "metadata": {"window": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.  ", "original_text": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  "}, "hash": "02a2a82cc8261ea6e6605c05f05af4d1e32cffee7f3c8a42508cc0839ff388e5", "class_name": "RelatedNodeInfo"}}, "text": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "start_char_idx": 2628, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99dd249d-397c-42b9-8a54-a0f10dacd806": {"__data__": {"id_": "99dd249d-397c-42b9-8a54-a0f10dacd806", "embedding": null, "metadata": {"window": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.  ", "original_text": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "892dbee9-e9c0-4b26-9203-36e0b58879c1", "node_type": "1", "metadata": {"window": "So when I think about the two different segments, what that really comes down to is that certainly, the \ngreatest impact -- we have a headwind built into this guidance and that $100 mi llion associated with \nthe pharma business, and we have now more of a tailwind for the medical business.  \n \n And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "original_text": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49a3b49bc9b5c594e0977c4559ce8d8d18957f84267ec817a28e6f700edb534d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7", "node_type": "1", "metadata": {"window": "And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.  ", "original_text": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  "}, "hash": "5a456ed81b167e1f32a810be81c88d0af9ab7ad4e8c0bf8c1157719413680723", "class_name": "RelatedNodeInfo"}}, "text": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "start_char_idx": 2749, "end_char_idx": 2844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7": {"__data__": {"id_": "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7", "embedding": null, "metadata": {"window": "And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.  ", "original_text": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99dd249d-397c-42b9-8a54-a0f10dacd806", "node_type": "1", "metadata": {"window": "And so we highlighted that from a year -over-year perspective as well in the prepared remarks that it's \na meaningful impact in both this year.   And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.  ", "original_text": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c516a68d1afe93d87074bff2dd20fa43458b78968eea9e854aa0b61caf4149bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1668e4d9-1d23-4e7a-87e9-370aa8265587", "node_type": "1", "metadata": {"window": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n", "original_text": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n"}, "hash": "947dfe70b422c7069dd0790c36ba09f7bac3d0407955e87356446f9856c04aa9", "class_name": "RelatedNodeInfo"}}, "text": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "start_char_idx": 2844, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1668e4d9-1d23-4e7a-87e9-370aa8265587": {"__data__": {"id_": "1668e4d9-1d23-4e7a-87e9-370aa8265587", "embedding": null, "metadata": {"window": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n", "original_text": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7", "node_type": "1", "metadata": {"window": "And so they will behave then differently next year.   And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.  ", "original_text": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72e7fd2b3dfa711c8bdb4f3ba65acbb3354ecc11ce7c432d9d91461132accc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2d5ba1-1244-47d1-b5be-160791770ddf", "node_type": "1", "metadata": {"window": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "original_text": "Lisa Gill:  Great.  "}, "hash": "f83b4fc667161599ddba1309438b854844e98283c26a59fc1f702eea99507ddf", "class_name": "RelatedNodeInfo"}}, "text": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "start_char_idx": 2960, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2d5ba1-1244-47d1-b5be-160791770ddf": {"__data__": {"id_": "bd2d5ba1-1244-47d1-b5be-160791770ddf", "embedding": null, "metadata": {"window": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "original_text": "Lisa Gill:  Great.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1668e4d9-1d23-4e7a-87e9-370aa8265587", "node_type": "1", "metadata": {"window": "And then, \nof course, the other key piece to think about the puts and takes is the announcement of the sale of \nCordis.   So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n", "original_text": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50f5ef40310f772b84e7974a5ae07e7e2d2fe76ad66113f3346bef4c633111d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a551d970-41dc-4a37-b5f3-2694c71c61dc", "node_type": "1", "metadata": {"window": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Very helpful.  "}, "hash": "c4189c6bc0252e186591a54e3fb8b733eb73b268382b431e342db91a7ccfaba4", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Great.  ", "start_char_idx": 3124, "end_char_idx": 3144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a551d970-41dc-4a37-b5f3-2694c71c61dc": {"__data__": {"id_": "a551d970-41dc-4a37-b5f3-2694c71c61dc", "embedding": null, "metadata": {"window": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Very helpful.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2d5ba1-1244-47d1-b5be-160791770ddf", "node_type": "1", "metadata": {"window": "So we do anticipate that being in the first quarter, hopefully, earlier in the first quarter.   And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "original_text": "Lisa Gill:  Great.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2521e6238944e2e1c776815345f073e53256936638e2ad9b5634c49adc1e9f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51c6c9d-d8dd-40bb-9750-16f301ee91fd", "node_type": "1", "metadata": {"window": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Thank you.  \n \n"}, "hash": "9a59f08bd0125a0ac9511f3b69acb32cc96b2ad799d98c9d6c690b92aa7ca544", "class_name": "RelatedNodeInfo"}}, "text": "Very helpful.  ", "start_char_idx": 3144, "end_char_idx": 3159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51c6c9d-d8dd-40bb-9750-16f301ee91fd": {"__data__": {"id_": "c51c6c9d-d8dd-40bb-9750-16f301ee91fd", "embedding": null, "metadata": {"window": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Thank you.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a551d970-41dc-4a37-b5f3-2694c71c61dc", "node_type": "1", "metadata": {"window": "And \nwe disclosed prior that, that business carries about a $60 million to $70 million annualized earni ngs \nrate.   And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Very helpful.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b0f8b444e8e02fdce683265d64a336aa8d1d3939ec24f11d80c35a5e41f207b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "142bd23a-7394-483b-b966-9ea8c07ffdb3", "node_type": "1", "metadata": {"window": "Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  "}, "hash": "c75b9b9fd537546ad26b29374c0ff58b43fca943c87282f0c386159103fd1cc8", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 3159, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "142bd23a-7394-483b-b966-9ea8c07ffdb3": {"__data__": {"id_": "142bd23a-7394-483b-b966-9ea8c07ffdb3", "embedding": null, "metadata": {"window": "Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51c6c9d-d8dd-40bb-9750-16f301ee91fd", "node_type": "1", "metadata": {"window": "And so as we get more specific to the exact timing and other details around that, we will provide \nmore color as to what the impact will be for our fiscal '22.  \n \n Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Thank you.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4df8e658b512b2570b997aad8c415a9a3b8682045408c4cd23ab91db9a7cbe1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a", "node_type": "1", "metadata": {"window": "Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Please \ngo ahead.  "}, "hash": "ce72cfb241c3da629a632aca76e35e20079d34df1fab144776f72eb14d5fa498", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "start_char_idx": 3174, "end_char_idx": 3267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a": {"__data__": {"id_": "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a", "embedding": null, "metadata": {"window": "Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Please \ngo ahead.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a7c6414f59da90da138128644a9f7aa20ba443610f8ceee86676da6c58bc5f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "142bd23a-7394-483b-b966-9ea8c07ffdb3", "node_type": "1", "metadata": {"window": "Lisa Gill:  Great.   Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8115937caacc1516b688c104594d393d8a5f7d8acc945f5e1521e93914f74706", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5342fa18-a9ce-4dd1-9daf-5fca30f839c3", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "original_text": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.  "}, "hash": "fc5869da73ebd07c51e340cff8a2a35a3c44d12bcd33512fbf97d0c5589abef0", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  ", "start_char_idx": 3267, "end_char_idx": 3286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5342fa18-a9ce-4dd1-9daf-5fca30f839c3": {"__data__": {"id_": "5342fa18-a9ce-4dd1-9daf-5fca30f839c3", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "original_text": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a", "node_type": "1", "metadata": {"window": "Very helpful.   Thank you.  \n \n Operator:  And we'll move on to our next q uestion from Eric Percher from Nephron Research.   Please \ngo ahead.  ", "original_text": "Please \ngo ahead.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e60afc9f85937185715b5597cb59d49d96af2811b08ec76557df8dec9819fdc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d59b8ff-0ad9-4249-9d4b-f49382350057", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "original_text": "A question on the specialty business.  "}, "hash": "727a44fd3cc5bb7f62a9c83883e5cd78eca7beba089ce69b11f63d23b7497e59", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.  ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d59b8ff-0ad9-4249-9d4b-f49382350057": {"__data__": {"id_": "9d59b8ff-0ad9-4249-9d4b-f49382350057", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "original_text": "A question on the specialty business.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5342fa18-a9ce-4dd1-9daf-5fca30f839c3", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "original_text": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2147f4e34f7730d330a57c74dc5c3116c3ae94fe2062df6d3f0cce0cdda93031", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d4d0f3d-0f01-4227-983b-e6700350d264", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n", "original_text": "It sounds like you're expecting that \ntrend to normal e in that business.  "}, "hash": "aebaeace9ddff55181acee03f191f2907dc14c577dec5c1a958c0c1e58035c3a", "class_name": "RelatedNodeInfo"}}, "text": "A question on the specialty business.  ", "start_char_idx": 48, "end_char_idx": 87, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d4d0f3d-0f01-4227-983b-e6700350d264": {"__data__": {"id_": "1d4d0f3d-0f01-4227-983b-e6700350d264", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n", "original_text": "It sounds like you're expecting that \ntrend to normal e in that business.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d59b8ff-0ad9-4249-9d4b-f49382350057", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "original_text": "A question on the specialty business.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e956a489df5be7a44eb72b7d26a28a115aa60c9c55b2a77460916abf32da00ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591c84a1-0349-4241-ba32-a093abfc0779", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  "}, "hash": "8a0bbbc8b15cadd72171c24ac1c89a0deb097e86cb3cca04f2d2782fe85c504a", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like you're expecting that \ntrend to normal e in that business.  ", "start_char_idx": 87, "end_char_idx": 162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591c84a1-0349-4241-ba32-a093abfc0779": {"__data__": {"id_": "591c84a1-0349-4241-ba32-a093abfc0779", "embedding": null, "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d4d0f3d-0f01-4227-983b-e6700350d264", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n", "original_text": "It sounds like you're expecting that \ntrend to normal e in that business.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fb2115b204def152736e797259e3f4aea64a4ed373e186c21a65d61fa68ce81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "295e09dc-cfcb-44de-aa6b-8ff738c7008d", "node_type": "1", "metadata": {"window": "A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "original_text": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  "}, "hash": "28e64e1dfe7e7f3ab9a21e21459a42c054e18b7e854157e3e3ca43a8505a59f6", "class_name": "RelatedNodeInfo"}}, "text": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "start_char_idx": 162, "end_char_idx": 293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "295e09dc-cfcb-44de-aa6b-8ff738c7008d": {"__data__": {"id_": "295e09dc-cfcb-44de-aa6b-8ff738c7008d", "embedding": null, "metadata": {"window": "A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "original_text": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591c84a1-0349-4241-ba32-a093abfc0779", "node_type": "1", "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e703f56aa47e55a4896ae4b78481118a2b134c6e9d39987d88db6a74d3c4ae02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea", "node_type": "1", "metadata": {"window": "It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "original_text": "Are you \nparticipating in economics on those?  \n \n"}, "hash": "675c806dfca3662e3849dafaba58d0b1dca0b9dc08679e8023af2cabd3d13088", "class_name": "RelatedNodeInfo"}}, "text": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "start_char_idx": 293, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea": {"__data__": {"id_": "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea", "embedding": null, "metadata": {"window": "It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "original_text": "Are you \nparticipating in economics on those?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "295e09dc-cfcb-44de-aa6b-8ff738c7008d", "node_type": "1", "metadata": {"window": "A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "original_text": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7292c09c3e2e5820d7b2a573b4f07d6c38a51d5114a8bd71c9589f36038678fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc15c02a-be96-4175-a380-f819d459ca6b", "node_type": "1", "metadata": {"window": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "0733ae82e909ec95d047cfa4ce5a34c80f83e2a9d90380c707ef308bcd44159e", "class_name": "RelatedNodeInfo"}}, "text": "Are you \nparticipating in economics on those?  \n \n", "start_char_idx": 422, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc15c02a-be96-4175-a380-f819d459ca6b": {"__data__": {"id_": "dc15c02a-be96-4175-a380-f819d459ca6b", "embedding": null, "metadata": {"window": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea", "node_type": "1", "metadata": {"window": "It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "original_text": "Are you \nparticipating in economics on those?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a512ab9c2c10f328ecaa53de0f1c23dffb36ee8ab0b3bc3c5268c36c6a9f076", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44b51939-27f1-4d57-9d03-c46fb5855d9a", "node_type": "1", "metadata": {"window": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n", "original_text": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  "}, "hash": "3e93c9a5fcd02c6933b437c7354113161c4b826385f395e9a182993156e69482", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 472, "end_char_idx": 494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44b51939-27f1-4d57-9d03-c46fb5855d9a": {"__data__": {"id_": "44b51939-27f1-4d57-9d03-c46fb5855d9a", "embedding": null, "metadata": {"window": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n", "original_text": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc15c02a-be96-4175-a380-f819d459ca6b", "node_type": "1", "metadata": {"window": "I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?   And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64f25beb33297d259f9a288d02daf72637acac550b46839044c6cdf4df121082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dae8d717-39d0-4259-b596-b28323fb1df3", "node_type": "1", "metadata": {"window": "Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "original_text": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  "}, "hash": "005da2d65f6efebda5b7e95d8ffa721930b6f2cdfbc976d3a66a271992912da8", "class_name": "RelatedNodeInfo"}}, "text": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "start_char_idx": 494, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dae8d717-39d0-4259-b596-b28323fb1df3": {"__data__": {"id_": "dae8d717-39d0-4259-b596-b28323fb1df3", "embedding": null, "metadata": {"window": "Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "original_text": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44b51939-27f1-4d57-9d03-c46fb5855d9a", "node_type": "1", "metadata": {"window": "And of late, there's been a call out of \nmaybe some of the oral solid products that are more specialty generic and biosimilars.   Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n", "original_text": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "decfe15a7dd643d298cbfb4115017becad27c9d454ff0dbaad4321356c702cee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06ec98f8-d47c-4a29-a086-cda55ccbec09", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "We're \nparticipating in all of those activities.  "}, "hash": "2e5eb230ccd93927bf877ab301c158cc750102f5d4d28fd7be8e6dfa36f0badd", "class_name": "RelatedNodeInfo"}}, "text": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "start_char_idx": 735, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06ec98f8-d47c-4a29-a086-cda55ccbec09": {"__data__": {"id_": "06ec98f8-d47c-4a29-a086-cda55ccbec09", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "We're \nparticipating in all of those activities.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dae8d717-39d0-4259-b596-b28323fb1df3", "node_type": "1", "metadata": {"window": "Are you \nparticipating in economics on those?  \n \n Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "original_text": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e635241f3416b3427bc44d146b188f862d5dd5cd242db3365745c79b0854838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50563dfc-3890-4a23-ac27-e33139d33702", "node_type": "1", "metadata": {"window": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "original_text": "We're seeing increased volumes on certain key drugs.  \n \n"}, "hash": "d5770e8c93e9bcc3f7d8b2fe141aed0d4f60b0decd7ee4320a8b6e71c131d236", "class_name": "RelatedNodeInfo"}}, "text": "We're \nparticipating in all of those activities.  ", "start_char_idx": 877, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50563dfc-3890-4a23-ac27-e33139d33702": {"__data__": {"id_": "50563dfc-3890-4a23-ac27-e33139d33702", "embedding": null, "metadata": {"window": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "original_text": "We're seeing increased volumes on certain key drugs.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06ec98f8-d47c-4a29-a086-cda55ccbec09", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "We're \nparticipating in all of those activities.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74575abc434158fb23066d72bd4231366c8796a65db82d7d5d59d70150816f23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23f4f37d-f2dc-4680-9144-ebcccff52991", "node_type": "1", "metadata": {"window": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n", "original_text": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n"}, "hash": "810d962c7ed86537af299cde9daee0b349d4f73e2e1a26fc26d65d6e4c50bdf0", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing increased volumes on certain key drugs.  \n \n", "start_char_idx": 927, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23f4f37d-f2dc-4680-9144-ebcccff52991": {"__data__": {"id_": "23f4f37d-f2dc-4680-9144-ebcccff52991", "embedding": null, "metadata": {"window": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n", "original_text": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50563dfc-3890-4a23-ac27-e33139d33702", "node_type": "1", "metadata": {"window": "I would say there's nothing I would call out that's dramatically changing in our \nspecialty, particularly as it relates to the sales of drugs to the -- into the physician office space that \nwe're seeing generally consistent profitabil ity.   We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "original_text": "We're seeing increased volumes on certain key drugs.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1142f45b5671fba0c8f16d4ae9acb9d6e5bb902382e5614d9b3db2c9b01f84e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bef7681-9dbd-438d-b203-a4b9a6ada65f", "node_type": "1", "metadata": {"window": "We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.  ", "original_text": "Kevin Moran:  Next question, please.  \n \n"}, "hash": "cd5fe975a918386258695cbceb2b1297bd8a82a4a8ae17e746361ace85c6a601", "class_name": "RelatedNodeInfo"}}, "text": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "start_char_idx": 984, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bef7681-9dbd-438d-b203-a4b9a6ada65f": {"__data__": {"id_": "4bef7681-9dbd-438d-b203-a4b9a6ada65f", "embedding": null, "metadata": {"window": "We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.  ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23f4f37d-f2dc-4680-9144-ebcccff52991", "node_type": "1", "metadata": {"window": "We are participating in the various different \nopportunities in there, whether it be actual generics that are in specialty, the biosimilars.   We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n", "original_text": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "325e421aa437f014775dc0f7921167a0c4fde559b1b1f759320a8aed19ed68d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acbcea85-ded1-45c3-a296-1dfb125330c8", "node_type": "1", "metadata": {"window": "We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "original_text": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  "}, "hash": "7ebb9c05429ff3b8f4a20ede009d040dcf8421baa1f50963ceec4432919f24d5", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n \n", "start_char_idx": 1452, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acbcea85-ded1-45c3-a296-1dfb125330c8": {"__data__": {"id_": "acbcea85-ded1-45c3-a296-1dfb125330c8", "embedding": null, "metadata": {"window": "We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "original_text": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bef7681-9dbd-438d-b203-a4b9a6ada65f", "node_type": "1", "metadata": {"window": "We're \nparticipating in all of those activities.   We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.  ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "673776459eaafc8a059d0f563a0093c46c1bcc053753e52b59cee65242d98b2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98062b59-75a3-4d04-9287-e75df2bdd35e", "node_type": "1", "metadata": {"window": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?  ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "ac7533fc53cfa992af3a60210bfd846b17fddb59561ce11002d1a111ed7a31f6", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "start_char_idx": 1493, "end_char_idx": 1586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98062b59-75a3-4d04-9287-e75df2bdd35e": {"__data__": {"id_": "98062b59-75a3-4d04-9287-e75df2bdd35e", "embedding": null, "metadata": {"window": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acbcea85-ded1-45c3-a296-1dfb125330c8", "node_type": "1", "metadata": {"window": "We're seeing increased volumes on certain key drugs.  \n \n And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "original_text": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed00a17f33a4f19d7178e3e2f0073cd180afc09d0c66863144b9fee26e474848", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "original_text": "Jailendra Singh:  Yes, thanks, and good morning.  "}, "hash": "6331b4356361673a94ccd1e9503a1ba14b83918c0dc5c421a443ecaa017ed0b5", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 1586, "end_char_idx": 1608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7": {"__data__": {"id_": "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "original_text": "Jailendra Singh:  Yes, thanks, and good morning.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98062b59-75a3-4d04-9287-e75df2bdd35e", "node_type": "1", "metadata": {"window": "And as  you know, we've been saying for a while, we have seen oncology come back more quickly \nthan the other areas, but we do expect all the classes of the trade at this point in time within specialty \nto be at or near pre -COVID levels by the end of our fiscal yea r.  And then as it goes to our upstream \nservices businesses like our 3PL, our hub and other businesses, those businesses continue to \nperform well and compete very effectively in the marketplace.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?  ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c092a9bb98fb8379ce7d6a2970c10e8e907698a28d7ae1bb684168df855ea4df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a42a6381-1c0f-4eaf-9f94-6874cec5113f", "node_type": "1", "metadata": {"window": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  "}, "hash": "42454889ba364293bf065db1d3dcdb23cef47636e426fa7f235955b56bb94f8b", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  Yes, thanks, and good morning.  ", "start_char_idx": 1608, "end_char_idx": 1658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a42a6381-1c0f-4eaf-9f94-6874cec5113f": {"__data__": {"id_": "a42a6381-1c0f-4eaf-9f94-6874cec5113f", "embedding": null, "metadata": {"window": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "original_text": "Jailendra Singh:  Yes, thanks, and good morning.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aabddb3f2164d9923fa95e68a0977e89b16f47c99a27629132ea9bcb5d91ed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d73363ec-3edc-458b-9520-093d61a1c56c", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "original_text": "Can  you provide some details \nthere?  "}, "hash": "bf88de25aac711718a8a2dbeab82bdde9ffb3a2a44743ec487a426d7869b7fe4", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "start_char_idx": 1658, "end_char_idx": 1774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d73363ec-3edc-458b-9520-093d61a1c56c": {"__data__": {"id_": "d73363ec-3edc-458b-9520-093d61a1c56c", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "original_text": "Can  you provide some details \nthere?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a42a6381-1c0f-4eaf-9f94-6874cec5113f", "node_type": "1", "metadata": {"window": "Operator:  And we'll m ove on to our next question from Jailendra Singh from Credit Suisse.   Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.  ", "original_text": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d50528b8f5ea5a9786a7dac767c486172209db2117d55aff69fbe0922116362", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08a52047-d2f1-409b-9909-411f1a282da5", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "original_text": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n"}, "hash": "57745de188dd496dd5fa1b274a5ad3aaa44f60d417251d8dfe26e995c23335bf", "class_name": "RelatedNodeInfo"}}, "text": "Can  you provide some details \nthere?  ", "start_char_idx": 1774, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08a52047-d2f1-409b-9909-411f1a282da5": {"__data__": {"id_": "08a52047-d2f1-409b-9909-411f1a282da5", "embedding": null, "metadata": {"window": "Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "original_text": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d73363ec-3edc-458b-9520-093d61a1c56c", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "original_text": "Can  you provide some details \nthere?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c498bad81fc7d252193618f399556464bff8e6ab27f93a67a5fe3e0d02f64dab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "539eb692-a0f9-45b5-ba31-5a294cba36fe", "node_type": "1", "metadata": {"window": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "1e5e78ca2242aba7cd9ca5f9f500eeb107a9c82d7c1d9ee7390c26b6c56b678c", "class_name": "RelatedNodeInfo"}}, "text": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "start_char_idx": 1813, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "539eb692-a0f9-45b5-ba31-5a294cba36fe": {"__data__": {"id_": "539eb692-a0f9-45b5-ba31-5a294cba36fe", "embedding": null, "metadata": {"window": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08a52047-d2f1-409b-9909-411f1a282da5", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Yes, thanks, and good morning.   I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "original_text": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd3ceee8aab880d1b983bfe7e16229792d0d8911f684c46daa6772618e9a8890", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c28c77-37ab-46a2-97a3-d073d79b782c", "node_type": "1", "metadata": {"window": "Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.  ", "original_text": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  "}, "hash": "acb6b1b9381aac283c89161afe8c158ec3b6c4468adf2dc79c451d5477b4287c", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 472, "end_char_idx": 494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c28c77-37ab-46a2-97a3-d073d79b782c": {"__data__": {"id_": "42c28c77-37ab-46a2-97a3-d073d79b782c", "embedding": null, "metadata": {"window": "Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.  ", "original_text": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "539eb692-a0f9-45b5-ba31-5a294cba36fe", "node_type": "1", "metadata": {"window": "I was wondering if you could double click into \nmanufacturing efficiencies you highlighted in the Medical segment.   Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7be39ab344451d77addac68495f4db53c2c68a6354b980785d6a8fc531fbae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcda6c3e-e93d-4888-af79-cd8cc9c9027f", "node_type": "1", "metadata": {"window": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n", "original_text": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  "}, "hash": "b301c99572ed6ff1f039797a89b919e925204364c035176301458d209aa80552", "class_name": "RelatedNodeInfo"}}, "text": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "start_char_idx": 1949, "end_char_idx": 2070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcda6c3e-e93d-4888-af79-cd8cc9c9027f": {"__data__": {"id_": "fcda6c3e-e93d-4888-af79-cd8cc9c9027f", "embedding": null, "metadata": {"window": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n", "original_text": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c28c77-37ab-46a2-97a3-d073d79b782c", "node_type": "1", "metadata": {"window": "Can  you provide some details \nthere?   And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.  ", "original_text": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4275e2c2625d2a26ebac47105cadc5cbd4e2f62b50dfd058575f3209791486cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f513e43-483b-44c1-ace0-7b6b54a5c20a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "original_text": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n"}, "hash": "6390d9d0a08282798ee96494905a9cf77be204b6f6c4e019f59070a7963fd424", "class_name": "RelatedNodeInfo"}}, "text": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "start_char_idx": 2070, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f513e43-483b-44c1-ace0-7b6b54a5c20a": {"__data__": {"id_": "7f513e43-483b-44c1-ace0-7b6b54a5c20a", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "original_text": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcda6c3e-e93d-4888-af79-cd8cc9c9027f", "node_type": "1", "metadata": {"window": "And are any of those efficiencies in the Cordis business that will be rolling off versus your core \nbusiness?  \n \n Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n", "original_text": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b361af7719f7fa1eb89065266e70cfd456febb66e427a3e18a72b3fa5b8b84b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a91b2e48-ecb4-4f40-9108-f5939662a5c2", "node_type": "1", "metadata": {"window": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n", "original_text": "Jailendra Singh:  Okay.  "}, "hash": "3b631b06ea1c688e6c7f6f2026fa918c347e4b350ff49158fa24e35833dce72c", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "start_char_idx": 2200, "end_char_idx": 2500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a91b2e48-ecb4-4f40-9108-f5939662a5c2": {"__data__": {"id_": "a91b2e48-ecb4-4f40-9108-f5939662a5c2", "embedding": null, "metadata": {"window": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n", "original_text": "Jailendra Singh:  Okay.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f513e43-483b-44c1-ace0-7b6b54a5c20a", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "original_text": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa8990763bbd5b77b231eaa5354fb3fe55ab8eaa415c678c270822df04ba745", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "134222ac-edca-425c-be64-463878f959ee", "node_type": "1", "metadata": {"window": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.  ", "original_text": "Thank you.  \n \n"}, "hash": "c1476e1b1800e29d8a20ac467ee5b7c243442194c9a34dfec49b8cb1acf805a8", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:  Okay.  ", "start_char_idx": 2500, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "134222ac-edca-425c-be64-463878f959ee": {"__data__": {"id_": "134222ac-edca-425c-be64-463878f959ee", "embedding": null, "metadata": {"window": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.  ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a91b2e48-ecb4-4f40-9108-f5939662a5c2", "node_type": "1", "metadata": {"window": "I mean we've clearly had manufacturing efficiencies in our Cordis business, \nlike all of ou r manufacturing businesses.   The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n", "original_text": "Jailendra Singh:  Okay.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9ad8e78dab792d48dc69897d3bfb9040dee15449886d81fd2bf2044a98977b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8037b989-a007-4ae8-9ef9-4658815b1715", "node_type": "1", "metadata": {"window": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "original_text": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  "}, "hash": "cd2c5c31ced50559da07815e7d56d2b67b63b771cd1d14619e5a08d5b4c8af9f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 2525, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8037b989-a007-4ae8-9ef9-4658815b1715": {"__data__": {"id_": "8037b989-a007-4ae8-9ef9-4658815b1715", "embedding": null, "metadata": {"window": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "original_text": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "134222ac-edca-425c-be64-463878f959ee", "node_type": "1", "metadata": {"window": "The team there has just done an excellent job across all of \nour 30 or more global manufacturing plants at driving efficiencies.   There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.  ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63031a6abc9b6b4aa71a88cabf0c1f1117ed74a466b125cec73dd3eaed3f5c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "654ef58d-0f6b-4d4e-830b-6657a982e4ce", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Please go \nahead.  \n \n"}, "hash": "f5310fc5d3356db8a13e33be978ca5cb29174c855a72b93d49939f89a523a7c1", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "start_char_idx": 2540, "end_char_idx": 2625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "654ef58d-0f6b-4d4e-830b-6657a982e4ce": {"__data__": {"id_": "654ef58d-0f6b-4d4e-830b-6657a982e4ce", "embedding": null, "metadata": {"window": "Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Please go \nahead.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8037b989-a007-4ae8-9ef9-4658815b1715", "node_type": "1", "metadata": {"window": "There's nothing in particular about \nthe Cordis efficiencies that would change the estimate that Ja son just gave you that, that business, \nwhen it rolls off, hopefully, in our -- early in our first quarter of next year would have about a $60 \nmillion or $70 million earnings associated with it.  \n \n Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "original_text": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5c19742240bb8fea1eb043bd7f5f394f0fc73916e3385f37a042e276364f0a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "529804ed-7978-44f1-a9cf-05563382d3c9", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "George Hill:  Good morning, guys, and thanks for taking the question.  "}, "hash": "1ea5331c8013ea8f4d0c9a1d4b78ea575aa27eae0efa3802560da8947ca52891", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 2625, "end_char_idx": 2647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "529804ed-7978-44f1-a9cf-05563382d3c9": {"__data__": {"id_": "529804ed-7978-44f1-a9cf-05563382d3c9", "embedding": null, "metadata": {"window": "Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "George Hill:  Good morning, guys, and thanks for taking the question.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "654ef58d-0f6b-4d4e-830b-6657a982e4ce", "node_type": "1", "metadata": {"window": "Jailendra Singh:  Okay.   Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Please go \nahead.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dc376d0d7770659e410f86a42571e99fbcfd4cbd6d6b6924443d54cf406250d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ca31ab-26e4-40e5-b446-3a5cbf97d495", "node_type": "1", "metadata": {"window": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  "}, "hash": "1bfb8e8bcd6aa311d8a9beefd3b1c82350a8dd76b3f87e196a67a2ebfdec03f6", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Good morning, guys, and thanks for taking the question.  ", "start_char_idx": 2647, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ca31ab-26e4-40e5-b446-3a5cbf97d495": {"__data__": {"id_": "50ca31ab-26e4-40e5-b446-3a5cbf97d495", "embedding": null, "metadata": {"window": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "529804ed-7978-44f1-a9cf-05563382d3c9", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "George Hill:  Good morning, guys, and thanks for taking the question.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dde516e457e03832047e04e90a69c78623aac267ddbc7a355815101e5f5d9fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your "}, "hash": "2b6fe38e9ecc23953aed2c81a24a20fe819cbac0a20d62aa8a3e1a0090457dd3", "class_name": "RelatedNodeInfo"}}, "text": "Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "start_char_idx": 2718, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d": {"__data__": {"id_": "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d02900aad22235d53f58f0aeb4ea4b528757df76e341e0a6c1296494c3735986", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ca31ab-26e4-40e5-b446-3a5cbf97d495", "node_type": "1", "metadata": {"window": "Operator:  We'll move on  to our next question from George Hill from Deutsche Bank.   Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d80b9317ec3da24d6d332921eb1d6cb7376ccca5410966f22e29feaf9b2682a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84835735-cc5c-448f-b388-d592486ab143", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": " \nPage 13 of 14 \n \ncustomers?  "}, "hash": "40e0807e60ede7db9c25d775a812e910cd7726514ff8ef3db517a9674042bb78", "class_name": "RelatedNodeInfo"}}, "text": "And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "start_char_idx": 2909, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84835735-cc5c-448f-b388-d592486ab143": {"__data__": {"id_": "84835735-cc5c-448f-b388-d592486ab143", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": " \nPage 13 of 14 \n \ncustomers?  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n George Hill:  Good morning, guys, and thanks for taking the question.   Jason, you kind of alluded to \nthis already, but have you been able to fully capture the pricing gap that oc curred earlier this year as \nit related to PPE and supplies in the med business?   And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "original_text": "And I guess also, could you update us on the \nsupply side as we think about your things like access to gloves and gowns to provide for your ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3be821229f02b73341dd02aa2b78bc35b97fefc0b67f71b9463e59cf887fd9a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.  ", "original_text": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n"}, "hash": "16d525acbf2bf632956577b5def2accc3fe623076da6908a8af4767babe74cd2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 14 \n \ncustomers?  ", "start_char_idx": 0, "end_char_idx": 31, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f": {"__data__": {"id_": "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.  ", "original_text": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84835735-cc5c-448f-b388-d592486ab143", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": " \nPage 13 of 14 \n \ncustomers?  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dda00628863e8f13face2e437bb1d1ab3105eef0920665187db78637440388d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "original_text": "Jason Hollar:  Sure.  "}, "hash": "01fb160e2d208e1f4c6c23dea4946a9f90704ab860a9d1efb2227ef6c92c9d2c", "class_name": "RelatedNodeInfo"}}, "text": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n", "start_char_idx": 31, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2": {"__data__": {"id_": "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.  ", "original_text": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f466be336324e171b3224224ba721a89797c42020d89f95b0adc584bc418b875", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f61a4858-9213-47fc-a0d8-6a65c3cff8b1", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "original_text": "Yes.  "}, "hash": "f2a86748b6508a28fe420a9115b142f90b0c84671878071e5e49a6f545f3d428", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure.  ", "start_char_idx": 163, "end_char_idx": 185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f61a4858-9213-47fc-a0d8-6a65c3cff8b1": {"__data__": {"id_": "f61a4858-9213-47fc-a0d8-6a65c3cff8b1", "embedding": null, "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "original_text": "Yes.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "original_text": "Jason Hollar:  Sure.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3371d66ebdabf4343a04c6f68ffac79e5fd9f3d64abd08d9835c9ada8612155f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a9d54c3-b424-474e-b4a5-ece77ec147a8", "node_type": "1", "metadata": {"window": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "original_text": "So yes, we have captured the cost increases.  "}, "hash": "8e310d99cb00756fa1e2aece43e918f6cbdd45568450f6ac5d416644c394ea9e", "class_name": "RelatedNodeInfo"}}, "text": "Yes.  ", "start_char_idx": 185, "end_char_idx": 191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a9d54c3-b424-474e-b4a5-ece77ec147a8": {"__data__": {"id_": "4a9d54c3-b424-474e-b4a5-ece77ec147a8", "embedding": null, "metadata": {"window": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "original_text": "So yes, we have captured the cost increases.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f61a4858-9213-47fc-a0d8-6a65c3cff8b1", "node_type": "1", "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "original_text": "Yes.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66b62dc59351394e4d28eb9e450e78538ee2f942e3196b097d2cb3d13cb81dca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c017ed-355f-4836-9c35-7853d96bbf76", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.  ", "original_text": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  "}, "hash": "4d6f29d2b4dc6971f680612646b2723b272043571e256fad15f2fc4e1025abb7", "class_name": "RelatedNodeInfo"}}, "text": "So yes, we have captured the cost increases.  ", "start_char_idx": 191, "end_char_idx": 237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c017ed-355f-4836-9c35-7853d96bbf76": {"__data__": {"id_": "74c017ed-355f-4836-9c35-7853d96bbf76", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.  ", "original_text": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a9d54c3-b424-474e-b4a5-ece77ec147a8", "node_type": "1", "metadata": {"window": "And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "original_text": "So yes, we have captured the cost increases.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5db9c156d226f30b47d414dfcfaa149b163fd68c723b5fbd1d93d7c3e5f289c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d6782ba-ba5f-44c4-8758-d9499b3081ac", "node_type": "1", "metadata": {"window": "Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "original_text": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  "}, "hash": "a69c13405e3a175732c3296dfb4a96e604fe00a5fd19c4ac1718e27952f15ad9", "class_name": "RelatedNodeInfo"}}, "text": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "start_char_idx": 237, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d6782ba-ba5f-44c4-8758-d9499b3081ac": {"__data__": {"id_": "6d6782ba-ba5f-44c4-8758-d9499b3081ac", "embedding": null, "metadata": {"window": "Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "original_text": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c017ed-355f-4836-9c35-7853d96bbf76", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.   Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.  ", "original_text": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdbebbd3c0054539046b356f98eb016aadb3a62dcf55efa080bdd5f5566beb16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4232b34-6296-4411-ad17-65db7547935a", "node_type": "1", "metadata": {"window": "So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.  ", "original_text": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n"}, "hash": "eea9c6c73245b0254cdde0bdf603fa81eef44f18ea41f04171bfabc7eadfe543", "class_name": "RelatedNodeInfo"}}, "text": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "start_char_idx": 452, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4232b34-6296-4411-ad17-65db7547935a": {"__data__": {"id_": "d4232b34-6296-4411-ad17-65db7547935a", "embedding": null, "metadata": {"window": "So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.  ", "original_text": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d6782ba-ba5f-44c4-8758-d9499b3081ac", "node_type": "1", "metadata": {"window": "Yes.   So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "original_text": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2cef780891b6ced02e7c18d2f79e74bb433cb03f8fc05c65a394d84122a7e26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82336a5b-e643-4314-b0af-4436d0635be4", "node_type": "1", "metadata": {"window": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "original_text": "And then as it relates to -- I think your question was about access to the products.  "}, "hash": "f1acd8487d1f179558e3f5efe95d50793df8b0df0531d8cbe0356aa6a9df68d5", "class_name": "RelatedNodeInfo"}}, "text": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "start_char_idx": 723, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82336a5b-e643-4314-b0af-4436d0635be4": {"__data__": {"id_": "82336a5b-e643-4314-b0af-4436d0635be4", "embedding": null, "metadata": {"window": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "original_text": "And then as it relates to -- I think your question was about access to the products.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4232b34-6296-4411-ad17-65db7547935a", "node_type": "1", "metadata": {"window": "So yes, we have captured the cost increases.   The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.  ", "original_text": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1727644444e5b9466fc1440a489b2294c76e4565c9616bce8dc40a5d82a00258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e9c0b35-2705-4d89-83e5-9fd434f816e9", "node_type": "1", "metadata": {"window": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "original_text": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  "}, "hash": "056cee2ee5e3fc4cb5ef1390cfda08cea248de88917340c1438396782a010bcd", "class_name": "RelatedNodeInfo"}}, "text": "And then as it relates to -- I think your question was about access to the products.  ", "start_char_idx": 828, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e9c0b35-2705-4d89-83e5-9fd434f816e9": {"__data__": {"id_": "8e9c0b35-2705-4d89-83e5-9fd434f816e9", "embedding": null, "metadata": {"window": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "original_text": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82336a5b-e643-4314-b0af-4436d0635be4", "node_type": "1", "metadata": {"window": "The Supply Assurance \nProgram that we've referenced was created to do exactly tha t, to provide certainty to supply for our \ncustomers, but working with them closely to ensure that we're able to cover those costs.   What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "original_text": "And then as it relates to -- I think your question was about access to the products.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd2d74962eb9263bd828498df50d07664431de19c9bc03a9a2b15de86eb642e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a29eb737-8a01-4dac-a541-f3cff5dfa4d1", "node_type": "1", "metadata": {"window": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "original_text": "There's \nclearly capacity that's being worked in to provide more supply.  "}, "hash": "a6f885be5ba73a5be16bbd090b0d08538deead8a4454bb0385797a83eb237a67", "class_name": "RelatedNodeInfo"}}, "text": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "start_char_idx": 914, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a29eb737-8a01-4dac-a541-f3cff5dfa4d1": {"__data__": {"id_": "a29eb737-8a01-4dac-a541-f3cff5dfa4d1", "embedding": null, "metadata": {"window": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "original_text": "There's \nclearly capacity that's being worked in to provide more supply.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e9c0b35-2705-4d89-83e5-9fd434f816e9", "node_type": "1", "metadata": {"window": "What I have \nreferenced, I think, fairly consistently the last couple of quarters is that the timing of when that cost is \nrecognized versus when the price is recognized can be uncertain, can be relatively volatile and that's \nwhat we continue to look at and to manage.   But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "original_text": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2250e389868c79308034562463576c2c6e546ae9971de972132800d2ebdf892", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "798ec7c9-2caf-47f1-9367-9f5fdc422e8f", "node_type": "1", "metadata": {"window": "And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "original_text": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n"}, "hash": "12f7e1039fd553f0d2f706dca36c20c194ab2922e38fd3f444f10fabeea807ea", "class_name": "RelatedNodeInfo"}}, "text": "There's \nclearly capacity that's being worked in to provide more supply.  ", "start_char_idx": 1026, "end_char_idx": 1100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "798ec7c9-2caf-47f1-9367-9f5fdc422e8f": {"__data__": {"id_": "798ec7c9-2caf-47f1-9367-9f5fdc422e8f", "embedding": null, "metadata": {"window": "And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "original_text": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a29eb737-8a01-4dac-a541-f3cff5dfa4d1", "node_type": "1", "metadata": {"window": "But the overall economics of the program are as \nexpected and intended, which is to cover that cost.  \n \n And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "original_text": "There's \nclearly capacity that's being worked in to provide more supply.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de16bc3d20116098cb49cc1c9dbcafc5c0aced7e20c29b14a7bb7c4b95aec721", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce720de9-8da5-4d81-86f4-7e7550eceec8", "node_type": "1", "metadata": {"window": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.  ", "original_text": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  "}, "hash": "4b789a169fb204ca27350e344bd4b59fe9a5c67dd9ca6c0a7794a99331d4a205", "class_name": "RelatedNodeInfo"}}, "text": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "start_char_idx": 1100, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce720de9-8da5-4d81-86f4-7e7550eceec8": {"__data__": {"id_": "ce720de9-8da5-4d81-86f4-7e7550eceec8", "embedding": null, "metadata": {"window": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.  ", "original_text": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "798ec7c9-2caf-47f1-9367-9f5fdc422e8f", "node_type": "1", "metadata": {"window": "And then as it relates to -- I think your question was about access to the products.   It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "original_text": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdaaef91e69fce749af083a3a0040f8709f249b5d7670cfca705d5f888089305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c13eb35-4716-405a-a642-5899a627b48e", "node_type": "1", "metadata": {"window": "There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.  ", "original_text": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  "}, "hash": "419832fac69a321982e57c6dc700269211359bca581af38adf2d07bb442119bf", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "start_char_idx": 1201, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c13eb35-4716-405a-a642-5899a627b48e": {"__data__": {"id_": "1c13eb35-4716-405a-a642-5899a627b48e", "embedding": null, "metadata": {"window": "There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.  ", "original_text": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce720de9-8da5-4d81-86f4-7e7550eceec8", "node_type": "1", "metadata": {"window": "It continues to \nimprove, but especially on the gloves side, it's still constrained, but improving day by day.   There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.  ", "original_text": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02305175b749ca7e716dc9499e4e3fc4def5c05571355cf9e0d687db22c9dc12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b870875-a919-4547-9cff-6a2770c2f2e4", "node_type": "1", "metadata": {"window": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "original_text": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n"}, "hash": "cea5a99e5d86a50df92e1521a94893bf4f871097cf7211c0ce8ca5ba63a9b81f", "class_name": "RelatedNodeInfo"}}, "text": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "start_char_idx": 1281, "end_char_idx": 1407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b870875-a919-4547-9cff-6a2770c2f2e4": {"__data__": {"id_": "7b870875-a919-4547-9cff-6a2770c2f2e4", "embedding": null, "metadata": {"window": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "original_text": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c13eb35-4716-405a-a642-5899a627b48e", "node_type": "1", "metadata": {"window": "There's \nclearly capacity that's being worked in to provide more supply.   But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.  ", "original_text": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc696b0df65fc20094b3e4159186efa70ba4d7a1b543c1ffc741fbbd441e50eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e05c93f-85a9-4a66-bef9-c97681177ebe", "node_type": "1", "metadata": {"window": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "original_text": "We would not anticipate that there are other issues.  "}, "hash": "ef0030d0837120e3116928a707ca5ba729421c2de1121290effbc391f3dd567d", "class_name": "RelatedNodeInfo"}}, "text": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "start_char_idx": 1407, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e05c93f-85a9-4a66-bef9-c97681177ebe": {"__data__": {"id_": "0e05c93f-85a9-4a66-bef9-c97681177ebe", "embedding": null, "metadata": {"window": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "original_text": "We would not anticipate that there are other issues.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b870875-a919-4547-9cff-6a2770c2f2e4", "node_type": "1", "metadata": {"window": "But especially in gloves, it just takes -- \nit's a longer process to get that supply to market.   \n \n As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "original_text": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20fd3e69f635dc2d9d5db0bc728dbb683bd7092d0b0aea79fec77c772e33fb37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a23187a-fa82-4fda-95bb-0158ce3c0e5b", "node_type": "1", "metadata": {"window": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "original_text": "In fact, I'd go the opposite way.  "}, "hash": "b86cea2d94e7d076c61f1198ffaaf167a8c6474bbe4633254275a63dd381b1e3", "class_name": "RelatedNodeInfo"}}, "text": "We would not anticipate that there are other issues.  ", "start_char_idx": 1520, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a23187a-fa82-4fda-95bb-0158ce3c0e5b": {"__data__": {"id_": "3a23187a-fa82-4fda-95bb-0158ce3c0e5b", "embedding": null, "metadata": {"window": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "original_text": "In fact, I'd go the opposite way.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e05c93f-85a9-4a66-bef9-c97681177ebe", "node_type": "1", "metadata": {"window": "As it relates to Cordis and any dissynergies, I wouldn't call it dissynergies.   There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "original_text": "We would not anticipate that there are other issues.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbb027b80d074c339a93b77071563ca4ad85f076748fefe0ff416b0101e6a3b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c83b6864-9088-495e-a051-5eba50aafabf", "node_type": "1", "metadata": {"window": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "original_text": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  "}, "hash": "2d0aba46fa06e2ddefe739874add640cc4ca1cef9bb95b7d603b909c49da7d4b", "class_name": "RelatedNodeInfo"}}, "text": "In fact, I'd go the opposite way.  ", "start_char_idx": 1574, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c83b6864-9088-495e-a051-5eba50aafabf": {"__data__": {"id_": "c83b6864-9088-495e-a051-5eba50aafabf", "embedding": null, "metadata": {"window": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "original_text": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a23187a-fa82-4fda-95bb-0158ce3c0e5b", "node_type": "1", "metadata": {"window": "There are -- certainly, \nwhen we look at just our overall cost st ructure and stranded costs, there's things of that nature.   But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "original_text": "In fact, I'd go the opposite way.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f91e66e8c67e19100c0e25e66cce85ea99997eb1d5063a94b3c4b7b06e229a1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1a9e06d-c733-4bfa-9253-54f232e8c7e4", "node_type": "1", "metadata": {"window": "We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.  ", "original_text": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n"}, "hash": "eec1205adf34c8b4b65c8df1dc9dd62187de24e19db89091bb5297affa2562dc", "class_name": "RelatedNodeInfo"}}, "text": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "start_char_idx": 1609, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1a9e06d-c733-4bfa-9253-54f232e8c7e4": {"__data__": {"id_": "e1a9e06d-c733-4bfa-9253-54f232e8c7e4", "embedding": null, "metadata": {"window": "We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.  ", "original_text": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c83b6864-9088-495e-a051-5eba50aafabf", "node_type": "1", "metadata": {"window": "But \nwhen we estimate the $60 million to $70 million, that's the all -in impact that's associated with that.  \n \n We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "original_text": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e99a7bbed8ab05e2b9cbc9c164ba6dc2566a42b155ccb925ec818a742af488a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e70729dd-9cd4-4f56-bd39-dbc17241f5da", "node_type": "1", "metadata": {"window": "In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "original_text": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  "}, "hash": "a0593363493de53e81dc4fec2b0de51c9182e357fb26fe50c6e3ba8e10a5515b", "class_name": "RelatedNodeInfo"}}, "text": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "start_char_idx": 1776, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e70729dd-9cd4-4f56-bd39-dbc17241f5da": {"__data__": {"id_": "e70729dd-9cd4-4f56-bd39-dbc17241f5da", "embedding": null, "metadata": {"window": "In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "original_text": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1a9e06d-c733-4bfa-9253-54f232e8c7e4", "node_type": "1", "metadata": {"window": "We would not anticipate that there are other issues.   In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.  ", "original_text": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d34f2adfaa146b876c02143769e530889314d0147edda5416cd49b9d4a0607e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1", "node_type": "1", "metadata": {"window": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "original_text": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  "}, "hash": "c6f426befd9c001cdda016e7d11610a351919f56faa3414fce329dda51cf0e18", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "start_char_idx": 1958, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1": {"__data__": {"id_": "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1", "embedding": null, "metadata": {"window": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "original_text": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e70729dd-9cd4-4f56-bd39-dbc17241f5da", "node_type": "1", "metadata": {"window": "In fact, I'd go the opposite way.   Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "original_text": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49d081d12f2e655fb69f9d68d1ebd4301e18e9c8eb437beb1d9a5ef6a571e206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de1702b7-d87a-40df-891b-50ce93c388ad", "node_type": "1", "metadata": {"window": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n", "original_text": "We've increased our capacity there by 15 million units on an annual \nbasis.  "}, "hash": "aa87555f28b688ea302cab6ba64c87e9519d215dc3f67c1d4187bc1edd4ac0cf", "class_name": "RelatedNodeInfo"}}, "text": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "start_char_idx": 2112, "end_char_idx": 2203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de1702b7-d87a-40df-891b-50ce93c388ad": {"__data__": {"id_": "de1702b7-d87a-40df-891b-50ce93c388ad", "embedding": null, "metadata": {"window": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n", "original_text": "We've increased our capacity there by 15 million units on an annual \nbasis.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1", "node_type": "1", "metadata": {"window": "Part of what \nwe've highlighted before about this transaction is that it allows us to focus and to simplify our \noperating structure around the remaining businesses.   And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "original_text": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c15928411334ffa865bff54cc91571cf3404d7d5cf33ea4bf0bd5a63e26c6e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba91c43b-9233-4857-9d21-55faf1a5a9e7", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "original_text": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   "}, "hash": "6e7dd1eb953ad3cae2f825364fb1a62f7191c7388aa3b36ba54a208ce5e8e164", "class_name": "RelatedNodeInfo"}}, "text": "We've increased our capacity there by 15 million units on an annual \nbasis.  ", "start_char_idx": 2203, "end_char_idx": 2280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba91c43b-9233-4857-9d21-55faf1a5a9e7": {"__data__": {"id_": "ba91c43b-9233-4857-9d21-55faf1a5a9e7", "embedding": null, "metadata": {"window": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "original_text": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de1702b7-d87a-40df-891b-50ce93c388ad", "node_type": "1", "metadata": {"window": "And so we think it will create some \nopportunities for additional synergies more of -- than more of dissynergies by being more focused on \nthe cost efficiencies of what remains.  \n \n Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n", "original_text": "We've increased our capacity there by 15 million units on an annual \nbasis.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5f0230e9899f0d49ae87d13fe35b593fb805c6e8e46fdddeafbb79c63fd5aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2bffa14-596a-4a42-acd3-ea235c37298f", "node_type": "1", "metadata": {"window": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "original_text": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. "}, "hash": "f17903855989f30860f39930586d1daca76eed663e672d66ba285bc1eae3f7b6", "class_name": "RelatedNodeInfo"}}, "text": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "start_char_idx": 2280, "end_char_idx": 2364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2bffa14-596a-4a42-acd3-ea235c37298f": {"__data__": {"id_": "a2bffa14-596a-4a42-acd3-ea235c37298f", "embedding": null, "metadata": {"window": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "original_text": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba91c43b-9233-4857-9d21-55faf1a5a9e7", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  The only thing I would add to that, too, to be helpful is we have really invested in our \noverall own global manufacturing capabilities.   And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "original_text": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.   ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28d99bd50f4a3f4e36c9eaa9e322e264fc0422ef18ea8a09ba0a3516538fa59d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5876621d-2cdc-4af3-b3a5-9c943e61a519", "node_type": "1", "metadata": {"window": "We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "original_text": "or near U.S., they're all North American types of facilities.  \n \n"}, "hash": "11b557f72d690e8cb14f3e387a56fff0f923883df216ff1e2fb9981719271d96", "class_name": "RelatedNodeInfo"}}, "text": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "start_char_idx": 2364, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5876621d-2cdc-4af3-b3a5-9c943e61a519": {"__data__": {"id_": "5876621d-2cdc-4af3-b3a5-9c943e61a519", "embedding": null, "metadata": {"window": "We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "original_text": "or near U.S., they're all North American types of facilities.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2bffa14-596a-4a42-acd3-ea235c37298f", "node_type": "1", "metadata": {"window": "And if you remem ber in my script, for instance, we're a \nlarge manufacturer of syringes.   We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "original_text": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S. ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "996dc7ce45608145cedc868e2bfe059f5b3d287276135fa6249128fd143a77ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f816df56-2979-4108-8020-9060c6db320e", "node_type": "1", "metadata": {"window": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n", "original_text": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  "}, "hash": "03aaa3c775945c58e594a7566151c265e486bc930b8333d1b598bae741731236", "class_name": "RelatedNodeInfo"}}, "text": "or near U.S., they're all North American types of facilities.  \n \n", "start_char_idx": 2480, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f816df56-2979-4108-8020-9060c6db320e": {"__data__": {"id_": "f816df56-2979-4108-8020-9060c6db320e", "embedding": null, "metadata": {"window": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n", "original_text": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5876621d-2cdc-4af3-b3a5-9c943e61a519", "node_type": "1", "metadata": {"window": "We've increased our capacity there by 15 million units on an annual \nbasis.   On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "original_text": "or near U.S., they're all North American types of facilities.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "686c6ce7eefa3e877fa311fa8ddd46928469444e867a283fc1375bdf5dfce185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9203473d-e64e-49ba-a1bb-c99a67393f6b", "node_type": "1", "metadata": {"window": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "original_text": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  "}, "hash": "61449e5a1520a9256a3e1658b334db07fc5f7ba3b1bae9bcc2d0961a4f04ce4b", "class_name": "RelatedNodeInfo"}}, "text": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "start_char_idx": 2546, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9203473d-e64e-49ba-a1bb-c99a67393f6b": {"__data__": {"id_": "9203473d-e64e-49ba-a1bb-c99a67393f6b", "embedding": null, "metadata": {"window": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "original_text": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f816df56-2979-4108-8020-9060c6db320e", "node_type": "1", "metadata": {"window": "On gowns, we've added capacity to add 20 million self -manufactured gowns a year.    And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n", "original_text": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47de79073b3413b75b3389f0223ba89a51fb489dea41ca7927c8288b03023671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e17e4ea3-f3de-46c4-8082-dd73532e6543", "node_type": "1", "metadata": {"window": "or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n", "original_text": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n"}, "hash": "a511b952b2a66c4292f61db934775bed6f9850544298c0c55cf7e7ba8817135d", "class_name": "RelatedNodeInfo"}}, "text": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "start_char_idx": 2711, "end_char_idx": 2814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e17e4ea3-f3de-46c4-8082-dd73532e6543": {"__data__": {"id_": "e17e4ea3-f3de-46c4-8082-dd73532e6543", "embedding": null, "metadata": {"window": "or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n", "original_text": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9203473d-e64e-49ba-a1bb-c99a67393f6b", "node_type": "1", "metadata": {"window": "And on \nmasks were at 15 0 million more masks a year annually all in our own facilities, which are all either \nU.S.  or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "original_text": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26b98d14153f541312930ff81dd307e7e6e2971008d388b133a9e0775b2678e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a599b0-376c-4f7a-b951-bfb3a5c134be", "node_type": "1", "metadata": {"window": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.  ", "original_text": "George Hill:  Thank you.  \n \n"}, "hash": "53521717025bc8ab753f2bc4b71541f3dc42b4ecd8e6c4a0db6d0da3635ebe11", "class_name": "RelatedNodeInfo"}}, "text": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "start_char_idx": 2814, "end_char_idx": 2936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a599b0-376c-4f7a-b951-bfb3a5c134be": {"__data__": {"id_": "f5a599b0-376c-4f7a-b951-bfb3a5c134be", "embedding": null, "metadata": {"window": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.  ", "original_text": "George Hill:  Thank you.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e17e4ea3-f3de-46c4-8082-dd73532e6543", "node_type": "1", "metadata": {"window": "or near U.S., they're all North American types of facilities.  \n \n So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n", "original_text": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e12ec7acd6cc008eff2527f999144d496231dae57e3383d54b70e02540331bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d5535f2-91f0-482d-a4d7-c48011771b24", "node_type": "1", "metadata": {"window": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.  ", "original_text": "Operator:  And our last question comes from Kevin Caliendo from UBS.  "}, "hash": "ecd1ba20696f784b19a30c079fb6fc789ab1dbdf636bf7c2363084818d1eb023", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Thank you.  \n \n", "start_char_idx": 2936, "end_char_idx": 2965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d5535f2-91f0-482d-a4d7-c48011771b24": {"__data__": {"id_": "1d5535f2-91f0-482d-a4d7-c48011771b24", "embedding": null, "metadata": {"window": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.  ", "original_text": "Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a599b0-376c-4f7a-b951-bfb3a5c134be", "node_type": "1", "metadata": {"window": "So we've done, I think, a very excellent job in the medical segment of increasing our capacity and -- \nwhich -- what really, I think, strengthens our supply chain.   And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.  ", "original_text": "George Hill:  Thank you.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59cad966e2df34fa85ec5aef8a8d3294da30464c970e95ed1793213b6817a1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8497137-e23e-4627-a0d2-3bb1f19c2f99", "node_type": "1", "metadata": {"window": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "original_text": "Please go ahead.  \n \n"}, "hash": "2bc5f40eb4af5f49121d28ddf9a05083287d7dfaa185ef184418ed6bbcbf3edd", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "start_char_idx": 2965, "end_char_idx": 3035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8497137-e23e-4627-a0d2-3bb1f19c2f99": {"__data__": {"id_": "b8497137-e23e-4627-a0d2-3bb1f19c2f99", "embedding": null, "metadata": {"window": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "original_text": "Please go ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d5535f2-91f0-482d-a4d7-c48011771b24", "node_type": "1", "metadata": {"window": "And we've also invested in our sourcing \ncapabilities and broadened our relationships with suppliers.   So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.  ", "original_text": "Operator:  And our last question comes from Kevin Caliendo from UBS.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cbc624e3a9fb7ffde90ed8719fab7d9dd284e8b124d26c44f089a0631ea7e74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d42c246c-5203-4a44-9d63-2839b2f53fd6", "node_type": "1", "metadata": {"window": "George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Kevin Caliendo:  Thanks.  "}, "hash": "291cb431bf4e6e9011f90b5a3ff85afbdbc7621c86c89cc0e424d711672e34c9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 3035, "end_char_idx": 3056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d42c246c-5203-4a44-9d63-2839b2f53fd6": {"__data__": {"id_": "d42c246c-5203-4a44-9d63-2839b2f53fd6", "embedding": null, "metadata": {"window": "George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Kevin Caliendo:  Thanks.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8497137-e23e-4627-a0d2-3bb1f19c2f99", "node_type": "1", "metadata": {"window": "So we feel really good about some of the \nchanges in developments we've made in our overall su pply chain in Medical.  \n \n George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "original_text": "Please go ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5214d713f5fefcdc55d97e825a66ae2fbe5b926ca6488a425074f5dbe1203283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4473382b-1cf4-4188-b963-0019a09f5abb", "node_type": "1", "metadata": {"window": "Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Thanks for taking -- thanks for taking my question.  "}, "hash": "f5c77a2b1967c7020c164af78c46481b2f89eb421cf39d7d90438e5d67c5735c", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Thanks.  ", "start_char_idx": 3056, "end_char_idx": 3082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4473382b-1cf4-4188-b963-0019a09f5abb": {"__data__": {"id_": "4473382b-1cf4-4188-b963-0019a09f5abb", "embedding": null, "metadata": {"window": "Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Thanks for taking -- thanks for taking my question.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d42c246c-5203-4a44-9d63-2839b2f53fd6", "node_type": "1", "metadata": {"window": "George Hill:  Thank you.  \n \n Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Kevin Caliendo:  Thanks.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef1804a0f0e283a575dcecc62662727a13b700a0e89e5c3eff3a9c72bdb9811d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  "}, "hash": "2ff6370fb07e606a571d4f95252181efdc0829cb27627f73308edf6d3046c9ba", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking -- thanks for taking my question.  ", "start_char_idx": 3082, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91": {"__data__": {"id_": "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4473382b-1cf4-4188-b963-0019a09f5abb", "node_type": "1", "metadata": {"window": "Operator:  And our last question comes from Kevin Caliendo from UBS.   Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "Thanks for taking -- thanks for taking my question.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca1862d0bfffb46dc6663bb46825293a8f1e8ae35d327183d0126933dbc90166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581e09ba-2aed-41d7-b716-9b05627bea64", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "If I'm sort of netting everything out, it sounds "}, "hash": "9e21e5e62c6563bc23ac3336ccdd9fb7b422884ae9a6aa6f0b667585434625da", "class_name": "RelatedNodeInfo"}}, "text": "I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "start_char_idx": 3135, "end_char_idx": 3220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581e09ba-2aed-41d7-b716-9b05627bea64": {"__data__": {"id_": "581e09ba-2aed-41d7-b716-9b05627bea64", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "If I'm sort of netting everything out, it sounds ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdd39ba1-fb10-49a1-9170-121456540707", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c436699fecaa6160c0564b9462a7c828de271185bb9978826ee0c7d6007f3a32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f68f16fc5c3428235d5f3881cf8dce2c4d883c18c3001e02f4af7c73176f2d39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55b46c80-2593-4ed7-86a0-0dae5d89a535", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.  "}, "hash": "3e16a4f21e09bf13ef34828ddd893fbdeb6fed5fe751f0be122fc7aaad73c4c3", "class_name": "RelatedNodeInfo"}}, "text": "If I'm sort of netting everything out, it sounds ", "start_char_idx": 3220, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55b46c80-2593-4ed7-86a0-0dae5d89a535": {"__data__": {"id_": "55b46c80-2593-4ed7-86a0-0dae5d89a535", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581e09ba-2aed-41d7-b716-9b05627bea64", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Thanks.   Thanks for taking -- thanks for taking my question.   I just want to go back to \nthe sort of t he headwinds and tailwinds for fiscal '22.   If I'm sort of netting everything out, it sounds ", "original_text": "If I'm sort of netting everything out, it sounds ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ece1a4a66a77ae58370281eaa0328ed5918a08263a6db425dce6fcbe880468bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066be56e-00a0-47e7-8b53-bb5357cd9734", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "original_text": "Did I think about that right?  "}, "hash": "a72357fdb904109a9753a5a58cfb84d3782ef858a72f37aeb023608cfc4c9dc7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.  ", "start_char_idx": 0, "end_char_idx": 124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066be56e-00a0-47e7-8b53-bb5357cd9734": {"__data__": {"id_": "066be56e-00a0-47e7-8b53-bb5357cd9734", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "original_text": "Did I think about that right?  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55b46c80-2593-4ed7-86a0-0dae5d89a535", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71e21e9b09b022483133082df6bf6501721a1ed74a6e796d8a48ef0ff4c3dca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd300703-2345-47fe-92ab-052e7c1c222c", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.  ", "original_text": "Can we just go through that one more time?  \n \n"}, "hash": "2804834ba8c92120e6f36151934e1a6f47c85074ca9f65f61c2a3ffefde59e08", "class_name": "RelatedNodeInfo"}}, "text": "Did I think about that right?  ", "start_char_idx": 124, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd300703-2345-47fe-92ab-052e7c1c222c": {"__data__": {"id_": "fd300703-2345-47fe-92ab-052e7c1c222c", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.  ", "original_text": "Can we just go through that one more time?  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066be56e-00a0-47e7-8b53-bb5357cd9734", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "original_text": "Did I think about that right?  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6356e3a529fe018f64c092d403d2bd92db58e7588e8ff53994395f9a9906c322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "original_text": "Jason Hollar:  Yes.  "}, "hash": "a079174701425258074d05f8d50987dead174c1cefcd2efdaafa3ed80bec6d8d", "class_name": "RelatedNodeInfo"}}, "text": "Can we just go through that one more time?  \n \n", "start_char_idx": 155, "end_char_idx": 202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781": {"__data__": {"id_": "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781", "embedding": null, "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd300703-2345-47fe-92ab-052e7c1c222c", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.  ", "original_text": "Can we just go through that one more time?  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29c4ed417500e41808a7177ab4699a1ed52ce94266f2c0ad3d66c43443abc7dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a0c5a5-717d-4683-8031-cea3f420300a", "node_type": "1", "metadata": {"window": "Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "original_text": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  "}, "hash": "585de5334f9fc6b6e2d38ece52fc4ecae94f86d1749fc50a2ee06bb48ea73248", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes.  ", "start_char_idx": 202, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a0c5a5-717d-4683-8031-cea3f420300a": {"__data__": {"id_": "29a0c5a5-717d-4683-8031-cea3f420300a", "embedding": null, "metadata": {"window": "Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "original_text": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781", "node_type": "1", "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "original_text": "Jason Hollar:  Yes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e5ddfb1953fa9199b2c73767ee76afcf49288aa0d9e953c2dc33733f40ead32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee007b7b-f274-4537-a93e-85bb3f7a646e", "node_type": "1", "metadata": {"window": "Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "original_text": "So the question is, we ll, what are those same types of dynamics next year.  "}, "hash": "805cd4cedae676997593a11d16e3087bdf2530d43bd0ad32aa4e87a6c321b584", "class_name": "RelatedNodeInfo"}}, "text": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "start_char_idx": 223, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee007b7b-f274-4537-a93e-85bb3f7a646e": {"__data__": {"id_": "ee007b7b-f274-4537-a93e-85bb3f7a646e", "embedding": null, "metadata": {"window": "Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "original_text": "So the question is, we ll, what are those same types of dynamics next year.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a0c5a5-717d-4683-8031-cea3f420300a", "node_type": "1", "metadata": {"window": "Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "original_text": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fe78cbbcc1d55c2c7cd988d49e01b4a6f933b4393c25c2b4210f3bd4c8835fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d644215f-ee9f-46fa-aea5-7890ff942042", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "original_text": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  "}, "hash": "e1e7ac1d72afebc7b16a3d7d0a9f49d9543927dd275a24378b5691cab34ce058", "class_name": "RelatedNodeInfo"}}, "text": "So the question is, we ll, what are those same types of dynamics next year.  ", "start_char_idx": 423, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d644215f-ee9f-46fa-aea5-7890ff942042": {"__data__": {"id_": "d644215f-ee9f-46fa-aea5-7890ff942042", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "original_text": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee007b7b-f274-4537-a93e-85bb3f7a646e", "node_type": "1", "metadata": {"window": "Can we just go through that one more time?  \n \n Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "original_text": "So the question is, we ll, what are those same types of dynamics next year.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3664de28a9ee63ed3fb267765a6041808174b26251bf8f6f45f155e63dfc7b20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46964758-3b5c-4d18-a916-ab15b7c854b0", "node_type": "1", "metadata": {"window": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "original_text": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n "}, "hash": "3f7d0ffc15595cb5f83911eeeb880dbffc562578015ee586815c1c2461b9a3f9", "class_name": "RelatedNodeInfo"}}, "text": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "start_char_idx": 500, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46964758-3b5c-4d18-a916-ab15b7c854b0": {"__data__": {"id_": "46964758-3b5c-4d18-a916-ab15b7c854b0", "embedding": null, "metadata": {"window": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "original_text": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d644215f-ee9f-46fa-aea5-7890ff942042", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.   For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "original_text": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ecc4a3744508d9f148b4ea572448d62551d8fb0726f4fb1f27a230ecc3e122e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50a0d708-59d1-49db-b9df-9d3fe66d9472", "node_type": "1", "metadata": {"window": "So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "original_text": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  "}, "hash": "c709d638dd91011bca2830af14bc639db8e40d01ccce5f0c6506c0686abce396", "class_name": "RelatedNodeInfo"}}, "text": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "start_char_idx": 569, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50a0d708-59d1-49db-b9df-9d3fe66d9472": {"__data__": {"id_": "50a0d708-59d1-49db-b9df-9d3fe66d9472", "embedding": null, "metadata": {"window": "So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "original_text": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46964758-3b5c-4d18-a916-ab15b7c854b0", "node_type": "1", "metadata": {"window": "For the medical business, I would anticipate that the impact of COVID in the \nfiscal year, so not a year -over-year comparison, but just what's the impact of COVID will be a tailwind \nfor this year.   So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "original_text": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c252975a7fc73c740b8793d9113e19c4ce11792ce9c83abcba13b87af748ef2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46274bae-2179-4cbb-8e9f-440f7387602e", "node_type": "1", "metadata": {"window": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.  ", "original_text": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n"}, "hash": "598e94d5c38b0e443b5c57d26088fbccd8c327be105293c517c2193955bc6bf3", "class_name": "RelatedNodeInfo"}}, "text": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "start_char_idx": 683, "end_char_idx": 798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46274bae-2179-4cbb-8e9f-440f7387602e": {"__data__": {"id_": "46274bae-2179-4cbb-8e9f-440f7387602e", "embedding": null, "metadata": {"window": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.  ", "original_text": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50a0d708-59d1-49db-b9df-9d3fe66d9472", "node_type": "1", "metadata": {"window": "So the question is, we ll, what are those same types of dynamics next year.   Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "original_text": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b5cb51cd043e1997b77bb2b90f8e53a66bf1a8abd46ab795b9a49f33530103e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d", "node_type": "1", "metadata": {"window": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n", "original_text": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  "}, "hash": "f525b5509c5fff77bea883924d015984c9a5450ef3de2af6d850b33e310d6cc8", "class_name": "RelatedNodeInfo"}}, "text": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "start_char_idx": 798, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d": {"__data__": {"id_": "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d", "embedding": null, "metadata": {"window": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n", "original_text": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46274bae-2179-4cbb-8e9f-440f7387602e", "node_type": "1", "metadata": {"window": "Do we see \nmore permanent longer -lasting PPE volumes, lab volumes.   I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.  ", "original_text": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bda015f6b9717023364474b9df73de2322cbd8a86d7e5d2c369ced43478cb2a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea5d742-3b42-4117-a2a9-4693858f55a6", "node_type": "1", "metadata": {"window": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.  ", "original_text": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n"}, "hash": "19490d18dbfa95165515524125d2238f68627b9900ed7df2818970f59bc8a468", "class_name": "RelatedNodeInfo"}}, "text": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "start_char_idx": 971, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea5d742-3b42-4117-a2a9-4693858f55a6": {"__data__": {"id_": "6ea5d742-3b42-4117-a2a9-4693858f55a6", "embedding": null, "metadata": {"window": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.  ", "original_text": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d", "node_type": "1", "metadata": {"window": "I've referenced the timing associated with \nthe price and cost of PPE that could carry over into next year.   \n \n  But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n", "original_text": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc1782a543e51ceec72beda9750a7b3807c31510fb0f32cd98504741bd60ef92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0df7b2a-e25d-45a0-8694-d4d10d414b1a", "node_type": "1", "metadata": {"window": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "original_text": "Kevin Caliendo:  Okay.  "}, "hash": "37b6a9d0568c88789953be1f16a42fa88cb13bc0bc86477ccc017668cba4fbb3", "class_name": "RelatedNodeInfo"}}, "text": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "start_char_idx": 1239, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0df7b2a-e25d-45a0-8694-d4d10d414b1a": {"__data__": {"id_": "b0df7b2a-e25d-45a0-8694-d4d10d414b1a", "embedding": null, "metadata": {"window": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "original_text": "Kevin Caliendo:  Okay.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea5d742-3b42-4117-a2a9-4693858f55a6", "node_type": "1", "metadata": {"window": "But if it goes all -- if everything goes back to what a pre -COVID world looked like, it would \nimply a headwind.   Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.  ", "original_text": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45ccec5ba9e153a78116cc0569c569ceac47c0d407da293cb5a25f7bb0a1bc67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8bb79a2-c50e-4235-8a61-6782d32c206e", "node_type": "1", "metadata": {"window": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Thank you.  \n \n"}, "hash": "5abe49c7dbb4fb5a5f755fa93569d6779b0ac71755d530001ee0f84d7df13321", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Okay.  ", "start_char_idx": 1414, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8bb79a2-c50e-4235-8a61-6782d32c206e": {"__data__": {"id_": "b8bb79a2-c50e-4235-8a61-6782d32c206e", "embedding": null, "metadata": {"window": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0df7b2a-e25d-45a0-8694-d4d10d414b1a", "node_type": "1", "metadata": {"window": "Of course, we expect there to be a more significant tailwind opportunity on the \npharma side, but specifically to the med business, that's the right way to look at it.   \n \n And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "original_text": "Kevin Caliendo:  Okay.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab9a725419128a70c867766a8130dabfef055c649bd32f75414644b2b9dfd1f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "652ceb2d-3e96-4915-80e3-baaecb6dd435", "node_type": "1", "metadata": {"window": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.  ", "original_text": "Operator:  And with that, that does co nclude our question -and-answer session.  "}, "hash": "14ee8f50fe69546df35b648bacad7ec47857e442002a5946936304ac28cd9965", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 1438, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "652ceb2d-3e96-4915-80e3-baaecb6dd435": {"__data__": {"id_": "652ceb2d-3e96-4915-80e3-baaecb6dd435", "embedding": null, "metadata": {"window": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.  ", "original_text": "Operator:  And with that, that does co nclude our question -and-answer session.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8bb79a2-c50e-4235-8a61-6782d32c206e", "node_type": "1", "metadata": {"window": "And just one thing to add additional color to where I'm sure you're trying to go with the question, is \nthat when we think about our full year guidance of the low to mid -20s percentage growth, obviously, \nwe have within that some of that benefit I'm talk ing about.   And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.  ", "original_text": "Thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa2010a48ab4204c115b0fef54e6af91eefef58570f4ffe9a6b41907d39a92a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d291f53-19b9-4906-b116-4d582f872127", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "original_text": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n"}, "hash": "df5d2cdc484bcb324dc3c78075d8b1383cf78d856779e9debcb3b744f3576315", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And with that, that does co nclude our question -and-answer session.  ", "start_char_idx": 1453, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d291f53-19b9-4906-b116-4d582f872127": {"__data__": {"id_": "7d291f53-19b9-4906-b116-4d582f872127", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "original_text": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "652ceb2d-3e96-4915-80e3-baaecb6dd435", "node_type": "1", "metadata": {"window": "And just to be real clear, even if you back \nthat out, we do have growth in the medical business, but it is a key part of the growth that we're \nseeing this year as well.  \n \n Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.  ", "original_text": "Operator:  And with that, that does co nclude our question -and-answer session.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6529c0fc825f0fc3babc2399007661643e08834ea7501c4223df84a4d07b3e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff15496b-15b9-4146-a39d-0e87bc8f544c", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.  ", "original_text": "Mike Kaufmann:  Yes.  "}, "hash": "f965f703d61c32b5a2d720a206f28b7ffd5450600570f4f97773c00cc1b8706b", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "start_char_idx": 1534, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff15496b-15b9-4146-a39d-0e87bc8f544c": {"__data__": {"id_": "ff15496b-15b9-4146-a39d-0e87bc8f544c", "embedding": null, "metadata": {"window": "Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d291f53-19b9-4906-b116-4d582f872127", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Okay.   Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "original_text": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7efb8fc42c36f06229b7f074626b6c2fd195b09e58441be3d9dfe772bc09b587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a59d75-dac7-4290-a172-107ead92fc52", "node_type": "1", "metadata": {"window": "Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.  ", "original_text": "I just want to thank everyone for joining us today.  "}, "hash": "c961670378a179e1b6e6f7a17a772d3a114e58b24361a5a538df04baf1309bb0", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yes.  ", "start_char_idx": 1626, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a59d75-dac7-4290-a172-107ead92fc52": {"__data__": {"id_": "54a59d75-dac7-4290-a172-107ead92fc52", "embedding": null, "metadata": {"window": "Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.  ", "original_text": "I just want to thank everyone for joining us today.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff15496b-15b9-4146-a39d-0e87bc8f544c", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.  ", "original_text": "Mike Kaufmann:  Yes.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87c017962c0f6bd99158ce8c35d876cedf3342628bd4d262172e1c8434b55f64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58e337f8-0efd-43f4-b8c8-32d5705becf6", "node_type": "1", "metadata": {"window": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n"}, "hash": "e1a62964f15f8120c5f18d5939cd6887c4132b0e5220933a980c4650000a8603", "class_name": "RelatedNodeInfo"}}, "text": "I just want to thank everyone for joining us today.  ", "start_char_idx": 1648, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58e337f8-0efd-43f4-b8c8-32d5705becf6": {"__data__": {"id_": "58e337f8-0efd-43f4-b8c8-32d5705becf6", "embedding": null, "metadata": {"window": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a59d75-dac7-4290-a172-107ead92fc52", "node_type": "1", "metadata": {"window": "Operator:  And with that, that does co nclude our question -and-answer session.   At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.  ", "original_text": "I just want to thank everyone for joining us today.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20006684d594a758f9165598cba7a892d6dd07f293429d5fa8e5426e9bea1bb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b556ec5d-4e78-4727-8d86-6e8ac891b685", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Operator:  And with that, that does conclude today's call.  "}, "hash": "40c20d8749bcb9ab4007b27121f13e7e90f630805ffe0e843ccbdada0afd8f43", "class_name": "RelatedNodeInfo"}}, "text": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "start_char_idx": 1701, "end_char_idx": 1848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b556ec5d-4e78-4727-8d86-6e8ac891b685": {"__data__": {"id_": "b556ec5d-4e78-4727-8d86-6e8ac891b685", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Operator:  And with that, that does conclude today's call.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58e337f8-0efd-43f4-b8c8-32d5705becf6", "node_type": "1", "metadata": {"window": "At this time, I would \nlike to turn the call over to Mike Kaufmann for closing remarks.  \n \n Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73740575376e82d8e9078586a6708439f0a87cbb9d555df83f58b68b6d28e85a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d", "node_type": "1", "metadata": {"window": "I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Thank you for your participation.  "}, "hash": "45f28d6fc2160f91a8e056cbb9f2f3172c9486dae4ab7992183c7b9f6b062968", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And with that, that does conclude today's call.  ", "start_char_idx": 1848, "end_char_idx": 1908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d": {"__data__": {"id_": "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d", "embedding": null, "metadata": {"window": "I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Thank you for your participation.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b556ec5d-4e78-4727-8d86-6e8ac891b685", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yes.   I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Operator:  And with that, that does conclude today's call.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "677f2eed89e6631c34fe65208a4073f419423099f373bde6cb55d14dd7dc00ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b4cacc2-e556-4bee-a82d-c03e8bf1c181", "node_type": "1", "metadata": {"window": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "You may \nnow disconnect.  "}, "hash": "640fb4f01a0fe6cecac0733d175dd53fed209a5463bf6062e990a5dac8edee2e", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your participation.  ", "start_char_idx": 1908, "end_char_idx": 1943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b4cacc2-e556-4bee-a82d-c03e8bf1c181": {"__data__": {"id_": "1b4cacc2-e556-4bee-a82d-c03e8bf1c181", "embedding": null, "metadata": {"window": "And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "You may \nnow disconnect.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcbed3d454e3bbb1f6ec4d7b5063a79414376b3f1623f363817a3dc6ffe43f7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d", "node_type": "1", "metadata": {"window": "I just want to thank everyone for joining us today.   And we and the entire \nCardinal Health team hope you and your family stay safe and well, and we look forward to speaking \nwith you again soon.  \n \n Operator:  And with that, that does conclude today's call.   Thank you for your participation.   You may \nnow disconnect.  ", "original_text": "Thank you for your participation.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a642944fcefee5025fb4127780bd87e3fbfd8e0f660102b65dac84fb2e53d6d6", "class_name": "RelatedNodeInfo"}}, "text": "You may \nnow disconnect.  ", "start_char_idx": 1943, "end_char_idx": 1969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"8beb377c-a871-454d-a190-40a59f113749": {"doc_hash": "0daf6418348bd32313a7f405e02922f71c33a9a180f5e0f697cc4ae23fef47f7", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "496cb412-8c22-4165-a632-a1fde8751108": {"doc_hash": "abbcb35bde912e72b598d19cd0766aa6e57b78eecf434ba25db642f554de6267", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "8bd2598f-9126-4dda-92e6-caf7228e2a59": {"doc_hash": "fdd73b398931520f395bad5248fe3ec5e34206858e844a50342360980070192d", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "14d3e932-3ae5-465e-840c-5a28a2085a20": {"doc_hash": "4f8a248f9c3fce7042be548815085ff86aa73b1e6b04bc21d11000dc8abaa474", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "31b499e4-bcd0-48eb-aa5d-b2444b8d4491": {"doc_hash": "201402b925389d3fba68ce03cb001080f91ee496b4601183110f4df446606661", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "e0c1c555-51c3-418a-a6f9-1be9282da356": {"doc_hash": "a8227d29840777cadff59c95434e026a9ac01a7726a0fbb8e3b8fcf9eb97beea", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "3fbb80f7-2542-443f-a077-5ee48929f542": {"doc_hash": "bebf2573888929ae1a35baf6e2582aa6da587d3be82ce5175ac3c64f9025dc1b", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "7cd213ee-49f3-4f69-82ff-8b81d38bae29": {"doc_hash": "f0e4666f2830047cd27487030eb60706cd5445c0d4f488a6ad2cd4ccb45cefd3", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "15d6c122-f5d1-4f2c-b08d-f89042b63ffb": {"doc_hash": "baaec8e56a23f9f750d73a37b85d7f9871c3b16d59efeb3fe5c8db81b11c32e0", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "e8869667-ce0c-446d-8054-e7995c86ab5f": {"doc_hash": "da6c2d04cf960cacbdae97368b51a480b5a29a9ccfb30b07ed2abc52ce79f725", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "1587a637-ec15-4b5a-83d9-732b3e1f45ca": {"doc_hash": "ed7e55e96f16e70f49fab22ac84766a9237ac04bc13ade5cbf5e0e9a671540c1", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "44ee8614-ccbb-4016-b6eb-2d7d5902581b": {"doc_hash": "28a96466f3c729abb90af10f8e0167e60fdd0b22e68b6b86e3d03abb10653cfa", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "2507baf1-7ec9-47f6-b8e9-23e511fdae53": {"doc_hash": "9be65fdd952363c886923ad8a8a0c88adb54b5297116bdb6cb6a7ec4c1c2a4ea", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "140d34f2-6eb4-4c64-a104-8dff33c05b0b": {"doc_hash": "57b626b89e8f50f298dac74cfa982f8f8b600dbf5e0e688eef0d2128a569e723", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "a5000e02-0577-481a-a48b-a47e0d963d7a": {"doc_hash": "d430c3ebcb104f2d3391bd86864131fdeb7d1c9072544180da0a066bf5a01b95", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4": {"doc_hash": "9ec9ad82b9afad6c78238bab67e46f41e97b210cd6d7bd74c1c3d535ecee0b60", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "b426df16-bf28-4931-8c0e-8f5e0678eca4": {"doc_hash": "274644d8dcb18714243d75ba6584248219762d98090e166e8ed75be0dfa319ee", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "ecfcbae9-f33e-40d2-8587-15827497aab4": {"doc_hash": "5b49d67337ad8781c50a120aef1ff76d06e51f4fc46c640c34fbf6a2ffb0a106", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "49ddd235-9682-430d-a22d-92871c4f55dd": {"doc_hash": "dbc212156a0d0b25c86acf2132f65bd4c197fa37c0ddd7cc1aa6021bf66edaa9", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "942b2370-8993-42b8-8413-e0baf35b6e0c": {"doc_hash": "1af1c7cf4ceedf10f4f0844d7ae3b1cfa62777f7cc919c939607fda58b10ed8a", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "aab9ef67-62fe-4869-9bb5-c63abcbaf373": {"doc_hash": "f9b7e46204390fc24666b62f638ff2353ee0fcb6aaecd3b123e1cfd9d25346a3", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "390c8658-af12-4e0b-a275-69da913bfbf1": {"doc_hash": "804eedd468aab6c161ffd0dd51c94033b8735edb1d50c6e4bead6e3b72771cc5", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee": {"doc_hash": "3269b4a6b584de4fb467130b0752458c7314eb2e66321a69a1eccc45d54e8dde", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "28e83bc7-4f57-4189-8db0-a342bf649477": {"doc_hash": "a7b708d1de84d54b1442eb9af793b297e6cb64e18e5e4d527bed56bbe0981c36", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "146db715-528f-41aa-85d2-f711536ab1ce": {"doc_hash": "0be22ebccc875ca7dd0b8c7d57df4877230bdf5b7b53b2087e2cba146618501a", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "a678addb-29d7-4ada-bb87-de3c5adc552a": {"doc_hash": "f33689f0420993b16caf186fc6643a9aaad8d4c4708e5c40d1203238913e23e1", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "73bbfac3-28f8-4f54-8470-e5de66e4a1d1": {"doc_hash": "387b96b26891332437d0cfe7388542762dccef2c5717ca9405b16d5e0a930629", "ref_doc_id": "137c400c-b5db-43bf-a8d6-4c8be35f8b14"}, "066cd2ee-3f53-4003-aded-cc2b3f98d309": {"doc_hash": "d76c4f1f290feff394bd4cefe8ff7eda358369573b0bd619bbf4192b1387ee42", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "a085bdf0-943a-47a9-af27-8a9ce3fe6389": {"doc_hash": "16e25402e942547384c434367976e776c68ce670f0bfa502dd5ef3bf5525be01", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "6378db28-b35c-45d0-8ceb-afccd2a4fa47": {"doc_hash": "50600da77ff6fd7c928a0b316c92a605c31912394ec8b2ef51b46302d861499b", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c": {"doc_hash": "003f68c559643b3c139d5935b5514dad73d319dafe322ef48189e010383ff360", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "f1859a71-7f53-42eb-9a3e-6cf5afedb668": {"doc_hash": "2b202192092a804b3a87cb4deb3b72cdd9b08fbfaf4caabbff6444e3cfffb735", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "2ae28b9a-6a30-4f4e-b752-77958f987840": {"doc_hash": "9f010601225bf8b2e313a164a4f369becf4be44626ca2e6af93157c2331c354a", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "7678b756-eabe-47ef-8f4d-d018d4fd416d": {"doc_hash": "48fe033f7f34045e8a42d1a48e3071810836819521ded926f84ad3fd95c2fe36", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "cc02e04b-0c30-490c-ba41-bfa1612d5068": {"doc_hash": "8b380444adb01649656ccc845468e75fea365148e65ef47cd977e47583346e09", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "069e4c99-a628-4a78-aa04-a13b7e6d846e": {"doc_hash": "7b56f01fb088070570b3d9a94e67d0d136449a20a994ee5f899b2882d370e538", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "0ad081e7-351a-45c8-aef2-514a938f717b": {"doc_hash": "68dfd79111d0c67a729eef0ff2f541e6f1e84fc3b008368e5c71f4b18fc9a763", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c": {"doc_hash": "781c0742f1f1e6eed36f8b38ef11c84cdfb039eed99ee5f2b7ae5715035ca403", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "f1981c8f-c334-415d-9f27-c457ebc19f82": {"doc_hash": "343217b638bf8349590ae383454a51dd01949d18166ebf22ea16d704e6325a7c", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "1ac8557d-2ce7-4ab3-8893-342337dfed35": {"doc_hash": "ed4e093d7bd8bd41274a38331297f8447557b95e16ada5a5a0cfa4d9febacef9", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "4663a1f5-23a0-425a-bc28-cd35f827239c": {"doc_hash": "61fe74d6b719a9f7c2b646edbb3d0e19e2a1b949eef256b9c0a18a8132b73a8a", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "59e3fa8d-f058-4e23-a2cc-1aba133bced1": {"doc_hash": "93e9569e731b7b5e441858342c9e0407d95078d7d2b2d1962b6dc6e105c477d0", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "79a49e34-7bc5-403c-8950-832f91442e8b": {"doc_hash": "7786903c363d8cc85e69c5678687deab656437b957eb6057d56775b827ec6a15", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba": {"doc_hash": "e30b81637e79b2afcbb3fcb4d109e74891f713b7b403032bc549242db3ade1ab", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47": {"doc_hash": "92f0b57bdb38e9c9b12ab28d5c1d6756addf735369cb54b9d33fd55b90178b99", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "e15210ed-8502-4920-b869-c26d6a7b0aa2": {"doc_hash": "b79de231d6c7e6d7ada53c18e2d28dc4cb7935beb339f1abdcd3d40e4c53cbe0", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "c1f1dcbb-9bff-4823-9072-54855381e1c5": {"doc_hash": "f6b3f9961f358200e8633c679ea837911228106c666e736b4a49aa1a16ffc7b6", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "64c08634-b82d-4fdc-a41e-6a50e5f1d36c": {"doc_hash": "6d133fe80d8011f96bb506d8e55cf373e8005805aaf0347dbaae7f3d24bddc38", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "94348840-d81a-4deb-8c34-bef36b3fe554": {"doc_hash": "9243df68fcb36a42bb33975fd45d4fc6c4b34e2d7ee168a682579bd80f2bf838", "ref_doc_id": "6bbbd46e-4051-45e3-941b-281d1fc5f4e6"}, "1ea61269-732d-4fe4-9816-182772aa4ef0": {"doc_hash": "529b81cf19f24758c09b2a2c5433f6d9cf3914f5369119939c3e981ea1fa11b3", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "44e0c185-c8e8-4747-8485-c9f18d4759c4": {"doc_hash": "e9451fc5083a62e2f227b8600757691e1ac64a4e5b56a6fe08824dc35ab815b0", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "e773678a-c457-4fdb-9a9d-b03073e411a3": {"doc_hash": "ff3c68fcb5af63a3e42ccdddd6ddbb17f755de75b31282116d6005b37df031c0", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "ebbec759-af7d-4521-b9be-02b41c944cda": {"doc_hash": "0f809681991936e333313f7909f25d00bb9bbec81594e22d0312c9ee34f236b1", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "5e10e9cb-5835-4c94-bc8b-c1c041872d1e": {"doc_hash": "fe8bb9e1a7525c55a7a7bc84dc746985ece08ace3816e34a3dfe047cb3f190b6", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d": {"doc_hash": "88c051213dbe742ef1de7202577a738cbf29a9bfe1687696c8941bd860551637", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "93e1967a-b5b8-44d7-ba15-e90ee09eb529": {"doc_hash": "1365836820f542b691b908ccd18afade2af1d2ab3c17ffcc1643a0f4b58c833d", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "22e10ace-2871-4bb0-9233-9aa7cb24b455": {"doc_hash": "a205d7eef1daa78385f7480ef8aebad321d75b2319d5f4f998d9c87b70d1f35c", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "d0251ac7-cef8-4b12-ad30-634bde10f084": {"doc_hash": "3c4faa017c1fd971b607d8c6517dfd1429d299a938ed1ddfaeb1007b082ee4f3", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "5b25cf9a-3537-460a-afd9-e6e0de6422f8": {"doc_hash": "034a9865a687a3ee3b3ddd27198b89eb7e171de1a8e94d454ab0db1c1cc8fce6", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "71bfec4e-723e-428a-93cb-78364dd38a78": {"doc_hash": "db2416da77d73389ecac13d5e204c243e592fc238219d7c6936db34dbcc60707", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "44690154-b479-4035-b422-2109bc827d4b": {"doc_hash": "0405137d631a5512609adbbbf70de22af3a23fb20ebf2c26f769d70f94ca43e0", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "de447f9f-0989-4229-b785-781ac18c4395": {"doc_hash": "776db9af69e6ecf99086c68b23b4dfa04b2933b17fe38fe6c5bcc60bfd308a0f", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "b1882b37-a83a-4613-9f0f-de402e6c09b8": {"doc_hash": "d08f9bfa15ea9d46e31af9ecde150f72c9dc3cefe6c4d34e4e282ae913142897", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "7d4cf190-65b5-4636-9962-9357c7b15855": {"doc_hash": "55291dfc29b959889a5394322e1e4e81c520e8b82d2daa5451c796a44e7018df", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "8ca34b06-46fe-4f1c-899a-27f828c6857a": {"doc_hash": "b41b2f90ea7c99689d606a5087486f4f0c3f706f6f9ec2cc62c8bcaa12f1aaaa", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "838cdfd2-af73-41eb-9298-2d0c4d5d23b6": {"doc_hash": "31e4226ff1e20893e2c917df1d6e3a412ff5c701479e1ada5ae65309ef1415bd", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9": {"doc_hash": "21674f70dccf86ee6cc27640c10e31c38b29269934429bd391a3e9e8f99de840", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "0fd32894-812b-4a08-b285-f20f7dd7f5c1": {"doc_hash": "210404eedf813bbacf8331f1ffe11388eb3d712ef11fbbe1f8dbc01d9d09d74e", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "65f7a0bd-bf26-4d5d-ad38-efca53aae941": {"doc_hash": "2d774a4e3ad82aaf1b25de17c132cd5bd9bb0220444b907643f5eeebbe051840", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "e5e603a2-3733-4cd7-922d-ededb7583d37": {"doc_hash": "6b131b488c79261e58fa5db861ef4822d56cf4b9fac1aa0ee334338175da352a", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "6de7dd80-0b69-452b-bc3e-5dbd597f8152": {"doc_hash": "89a580eaf3959d0e64e7d41f2ad4121fd755bafb426dc885f0be37332f1eac7b", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "4f45cbfe-1512-42e8-af70-f4a785491a90": {"doc_hash": "023b83f50f5f9da1ebfd74d91a729b8dfa1a76a1c23217bc4240f9e2e36218c9", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "41a77174-c675-42a5-ba6e-71e9b5f41dcb": {"doc_hash": "d26e9756ac07f197140f5eb8c6fe5092c5fcc8c6920ab833cac5deb6e27db4ee", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "4ff5dc63-26c7-41f7-a908-42796b8daef6": {"doc_hash": "0cb7821d72608d996bb83c0045dda4bf9b7a197ef4b2bbca10d8e6669cee2e58", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe": {"doc_hash": "662021bd4e872ef591a0155f459c9515db6713068baaf6031733b4d33a1a4913", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "9f5b7cdf-3055-4d8a-ad21-1865fb64131b": {"doc_hash": "a1d4a43ea88ba6e41877397e0e6affa4b587390499d297f3297f6493c9d9d4e1", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "33fff532-487b-4496-8bf4-e8c71f47eee8": {"doc_hash": "97e7fbeb23d3cf4663b1a7c4e485114426a5a769e7bb7c0b62fad38c337602f0", "ref_doc_id": "c6e6fd28-cc44-4008-ad5c-67eff77e373f"}, "05baa260-0d9f-4b66-8f22-a925c2442af3": {"doc_hash": "1680c4cc3034f99bf5cd5010796b2950488714cbadf3a700b148bd909dd60777", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "459334b1-bf15-4dda-ae1a-60178b47c32f": {"doc_hash": "ac5d3a94d3cc0fc416018399205184c51e19b75fff84f161c6640a2dfcb917c2", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f": {"doc_hash": "23755ecf9136b5f1b2086aea40cf92a2c76544d4b518d365aa4ad9ca4d9dceee", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "76aa1ac1-bfe9-4d52-93b2-ad54fc307953": {"doc_hash": "8d016dbe20a1c42a20383f7e847b9ff1589a7b025455cc3c01dc6f999b85933d", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "a0d8dd74-2054-40e1-8eb8-0ea7cd872292": {"doc_hash": "c5886ebf9cac6613553eb135ad66621c27e7813b7f3e70ef6b85e814eb0941ff", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "b3eeb89f-0c30-48a8-8780-4f9b9ff49355": {"doc_hash": "f26dcec84377a1882ad4f516ba781143d52d7a81b94e45c695a75ee2984653fa", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9": {"doc_hash": "edd3ab0e893079919f4bf8c5b0e3bb843062626bafbccaedb526b2f29aeb9eb8", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620": {"doc_hash": "96d7b0892ea6080e28d408d9e0fcf9bb58bfa6f31c4ffb1b3e17ba5bbb28a9f3", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3": {"doc_hash": "01f79ba39d0ec343be357fde26993a92fb4692c76ea4e4e83edc966633a98e9b", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "bc0f3ed6-52c8-4996-88e7-97ee099c9505": {"doc_hash": "925d11746c711618f9938611ed2c0c12df7662b689f479f6d352cee737ff8b15", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "262e2047-5ba8-4bc6-96ea-02a342036f26": {"doc_hash": "a4ebffca59969450999561520c717d5521baf3ccc2a5f72fe436876827324e3a", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "b5e3ed92-5db8-4f47-9202-652722cd863e": {"doc_hash": "f009ed58d66b0203137395fca782e49ed10d062ca175301a99acae3d9b178dbe", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "153e5912-87bb-4afd-b8b9-38416f2dbc0e": {"doc_hash": "24031e2dfc6b82dd181b1d4420a68cd5affc399568d8dcc649b88972b3e73b9c", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "acd95833-236c-48fd-bc2f-d85ac86ae9f4": {"doc_hash": "158e4a550059a57dffcba89177f4e9430182bb56937b8ca790ab9ef7c05b5afc", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "da63a396-a4b5-4da5-862c-e9738beba8cd": {"doc_hash": "664313efa2791c741b92b57b2e3f6153ae72e9789f73ccf7a2deb8cdeb9d77cb", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "6a13a1d4-325f-47e0-8ac7-634f6349caab": {"doc_hash": "8a793eb13a6a58330a7b0653f55e48c23a3c9007b50c9d7a0b76cf6670938f1d", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "6570468b-1fe1-43f2-9a1a-65d046e123cb": {"doc_hash": "f2b5f71676f3539b9ef81a8930d41ba78754efc9cf777c029d0e6d644d64d50c", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "f63b7165-4b10-4729-885f-ac9830b070d4": {"doc_hash": "1ab56b54591f567b1994297d322121245628fb7eae7d361a9f804bd2ce5dadc7", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "38d02a1c-3913-4569-bb38-ba79482217bc": {"doc_hash": "7cb0e204552fb328bf662646764389388edfc528c42af031429d0560dd4e99f5", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "37e1e5ca-11ee-4686-9411-0951f3e11071": {"doc_hash": "69eda99dff76a1ca6938782509eaae0868239cfb5b3f36b27973c34f669f6388", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "b5047f53-7729-449a-a767-8ea0b5d209ab": {"doc_hash": "f253c1c3aace0bbd35335ac90e38586bcd6f9012e4a537a6d078b84b48c6b050", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9": {"doc_hash": "0603d54155038ccf585baace391cacb1153efb79e8ee54fadf1f1aef9ea78704", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "8cf5049f-967c-4115-a8df-ee338b357cdf": {"doc_hash": "aa4f99ffe611395ad134255378b133a6ca82b0652320955b8e11a7df1b31df59", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "da6e86e1-9912-4bf1-b432-08757e0cf441": {"doc_hash": "1d3c3509c2a5f2a9d06e28dbc07c65f9c6ae8bdf166bd588deda389a7c1de30c", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "418c33a6-f6b3-4e31-a438-f0cae45b9cee": {"doc_hash": "b77c21312c58d3c043d5d4ad2b524080c1f9c9d639282300456d8317fb7579e1", "ref_doc_id": "61338c6e-1cca-4286-9dc6-c84fe0097e72"}, "5b2aad3e-569d-49d6-ac61-29d3e7933a66": {"doc_hash": "9c3451c263617e978c7bbe7f86883dd79ea6bb401ecb34a593eda6d822e27155", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "bb887675-d93d-4a7c-ab82-3357bf947839": {"doc_hash": "1ba3ecc153e2fbb6537255d5555f0b9a7c7ebe2c879929bb67c5dc2d1e0dbf65", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1": {"doc_hash": "bbd69df84bdd4dca84856bf24492f2d503728b5227cb6bb6510b5263980f8bff", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "ef79d564-7d7f-4b65-b4a6-4734763fddb8": {"doc_hash": "53810d8ab88fcdd8c431d18b78cf39cc84ca6cc4f400f335353d804edb048fe2", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "7c0ddfcc-1609-4822-b5ab-0a02df0e163b": {"doc_hash": "2833e233a4673a9ad07f9fecce0aa4b900d2138c0a65facd3c4657ddbca1d52e", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "208d54de-cacd-48b6-8ad7-5929f8e6c6ef": {"doc_hash": "674c7d587c5177383858f43315759c3d22c113f4d38f6d8ee341b90921ab9d9e", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "4ccdcf75-a189-4b8c-88dc-05833a4f80f5": {"doc_hash": "33c002cd090a508b87bc4c8204f37afeba8e7763d3ec4ff205488a9bae4dc532", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "8f899676-dfc9-4f37-ab22-a7603026db76": {"doc_hash": "de4d8b35da9e9142d0c22ed1e86108bf060abae181c8761beadbe7de3b9d1732", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "a7e154f8-470d-4b5e-9d23-08e890615e84": {"doc_hash": "16abcef0d6e6e2d38b6a4531d5e48ed441006573f41b470a7a2c5f24f2a71f50", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "a5786927-bd45-45df-88e5-f4294baa073b": {"doc_hash": "ddb49b6ed0edd9f067430cd45a78464cc38692e9e99d31acb859f62edde303b8", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "e91b913e-7520-458d-9bab-d87e670a0d5e": {"doc_hash": "4f3da5854d9d47f6b71391da5e378773fb6fdef26201aff4268dd065343627b6", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "db154aa5-3c99-4693-a245-5e82ec80fabb": {"doc_hash": "7540a696d0afe017841dcfa29b083d671e398b0ed563b49727452a5b91d0525d", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "4d40534c-5bdd-44db-ae56-c88df2301c16": {"doc_hash": "de27ee10144e4014c717b83acf04222c8efad25223bfb27d1a47e3e688a1405c", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "293d38b5-fdcf-4606-a456-2ec46b413071": {"doc_hash": "b0a8023f9bf5feba40e76b8475a6e1fef2abd359f05494d739707a4bb25211d8", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0": {"doc_hash": "c49861f3ba8811f4c8db4d2874433b874333138fb671f1cc309417f5337b8341", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "8f645b43-96e2-4fc9-89d6-ce270cb1a28c": {"doc_hash": "e68afe0585edc94c4605894e1971089dbc62a512612935e01764bd9b3ef29e2f", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "5da988f8-232f-4b90-8703-c8f731d893d5": {"doc_hash": "6b44aa1eea750f3b5826b28d2195306d25127185b6411b7457c7463dee99921a", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "dcc9d668-2570-4b39-83e8-3109c60ee090": {"doc_hash": "cdbe5d0a59712cf74106ba37c9b9ff71fe84cf952cd3bf1a60da36e4f1bb9dc8", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "0860d945-f451-4735-943c-a57ba78f73cc": {"doc_hash": "ff0ed5ce830cbed214c4e2ae822da5bb694ab3746ea2351c022a9950281693da", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "22343999-c1c4-476f-ad6a-47d3ec681a2d": {"doc_hash": "2ccb07624d1341a237bae10a11017be49f3b23b01da60a5ab8a62de4332487d8", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "e254792b-89fd-4e5a-9a30-cf9a00298dfe": {"doc_hash": "e0b6d2519552c9951f2a65811d6889b3e9e640e5d534eac93a689150b6521ad0", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "cd65626b-d42f-46b7-9502-27237d86a408": {"doc_hash": "daab336839447700b183eef2ead97305387f3e3bd127418890f70fe072305b1c", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6": {"doc_hash": "265715db7c3330ae6bd4966a0d132bc6d12fd831c5150355d77ef44a20760367", "ref_doc_id": "1aeed82f-a96b-4efd-b34f-5be8681e4c25"}, "7b7c5d28-1a07-4880-b6cc-240aa2f775f9": {"doc_hash": "b9c8cb25b223273b563a38258f1dbed104c703fea1ce06e657183ba4b35b4413", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "67a9fc82-c3bc-4ae7-a56f-caa106895f14": {"doc_hash": "337dfd64e632374044910cfd0affaa3bf4a3fd5a112fc296fe8ac6cf941da388", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "594d167e-0c25-421d-8b78-f20f1425bb4c": {"doc_hash": "c11a1ad92cba3c717f10f3a963b32a7187c918e70e5e09eb440fd7857b2124ca", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "409128f2-9cb0-4d15-a072-82450c173a7f": {"doc_hash": "c25a4fc7f87905832d5c08645e3875b9111ed0a6ecf4dfaa2d9157a0dae0dd5a", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "6f17ac49-de54-42d4-b149-7b9bd9aaa728": {"doc_hash": "04ce72947ef2fd9063448726f146493265d6ecff005685fdf5e728410d29fbaf", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "2696cb6c-6ce9-48b5-b044-166a5e561fd0": {"doc_hash": "50fbb868584a84f5e9c240bd779c366b4a026e9acac889872b0fe0122b19d279", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "2dcf2000-aa61-4d85-8db0-b83499056baa": {"doc_hash": "77b86282b5a184f1a1ab666aa04f8ad5761013945ad55ee14d9f53a7799e60ee", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "8fe033e2-7c12-4616-809d-945340d3a7b0": {"doc_hash": "3363b7ee87917aa37e85da6fdf30c200f2c81e6fbe9dfa9dc904654939c4a736", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f": {"doc_hash": "e1ea1110745a88aa583c9e1497fc44e0938f9a9bf04c0f90cdc00c61a87163f5", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3": {"doc_hash": "41788cbd99414592473f80578206a7ee7d43e1bff8a907b244c0054c412abc40", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0": {"doc_hash": "5e2d1170a42203b350018fc612487d72d74412f9dfe5b128f719c8b0f7f1bc71", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "a070461e-6ac7-4879-8f66-b7ff663ba1e1": {"doc_hash": "b753405fda6c1f77e23034e79a67ebc20fc776ddac83f0ad9ccd9e4d145bd23d", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "45af1486-299d-474d-88cb-011c65998cf5": {"doc_hash": "2898e17579c92861b264ea99d5c36353ec2f380098bdbd7f2ee67804d32fe676", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "7cf061c9-97f6-48b8-be19-bbe33eec6f37": {"doc_hash": "1db50365ef245cd63ea6d5a1c34fe565e9f168a21387f55631ab03ebdcd4d988", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "73ae0781-98fa-4778-8d13-9b48ee5af840": {"doc_hash": "904932ac095ad3ce50da3be92e366c8b42ca9479687ecf3ca1eb41ef9d7c8a8a", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "2bc7cbce-92ea-4572-9729-f97c300445d5": {"doc_hash": "b60c495504ea98b8bf9c5c4f8538086cf5005ab20c502ca03a1876c7ae99c667", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "10eefb74-22c3-4e62-9193-5b34e671b57d": {"doc_hash": "7a29ffe30cea09d51f0251eb38ddf4e0765c97c6460df8e32e15a7e11d30d1dc", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "1a6ea236-58a6-4b08-811b-21f92e359dad": {"doc_hash": "3790de521959e8d3da4b3ca2b28b452791584d748389e02ce423272f7a7af77f", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "ee124cba-fd27-4503-84a8-3567722d045c": {"doc_hash": "3078571d24896a30989f796ef738fbf14ac1f3903f984f57b47fd9442dc49bf0", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "70d549ff-c723-4bd1-9df3-3be6f419cc9f": {"doc_hash": "fa08fefd776a945336b196c0ddd6bedb20b9a2546defe957ce018d4ab5f57ec8", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "bf319f61-67ba-46a0-aa39-3e99ae4e716d": {"doc_hash": "9a101112104941ef6d9bca1e1b7ade676473ff4f2729da1e29a1beec8a225380", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "bfe658aa-62a8-48a8-8b6e-480de935ee16": {"doc_hash": "3b9f0b68a553a7c67b41f4d7ebd021b653c8219b7b01d57715c54e96f80a0b77", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "ef1388a4-13ad-4a75-b666-72a2f11b5435": {"doc_hash": "63423244811a42026f31fc70e890bb0ce857eb4439e65c846fe549359ae1a84e", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "d0a9dfb0-50c8-4dac-958e-dfed2e906c33": {"doc_hash": "ffe9cf5af850d924d2d821e85c802bf028915be412aff4dae88df489bf448403", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "cf6eb5a4-295a-4df3-962f-238a145ac64f": {"doc_hash": "45dc26bf853fb918318fbff036e66e9af375c07fa466fe57254d66dd78efa3b8", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "12bda2bb-2bc7-454f-ada5-f973653b7a94": {"doc_hash": "05d90a163ab715131c07c606126e5234c311e13d5f7efb0ccd756da9227c9aaf", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "5778de3c-90b3-4519-af60-3b9d82ebee63": {"doc_hash": "638e90beb2b29d23e4452be2183f9310f436d223bb156b70d4b7eb8edc8d928d", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "75914680-435d-49e9-9b27-832ed28fdfd8": {"doc_hash": "bdeb7238d239952f1298a5c392e9712159755094ead89970470b9101181c19e3", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "bd75096a-f09f-46d7-845e-5059e4590a5a": {"doc_hash": "142eb98c0aec1dfe073c8303fa682d0c4b00f9c0e9383e361263952bcf109a3b", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "96ffd680-3d7b-4043-9915-edbee5b39ddf": {"doc_hash": "c045295dfb1a0e8621ac76327f3e312c15f97e5fbcc171ff99ffa42df5e43f74", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "bb60112f-e943-4e51-ac8a-4a86c001cc91": {"doc_hash": "82aee3786f704c860ce0f463d27adb361a724587a5ee8bd914da39392ec9b516", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "4bc1aea3-b5cb-498b-9223-8a15460c9cf1": {"doc_hash": "bdca42f1844ff26220c9ba101a8018d106ca600ad9198d6572fd32047cd544a6", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00": {"doc_hash": "12ca3cba300c7898cc9fac73d6ba95a982c673c846808e0316f377509dd9b91f", "ref_doc_id": "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1"}, "37066222-a152-4f2a-a6f6-8d2663e1b09e": {"doc_hash": "348c53bd265811829993a8389de8e503e91f502573413d5f681c75a287e31873", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "17e374ab-051d-4bef-8b28-c6811643176c": {"doc_hash": "fba00b5d8901ccfda1941c793af9fe18360a51f038456e75188c0bbb913379d9", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "60330a11-96d6-44d5-9beb-e1fc29898633": {"doc_hash": "b72a35f5f0b6f249dfc328574d4d79a201b1d5c73b2d67d248e3003741dc3034", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "3e9de19b-e263-44ae-ab37-80ba68cb128b": {"doc_hash": "8dc03454eb39c3a2aea8a62c8b931c844b3073777ba85dfb35c1250108b8dd50", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "a6fdd9c1-30db-408e-a233-0b49e61e999d": {"doc_hash": "ff3f5abc0a38c80cfe1bcc16a6459c2f6f64e9aa4ce77814cf392bddae036535", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "e9f9646d-4120-4933-99fe-c2716e3c06e4": {"doc_hash": "cafb37fb6b6bd677fedf300dcc8e64866bebad9912c555be80eb3385bb67f657", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1": {"doc_hash": "cc04b4d09f14923e005b07e3460c28aa023b565b7cc6513996c62685faa4d8f8", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "0ec18de9-1014-4107-a938-6648c52a5a89": {"doc_hash": "17ee41f6fe600552f13334d70d34bd81d822065565cc7ef48fc29aa676247f72", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "8970f95b-66fe-45c5-acac-603efb4c2334": {"doc_hash": "6e5262095df73fe3e4215d30afd2ee200b7e2173e49366d474984d2417a15474", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "9d63e035-b793-40a4-bfe4-9d5336bb32f8": {"doc_hash": "554d9221bc7d1420d60fcb21ecfa7585e1de4723e745447cc981c357b14fe4b2", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "2c8d1933-67ee-45d8-bba4-f3811937b2ea": {"doc_hash": "2d34c661466d4d463a69e83fc20c2e9ecc7acdcaef5cc5a4314cd642675ee729", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "249487ae-256d-40de-8c7e-f7d459d12af9": {"doc_hash": "4f7c1f385e1cbf95476b76edc46f5b9d7c2a2d3529f51b105330dc82ca216efa", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "b9714f56-c652-450f-a349-0ec2f490baec": {"doc_hash": "a1021a7326eb9762c6dd7960ed7be3befbd255978a78b369198f2c63f98dffc3", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "2bc90613-0d31-4df0-a236-f5198e45cf46": {"doc_hash": "812b334509e315a8026c3a1ba22422c61ce77fca2e79c9e9d3592d59c24ef7c7", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "78f18a19-4998-4cc7-b0e3-78387247646b": {"doc_hash": "a032ad67f61555fc81f7584d90923132871f15e2fdaf9a522b6eb289f931b79b", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "d8361e8e-5473-446a-b895-d7f262260012": {"doc_hash": "df32a4b524811ef1afdef5d0ee05ea586be2c0e30075263b86e4750ac6a1391a", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "a56b0f2f-2f15-4533-8ce1-81adc25b2725": {"doc_hash": "977ea615451037d39eec9c3f8dd3ac12a11c236c0f23c007a684234764fd500e", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "2ddb327e-d59a-4b8a-9d22-3959f52ade52": {"doc_hash": "dda67e9673cd4bc5c88367e694d502f73d8bdb2ff2033e25afb31884733803f3", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "612b0421-eeb5-42f6-8fcb-74ccdf25e976": {"doc_hash": "9a19deded3050bdb701171f5fd2f4c844974ea1f2fb6e468764fd09143800ec9", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "6fee5ecd-a777-4770-92b5-0d26b08583fb": {"doc_hash": "e448414176882790cd0d74a42effcf08cb801bb5e0ee721ad70a7151d61f485e", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "2f5bcf21-1e8f-40e5-8603-505407482277": {"doc_hash": "5da9a72e64758d3461d7a403cffbe1fdaf2b09beb82a2a03974f9c4d982f1e44", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "f49bf105-cbf0-4033-9f03-7c16fd34c701": {"doc_hash": "5daffb586bfbfae2da3ca79c4438a1cac368ea6c4ddacb311893236d99021e66", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "8009b2d7-913f-4f84-8938-58d77c400890": {"doc_hash": "e60c50a0b73e9bd3ce916aa107979dcc9166413b92b18bbaf34c47610b9821b1", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "122b460e-b1be-49f1-9554-d076a6c0245e": {"doc_hash": "6803b17cdb0bf90723c3ecd38b3dd2f58e7d820b8cd752c0f0e237eabac6f378", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "5f22c999-ac2e-4537-b9d1-f007df441296": {"doc_hash": "3aa3ae4925767bb62ce5a701f119969c88d6c4fa785921a711b6fcfc6193d444", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "8fc66d8e-61c9-4906-aac7-ca402f125d63": {"doc_hash": "487a4d93eae914dc11ea37ac2a5ee6ae7e6d2bcad047dc6395ccc275badf8fe8", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "c4980837-814b-4947-804d-2641dc0fdbd0": {"doc_hash": "63e0ff0b4e5d7f07f9b4c449bd55482e8514f7e6eeaefda430c0d40df8084ce2", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "234442cf-8d4e-46f2-915b-f3d67e7e91d2": {"doc_hash": "048b2e331fe29c00be8263314dc8f8eafd757ea2fd3cfbe5400a19c69a856de5", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "ea5e92a7-5303-4abb-bfe8-829a244cc39d": {"doc_hash": "6ca3cfe52dfbe3b8217df4a5adce8d9c42d29848adf4208253bab3d538d04465", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "09222fa2-8fdd-4b8c-a641-51cae817ccd1": {"doc_hash": "810df5a3935b2bb9597f70aa002aaa3c8a2ea0afcb6c2dbda88a2b7b40da09d6", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "b376c7d6-4227-4f91-9332-c0e3123443f4": {"doc_hash": "12dee4e73d86e519543edc16d1b6984078e376395495e23537c968109527c568", "ref_doc_id": "610f525b-1228-48cd-9459-b6dfe9861109"}, "c9e0cd6e-35b4-45f7-a0df-70ce442d3271": {"doc_hash": "2783ae1478db81786e67bab59e5a579ae0468cf67c6a691e75c0f97212dfa200", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "a700827e-6225-41a1-b9ee-fdcd783efc4f": {"doc_hash": "94a3e33d5138a032356f06baed3c79a6e366a9c8838deac1f68c81713521a8d6", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "f8710d00-4346-466b-80ac-7504eaebb158": {"doc_hash": "c3007a344df60e6004f5eda133540fd5e19ff4f5230feb297cfb2576c679171f", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8": {"doc_hash": "5aec6e93850273a5a534d46fe2c30ff752817ce58372754ada5ab949c849f149", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d": {"doc_hash": "560117c81e0650b28210b938d309742e065fa89fdda7424c40e506776a6d3fbc", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "7afa82b8-c91f-4014-90f5-5dc54874624d": {"doc_hash": "50ec36b96b83d5041fe02e47495a81c4f85b5aae5c14207a17d5356b267af09f", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "8d25315c-bb90-44ec-ae6e-e87ba96d59f2": {"doc_hash": "07950872b29798ca5ee22754adb4021a80482ba3774b8460aa4a381b51cc2c01", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "35019b05-e992-4b14-8575-7fb6f5264087": {"doc_hash": "eeafc133d5b47105d33b58cc3f7b377c05170a9f9379142a254aab056050f8d2", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "5d394f55-2286-46f0-b208-ff1f39bdead3": {"doc_hash": "ee2ae58cca709a88e777922b67814a72a86451c698b5c605ec8a40d43d6def75", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "af0639e5-296d-4341-b79e-9cc165ecbaa9": {"doc_hash": "e223f93685b894be9b05d0e8626766ce351243fc8750f8e4f2d6128476f10ddb", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "7ff95534-2d60-48ae-924b-96ef7ba19f76": {"doc_hash": "7c43cac3b7a8aa6aa09f6f951b2ea82701698da7788211747fc11a14890f46f4", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "b25c7311-f66f-44f0-b4cc-2bd076136279": {"doc_hash": "c70d76a185a634efe52c66b3652113e0fce05ae8cbdb9a9dcae677269c2c9df4", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "7accb29c-cfa4-45a2-a3f9-7fcb18233e51": {"doc_hash": "0dedc1b6a34f40afeece17c2bff0e54ee647962fa707dd298d89388dc02b5e18", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "32775294-3530-4b3e-a9e4-28a2da3b7f77": {"doc_hash": "d0ed14b86708cc898420e15fff7ca5c66965ea8cdff71eeca518f041685a1707", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "1d60de4d-0465-4590-ae96-aecd11ffbdc4": {"doc_hash": "829055e38eaaf8e1fb8f5058cf935ffde8cc65c31b98461013dc6939f957690b", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "248bb780-e9fc-4005-9ae9-2e31f32f48db": {"doc_hash": "ac511dd8279b78926e5c49713c4f2730561b30ce76da4864cdd2fd2f6c729aee", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "69fbc218-5940-490a-9c54-fbd33f013a9f": {"doc_hash": "b7831a9946cee972137b558666bf66350124fec139f79be7c674b2111c938561", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "4641f689-7662-4594-a354-c5e780aa1ce6": {"doc_hash": "44cfadac9118fa6e5e2177b2893f8efc48cd3ff941ab3aee85d5231f1c587def", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "4ab74aa1-2596-467f-8cae-eeb7723936bd": {"doc_hash": "edc1d9da4f0676b338d77859e5bd407bffff4ff373502ecf6df53efeae59050b", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "32ac90d9-cf26-411b-8ccd-1809e9ed8abc": {"doc_hash": "002ea3930f0e4da4be762ffc607af86b40e044f2b40098e6392bf2ac2f97df51", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "5ea72776-28fa-4436-816b-d320fae30087": {"doc_hash": "2652abebfff0cb69640f7b5e37d77b36475f88c5d395a3097e6815e3cb04cb35", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "db656077-de90-4395-9376-53743860018a": {"doc_hash": "4af5b3341e1128f0de305c7e5b9a53e1936463444c7ebc7c636e891c9ce7e456", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "22efa82d-8a48-4003-ba93-e524f5869f86": {"doc_hash": "0b7a3def164848a70a8bee0902f73bede2c9437be7171503edb7b06af27f9c58", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "db934e86-d388-4680-abb9-c7109944387a": {"doc_hash": "39b12c7e3be0449de246e34e33667c88ade6540ff1b73d8cb15849c013316061", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "18b99f08-5ec1-47a0-a699-f3de6765e8bf": {"doc_hash": "280917fd74d3e7809f8c82ad7c3b1a38dc8fafec68b739fd2573c13f6a996212", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "54d47371-0848-4941-9297-b30a7e9334dc": {"doc_hash": "e6b84ce03cd35f62369e069ab793f430e9b82d7bf4030932a8ba1654730411e1", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "906ed183-6d01-45ae-a52b-682c81cff839": {"doc_hash": "bfcba68eaba2cb6fcc39dcbb6f66198975103d73903961b9def0f0e2c37d1db0", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "fe2a8063-1a03-46f4-b17f-91952cd646a6": {"doc_hash": "0514e6bd3d758dc5b8e14eb9923d8c6eebe66b64f37abc1479a3a972c8a4e0a8", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "3a0e0b48-f006-42a7-84a3-072c9bb00a06": {"doc_hash": "05d29544e2eb3d3227bc9ddd0bd3ce49004363e271b34ee704137eaf2023f690", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "0c34caac-0898-43d0-bf94-d93c7d13ef11": {"doc_hash": "fa75aced37fd26e3d0d5a122f80b9253482713477af7d95557e06c8af4630a7d", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "78a17efe-a9eb-4caf-abc4-5422db2a0cf7": {"doc_hash": "a709ff4dbfc016e070bd3b096ec9b3b4d9cbf1d528de58c5925f9b32e49bca31", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "7d89edbf-38bd-436a-a24f-f11e255953eb": {"doc_hash": "2c7022f0671946724e709c904951cdfdc90890544e96cf58c392a87f3c33aaf0", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "7fbb3654-ea29-40bc-8e83-6e9a3408b315": {"doc_hash": "5adee715129a11a9a42b1d9820e3d07a264e7caffa0a27258e5d3c9113f6e0fe", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "4a53f78c-79cb-4f66-a582-68381004215d": {"doc_hash": "711ba04f0c0a61b9f35565bb6b65d000171b9a6ac4bd602d6f4ce4bd8864c36b", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "c1a4e4fb-7401-48f0-8a82-d09de2e71df3": {"doc_hash": "b1b7fbc238d10089edafe6cf3582840cba00feb62cfa0cee7b2ba562928225cf", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c": {"doc_hash": "08d60c3f22b1b8be2c12decd7e42c7208fbab06d1eb1bded14f643ef025e6ad9", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "f7fc6563-99e4-49e4-a573-17c58195e5ce": {"doc_hash": "1e3488155e756b11e49677285848726d813ebf35ef449cb122f703aacb4dee29", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b": {"doc_hash": "e2bb9af562f30b05831ec87d8ae86431f564c47af6d18a15ae90d2c942993467", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "e39035b0-03c1-4635-8385-fb1af6fc9b26": {"doc_hash": "35da50b366e6463e75cca4f161764927599403eab5c44e5e1bdd23a92b7e370f", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "bace7d26-825b-4412-9444-2364c9d82138": {"doc_hash": "22ea99d89b61a2e29308f13172248b3d069a57b9951af229295b6c9ab873e6c4", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "6385328d-86d4-461d-a64d-91e1ee22a207": {"doc_hash": "c7351a6800f6ef38223e948039d22a9d1771c6eb8e221b0ba04c3040d5f8c5af", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "55fc10d0-7610-4553-9e93-6bc2c4c622d9": {"doc_hash": "358d0e671591eb35a3d432f33dfb6039287f889242bbeed7c7ed2ca04bb1a3c0", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "a4d210d4-e68e-4651-965a-2891a91fa9c9": {"doc_hash": "763fc98217363924c077cb0236add44dce4aaf0e5d7d44fdcb2ee35785b2f0cb", "ref_doc_id": "16391025-22a1-4d2d-8722-f0da12761ad5"}, "a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9": {"doc_hash": "8c80967731b6a5dde73a81afe6965585a3f4614a743b9b42b9fdab34fe547b41", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "f3009e2c-984a-4b6a-a1bf-25040124b3ec": {"doc_hash": "0e51b0c50ad924c2116cc8ff5311d2cd13be512a11cdb1c73c734257031dfa85", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "8595e5fb-a582-4093-ace2-f7a185deb709": {"doc_hash": "5ee28c54ffacd07ecc69a5c8068a57d814926fe2d3feb65f9bca6125b7106de0", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "452dc75a-541a-41e9-b8fd-103e288a9208": {"doc_hash": "332d833c9df25d4eb21e72a21d4625da82c1cc6038a4d836ccd6fad7be75fac7", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "391fabc8-3be9-490c-9db1-780371666771": {"doc_hash": "bd54c63f2931b0dc0595d20b55c862cec8ebec26cbece7a8f381018b16290703", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "2a49a769-f81b-4052-859b-dad86ecad1ee": {"doc_hash": "213366211aa8f6da6044e99ceffe00122523d4f2cfd02263760814e90e48b90a", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "8a62dfb0-d771-46fb-9567-ac2231f1ab19": {"doc_hash": "0d4c89009012f67040efea827fedc497964f82f32aaa6ad2a9d4027f520ad503", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "7c860879-0b4c-44ce-b5fb-dd7df32d486b": {"doc_hash": "3d4fd47e045a283875720d28cb177b8baf254d19a9c837d3eb1590d136cfef47", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "cbae3d10-ee5a-4968-9ac7-1461f40ce83f": {"doc_hash": "05e14b9a4bcabf11f758e0d98b6356cbed46dd6b0df30362e0fd41903432f5bc", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "9da43c84-d05d-4983-8ab0-11a6e545dd28": {"doc_hash": "bc6032742ea67e93911020ad22e4424ff01966d0083a8c7fe00a45455f0ceea7", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "ea60b11d-29ff-4613-a294-a7c3f520ae1c": {"doc_hash": "553a40aae95dca004706a4dd733f5a1762a257a3d0ca32a6c759da2aff52ecbb", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8": {"doc_hash": "491dabc41519e179777a1b5b10fa4e48175fada3b58592f74945a8d1438d21b4", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "e3c64642-ad48-4923-83dd-8856980a3e90": {"doc_hash": "12a34cb3dffe8e92e9491e0e972460877e5a0c5c86c935fbbeb2b47782fff76e", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "c1f616ec-87b0-4faf-9025-b3bf5203434e": {"doc_hash": "52f94c42847657d90b8e5790ebf2cb32e884b319981e9b120ba9ee8b7e2b3e24", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "218115ee-a111-43fa-bdf0-fb93cfe0d177": {"doc_hash": "b5f9855992b707722f5f450d231aee6ee8219b0ceea1744e89a717d2f4dd5066", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "250df231-868a-450a-b6c5-7db52ff8b7d3": {"doc_hash": "f4a8e10bd4ebf4cfbc01defa66e3f2caaf47e1bf54879414e9c45ef0b3f51606", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "ae1ae84a-ede3-4cc1-ab47-eab7a5195051": {"doc_hash": "7510021c701ef2072b9fd45ad0fdce725f066dd86e292466145e26938d564f25", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "e6be404c-c056-4ec4-8a30-ee223adf30af": {"doc_hash": "c35c4166967fb3ca300bb200175e7f0ed3aaa37fcec265884ab0223b007fc2fb", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "1cf7e2e9-b026-4c07-9882-7514209e912c": {"doc_hash": "7a70e7430478c2ecbd08c52e5facefa9ebbbdd5831a09ca5aa40edfe36a87294", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "c746874b-6973-44f4-89b4-8d1379ac92d9": {"doc_hash": "2f07bc68991e891c7220c93cb70af55283ae2870955a65875bdb06e882f3f3ac", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "a1cc786a-cedd-4017-9f9e-14b044c2b7c0": {"doc_hash": "511ce9e185971b87af136b94f292c35ccf7cc316359594647c7a68b37b7ecab9", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "5f178c35-9f67-4e42-97e8-54142dbf3e6d": {"doc_hash": "20ae6033d9738013d09c2253db25ffc7a2da45ea694ea25f4d8ade7eb0918f93", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "9a4b9c11-2240-4e02-b3e4-4388e189334b": {"doc_hash": "b5f1af2ca6373411d6913e727a4996aa0861265bcf4845d253baeb5fd6583144", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "4300b776-a7e3-4dee-af8d-3469cd08ac02": {"doc_hash": "ab3867f5fdbfa74a6f9b6c79c703b1969a36b214dfb2b0b0af693457626b72c5", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "3364da33-91f8-420f-9666-fc9670c59d0f": {"doc_hash": "4a0ad2a5e41f1cce910c4d32eb87bf9b28d14a273b4cb7449ece0f8275ebb7df", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "f09d1ca8-8f1d-4f85-88ac-4f67957602d3": {"doc_hash": "90d3cadf3aa55a7c5770d3702185a6b8faeab6a0f3341c72a14736945b2c2270", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "fbf67aa8-08bc-409e-9044-72e0ee47a7e8": {"doc_hash": "403f66fd8dd35134cd2956ea9a5e67c59d8c463b10fd4fd3b51259c5a2cdb4d4", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "34841d75-9253-47f3-b46e-d525802fb945": {"doc_hash": "039d165017ce7d8bf959c2c2732b1b49179efe657b339e6ac1cf887de56f059f", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "812ae11a-e69f-4e47-b0f3-f940fc20d6ed": {"doc_hash": "c169908649d352ccb5a074b7ccde218ffe93fd02b78a5c5482f1680344cd40c1", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "8af4a3b8-b1ac-497e-9be1-02fc1a730f14": {"doc_hash": "98694fce38ed934640524920cecff7680e24a008f7609f04406910282546740b", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "a9fe0325-5182-4dbc-be26-73e441c42096": {"doc_hash": "fcb63fde037dce0ed73c6c1c04d2e4e70fbc1072bd7b8444f7b0f84e445d8dcd", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "9252b78f-9ae6-4484-b419-9c6c332802f9": {"doc_hash": "6b0f06c3b9f0809cffdc3c20b429f3df13bb9f66d20016a3bf9b5917aac0bdf4", "ref_doc_id": "880d9008-ddfd-47e4-9575-109e5311232f"}, "b8d360d2-d85f-4881-8af2-30735f17ffda": {"doc_hash": "69a14aaf7a4a5a1c4bf21e988127df901316aa136aebc73a3d16a09f72f8662b", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "6445f51d-073f-44d5-89d9-41eb445c5239": {"doc_hash": "7d5dae201fdfbc4b50b9067946ac130e9d7529e0222f889dd8078841ab2f1dae", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "2edb8b29-c778-4a95-93ba-3351b0a4ce98": {"doc_hash": "e06fd96f0ac50ef8509994e01560529238f402aae96a4cced74b3fb595201bcf", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "d201a471-b72e-43e5-8cf6-d0b4bf007294": {"doc_hash": "57b7714ca35342c4bbe4b126b1fd40c213dcd2e5c9953603f91efbaab23a430f", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "e5de277c-edc3-420e-96c0-6549e4a886a9": {"doc_hash": "38caa7e8152b4bd032d0bfb43db1810eac125219323a45554e0ea9594b9e7c45", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "38beeca2-b856-4cc4-b35a-f408d27f02d9": {"doc_hash": "b4da1fa3699e2ceeb6f84af1c9192450647e1df0f1b406dc102426acbcf35f27", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "ade424f1-82b1-44e0-a68e-221362971b95": {"doc_hash": "56314b60164c57550ea052e9aa950b9405e6ed0bbe9d6ffa07be19713ebb5e04", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9": {"doc_hash": "f0fa9e1af8ce0745d2a6d9a7be0f2d59611de23e8c30d85ecba473046a6e68e1", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "5f25631a-708e-4f79-a3ba-2d405df247df": {"doc_hash": "9fd9fe59bc6e9d546b621586c86a72fa3dd5720b58eff13fc47c8ac841fc45c9", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711": {"doc_hash": "c8f4dd81790e723b2ba6a19af54086d3e945f53a3e6b0bd212ddbc86ebd4df18", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "129dd82f-985b-41ef-af0c-414af3fac587": {"doc_hash": "1599f4b16395db47777578ce2f933fe0d089abc096a3908b894cf7bb3a348573", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "35aed165-5d68-446a-8260-4af44af5781c": {"doc_hash": "b7d78423bb06c53cd5dc0c8218a023fa7a517436834f0db26563ecde320443b2", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "1ca90702-7116-43f8-b562-32f4d1457334": {"doc_hash": "6baaee9c9ea66faffb4b977e9a655a3bb7fb8a888ba7d86dfd3be1066d8508f9", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "dc2d91e3-7511-490d-be2a-87aabd798a79": {"doc_hash": "7086fe5b96c88b20004837e8555b947f04116b6179e90ea4f406356492e587e3", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef": {"doc_hash": "915acf40e516ab37259fe0394c1ac7617ec9a479ee9aa19c52ee4b4188105406", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f": {"doc_hash": "46600f14e62243b3d99f11abf42433635397b84ba41a4ef29bf406f0c28b78a0", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "b0563140-608f-43f1-9704-83d84f28f481": {"doc_hash": "49f84519a60df97423ce740f24e7f73dbbaa1045eba150b8cb4b8f7e989c30ff", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "af93bc6c-8e7c-4d32-b074-b5501139faac": {"doc_hash": "46a0ef5ee44e42ef89e94bc618d6102180584be1fbe29cc3ab9f45a348e8d7f2", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "2f945123-54eb-4191-a9a4-4e2ad371f67d": {"doc_hash": "f68fdb2f4d7aab4d7c8d96a6360cde773d2a70c7b6264ffa1e83c0c6877d2787", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5": {"doc_hash": "ba384ca866b50c76e508f946c9c523ad1005c08c3907bcd68415b0c50cf05381", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e": {"doc_hash": "c5bccdab4c3f8541a848d886d55ab8468594b2628c30df63cee3d31b97769a41", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "646b7f65-0d94-4154-825b-58f1a6df4d7e": {"doc_hash": "3f303eb0e8094707de58bd5e37ec155788b4331a914777915292c148ce6842e7", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "04741d67-dd61-4ecc-ae85-6565bfa16368": {"doc_hash": "828941c45cdb20c8cbd969399a2d0e79ab25cade0139bdec60d94c42a77d71b4", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "c313822b-6c9d-47c6-9ef3-ef7eec23143b": {"doc_hash": "9acdbd3191c7817834e4dd14bc89349ea3f139ef853d5003646571920cdd6484", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "03a6e726-26bb-4d57-9614-3dc47cbe817d": {"doc_hash": "93ec0b9ea4631d32223ace3836e9cfaeda19a41fb4c39925504400f243d6af5e", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "9a418f7b-7578-4777-b214-bbe9d20ddba2": {"doc_hash": "afeaa5111a18e97ce6bfa073a10eb2cfbf6f06bc9f45558fee1e7abd297482f2", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "80dd576d-12af-4821-a5bf-5477db9b4257": {"doc_hash": "848b4b2774d46519d259b7ead7625e03b46c63227248c4dd20f08f832dcdd1f0", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "ff9ee9e4-7df3-4779-b362-2bb511cb208f": {"doc_hash": "da467e1411bb38c3ba20da8be444c8c419f708b67681288f935821d1613e1ef9", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "0d8cdcfb-63e9-424c-b06c-12864c385745": {"doc_hash": "ee0135e5b0981e93b1353331812fdbf67257aa5b72dc64c3302f601347240c6a", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "d18f3f50-3610-4d00-a06e-aec47fa1cc38": {"doc_hash": "135cc5693d43e84da3e07660c278d9d4880795a51d45961da1f58c31ea04abad", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319": {"doc_hash": "c877e37ad7545b39752d07c77fbbe36b7362397338ac3e2cb1fcb247c5af6d72", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "158b3ee0-e1b6-4311-8470-63a9eb958b88": {"doc_hash": "8f36f4fd7840a2b9a891afe632c2c3f4daed6cf252da80ecab1d09005e40fd2f", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "ecee0e46-5ec0-4776-9e76-5313e43dd083": {"doc_hash": "c3cda9794ac107ddcea5c71fb886ae5068840204bb76c71c2130b0f4ddd23eb9", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "9d39416e-829a-4cec-be1a-75868abadda6": {"doc_hash": "f830446a5393515320c2f6785591437cce72ab92422c73f0e6471d6f752f66a0", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "0b365270-3af7-45c7-82f3-376d386bfe70": {"doc_hash": "217da00c7e3e4333a2391868a23f0b90fcc6801357843ff58bb4715df8e817aa", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "e99b6fbf-9f1e-47c5-9364-532816425dbc": {"doc_hash": "f7d7670750b70051820d85c07c797b9406d053a84472ee41e017ccfa5a25201f", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "50325fc1-a663-4da1-a8ac-9e5eafa8292a": {"doc_hash": "a8a0a5fae4afc699b6926153a14c76499e000c5f10e1f909604886a58fff6064", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "54a536b0-7a68-4e81-adfd-c524245e2f1d": {"doc_hash": "5da38d8fd3b8deba74369bd0b463875c107174244e3c8402a198d31f958731c8", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "ca1af5c3-58e7-43ce-bd1a-7d5964819955": {"doc_hash": "d06f31c3ee9b4a1efd59d5cedaf59a2e12078f43f55dd5978a5f2965533d104c", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "fe75f863-7c19-44db-b9db-2ec5b7f75979": {"doc_hash": "95260ecd2d04af15887755cbd858249f3c5253261370da3d4062ea0f10a9144a", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "8c8c7523-ba18-49d0-a63c-d87b82a64ccd": {"doc_hash": "11aa0b2a5492859acee6bfd34c0d4d0a35e5873cbd3555b26277e89fe7e93def", "ref_doc_id": "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7"}, "369c9ca2-833c-4b87-bc30-c07cc75bb060": {"doc_hash": "f9a1d27de447375a2bfd1fd36f914ecb5fa44038bf44b85708743cae70494a1b", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "6137a5de-b0e6-467b-95e7-f0f25b15f0b0": {"doc_hash": "76b4edc82371e6388a9a425c2638ce1ff9347eadeed26295e6c97f55b3eb5add", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "16299bb6-77db-4803-8a1b-dd0a2c7596a9": {"doc_hash": "b9242ff3ea7ebb5316c2f955bcf011f49a509ff2df74ce131a3d9e34edecf83a", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "80b354b2-d521-4469-8308-298a92ce654b": {"doc_hash": "4a83d7fd2037e4a05d41e4428f28916187ce8edecf09d08c4ba47251b7f8db1e", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "eb369d08-764d-4f5a-86b0-2d7346d69cb4": {"doc_hash": "fc77a7b0a7b773638c4c7f527dc1e92e06f4622afd0f8202a2c9c0b3eac2ca53", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "5c443ed9-f54e-4b11-9444-2d1eddc21b74": {"doc_hash": "89e8219641df2af505d879ae2cd9ee24b9da70e383c1aa8fcf9a0adfec689b21", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "9122416a-8f5c-4533-a1ff-16fdf875d38b": {"doc_hash": "7c3298eae3c7dd5970f2bd24c6acc22e62e2070c91eac562f6c4720c1b5d79d7", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "7f7c8144-0ac4-4a98-99b6-7079421f5530": {"doc_hash": "fa4ed45f103cc0d31f0e538d72d3a70de3b710b3a25ea9281fdb1e34c68b1d8f", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "e23607b7-7762-435c-b191-32c891a5606f": {"doc_hash": "be9546e18712d0ecfd6e8ccdeb9bca84918009168071e141f0800bb94f2556a7", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "97430787-843e-4721-a75c-6e9fe7fd12d3": {"doc_hash": "d9393cbb54047f3b94dfe8920b87a6f800d0e6394febac4adcf626ab6a99772e", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "56263928-4223-406f-897c-9de894b6a51b": {"doc_hash": "f4c27b935b175e3c44bde68026216eb5f8df948102b16ba82cdd1a6c7aa0d946", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8": {"doc_hash": "08f6ecd0887652ce3452ef14e496028352c5f8edac911e05e69cae42a1218523", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "7cd22b3b-7b93-43a2-9289-de5d1dfcd197": {"doc_hash": "0e64a7c3871a1cc1bc00d433502a4d11d2bb3596b1e02930d7dc4d1340c3535f", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "7336e518-f3f0-404a-985b-625ed05b1b78": {"doc_hash": "b34fe25e6e984abb0253e27d913390942c06dd2b006b03ab633b031b3d952fe2", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "a0dbd568-f9b1-4166-b89a-7293aadd4957": {"doc_hash": "df48237735a85c4fcde8ad3dd1ecd339c3b0802575df42c986fa138b944ac8d9", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "96340b8e-8fdb-4523-92f3-4be0bc87e715": {"doc_hash": "e77d819dddce8ba953165dbfb121551f362b252806e0eaa72839ead30e92528b", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "85e2c8b6-ce8c-4ddb-975a-9139b9f35880": {"doc_hash": "9bd324f830f192bee0751f2cb0b4becc3f46c074b16c4ad032ab8d8656fda689", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "11b025d2-19e8-4757-a605-669d481f825f": {"doc_hash": "bcf325d1265fa322794c31bc9ac83d347953513efdf015a0d0f575d4b6964ca2", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "d7866d64-0860-4083-99e2-f4c64773e9ce": {"doc_hash": "5bb731541dfa81bc32e5d69583b0923498069dfd152899c7f283159f47735c39", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "dcb5569c-28c6-44e6-95b9-89fd49362705": {"doc_hash": "ad9c8f0d701f77d42bd8dcb6185bf1fea4b606d9055145b0b7e15fdedfb7e71c", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "892dbee9-e9c0-4b26-9203-36e0b58879c1": {"doc_hash": "49a3b49bc9b5c594e0977c4559ce8d8d18957f84267ec817a28e6f700edb534d", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "99dd249d-397c-42b9-8a54-a0f10dacd806": {"doc_hash": "c516a68d1afe93d87074bff2dd20fa43458b78968eea9e854aa0b61caf4149bc", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7": {"doc_hash": "72e7fd2b3dfa711c8bdb4f3ba65acbb3354ecc11ce7c432d9d91461132accc3a", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "1668e4d9-1d23-4e7a-87e9-370aa8265587": {"doc_hash": "50f5ef40310f772b84e7974a5ae07e7e2d2fe76ad66113f3346bef4c633111d3", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "bd2d5ba1-1244-47d1-b5be-160791770ddf": {"doc_hash": "c2521e6238944e2e1c776815345f073e53256936638e2ad9b5634c49adc1e9f9", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "a551d970-41dc-4a37-b5f3-2694c71c61dc": {"doc_hash": "3b0f8b444e8e02fdce683265d64a336aa8d1d3939ec24f11d80c35a5e41f207b", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "c51c6c9d-d8dd-40bb-9750-16f301ee91fd": {"doc_hash": "4df8e658b512b2570b997aad8c415a9a3b8682045408c4cd23ab91db9a7cbe1a", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "142bd23a-7394-483b-b966-9ea8c07ffdb3": {"doc_hash": "8115937caacc1516b688c104594d393d8a5f7d8acc945f5e1521e93914f74706", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a": {"doc_hash": "e60afc9f85937185715b5597cb59d49d96af2811b08ec76557df8dec9819fdc6", "ref_doc_id": "d30bbfcf-9d08-4cbb-8ff9-339b905774d4"}, "5342fa18-a9ce-4dd1-9daf-5fca30f839c3": {"doc_hash": "2147f4e34f7730d330a57c74dc5c3116c3ae94fe2062df6d3f0cce0cdda93031", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "9d59b8ff-0ad9-4249-9d4b-f49382350057": {"doc_hash": "e956a489df5be7a44eb72b7d26a28a115aa60c9c55b2a77460916abf32da00ae", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "1d4d0f3d-0f01-4227-983b-e6700350d264": {"doc_hash": "9fb2115b204def152736e797259e3f4aea64a4ed373e186c21a65d61fa68ce81", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "591c84a1-0349-4241-ba32-a093abfc0779": {"doc_hash": "e703f56aa47e55a4896ae4b78481118a2b134c6e9d39987d88db6a74d3c4ae02", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "295e09dc-cfcb-44de-aa6b-8ff738c7008d": {"doc_hash": "7292c09c3e2e5820d7b2a573b4f07d6c38a51d5114a8bd71c9589f36038678fd", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea": {"doc_hash": "9a512ab9c2c10f328ecaa53de0f1c23dffb36ee8ab0b3bc3c5268c36c6a9f076", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "dc15c02a-be96-4175-a380-f819d459ca6b": {"doc_hash": "64f25beb33297d259f9a288d02daf72637acac550b46839044c6cdf4df121082", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "44b51939-27f1-4d57-9d03-c46fb5855d9a": {"doc_hash": "decfe15a7dd643d298cbfb4115017becad27c9d454ff0dbaad4321356c702cee", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "dae8d717-39d0-4259-b596-b28323fb1df3": {"doc_hash": "3e635241f3416b3427bc44d146b188f862d5dd5cd242db3365745c79b0854838", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "06ec98f8-d47c-4a29-a086-cda55ccbec09": {"doc_hash": "74575abc434158fb23066d72bd4231366c8796a65db82d7d5d59d70150816f23", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "50563dfc-3890-4a23-ac27-e33139d33702": {"doc_hash": "1142f45b5671fba0c8f16d4ae9acb9d6e5bb902382e5614d9b3db2c9b01f84e6", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "23f4f37d-f2dc-4680-9144-ebcccff52991": {"doc_hash": "325e421aa437f014775dc0f7921167a0c4fde559b1b1f759320a8aed19ed68d5", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "4bef7681-9dbd-438d-b203-a4b9a6ada65f": {"doc_hash": "673776459eaafc8a059d0f563a0093c46c1bcc053753e52b59cee65242d98b2f", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "acbcea85-ded1-45c3-a296-1dfb125330c8": {"doc_hash": "ed00a17f33a4f19d7178e3e2f0073cd180afc09d0c66863144b9fee26e474848", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "98062b59-75a3-4d04-9287-e75df2bdd35e": {"doc_hash": "c092a9bb98fb8379ce7d6a2970c10e8e907698a28d7ae1bb684168df855ea4df", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7": {"doc_hash": "7aabddb3f2164d9923fa95e68a0977e89b16f47c99a27629132ea9bcb5d91ed8", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "a42a6381-1c0f-4eaf-9f94-6874cec5113f": {"doc_hash": "3d50528b8f5ea5a9786a7dac767c486172209db2117d55aff69fbe0922116362", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "d73363ec-3edc-458b-9520-093d61a1c56c": {"doc_hash": "c498bad81fc7d252193618f399556464bff8e6ab27f93a67a5fe3e0d02f64dab", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "08a52047-d2f1-409b-9909-411f1a282da5": {"doc_hash": "dd3ceee8aab880d1b983bfe7e16229792d0d8911f684c46daa6772618e9a8890", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "539eb692-a0f9-45b5-ba31-5a294cba36fe": {"doc_hash": "a7be39ab344451d77addac68495f4db53c2c68a6354b980785d6a8fc531fbae8", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "42c28c77-37ab-46a2-97a3-d073d79b782c": {"doc_hash": "4275e2c2625d2a26ebac47105cadc5cbd4e2f62b50dfd058575f3209791486cd", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "fcda6c3e-e93d-4888-af79-cd8cc9c9027f": {"doc_hash": "b361af7719f7fa1eb89065266e70cfd456febb66e427a3e18a72b3fa5b8b84b6", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "7f513e43-483b-44c1-ace0-7b6b54a5c20a": {"doc_hash": "eaa8990763bbd5b77b231eaa5354fb3fe55ab8eaa415c678c270822df04ba745", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "a91b2e48-ecb4-4f40-9108-f5939662a5c2": {"doc_hash": "e9ad8e78dab792d48dc69897d3bfb9040dee15449886d81fd2bf2044a98977b7", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "134222ac-edca-425c-be64-463878f959ee": {"doc_hash": "63031a6abc9b6b4aa71a88cabf0c1f1117ed74a466b125cec73dd3eaed3f5c55", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "8037b989-a007-4ae8-9ef9-4658815b1715": {"doc_hash": "a5c19742240bb8fea1eb043bd7f5f394f0fc73916e3385f37a042e276364f0a7", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "654ef58d-0f6b-4d4e-830b-6657a982e4ce": {"doc_hash": "6dc376d0d7770659e410f86a42571e99fbcfd4cbd6d6b6924443d54cf406250d", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "529804ed-7978-44f1-a9cf-05563382d3c9": {"doc_hash": "4dde516e457e03832047e04e90a69c78623aac267ddbc7a355815101e5f5d9fb", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "50ca31ab-26e4-40e5-b446-3a5cbf97d495": {"doc_hash": "0d80b9317ec3da24d6d332921eb1d6cb7376ccca5410966f22e29feaf9b2682a", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d": {"doc_hash": "3be821229f02b73341dd02aa2b78bc35b97fefc0b67f71b9463e59cf887fd9a5", "ref_doc_id": "65f21369-d1a5-41b6-bd01-1a3ef62a55bb"}, "84835735-cc5c-448f-b388-d592486ab143": {"doc_hash": "dda00628863e8f13face2e437bb1d1ab3105eef0920665187db78637440388d1", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f": {"doc_hash": "f466be336324e171b3224224ba721a89797c42020d89f95b0adc584bc418b875", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2": {"doc_hash": "3371d66ebdabf4343a04c6f68ffac79e5fd9f3d64abd08d9835c9ada8612155f", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "f61a4858-9213-47fc-a0d8-6a65c3cff8b1": {"doc_hash": "66b62dc59351394e4d28eb9e450e78538ee2f942e3196b097d2cb3d13cb81dca", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "4a9d54c3-b424-474e-b4a5-ece77ec147a8": {"doc_hash": "e5db9c156d226f30b47d414dfcfaa149b163fd68c723b5fbd1d93d7c3e5f289c", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "74c017ed-355f-4836-9c35-7853d96bbf76": {"doc_hash": "cdbebbd3c0054539046b356f98eb016aadb3a62dcf55efa080bdd5f5566beb16", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "6d6782ba-ba5f-44c4-8758-d9499b3081ac": {"doc_hash": "b2cef780891b6ced02e7c18d2f79e74bb433cb03f8fc05c65a394d84122a7e26", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "d4232b34-6296-4411-ad17-65db7547935a": {"doc_hash": "1727644444e5b9466fc1440a489b2294c76e4565c9616bce8dc40a5d82a00258", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "82336a5b-e643-4314-b0af-4436d0635be4": {"doc_hash": "dd2d74962eb9263bd828498df50d07664431de19c9bc03a9a2b15de86eb642e7", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "8e9c0b35-2705-4d89-83e5-9fd434f816e9": {"doc_hash": "a2250e389868c79308034562463576c2c6e546ae9971de972132800d2ebdf892", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "a29eb737-8a01-4dac-a541-f3cff5dfa4d1": {"doc_hash": "de16bc3d20116098cb49cc1c9dbcafc5c0aced7e20c29b14a7bb7c4b95aec721", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "798ec7c9-2caf-47f1-9367-9f5fdc422e8f": {"doc_hash": "bdaaef91e69fce749af083a3a0040f8709f249b5d7670cfca705d5f888089305", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "ce720de9-8da5-4d81-86f4-7e7550eceec8": {"doc_hash": "02305175b749ca7e716dc9499e4e3fc4def5c05571355cf9e0d687db22c9dc12", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "1c13eb35-4716-405a-a642-5899a627b48e": {"doc_hash": "fc696b0df65fc20094b3e4159186efa70ba4d7a1b543c1ffc741fbbd441e50eb", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "7b870875-a919-4547-9cff-6a2770c2f2e4": {"doc_hash": "20fd3e69f635dc2d9d5db0bc728dbb683bd7092d0b0aea79fec77c772e33fb37", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "0e05c93f-85a9-4a66-bef9-c97681177ebe": {"doc_hash": "bbb027b80d074c339a93b77071563ca4ad85f076748fefe0ff416b0101e6a3b3", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "3a23187a-fa82-4fda-95bb-0158ce3c0e5b": {"doc_hash": "f91e66e8c67e19100c0e25e66cce85ea99997eb1d5063a94b3c4b7b06e229a1d", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "c83b6864-9088-495e-a051-5eba50aafabf": {"doc_hash": "3e99a7bbed8ab05e2b9cbc9c164ba6dc2566a42b155ccb925ec818a742af488a", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "e1a9e06d-c733-4bfa-9253-54f232e8c7e4": {"doc_hash": "d34f2adfaa146b876c02143769e530889314d0147edda5416cd49b9d4a0607e8", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "e70729dd-9cd4-4f56-bd39-dbc17241f5da": {"doc_hash": "49d081d12f2e655fb69f9d68d1ebd4301e18e9c8eb437beb1d9a5ef6a571e206", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1": {"doc_hash": "c15928411334ffa865bff54cc91571cf3404d7d5cf33ea4bf0bd5a63e26c6e9c", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "de1702b7-d87a-40df-891b-50ce93c388ad": {"doc_hash": "f5f0230e9899f0d49ae87d13fe35b593fb805c6e8e46fdddeafbb79c63fd5aa0", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "ba91c43b-9233-4857-9d21-55faf1a5a9e7": {"doc_hash": "28d99bd50f4a3f4e36c9eaa9e322e264fc0422ef18ea8a09ba0a3516538fa59d", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "a2bffa14-596a-4a42-acd3-ea235c37298f": {"doc_hash": "996dc7ce45608145cedc868e2bfe059f5b3d287276135fa6249128fd143a77ff", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "5876621d-2cdc-4af3-b3a5-9c943e61a519": {"doc_hash": "686c6ce7eefa3e877fa311fa8ddd46928469444e867a283fc1375bdf5dfce185", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "f816df56-2979-4108-8020-9060c6db320e": {"doc_hash": "47de79073b3413b75b3389f0223ba89a51fb489dea41ca7927c8288b03023671", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "9203473d-e64e-49ba-a1bb-c99a67393f6b": {"doc_hash": "b26b98d14153f541312930ff81dd307e7e6e2971008d388b133a9e0775b2678e", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "e17e4ea3-f3de-46c4-8082-dd73532e6543": {"doc_hash": "4e12ec7acd6cc008eff2527f999144d496231dae57e3383d54b70e02540331bb", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "f5a599b0-376c-4f7a-b951-bfb3a5c134be": {"doc_hash": "59cad966e2df34fa85ec5aef8a8d3294da30464c970e95ed1793213b6817a1d8", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "1d5535f2-91f0-482d-a4d7-c48011771b24": {"doc_hash": "2cbc624e3a9fb7ffde90ed8719fab7d9dd284e8b124d26c44f089a0631ea7e74", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "b8497137-e23e-4627-a0d2-3bb1f19c2f99": {"doc_hash": "5214d713f5fefcdc55d97e825a66ae2fbe5b926ca6488a425074f5dbe1203283", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "d42c246c-5203-4a44-9d63-2839b2f53fd6": {"doc_hash": "ef1804a0f0e283a575dcecc62662727a13b700a0e89e5c3eff3a9c72bdb9811d", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "4473382b-1cf4-4188-b963-0019a09f5abb": {"doc_hash": "ca1862d0bfffb46dc6663bb46825293a8f1e8ae35d327183d0126933dbc90166", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91": {"doc_hash": "f68f16fc5c3428235d5f3881cf8dce2c4d883c18c3001e02f4af7c73176f2d39", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "581e09ba-2aed-41d7-b716-9b05627bea64": {"doc_hash": "ece1a4a66a77ae58370281eaa0328ed5918a08263a6db425dce6fcbe880468bb", "ref_doc_id": "bdd39ba1-fb10-49a1-9170-121456540707"}, "55b46c80-2593-4ed7-86a0-0dae5d89a535": {"doc_hash": "71e21e9b09b022483133082df6bf6501721a1ed74a6e796d8a48ef0ff4c3dca9", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "066be56e-00a0-47e7-8b53-bb5357cd9734": {"doc_hash": "6356e3a529fe018f64c092d403d2bd92db58e7588e8ff53994395f9a9906c322", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "fd300703-2345-47fe-92ab-052e7c1c222c": {"doc_hash": "29c4ed417500e41808a7177ab4699a1ed52ce94266f2c0ad3d66c43443abc7dd", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781": {"doc_hash": "3e5ddfb1953fa9199b2c73767ee76afcf49288aa0d9e953c2dc33733f40ead32", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "29a0c5a5-717d-4683-8031-cea3f420300a": {"doc_hash": "1fe78cbbcc1d55c2c7cd988d49e01b4a6f933b4393c25c2b4210f3bd4c8835fc", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "ee007b7b-f274-4537-a93e-85bb3f7a646e": {"doc_hash": "3664de28a9ee63ed3fb267765a6041808174b26251bf8f6f45f155e63dfc7b20", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "d644215f-ee9f-46fa-aea5-7890ff942042": {"doc_hash": "8ecc4a3744508d9f148b4ea572448d62551d8fb0726f4fb1f27a230ecc3e122e", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "46964758-3b5c-4d18-a916-ab15b7c854b0": {"doc_hash": "c252975a7fc73c740b8793d9113e19c4ce11792ce9c83abcba13b87af748ef2f", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "50a0d708-59d1-49db-b9df-9d3fe66d9472": {"doc_hash": "0b5cb51cd043e1997b77bb2b90f8e53a66bf1a8abd46ab795b9a49f33530103e", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "46274bae-2179-4cbb-8e9f-440f7387602e": {"doc_hash": "bda015f6b9717023364474b9df73de2322cbd8a86d7e5d2c369ced43478cb2a1", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d": {"doc_hash": "cc1782a543e51ceec72beda9750a7b3807c31510fb0f32cd98504741bd60ef92", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "6ea5d742-3b42-4117-a2a9-4693858f55a6": {"doc_hash": "45ccec5ba9e153a78116cc0569c569ceac47c0d407da293cb5a25f7bb0a1bc67", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "b0df7b2a-e25d-45a0-8694-d4d10d414b1a": {"doc_hash": "ab9a725419128a70c867766a8130dabfef055c649bd32f75414644b2b9dfd1f1", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "b8bb79a2-c50e-4235-8a61-6782d32c206e": {"doc_hash": "aa2010a48ab4204c115b0fef54e6af91eefef58570f4ffe9a6b41907d39a92a1", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "652ceb2d-3e96-4915-80e3-baaecb6dd435": {"doc_hash": "d6529c0fc825f0fc3babc2399007661643e08834ea7501c4223df84a4d07b3e1", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "7d291f53-19b9-4906-b116-4d582f872127": {"doc_hash": "7efb8fc42c36f06229b7f074626b6c2fd195b09e58441be3d9dfe772bc09b587", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "ff15496b-15b9-4146-a39d-0e87bc8f544c": {"doc_hash": "87c017962c0f6bd99158ce8c35d876cedf3342628bd4d262172e1c8434b55f64", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "54a59d75-dac7-4290-a172-107ead92fc52": {"doc_hash": "20006684d594a758f9165598cba7a892d6dd07f293429d5fa8e5426e9bea1bb1", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "58e337f8-0efd-43f4-b8c8-32d5705becf6": {"doc_hash": "73740575376e82d8e9078586a6708439f0a87cbb9d555df83f58b68b6d28e85a", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "b556ec5d-4e78-4727-8d86-6e8ac891b685": {"doc_hash": "677f2eed89e6631c34fe65208a4073f419423099f373bde6cb55d14dd7dc00ba", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d": {"doc_hash": "a642944fcefee5025fb4127780bd87e3fbfd8e0f660102b65dac84fb2e53d6d6", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}, "1b4cacc2-e556-4bee-a82d-c03e8bf1c181": {"doc_hash": "331c986b9b3f34c5c618bfce2d151b493b8cef0e1390248cbc9134fce2aac30c", "ref_doc_id": "caa89d30-eaa8-4385-8d94-ec09fb294b8a"}}, "docstore/ref_doc_info": {"137c400c-b5db-43bf-a8d6-4c8be35f8b14": {"node_ids": ["8beb377c-a871-454d-a190-40a59f113749", "496cb412-8c22-4165-a632-a1fde8751108", "8bd2598f-9126-4dda-92e6-caf7228e2a59", "14d3e932-3ae5-465e-840c-5a28a2085a20", "31b499e4-bcd0-48eb-aa5d-b2444b8d4491", "e0c1c555-51c3-418a-a6f9-1be9282da356", "3fbb80f7-2542-443f-a077-5ee48929f542", "7cd213ee-49f3-4f69-82ff-8b81d38bae29", "15d6c122-f5d1-4f2c-b08d-f89042b63ffb", "e8869667-ce0c-446d-8054-e7995c86ab5f", "1587a637-ec15-4b5a-83d9-732b3e1f45ca", "44ee8614-ccbb-4016-b6eb-2d7d5902581b", "2507baf1-7ec9-47f6-b8e9-23e511fdae53", "140d34f2-6eb4-4c64-a104-8dff33c05b0b", "a5000e02-0577-481a-a48b-a47e0d963d7a", "b4a1b7fa-baf1-4dbc-a63c-454bb20e50a4", "b426df16-bf28-4931-8c0e-8f5e0678eca4", "ecfcbae9-f33e-40d2-8587-15827497aab4", "49ddd235-9682-430d-a22d-92871c4f55dd", "942b2370-8993-42b8-8413-e0baf35b6e0c", "aab9ef67-62fe-4869-9bb5-c63abcbaf373", "390c8658-af12-4e0b-a275-69da913bfbf1", "fe8f9cae-ce5d-4446-8b1c-2c8052c1ddee", "28e83bc7-4f57-4189-8db0-a342bf649477", "146db715-528f-41aa-85d2-f711536ab1ce", "a678addb-29d7-4ada-bb87-de3c5adc552a", "73bbfac3-28f8-4f54-8470-e5de66e4a1d1"], "metadata": {"window": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 6 th, 2021 8:30AM Eastern  \n \nOperator:  Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2021 \nEarnings Conference Call.   Today's conference is being recorded.   \n \n", "original_text": " \nPage 1 of 14 \n \nQ3 FY21 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6bbbd46e-4051-45e3-941b-281d1fc5f4e6": {"node_ids": ["066cd2ee-3f53-4003-aded-cc2b3f98d309", "a085bdf0-943a-47a9-af27-8a9ce3fe6389", "6378db28-b35c-45d0-8ceb-afccd2a4fa47", "cc9a8ee8-c74d-4ffe-a178-e014c0519b3c", "f1859a71-7f53-42eb-9a3e-6cf5afedb668", "2ae28b9a-6a30-4f4e-b752-77958f987840", "7678b756-eabe-47ef-8f4d-d018d4fd416d", "cc02e04b-0c30-490c-ba41-bfa1612d5068", "069e4c99-a628-4a78-aa04-a13b7e6d846e", "0ad081e7-351a-45c8-aef2-514a938f717b", "606ac8ba-2cb3-49ef-8fe2-0d6816385b1c", "f1981c8f-c334-415d-9f27-c457ebc19f82", "1ac8557d-2ce7-4ab3-8893-342337dfed35", "4663a1f5-23a0-425a-bc28-cd35f827239c", "59e3fa8d-f058-4e23-a2cc-1aba133bced1", "79a49e34-7bc5-403c-8950-832f91442e8b", "147d1ebd-f2ee-42c2-a5af-e9bc7ade7aba", "2b7ccc71-e2bc-4180-b53a-291a8fdbfe47", "e15210ed-8502-4920-b869-c26d6a7b0aa2", "c1f1dcbb-9bff-4823-9072-54855381e1c5", "64c08634-b82d-4fdc-a41e-6a50e5f1d36c", "94348840-d81a-4deb-8c34-bef36b3fe554"], "metadata": {"window": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.   I'll \ndiscuss some of the changes we are making later in my  comments, but first I'll turn it over to Jason to \nprovide additional details on our results and outlook.  \n \n Jason Hollar:  Thanks, Mike.   Before I dive into the current quarter, as a reminder we are now \ncomparing against a prior year quarter that included a  benefit from accelerated pharmaceutical sales \nand increased PPE demand due to the onset of COVID -19.   \n \n", "original_text": " \nPage 2 of 14 \n \n \nAlthou gh the operating environment remains dynamic, it has reinforced our critical role in the supply \nchain, and it highlights opportunities for us to enhance our operation and evolve for future growth.  ", "page_label": "2", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c6e6fd28-cc44-4008-ad5c-67eff77e373f": {"node_ids": ["1ea61269-732d-4fe4-9816-182772aa4ef0", "44e0c185-c8e8-4747-8485-c9f18d4759c4", "e773678a-c457-4fdb-9a9d-b03073e411a3", "ebbec759-af7d-4521-b9be-02b41c944cda", "5e10e9cb-5835-4c94-bc8b-c1c041872d1e", "bb2ba7cc-6b5f-434a-aef1-e3c725f2b21d", "93e1967a-b5b8-44d7-ba15-e90ee09eb529", "22e10ace-2871-4bb0-9233-9aa7cb24b455", "d0251ac7-cef8-4b12-ad30-634bde10f084", "5b25cf9a-3537-460a-afd9-e6e0de6422f8", "71bfec4e-723e-428a-93cb-78364dd38a78", "44690154-b479-4035-b422-2109bc827d4b", "de447f9f-0989-4229-b785-781ac18c4395", "b1882b37-a83a-4613-9f0f-de402e6c09b8", "7d4cf190-65b5-4636-9962-9357c7b15855", "8ca34b06-46fe-4f1c-899a-27f828c6857a", "838cdfd2-af73-41eb-9298-2d0c4d5d23b6", "f94b193e-2ccc-41a4-ae3d-44fa7f57c1e9", "0fd32894-812b-4a08-b285-f20f7dd7f5c1", "65f7a0bd-bf26-4d5d-ad38-efca53aae941", "e5e603a2-3733-4cd7-922d-ededb7583d37", "6de7dd80-0b69-452b-bc3e-5dbd597f8152", "4f45cbfe-1512-42e8-af70-f4a785491a90", "41a77174-c675-42a5-ba6e-71e9b5f41dcb", "4ff5dc63-26c7-41f7-a908-42796b8daef6", "5bfe12b1-7372-4c7e-ab35-a1f86446d5fe", "9f5b7cdf-3055-4d8a-ad21-1865fb64131b", "33fff532-487b-4496-8bf4-e8c71f47eee8"], "metadata": {"window": " \nPage 3 of 14 \n \nmix.   Excluding the v olume impacts, our generics program continued to see generally consistent \nmarket dynamics.  \n \n Additionally, we were encouraged to see our Nuclear business continue its recovery as we saw an \nimprovement in volumes as we exited the quarter.   In Specialty, we c ontinue to see year -over-year \ngrowth and are excited about recent wins in our 3PL and Hub business es.  ", "original_text": " \nPage 3 of 14 \n \nmix.  ", "page_label": "3", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "61338c6e-1cca-4286-9dc6-c84fe0097e72": {"node_ids": ["05baa260-0d9f-4b66-8f22-a925c2442af3", "459334b1-bf15-4dda-ae1a-60178b47c32f", "c4969dff-8ad0-482d-ba0a-4dcf6281ab1f", "76aa1ac1-bfe9-4d52-93b2-ad54fc307953", "a0d8dd74-2054-40e1-8eb8-0ea7cd872292", "b3eeb89f-0c30-48a8-8780-4f9b9ff49355", "477cdceb-c6ab-4849-a2d1-9cfc2cec3dd9", "ba2b3a51-41ba-4d81-98bd-f00d4bb9a620", "fde1d932-8ac3-4ae1-8bd3-63ce961e50d3", "bc0f3ed6-52c8-4996-88e7-97ee099c9505", "262e2047-5ba8-4bc6-96ea-02a342036f26", "b5e3ed92-5db8-4f47-9202-652722cd863e", "153e5912-87bb-4afd-b8b9-38416f2dbc0e", "acd95833-236c-48fd-bc2f-d85ac86ae9f4", "da63a396-a4b5-4da5-862c-e9738beba8cd", "6a13a1d4-325f-47e0-8ac7-634f6349caab", "6570468b-1fe1-43f2-9a1a-65d046e123cb", "f63b7165-4b10-4729-885f-ac9830b070d4", "38d02a1c-3913-4569-bb38-ba79482217bc", "37e1e5ca-11ee-4686-9411-0951f3e11071", "b5047f53-7729-449a-a767-8ea0b5d209ab", "9e823fe9-7dea-4a59-bfac-6ac30bd1cac9", "8cf5049f-967c-4115-a8df-ee338b357cdf", "da6e86e1-9912-4bf1-b432-08757e0cf441", "418c33a6-f6b3-4e31-a438-f0cae45b9cee"], "metadata": {"window": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n As for the Medical segment, we continue to expect elective procedures to be at or near pre -COVID \nlevels by the end of the fiscal year as well as segment profit growth in the low to mid -20s percentage \nrange for fiscal '21.   \n \n With respect to the enterprise, we now expect COVID -19 to be a minimal net year -over-year driver.  \n This guidance assumes a meaningful year -over-year COVID -19 headwind for the Pharma segment \nand a similar tailwind for the Medical segment.  \n \n", "original_text": " \nPage 4 of 14 \n \nexit rates and what we saw in April, we still expect brand pharmaceutical volumes to be at or near \npre-COVID -19 levels as we exit the fisc al year, but we now expect the volume recovery of certain \ntherapeutic classes within generics to extend into the end of calendar year 2021.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1aeed82f-a96b-4efd-b34f-5be8681e4c25": {"node_ids": ["5b2aad3e-569d-49d6-ac61-29d3e7933a66", "bb887675-d93d-4a7c-ab82-3357bf947839", "bb3b9cd0-a8cb-4e07-8a49-a840408bb3c1", "ef79d564-7d7f-4b65-b4a6-4734763fddb8", "7c0ddfcc-1609-4822-b5ab-0a02df0e163b", "208d54de-cacd-48b6-8ad7-5929f8e6c6ef", "4ccdcf75-a189-4b8c-88dc-05833a4f80f5", "8f899676-dfc9-4f37-ab22-a7603026db76", "a7e154f8-470d-4b5e-9d23-08e890615e84", "a5786927-bd45-45df-88e5-f4294baa073b", "e91b913e-7520-458d-9bab-d87e670a0d5e", "db154aa5-3c99-4693-a245-5e82ec80fabb", "4d40534c-5bdd-44db-ae56-c88df2301c16", "293d38b5-fdcf-4606-a456-2ec46b413071", "fa2c0a42-0c70-4a35-a80d-cac81cf7afc0", "8f645b43-96e2-4fc9-89d6-ce270cb1a28c", "5da988f8-232f-4b90-8703-c8f731d893d5", "dcc9d668-2570-4b39-83e8-3109c60ee090", "0860d945-f451-4735-943c-a57ba78f73cc", "22343999-c1c4-476f-ad6a-47d3ec681a2d", "e254792b-89fd-4e5a-9a30-cf9a00298dfe", "cd65626b-d42f-46b7-9502-27237d86a408", "f476cb0e-3a43-4d81-a8c4-acaf1754e9e6"], "metadata": {"window": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.   These insights enable oncologists to improve outcomes and \nreduce cost as they transition to value -based care.   We are also off ering digital solutions in the \nconnected care businesses that we recently branded collectively as Outcomes.  \n \n Each year, medication non -adherence cost s the U.S. ", "original_text": " \nPage 5 of 14 \n \nIn Specialty, our  recently launched Navista Tech Solutions uses artificial intelligence to identify and \nmatch cancer patients to clinical trials.  ", "page_label": "5", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b227ffa3-67be-4cdd-9aa8-1867ffb69ea1": {"node_ids": ["7b7c5d28-1a07-4880-b6cc-240aa2f775f9", "67a9fc82-c3bc-4ae7-a56f-caa106895f14", "594d167e-0c25-421d-8b78-f20f1425bb4c", "409128f2-9cb0-4d15-a072-82450c173a7f", "6f17ac49-de54-42d4-b149-7b9bd9aaa728", "2696cb6c-6ce9-48b5-b044-166a5e561fd0", "2dcf2000-aa61-4d85-8db0-b83499056baa", "8fe033e2-7c12-4616-809d-945340d3a7b0", "5c59d1f7-e4f3-4c7c-8743-d6d9cbe34c5f", "dc3a343f-619a-4c3a-b3ca-fc5f468d75d3", "0b78db9b-4206-4ba3-916f-0b4b3b9bf4a0", "a070461e-6ac7-4879-8f66-b7ff663ba1e1", "45af1486-299d-474d-88cb-011c65998cf5", "7cf061c9-97f6-48b8-be19-bbe33eec6f37", "73ae0781-98fa-4778-8d13-9b48ee5af840", "2bc7cbce-92ea-4572-9729-f97c300445d5", "10eefb74-22c3-4e62-9193-5b34e671b57d", "1a6ea236-58a6-4b08-811b-21f92e359dad", "ee124cba-fd27-4503-84a8-3567722d045c", "70d549ff-c723-4bd1-9df3-3be6f419cc9f", "bf319f61-67ba-46a0-aa39-3e99ae4e716d", "bfe658aa-62a8-48a8-8b6e-480de935ee16", "ef1388a4-13ad-4a75-b666-72a2f11b5435", "d0a9dfb0-50c8-4dac-958e-dfed2e906c33", "cf6eb5a4-295a-4df3-962f-238a145ac64f", "12bda2bb-2bc7-454f-ada5-f973653b7a94", "5778de3c-90b3-4519-af60-3b9d82ebee63", "75914680-435d-49e9-9b27-832ed28fdfd8", "bd75096a-f09f-46d7-845e-5059e4590a5a", "96ffd680-3d7b-4043-9915-edbee5b39ddf", "bb60112f-e943-4e51-ac8a-4a86c001cc91", "4bc1aea3-b5cb-498b-9223-8a15460c9cf1", "d2c5c5c5-d4a9-4f0a-82eb-d8ca8b868b00"], "metadata": {"window": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.   This network facilitates inventory \nflow and gives our customers end -to-end visibility to see products in transit, enabling us to make any \nnecessary adjustments for our customers in real ti me so they can better serve their patients.  \n \n Regarding our capital allocation priorities, we have strong momentum.   We remain committed to \ninvesting for future growth, maintaining a strong balance sheet and returning capital to shareholders.  \n", "original_text": " \nPage 6 of 14 \n \nsupp ly chain visibility, machine learning and artificial intelligence.  ", "page_label": "6", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "610f525b-1228-48cd-9459-b6dfe9861109": {"node_ids": ["37066222-a152-4f2a-a6f6-8d2663e1b09e", "17e374ab-051d-4bef-8b28-c6811643176c", "60330a11-96d6-44d5-9beb-e1fc29898633", "3e9de19b-e263-44ae-ab37-80ba68cb128b", "a6fdd9c1-30db-408e-a233-0b49e61e999d", "e9f9646d-4120-4933-99fe-c2716e3c06e4", "e9ce4cae-42e6-4c69-8c3e-6fd26d3cb3b1", "0ec18de9-1014-4107-a938-6648c52a5a89", "8970f95b-66fe-45c5-acac-603efb4c2334", "9d63e035-b793-40a4-bfe4-9d5336bb32f8", "2c8d1933-67ee-45d8-bba4-f3811937b2ea", "249487ae-256d-40de-8c7e-f7d459d12af9", "b9714f56-c652-450f-a349-0ec2f490baec", "2bc90613-0d31-4df0-a236-f5198e45cf46", "78f18a19-4998-4cc7-b0e3-78387247646b", "d8361e8e-5473-446a-b895-d7f262260012", "a56b0f2f-2f15-4533-8ce1-81adc25b2725", "2ddb327e-d59a-4b8a-9d22-3959f52ade52", "612b0421-eeb5-42f6-8fcb-74ccdf25e976", "6fee5ecd-a777-4770-92b5-0d26b08583fb", "2f5bcf21-1e8f-40e5-8603-505407482277", "f49bf105-cbf0-4033-9f03-7c16fd34c701", "8009b2d7-913f-4f84-8938-58d77c400890", "122b460e-b1be-49f1-9554-d076a6c0245e", "5f22c999-ac2e-4537-b9d1-f007df441296", "8fc66d8e-61c9-4906-aac7-ca402f125d63", "c4980837-814b-4947-804d-2641dc0fdbd0", "234442cf-8d4e-46f2-915b-f3d67e7e91d2", "ea5e92a7-5303-4abb-bfe8-829a244cc39d", "09222fa2-8fdd-4b8c-a641-51cae817ccd1", "b376c7d6-4227-4f91-9332-c0e3123443f4"], "metadata": {"window": " \nPage 7 of 14 \n \nin the quarter due to COVID.   Now there were a lot of moving pieces, pluses and minuses, but netted \nout for no significant impact within the quarter.   \n \n As it relates to the pharma business, that driver i s driven by the generic volumes that Mike referenced \nin his comments and I referenced in my comments.   And I think maybe, Mike, you can provide a little \nbit more color behind the second part of that question.  \n \n", "original_text": " \nPage 7 of 14 \n \nin the quarter due to COVID.  ", "page_label": "7", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "16391025-22a1-4d2d-8722-f0da12761ad5": {"node_ids": ["c9e0cd6e-35b4-45f7-a0df-70ce442d3271", "a700827e-6225-41a1-b9ee-fdcd783efc4f", "f8710d00-4346-466b-80ac-7504eaebb158", "c40bd12d-e98c-44f3-bcf9-7d6c7c3c31a8", "e43e1683-f7e7-4dd7-92a0-2fea8e3f239d", "7afa82b8-c91f-4014-90f5-5dc54874624d", "8d25315c-bb90-44ec-ae6e-e87ba96d59f2", "35019b05-e992-4b14-8575-7fb6f5264087", "5d394f55-2286-46f0-b208-ff1f39bdead3", "af0639e5-296d-4341-b79e-9cc165ecbaa9", "7ff95534-2d60-48ae-924b-96ef7ba19f76", "b25c7311-f66f-44f0-b4cc-2bd076136279", "7accb29c-cfa4-45a2-a3f9-7fcb18233e51", "32775294-3530-4b3e-a9e4-28a2da3b7f77", "1d60de4d-0465-4590-ae96-aecd11ffbdc4", "248bb780-e9fc-4005-9ae9-2e31f32f48db", "69fbc218-5940-490a-9c54-fbd33f013a9f", "4641f689-7662-4594-a354-c5e780aa1ce6", "4ab74aa1-2596-467f-8cae-eeb7723936bd", "32ac90d9-cf26-411b-8ccd-1809e9ed8abc", "5ea72776-28fa-4436-816b-d320fae30087", "db656077-de90-4395-9376-53743860018a", "22efa82d-8a48-4003-ba93-e524f5869f86", "db934e86-d388-4680-abb9-c7109944387a", "18b99f08-5ec1-47a0-a699-f3de6765e8bf", "54d47371-0848-4941-9297-b30a7e9334dc", "906ed183-6d01-45ae-a52b-682c81cff839", "fe2a8063-1a03-46f4-b17f-91952cd646a6", "3a0e0b48-f006-42a7-84a3-072c9bb00a06", "0c34caac-0898-43d0-bf94-d93c7d13ef11", "78a17efe-a9eb-4caf-abc4-5422db2a0cf7", "7d89edbf-38bd-436a-a24f-f11e255953eb", "7fbb3654-ea29-40bc-8e83-6e9a3408b315", "4a53f78c-79cb-4f66-a582-68381004215d", "c1a4e4fb-7401-48f0-8a82-d09de2e71df3", "1f14b94c-fa0d-4fb2-ac02-bc8f3f3e8d3c", "f7fc6563-99e4-49e4-a573-17c58195e5ce", "bfcc0b74-bb7c-4f0e-b53b-a87d455b5f8b", "e39035b0-03c1-4635-8385-fb1af6fc9b26", "bace7d26-825b-4412-9444-2364c9d82138", "6385328d-86d4-461d-a64d-91e1ee22a207", "55fc10d0-7610-4553-9e93-6bc2c4c622d9", "a4d210d4-e68e-4651-965a-2891a91fa9c9"], "metadata": {"window": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n Charles Rhyee:  Thanks.   And if I could just follow up real quick.   Were these -- were we seeing these \ndynamics last quarter?  ", "original_text": " \nPage 8 of 14 \n \nacross the various classes of trade, it's very consistent in what we're seeing in terms of those \nvolumes coming back . \n \n", "page_label": "8", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "880d9008-ddfd-47e4-9575-109e5311232f": {"node_ids": ["a1e6b1a2-c5b2-4820-a819-aeec34bbb3e9", "f3009e2c-984a-4b6a-a1bf-25040124b3ec", "8595e5fb-a582-4093-ace2-f7a185deb709", "452dc75a-541a-41e9-b8fd-103e288a9208", "391fabc8-3be9-490c-9db1-780371666771", "2a49a769-f81b-4052-859b-dad86ecad1ee", "8a62dfb0-d771-46fb-9567-ac2231f1ab19", "7c860879-0b4c-44ce-b5fb-dd7df32d486b", "cbae3d10-ee5a-4968-9ac7-1461f40ce83f", "9da43c84-d05d-4983-8ab0-11a6e545dd28", "ea60b11d-29ff-4613-a294-a7c3f520ae1c", "c22ecff2-7fb9-4cd4-add9-a8f68c8928f8", "e3c64642-ad48-4923-83dd-8856980a3e90", "c1f616ec-87b0-4faf-9025-b3bf5203434e", "218115ee-a111-43fa-bdf0-fb93cfe0d177", "250df231-868a-450a-b6c5-7db52ff8b7d3", "ae1ae84a-ede3-4cc1-ab47-eab7a5195051", "e6be404c-c056-4ec4-8a30-ee223adf30af", "1cf7e2e9-b026-4c07-9882-7514209e912c", "c746874b-6973-44f4-89b4-8d1379ac92d9", "a1cc786a-cedd-4017-9f9e-14b044c2b7c0", "5f178c35-9f67-4e42-97e8-54142dbf3e6d", "9a4b9c11-2240-4e02-b3e4-4388e189334b", "4300b776-a7e3-4dee-af8d-3469cd08ac02", "3364da33-91f8-420f-9666-fc9670c59d0f", "f09d1ca8-8f1d-4f85-88ac-4f67957602d3", "fbf67aa8-08bc-409e-9044-72e0ee47a7e8", "34841d75-9253-47f3-b46e-d525802fb945", "812ae11a-e69f-4e47-b0f3-f940fc20d6ed", "8af4a3b8-b1ac-497e-9be1-02fc1a730f14", "a9fe0325-5182-4dbc-be26-73e441c42096", "9252b78f-9ae6-4484-b419-9c6c332802f9"], "metadata": {"window": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.   As far as contract renewals go, on the ones that we specifically talk about, our \nthree largest ones, which we have disclosed, those still have a couple of years left on them before \nthere's any renewals of those contracts.   And everything else as it relates to contract renewals for this \nyear is generally tracking as expected.   It's always one of those headwinds as a year -over-year basis, \nbut everything is tracking as we expected at the beginning of this year.  \n \n", "original_text": " \nPage 9 of 14 \n \n \nMike Kaufmann:  Yes.  ", "page_label": "9", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b402b6bf-7cf1-485e-9157-f2b7d3be4ce7": {"node_ids": ["b8d360d2-d85f-4881-8af2-30735f17ffda", "6445f51d-073f-44d5-89d9-41eb445c5239", "2edb8b29-c778-4a95-93ba-3351b0a4ce98", "d201a471-b72e-43e5-8cf6-d0b4bf007294", "e5de277c-edc3-420e-96c0-6549e4a886a9", "38beeca2-b856-4cc4-b35a-f408d27f02d9", "ade424f1-82b1-44e0-a68e-221362971b95", "8e2d0c49-0ed0-47cc-8590-fb6a0c5d0dc9", "5f25631a-708e-4f79-a3ba-2d405df247df", "f0e147d0-6b80-4a3a-a7f1-3205b8cbf711", "129dd82f-985b-41ef-af0c-414af3fac587", "35aed165-5d68-446a-8260-4af44af5781c", "1ca90702-7116-43f8-b562-32f4d1457334", "dc2d91e3-7511-490d-be2a-87aabd798a79", "bcb2f7f3-fa2f-40f3-9e3e-6f9f3d2ad4ef", "eb3bc59b-626b-4fe3-a87f-f0fa8cd1a60f", "b0563140-608f-43f1-9704-83d84f28f481", "af93bc6c-8e7c-4d32-b074-b5501139faac", "2f945123-54eb-4191-a9a4-4e2ad371f67d", "fcb073d1-4c41-46ce-b6d1-5791ee1d94b5", "073e1f9f-609d-4cfc-87a4-51a9dcad9a5e", "646b7f65-0d94-4154-825b-58f1a6df4d7e", "04741d67-dd61-4ecc-ae85-6565bfa16368", "c313822b-6c9d-47c6-9ef3-ef7eec23143b", "03a6e726-26bb-4d57-9614-3dc47cbe817d", "9a418f7b-7578-4777-b214-bbe9d20ddba2", "80dd576d-12af-4821-a5bf-5477db9b4257", "ff9ee9e4-7df3-4779-b362-2bb511cb208f", "0d8cdcfb-63e9-424c-b06c-12864c385745", "d18f3f50-3610-4d00-a06e-aec47fa1cc38", "0d790fa7-0dfe-4f13-a8b5-31cfb8cc5319", "158b3ee0-e1b6-4311-8470-63a9eb958b88", "ecee0e46-5ec0-4776-9e76-5313e43dd083", "9d39416e-829a-4cec-be1a-75868abadda6", "0b365270-3af7-45c7-82f3-376d386bfe70", "e99b6fbf-9f1e-47c5-9364-532816425dbc", "50325fc1-a663-4da1-a8ac-9e5eafa8292a", "54a536b0-7a68-4e81-adfd-c524245e2f1d", "ca1af5c3-58e7-43ce-bd1a-7d5964819955", "fe75f863-7c19-44db-b9db-2ec5b7f75979", "8c8c7523-ba18-49d0-a63c-d87b82a64ccd"], "metadata": {"window": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n Mike Kaufmann:  No, I think that sums it up well.  \n \n Robert Jones:  Great.   Thanks.  \n \n", "original_text": " \nPage 10 of 14 \n \nAnd anything else to add, Mike?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d30bbfcf-9d08-4cbb-8ff9-339b905774d4": {"node_ids": ["369c9ca2-833c-4b87-bc30-c07cc75bb060", "6137a5de-b0e6-467b-95e7-f0f25b15f0b0", "16299bb6-77db-4803-8a1b-dd0a2c7596a9", "80b354b2-d521-4469-8308-298a92ce654b", "eb369d08-764d-4f5a-86b0-2d7346d69cb4", "5c443ed9-f54e-4b11-9444-2d1eddc21b74", "9122416a-8f5c-4533-a1ff-16fdf875d38b", "7f7c8144-0ac4-4a98-99b6-7079421f5530", "e23607b7-7762-435c-b191-32c891a5606f", "97430787-843e-4721-a75c-6e9fe7fd12d3", "56263928-4223-406f-897c-9de894b6a51b", "7f79bff2-ef96-4ed7-8450-6aef3d8d2fb8", "7cd22b3b-7b93-43a2-9289-de5d1dfcd197", "7336e518-f3f0-404a-985b-625ed05b1b78", "a0dbd568-f9b1-4166-b89a-7293aadd4957", "96340b8e-8fdb-4523-92f3-4be0bc87e715", "85e2c8b6-ce8c-4ddb-975a-9139b9f35880", "11b025d2-19e8-4757-a605-669d481f825f", "d7866d64-0860-4083-99e2-f4c64773e9ce", "dcb5569c-28c6-44e6-95b9-89fd49362705", "892dbee9-e9c0-4b26-9203-36e0b58879c1", "99dd249d-397c-42b9-8a54-a0f10dacd806", "4e20bb50-c7a5-41b1-bc7f-1bf4ebdaf7e7", "1668e4d9-1d23-4e7a-87e9-370aa8265587", "bd2d5ba1-1244-47d1-b5be-160791770ddf", "a551d970-41dc-4a37-b5f3-2694c71c61dc", "c51c6c9d-d8dd-40bb-9750-16f301ee91fd", "142bd23a-7394-483b-b966-9ea8c07ffdb3", "4de18e3d-3fa8-43e2-aa03-aaf279b59d1a"], "metadata": {"window": " \nPage 11 of 14 \n \nin those businesses.   One thing to highlight is, as we've invested more capital over the last couple or \nseveral years, that will ultimately result in increased  depreciation that we would expect to flow \nthrough.   \n \n But of course, we would also expect the benefits of the programs, but we'll have some varying pieces \nthere going forward.   Beyond that element, again, investing our business being our highest capital \ndeployment priority, we have the other areas like debt reduction and returning capital to shareholders, \nsome of which will be through share repurchases that should have a tailwind associated with it also.  \n", "original_text": " \nPage 11 of 14 \n \nin those businesses.  ", "page_label": "11", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "65f21369-d1a5-41b6-bd01-1a3ef62a55bb": {"node_ids": ["5342fa18-a9ce-4dd1-9daf-5fca30f839c3", "9d59b8ff-0ad9-4249-9d4b-f49382350057", "1d4d0f3d-0f01-4227-983b-e6700350d264", "591c84a1-0349-4241-ba32-a093abfc0779", "295e09dc-cfcb-44de-aa6b-8ff738c7008d", "c33e1455-272a-4dae-9a82-2ebcf5a6a2ea", "dc15c02a-be96-4175-a380-f819d459ca6b", "44b51939-27f1-4d57-9d03-c46fb5855d9a", "dae8d717-39d0-4259-b596-b28323fb1df3", "06ec98f8-d47c-4a29-a086-cda55ccbec09", "50563dfc-3890-4a23-ac27-e33139d33702", "23f4f37d-f2dc-4680-9144-ebcccff52991", "4bef7681-9dbd-438d-b203-a4b9a6ada65f", "acbcea85-ded1-45c3-a296-1dfb125330c8", "98062b59-75a3-4d04-9287-e75df2bdd35e", "8622ed0a-4f2a-4bc1-a418-abd0c3b2f3c7", "a42a6381-1c0f-4eaf-9f94-6874cec5113f", "d73363ec-3edc-458b-9520-093d61a1c56c", "08a52047-d2f1-409b-9909-411f1a282da5", "539eb692-a0f9-45b5-ba31-5a294cba36fe", "42c28c77-37ab-46a2-97a3-d073d79b782c", "fcda6c3e-e93d-4888-af79-cd8cc9c9027f", "7f513e43-483b-44c1-ace0-7b6b54a5c20a", "a91b2e48-ecb4-4f40-9108-f5939662a5c2", "134222ac-edca-425c-be64-463878f959ee", "8037b989-a007-4ae8-9ef9-4658815b1715", "654ef58d-0f6b-4d4e-830b-6657a982e4ce", "529804ed-7978-44f1-a9cf-05563382d3c9", "50ca31ab-26e4-40e5-b446-3a5cbf97d495", "7f1e9b4b-50f6-4bc2-9190-eb9d89866c3d"], "metadata": {"window": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.   A question on the specialty business.   It sounds like you're expecting that \ntrend to normal e in that business.   I want to ask how the profitability levels ha ve been running in that \nbusiness, whether you're seeing benefits from biosimilars?  ", "original_text": " \nPage 12 of 14 \n \n \nEric Percher:  Thank you.  ", "page_label": "12", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bdd39ba1-fb10-49a1-9170-121456540707": {"node_ids": ["84835735-cc5c-448f-b388-d592486ab143", "2f9bc9b1-33ec-489b-b282-c8bfd353ff1f", "3d0b541b-8c2c-45a1-9706-f2803fb2e8c2", "f61a4858-9213-47fc-a0d8-6a65c3cff8b1", "4a9d54c3-b424-474e-b4a5-ece77ec147a8", "74c017ed-355f-4836-9c35-7853d96bbf76", "6d6782ba-ba5f-44c4-8758-d9499b3081ac", "d4232b34-6296-4411-ad17-65db7547935a", "82336a5b-e643-4314-b0af-4436d0635be4", "8e9c0b35-2705-4d89-83e5-9fd434f816e9", "a29eb737-8a01-4dac-a541-f3cff5dfa4d1", "798ec7c9-2caf-47f1-9367-9f5fdc422e8f", "ce720de9-8da5-4d81-86f4-7e7550eceec8", "1c13eb35-4716-405a-a642-5899a627b48e", "7b870875-a919-4547-9cff-6a2770c2f2e4", "0e05c93f-85a9-4a66-bef9-c97681177ebe", "3a23187a-fa82-4fda-95bb-0158ce3c0e5b", "c83b6864-9088-495e-a051-5eba50aafabf", "e1a9e06d-c733-4bfa-9253-54f232e8c7e4", "e70729dd-9cd4-4f56-bd39-dbc17241f5da", "71fc1b40-01d1-4465-9bd2-9f8a7b4b77d1", "de1702b7-d87a-40df-891b-50ce93c388ad", "ba91c43b-9233-4857-9d21-55faf1a5a9e7", "a2bffa14-596a-4a42-acd3-ea235c37298f", "5876621d-2cdc-4af3-b3a5-9c943e61a519", "f816df56-2979-4108-8020-9060c6db320e", "9203473d-e64e-49ba-a1bb-c99a67393f6b", "e17e4ea3-f3de-46c4-8082-dd73532e6543", "f5a599b0-376c-4f7a-b951-bfb3a5c134be", "1d5535f2-91f0-482d-a4d7-c48011771b24", "b8497137-e23e-4627-a0d2-3bb1f19c2f99", "d42c246c-5203-4a44-9d63-2839b2f53fd6", "4473382b-1cf4-4188-b963-0019a09f5abb", "a0ab8f5e-b0fa-47fd-85f8-8a7c8828dd91", "581e09ba-2aed-41d7-b716-9b05627bea64"], "metadata": {"window": " \nPage 13 of 14 \n \ncustomers?   And then I\u2019d tack on at t he end to relate to Jailendra's question is, are there any \ndissynergies from the Cordis divestiture?  \n \n Jason Hollar:  Sure.   Yes.  ", "original_text": " \nPage 13 of 14 \n \ncustomers?  ", "page_label": "13", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "caa89d30-eaa8-4385-8d94-ec09fb294b8a": {"node_ids": ["55b46c80-2593-4ed7-86a0-0dae5d89a535", "066be56e-00a0-47e7-8b53-bb5357cd9734", "fd300703-2345-47fe-92ab-052e7c1c222c", "076ef1ae-ccd2-4406-a6a8-4dbd44a0a781", "29a0c5a5-717d-4683-8031-cea3f420300a", "ee007b7b-f274-4537-a93e-85bb3f7a646e", "d644215f-ee9f-46fa-aea5-7890ff942042", "46964758-3b5c-4d18-a916-ab15b7c854b0", "50a0d708-59d1-49db-b9df-9d3fe66d9472", "46274bae-2179-4cbb-8e9f-440f7387602e", "423e8a4a-3fba-4cb4-9532-a3eee28d7d0d", "6ea5d742-3b42-4117-a2a9-4693858f55a6", "b0df7b2a-e25d-45a0-8694-d4d10d414b1a", "b8bb79a2-c50e-4235-8a61-6782d32c206e", "652ceb2d-3e96-4915-80e3-baaecb6dd435", "7d291f53-19b9-4906-b116-4d582f872127", "ff15496b-15b9-4146-a39d-0e87bc8f544c", "54a59d75-dac7-4290-a172-107ead92fc52", "58e337f8-0efd-43f4-b8c8-32d5705becf6", "b556ec5d-4e78-4727-8d86-6e8ac891b685", "d3dd0949-54bb-4691-8e02-eb4b1d8c0b4d", "1b4cacc2-e556-4bee-a82d-c03e8bf1c181"], "metadata": {"window": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.   Did I think about that right?   Can we just go through that one more time?  \n \n Jason Hollar:  Yes.  ", "original_text": " \nPage 14 of 14 \n \nlike COVID impact for Medical is going to be incremental, like you considered an incremental \nnegative.  ", "page_label": "14", "file_name": "CAH-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 176045, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}